

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

MEETING
OF
Public Workshop - Facilitating Antibacterial Drug
Development for Patients with Unmet Need and
Developing Antibacterial Drugs That Target a Single
Species

Conducted by Edward Cox, M.D., M.P.H.

Tuesday, July 19, 2016

8:30 a.m.

Food and Drug Administration
White Oak Campus
10903 New Hampshire Avenue, Great Room
Silver Spring, MD 20993

Reported by: Michael Farkas, RPR/CSR,
Capital Reporting Company

Facilitating Antibacterial Drug Development For Patients With Unmet Needs Volume II

Page 357	Page 359
<p style="text-align: center;">A P P E A R A N C E S</p> <p>1</p> <p>2</p> <p>3 Paul Ambrose, Pharm.D., President, Institute for</p> <p>4 Clinical Pharmacodynamics, Inc.</p> <p>5</p> <p>6 Luciana Borio, M.D., Acting Chief Scientist, FDA</p> <p>7</p> <p>8 Helen Boucher, M.D., Director, Infectious Diseases</p> <p>9 Fellowship Program and Associate Professor of</p> <p>10 Medicine, Tufts University School of Medicine</p> <p>11</p> <p>12 Samuel Bozzette, M.D., Ph.D., Vice President, Medical</p> <p>13 Affairs - Americas/East Asia and Global Health</p> <p>14 Economics and Outcomes, BioMerieux, Inc.; Adjunct</p> <p>15 Professor of Medicine and of International Relations,</p> <p>16 University of California, San Diego; Adjunct Professor</p> <p>17 of Health Policy and Management, University of North</p> <p>18 Carolina</p> <p>19</p> <p>20 Marco Cavaleri, Ph.D., Head of Anti-Infectives and</p> <p>21 Vaccines, European Medicine Agency</p> <p>22</p>	<p>1 Peter Kim, M.D., M.S., Medical Officer, Division of</p> <p>2 Anti-Infective Products, OAP, CDER, FDA</p> <p>3</p> <p>4 Joe Larsen, Ph.D., Deputy Director (Acting),</p> <p>5 Biomedical Advanced Research Development Authority</p> <p>6 (BARDA)</p> <p>7</p> <p>8 Thomas Louis, Ph.D., Professor, Department of</p> <p>9 Biostatistics, Johns Hopkins University Bloomberg</p> <p>10 School of Public Health</p> <p>11</p> <p>12 Lynn Marks, M.D., Senior Vice President for Projects,</p> <p>13 Clinical Platforms, and Sciences, GlaxoSmithKline, plc</p> <p>14</p> <p>15 Sumathi Nambiar, M.D., M.P.H., Director, Division of</p> <p>16 Anti-Infective Products, OAP, CDER, FDA</p> <p>17</p> <p>18 John Powers, M.D., Senior Medical Scientist, NIAID,</p> <p>19 NIH</p> <p>20</p> <p>21 John Rex, M.D., Senior VP and Chief Strategy Officer,</p> <p>22 Infection Business Unit, AstraZeneca, plc</p>
Page 358	Page 360
<p>1 Edward Cox, M.D., M.P.H., Director, Office of</p> <p>2 Antimicrobial Products (OAP), CDER, FDA</p> <p>3</p> <p>4 Aaron Dane, M.Sc., Director, DaneStat Consulting</p> <p>5</p> <p>6 Dennis Dixon, Ph.D., Chief, Bacteriology and Mycology</p> <p>7 Branch, NIAID, NIH</p> <p>8</p> <p>9 Michael Dudley, Pharm.D., Senior Vice President and</p> <p>10 Head, R&D; Co-Leader, Infectious Disease Global</p> <p>11 Innovation Group, The Medicines Company</p> <p>12</p> <p>13 Ian Friedland, M.D., Chief Medical Officer, Achaogen,</p> <p>14 Inc.</p> <p>15</p> <p>16 John Jenkins, M.D., Director, Office of New Drugs,</p> <p>17 CDER, FDA</p> <p>18</p> <p>19 Nick Kartsonis, M.D., Associate Vice President,</p> <p>20 Clinical Research; Section Head, Antibacterial,</p> <p>21 Antifungals, HIV & CMV, Merck & Co., Inc.</p> <p>22</p>	<p>1 Dan Rubin, Ph.D., Statistical Reviewer, Office of</p> <p>2 Biostatistics, CDER, FDA</p> <p>3</p> <p>4 John Tomayko, M.D., Chief Medical Officer, Spero</p> <p>5 Therapeutics</p> <p>6</p> <p>7 Kert Viele, Ph.D., Director & Senior Statistical</p> <p>8 Scientist, Berry Consultants</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p>

Page 361	Page 363
<p>1 C O N T E N T S</p> <p>2 SPEAKER PAGE</p> <p>3 Edward Cox 362</p> <p>4 Peter Kim 375</p> <p>5 Helen Boucher 380</p> <p>6 John Tomayko 399</p> <p>7 Sumathi Nambiar 418</p> <p>8 Marco Cavaleri 445</p> <p>9 John Rex 453</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p>	<p>1 There's conflict of interest disclosures. I</p> <p>2 believe they're on the agenda or at the table out</p> <p>3 front. So if folks are interested in seeing those,</p> <p>4 they are available.</p> <p>5 And we also in the afternoon will provide an</p> <p>6 open time for public comment. We wanted to reserve</p> <p>7 some time for anyone who wants to make any either</p> <p>8 prepared remarks or statements at that point in time.</p> <p>9 I think we do that in the afternoon, if I remember</p> <p>10 correctly. I'll bring the agenda up here in just a</p> <p>11 minute.</p> <p>12 Throughout the course of the day, too, we</p> <p>13 have the microphones. And just like yesterday, if</p> <p>14 folks want to get up, make comments, ask questions</p> <p>15 please feel free to do so and when recognized by the</p> <p>16 - either myself or Dr. Rex. We'll be moderating</p> <p>17 today's sessions.</p> <p>18 And I thought what we'd do today would be to</p> <p>19 start out with panel introductions so you know who's</p> <p>20 up here, and I think we'll start on the far side with</p> <p>21 Aaron and then work towards John.</p> <p>22 MR. DANE: Hi. Aaron Dane, Statistical</p>
Page 362	Page 364
<p>1 P R O C E E D I N G S</p> <p>2 DR. COX: All right. Good morning</p> <p>3 everybody, and welcome to Day 2 of our Public Workshop</p> <p>4 series here. It's quiet and it looks like mostly</p> <p>5 everybody sat down. It's 8:30, so I think it's time</p> <p>6 to go. So we're very glad to see folks back here for</p> <p>7 Day 2.</p> <p>8 Today is a slightly different topic, perhaps</p> <p>9 a little bit more challenging than what we even</p> <p>10 discussed yesterday, and I expect we'll have a fairly</p> <p>11 free-flowing discussion because this is such a</p> <p>12 challenging area. I will be very interested to see</p> <p>13 what folks' ideas are on this topic.</p> <p>14 We'll be talking about developing</p> <p>15 antibacterial drugs that target a single species. And</p> <p>16 as I mentioned yesterday this is a workshop, so it</p> <p>17 really is just an opportunity for discussion. It's</p> <p>18 not one to gain consensus. It's not an advisory</p> <p>19 committee, but that also should allow folks to feel</p> <p>20 comfortable to, you know, discuss the issue here and</p> <p>21 try to work through some of the scientific challenges</p> <p>22 we face.</p>	<p>1 Consultant.</p> <p>2 DR. BOUCHER: Helen Boucher, Infectious</p> <p>3 disease, Tufts.</p> <p>4 DR. TOMAYKO: John Tomayko. I'm an</p> <p>5 infectious disease physician, work for Spero</p> <p>6 Therapeutics as their chief medical officer.</p> <p>7 DR. BORIO: Lu Borio, FDA Acting Chief</p> <p>8 Scientist.</p> <p>9 DR. CAVALERI: Marco Cavaleri, European</p> <p>10 Medicine Agency.</p> <p>11 DR. NAMBIAR: Sumathi Nambiar, Director of</p> <p>12 Division of Anti-Infective Products, CDER, FDA.</p> <p>13 DR. REX: John Rex, Internal Medicine and</p> <p>14 Infectious Diseases, AstraZeneca.</p> <p>15 DR. COX: All right. Great. Thanks to our</p> <p>16 panelists. I was just mentioning, you know, to folks.</p> <p>17 I mean, there's -- this day took a fair bit of</p> <p>18 preparation in preparing the case, and hopefully you</p> <p>19 all had a chance to study it last night. And it was a</p> <p>20 lot of work to get to something that seemed to be, you</p> <p>21 know, really as spot on as we could possibly make it</p> <p>22 in sort of a simulated case.</p>

<p style="text-align: right;">Page 365</p> <p>1 So for today, we'll have first an</p> <p>2 introduction of the case. Peter Kim will walk through</p> <p>3 some of the slides. And then we'll hear from a series</p> <p>4 of different folks representing academia, industry,</p> <p>5 FDA and EMA provide some perspective on the case that</p> <p>6 we're presenting. And the case will be a particularly</p> <p>7 development issue for a drug that targets a single</p> <p>8 species.</p> <p>9 We'll also have time for questions, and then</p> <p>10 John Rex will go into more detail. And we'll sort</p> <p>11 walk through and sort of unfold the case over time and</p> <p>12 welcome folks' input during that.</p> <p>13 And you know, this is an area where there is</p> <p>14 interest. There is -- you know, there are compounds</p> <p>15 out there that folks are trying to develop, and I</p> <p>16 think if it's a compound that's targeting staph aureus</p> <p>17 and the goal is to see how it works in treating</p> <p>18 patients with staph aureus skin infections that's</p> <p>19 probably feasible, but if you move to a gram-negative</p> <p>20 rod that infrequently causes any variety of serious</p> <p>21 infections, whether it be HAP/VABP, complicated</p> <p>22 intra-abdominal, complicated UTI, it becomes much more</p>	<p style="text-align: right;">Page 367</p> <p>1 such drugs.</p> <p>2 You know, one of the ideas here, too, is</p> <p>3 that if you have a drug that is only active against a</p> <p>4 single species, maybe it will have less of an effect</p> <p>5 on your GI normal flora. And, you know, the normal</p> <p>6 flora that we have are very important to us and</p> <p>7 prevent, you know, colonization with other less</p> <p>8 favorable organisms, such as either those that have</p> <p>9 resistance, fungal colonization of the gut and then C.</p> <p>10 diff colitis.</p> <p>11 So the hope is that if you can target more</p> <p>12 narrowly maybe you can avoid some of these problems.</p> <p>13 And you know, how a drug would be used in clinical</p> <p>14 practice is, you know, still, I think, a challenging</p> <p>15 question, but we hope it's a question that we can get</p> <p>16 to.</p> <p>17 And what I mean by that is that oftentimes</p> <p>18 therapy for antibacterial diseases is empiric and</p> <p>19 you're targeting a range of pathogens that are likely.</p> <p>20 And you know, with a narrower spectrum agent, you</p> <p>21 know, how that will figure into the paradigm I think</p> <p>22 is still something that needs to be worked out. Rapid</p>
<p style="text-align: right;">Page 366</p> <p>1 challenging much quickly -- much more quickly.</p> <p>2 And that's really the case that we'll be</p> <p>3 focusing on today. So just for clarity purposes,</p> <p>4 we're talking about a drug that is only active against</p> <p>5 a single species. So this is not a choice that you're</p> <p>6 only going to develop it for a single species. This</p> <p>7 is because the drug really is only active against that</p> <p>8 single species, and you're looking to develop a drug</p> <p>9 in a serious infection.</p> <p>10 Rapid diagnostics -- and we talked about</p> <p>11 this some yesterday -- could be very important here,</p> <p>12 not only for identifying patients for a clinical</p> <p>13 trial, but also for how the drug might be used out</p> <p>14 there in the real world should a drug, you know, get</p> <p>15 out there and be available to clinicians treating</p> <p>16 patients.</p> <p>17 As I mentioned, there are compounds and, you</p> <p>18 know, at various different public meetings over the</p> <p>19 last so many months, whether it be ASM, the Barn</p> <p>20 meeting, another bio, I mean, people have talked about</p> <p>21 these compounds that are really only active against a</p> <p>22 single species, and they're interested in developing</p>	<p style="text-align: right;">Page 368</p> <p>1 diagnostic certainly can help there, but I think we</p> <p>2 look forward to trying to solve that challenge if we</p> <p>3 get there. I hope we do.</p> <p>4 I won't say too much about this slide but</p> <p>5 talked about this some yesterday. And that is, you</p> <p>6 know, disease characteristics for serious bacterial</p> <p>7 diseases make them particularly challenging to study.</p> <p>8 We talked yesterday about, you know, diagnostic</p> <p>9 uncertainty, the urgency, you know, the start -- the</p> <p>10 need to start therapy, that you really don't know who</p> <p>11 these patients are. They can show up at any hospital</p> <p>12 at any point in time, which can make it really</p> <p>13 difficult to actually conduct a study.</p> <p>14 And here, we're sort of taking it even one</p> <p>15 step further. Now we're looking at a particular</p> <p>16 species that makes this, you know, even more difficult</p> <p>17 to identify a patient for whom the test agent is</p> <p>18 likely to be -- you know, where you can evaluate the</p> <p>19 test agent. If you're only looking at pseudomonas</p> <p>20 aeruginosa, you've sort of cut down your set of</p> <p>21 patients in whom you can study the drug even further.</p> <p>22 So this brings us to the question of what do</p>

<p style="text-align: right;">Page 369</p> <p>1 you when the species of interest is infrequent. So</p> <p>2 you know, it becomes, in essence, sort of a numbers</p> <p>3 game on the human clinical trials side. You'll -- if</p> <p>4 you have fewer patients, you just simply can't enroll</p> <p>5 them. You can't find them. You'll probably end up</p> <p>6 with less precise estimates of efficacy and greater</p> <p>7 uncertainty around, you know, what you know about the</p> <p>8 drug. That's -- you simply have less data. And so</p> <p>9 you may not really be in a situation to practically be</p> <p>10 able to achieve the usual statistical conventions that</p> <p>11 you would expect for a clinical trial.</p> <p>12 And this is particularly challenging where</p> <p>13 the outcomes for serious acute bacterial diseases are</p> <p>14 variable. And you know, we know some of the factors,</p> <p>15 but I don't think we know them all. And we seek, you</p> <p>16 know, cure rates, or success rates that can vary, you</p> <p>17 know, by plus or minus 20 percent or more depending</p> <p>18 upon a lot of different patient factors, some of which</p> <p>19 we know, some of which we don't know.</p> <p>20 And we're not -- you know, following this</p> <p>21 we're not really in a situation where we have lights</p> <p>22 on, lights off. I mean if you could take something</p>	<p style="text-align: right;">Page 371</p> <p>1 is how do we make the best of it.</p> <p>2 And then if clinical trials are not</p> <p>3 feasible, one of the things we'll also be talking</p> <p>4 about today is the animal rule to evaluate efficacy.</p> <p>5 You know, in this setting you still need safety data</p> <p>6 from humans, and there are also within the animal rule</p> <p>7 provisions for restrictions on the conditions of the</p> <p>8 availability of the drug.</p> <p>9 And Sumathi in her talk will go through more</p> <p>10 of the specifics of the animal rule, so we're looking</p> <p>11 forward to some more details on that when she gives</p> <p>12 her presentation. And we also welcome other ideas</p> <p>13 folks may have about how to solve this particularly</p> <p>14 challenging problem.</p> <p>15 Just a comment or two about animal models</p> <p>16 for evaluating efficacy under the animal rule -- and</p> <p>17 as I mentioned, Sumathi will go through more details</p> <p>18 and the specific criteria. But just to sort of</p> <p>19 differentiate these from models where you're looking</p> <p>20 at activity of an antibacterial drug, you know,</p> <p>21 really, what we're trying to get at here is an animal</p> <p>22 model that allows us to predict efficacy in humans.</p>
<p style="text-align: right;">Page 370</p> <p>1 where, you know, there was a 90 percent bad outcome</p> <p>2 and you could drop it down to 10 and you were always</p> <p>3 at 90 and, you know, you clearly would never get to 10</p> <p>4 without some intervention, it would be much clearer.</p> <p>5 Here, I think we're in the range of -- you</p> <p>6 know, it's usually sort of around 60, and maybe we can</p> <p>7 drop it 40 or 30. But sometimes it may move from 60</p> <p>8 to 40 just depending upon the patients that you happen</p> <p>9 to enroll at a particular center or over time, so lot</p> <p>10 of variability here that makes this particularly</p> <p>11 challenging.</p> <p>12 So some of the options that we'll be</p> <p>13 discussing here today will be looking at clinical data</p> <p>14 when, you know, we have smaller numbers of patients.</p> <p>15 And there will be inherently greater degrees of</p> <p>16 uncertainty. And the uncertainty comes not just from</p> <p>17 the small numbers, but also from the challenges of</p> <p>18 studying an antibacterial drug. You know, concomitant</p> <p>19 therapy will probably be, you know, what patients need</p> <p>20 to get, and they'll probably get some pre-study</p> <p>21 antibiotics, too. So you know, this will be, you</p> <p>22 know, messy data, messy information. So the question</p>	<p style="text-align: right;">Page 372</p> <p>1 So it's more than just showing activity. And, you</p> <p>2 know, for some diseases, one of the first questions</p> <p>3 is, is there a good animal model of infection.</p> <p>4 And Sumathi will walk through some of the</p> <p>5 develop efforts that have been undertaken in areas</p> <p>6 where we have used the animal efficacy rule, and</p> <p>7 she'll be talking about animal model development for</p> <p>8 the disease of plague and some of the work that was</p> <p>9 done for that. And you'll see it's a fair bit of work</p> <p>10 to really try and understand these models.</p> <p>11 And there's a lot of difficult questions,</p> <p>12 and the questions may not be apparent until you start</p> <p>13 to get into this and trying to really figure out what</p> <p>14 you need in order to be able to predict human</p> <p>15 efficacy. You know, which species? Which species</p> <p>16 behaves similar to the humans? Some animals tend to</p> <p>17 be intrinsically more resistant to certain types of</p> <p>18 infections than others. What's the inoculum? You</p> <p>19 know, is it -- and you sort of engineer the model,</p> <p>20 too, so that it works within the model. And then the</p> <p>21 question is, is does that extrapolate to humans.</p> <p>22 When do you intervene with the test drug?</p>

<p style="text-align: right;">Page 373</p> <p>1 And you know, there's been enough experience to be 2 able to say that, you know, if you intervene at, say, 3 48 hours and the drug can, you know, reduce mortality 4 in the animal model of infection, is that the point in 5 time that translates to clinical benefit in patients? 6 And -- or do you need to be able to get out to, say, 7 four days or five days or six days in order to be able 8 to translate that finding in the animal model? 9 Because it's not just activity into human clinical 10 benefits. 11 So these are really challenging questions 12 that we struggle with. And you know, occasionally we 13 do have some human data, and that tells us something 14 about the animal model. And sometimes we learn that 15 we didn't know quite as much about the animal model as 16 we had thought we did. 17 And the other thing we run into is that 18 animals may metabolize or clear the drug differently, 19 and there need to be certain interventions to be able 20 to get something that's close to the human exposure. 21 We have an animal rule efficacy guidance document 22 that's out on our web that discusses a lot of these</p>	<p style="text-align: right;">Page 375</p> <p>1 And with that, I'll stop. And our next 2 speaker is Peter Kim, if I'm reading -- yeah, Peter 3 Kim will be talking to us. And he'll actually walk us 4 through the case at sort of a high level so you'll 5 know what we're dealing with. 6 Peter is a medical officer in the Division 7 of Anti-Infective Products. So he'll walk us through 8 part one of the tough case. And we'll continue to 9 build over the course of the session. So you'll see 10 as we unveil more information it'll get trickier and 11 trickier. 12 So Peter welcome to the podium, and walk us 13 through it. 14 DR. KIM: Thank you, Ed. 15 Good morning. I'll be discussing a 16 hypothetical case of an antibacterial targeting a 17 single bacterial species. The name of this drug is X- 18 1. 19 Overview. Drug X-1 is an injectable anti- 20 antibacterial with activity limited to pseudomonas 21 aeruginosa. It has no activity against gram-positives 22 or other gram-negatives, including enterobacteriaceae.</p>
<p style="text-align: right;">Page 374</p> <p>1 issues, too, that is quite helpful. 2 So today, we'll be talking about the pros 3 and the cons of different approaches, and we'll be 4 talking about human clinical data and also animal 5 data. And this isn't sort of a binary decision. I 6 mean, there is the opportunity to have both of these 7 two types of information. You know, matter of fact, 8 the animal rule talks about utilizing available 9 clinical data. So there is -- I don't want to present 10 sort of a binary decision here. I mean, there is the 11 opportunity to draw off information from both. 12 And I think, you know, the reason that we're 13 here today -- I mean, we know that folks are 14 interested in developing these compounds, you know, if 15 they can be shown to be safe and effective, utilized 16 clinically in a meaningful way. I mean, the hope is 17 that the narrower spectrum agents will do less havoc 18 on the normal flora that we all need and that keeps us 19 out of trouble. So we think it's important to have a 20 pathway for the development of these compounds so that 21 the potential for these drugs for treating patients 22 can be evaluated.</p>	<p style="text-align: right;">Page 376</p> <p>1 X-1 has a new mechanism of action. It acts on a novel 2 ribosomal target unique to pseudomonas aeruginosa. 3 Non-clinical safety. Hepatic and 4 hematologic toxicity have been identified in mice and 5 dogs. Hepatic toxicity signal is a dose-dependent 6 increase in liver enzymes associated with macrophage 7 infiltration at the mid and high doses as well as 8 reversible focal hepatocellular necrosis at the high 9 doses. 10 Concerning safety margins, the liver enzyme 11 elevations were observed at four times the target 12 therapeutic dose, and the focal hepatocellular 13 necrosis occurred at eight times the targeted 14 therapeutic dose. Regarding hematologic toxicity, 15 there is some evidence of neutropenia and it occurred 16 at eight times the targeted therapeutic dose. 17 Non-clinical microbiology and PK/PD. Drug 18 X-1 is mainly active against pseudomonas aeruginosa. 19 The MICs have a bimodal distribution of 0.06 to one 20 milligram per liter for wild type and greater than 4 21 milligrams per liter for non-wild type. Ninety-nine 22 percent of isolates had an MIC of less than equal to 1</p>

<p style="text-align: right;">Page 377</p> <p>1 milligram per liter in a recent global survey.</p> <p>2 The MIC distribution for wild type is</p> <p>3 centered on an MIC of .25 milligrams per liter with 5</p> <p>4 percent of isolates at the low and high ends of the</p> <p>5 spectrum. Therefore, both the MIC 90 and MIC 99 equal</p> <p>6 1 milligram per liter.</p> <p>7 The frequency of spontaneous resistance is</p> <p>8 low. Serial passage studies have shown no change in</p> <p>9 the MIC up to 11 passages. Drug X-1 has variable</p> <p>10 activity against other pseudomonas species and no</p> <p>11 activity against other gram-negatives, as we had</p> <p>12 discussed, or gram-positives.</p> <p>13 In animal infection models Drug X-1 wasn't</p> <p>14 effective in treating pseudomonas aeruginosa</p> <p>15 infections based on reduction of colony-forming units</p> <p>16 per gram in the thigh, pneumonia and peritonitis</p> <p>17 models and based on survival in the sepsis model.</p> <p>18 The PK/PD index associated with bacterial</p> <p>19 killing is the percent time that free drug</p> <p>20 concentrations are above the MIC over a dose interval,</p> <p>21 and this index was observed in the hollow-fiber model</p> <p>22 as well as in murine thigh and pneumonia infection</p>	<p style="text-align: right;">Page 379</p> <p>1 concentration ratios of Drug X-1 were approximately 40</p> <p>2 percent and 25 percent in humans and mice,</p> <p>3 respectively.</p> <p>4 Phase 2 proof of concept study. It</p> <p>5 consisted of a 14-day, uncontrolled study conducted in</p> <p>6 patients with non-cystic fibrosis bronchiectasis.</p> <p>7 Drug X-1 was given as monotherapy in 10 patients. At</p> <p>8 the proposed dose, the predicted PK parameters were</p> <p>9 observed. Microbiologic activity was assessed in</p> <p>10 terms of log reduction of pseudomonas aeruginosa in</p> <p>11 sputum. Greater than 1 log reduction was seen in 9</p> <p>12 out of 10 patients, and greater than 2 log reductions</p> <p>13 were seen in 4 out of 10. No adverse events of</p> <p>14 concern were observed.</p> <p>15 And now for perspectives on the development</p> <p>16 program from academia, industry, FDA and EMA.</p> <p>17 Thank you.</p> <p>18 DR. COX: Great. Thanks Peter</p> <p>19 (Applause)</p> <p>20 DR. COX: And now we'll walk through a</p> <p>21 series of perspectives. And first, we'll hear from</p> <p>22 Helen Boucher. And I think many folks know Helen.</p>
<p style="text-align: right;">Page 378</p> <p>1 models.</p> <p>2 Clinical studies. The sponsor has completed</p> <p>3 some Phase 1 studies and one Phase 2 study. In Phase</p> <p>4 1, the sponsors completed a healthy volunteer study, a</p> <p>5 long ELF study and renal and hepatic impairment</p> <p>6 studies. The sponsor is also planning a thorough QT</p> <p>7 and drug-drug interaction studies.</p> <p>8 Population PK model. Simulations of a</p> <p>9 population PK model based on Phase 1 data showed that</p> <p>10 a 100 milligram IV infusion over one hour every eight</p> <p>11 hours would provide greater than or equal to 40</p> <p>12 percent time above the MIC for an MIC of 1 milligram</p> <p>13 per liter in more than 90 percent of patients using</p> <p>14 parameter estimates from healthy volunteers and using</p> <p>15 a 40 percent inflated variance. Drug X-1 is excreted</p> <p>16 renally, and greater than or equal to 90 percent</p> <p>17 target attainment is possible for varying degrees of</p> <p>18 renal impairment based on dose adjustment.</p> <p>19 Additional data. The terminal elimination</p> <p>20 half-life of Drug X-1 in healthy subjects was</p> <p>21 approximately two hours. No significant drug-drug</p> <p>22 interactions are predicted. The ELF to plasma</p>	<p style="text-align: right;">Page 380</p> <p>1 Helen is current an infectious disease</p> <p>2 physician at the Tufts New England Medical Center but</p> <p>3 also has industry experience in that she was in both</p> <p>4 Pfizer and Cubist over the course of her career. So</p> <p>5 we greatly appreciate her perspective. And she'll be</p> <p>6 providing the perspective, really, from the standpoint</p> <p>7 of a practicing physician/academic physician on this</p> <p>8 situation of developing a drug that's active against a</p> <p>9 single species and providing us some information about</p> <p>10 what she's seeing out there as a clinician these days.</p> <p>11 So Helen, thank you.</p> <p>12 DR. BOUCHER: So much, Ed and Dr. Nambiar</p> <p>13 and Dr. Rex for inviting me. It's a real honor to be</p> <p>14 here to talk some more about this really important</p> <p>15 problem.</p> <p>16 So my disclosures are shown here. And I'm</p> <p>17 also involved with IDSA, as I showed on the first</p> <p>18 slide, and have been working on this problem for a</p> <p>19 number of years with many in this room.</p> <p>20 So as we sort of start to look at this case</p> <p>21 of X-1, I thought we could harken back a little bit to</p> <p>22 some stuff that we talked about yesterday where we</p>

<p style="text-align: right;">Page 381</p> <p>1 sort of said that in a perfect world all of us would 2 want, and certainly we in academia would want, the 3 most well-justified, statistically rigorous 4 development program and studies for these new drugs 5 that would help our patients in practice and, you 6 know, answer questions to the best scientific ability 7 possible.</p> <p>8 But I think we often learn that we have to 9 work in a world that isn't perfect. And when perfect 10 data is not possible, as Dr. Cox alluded to in his 11 earlier talk, these types of studies may leave us with 12 good preclinical PK and PD as well as animal studies; 13 an ability to understand what the needed exposure is 14 and how to dose these drugs; some amount of clinical 15 efficacy data, which I'm sure we'll spend a lot of 16 time talking about today; importantly, a reasonable 17 safety database -- and we talked a little bit about 18 this yesterday, but I think in this context today 19 we'll probably come back to this -- what is that; what 20 is reasonable; and all of this which will come 21 together to give us enough information to use these 22 patients -- these drugs in our patients who have</p>	<p style="text-align: right;">Page 383</p> <p>1 She actually did well that time. She was 2 treated for two weeks with IV tigesycline, IV and 3 inhaled colistin in combinations, so pretty aggressive 4 therapy and quite toxic therapy. She ultimately was 5 switched over to IV minocycline for a period and got 6 out of the hospital.</p> <p>7 So she came again, not entirely 8 unexpectedly, in late January and again now recently. 9 And most recently, she came in with respiratory 10 failure and now has a urinary tract infection. So she 11 was seen in the emergency room and discharged on a 12 five-day course of levofloxacin and very consistent 13 with the guidelines. And her sputum and urine both 14 grew this carbapenemase-producing Klebsiella.</p> <p>15 Back at the rehab she was doing worse. She 16 was requiring increased oxygen, comes back to the ER, 17 is really failing, very tired, having these urinary 18 symptoms, flank pain, fever now, needs more oxygen. 19 And the urine grows the Klebsiella again with a 20 carbapenem resistant, and it's identified as a 21 multidrug resistant organism.</p> <p>22 And this is what that multidrug resistance</p>
<p style="text-align: right;">Page 382</p> <p>1 really limited options for treatment.</p> <p>2 So I thought, for what it's worth, I might 3 start with a couple of cases, and these are cases that 4 we recently encountered.</p> <p>5 So the first one is a 71-year-old lady that 6 who had laryngeal cancer a couple of years ago, and 7 she had surgery and chemo and radiation back in 2012. 8 And she was cured. She has COPD now. She's home on 9 oxygen and was recently in the hospital with 10 tracheobronchitis and came to us transferred from 11 rehab where she was living with a new fever, flank 12 pain and respiratory failure. So her history is 13 complicated.</p> <p>14 Back in December of last year, she had sort 15 of a cough and sputum production and acute on top of 16 chronic respiratory failure. She wasn't otherwise 17 apparently ill with fever or other constitutional 18 symptoms. She was evaluated using rapid diagnostic 19 for viruses, and we didn't find any other source of 20 infection. But blood in sputum grew a gram-negative 21 that was ultimately identified as a multidrug 22 resistant Klebsiella that had a metallo-carbapenemase.</p>	<p style="text-align: right;">Page 384</p> <p>1 looks like. We got Rs to all of these antibiotics, 2 including the two new kids on the block, the 3 ceftolozane/tazobactam and ceftazidime/avibactam. So 4 were left with very few options for this very sick 5 lady.</p> <p>6 So after discussion with her and her family 7 about the limited options and the fact that there 8 would be predictable renal, neural and other 9 toxicities if we embarked on another 10 colistin/combination approach, she and her family 11 decided to pursue hospice care. So this lady who was 12 cured of her cancer was now left dying of this 13 infection, so certainly not something that we hope to 14 encounter in our practice very much.</p> <p>15 So another case I thought that was 16 instructive is a case that's actually almost a year 17 old now that came across on the Emerging Infection 18 Network, which is a really great tool that IDSA 19 sponsors whereby everyday people can post difficult 20 cases and look for advice across the country.</p> <p>21 And so this was a case of a 19-year-old 22 kidney transplant recipient who had developed</p>

<p style="text-align: right;">Page 385</p> <p>1 refractory blood stream infection due to 2 <i>Stenotrophomonas maltophilia</i> that was multidrug 3 resistant associated, as it usually is, with a 4 catheter. The catheter had been removed, but this 5 patient, because of their transplant and other 6 reasons, was on steroids more than the usual amount 7 for a transplant patient and had this organism that 8 was resistant to just about everything they tested 9 except maybe colistin. And that's what they were 10 using.</p> <p>11 So the question to us was does anyone do any 12 special in vitro testing of combinations, is there any 13 value of testing any other drugs with a fancier MIC 14 test and does anyone know anything about using 15 chloramphenicol, a very old drug that very few of use 16 and most of us don't even have in our hospitals, for 17 treating this kind of a complicated scenario. So this 18 is a 19-year-old patient who's gotten a kidney 19 transplant where we're kind of digging that deep to 20 think about.</p> <p>21 So the last patient I'll share with you is 22 kind of a different category of what we might consider</p>	<p style="text-align: right;">Page 387</p> <p>1 grows now in urine culture greater than 100,000 2 <i>Klebsiella pneumoniae</i> that is producing an ESBL that's 3 resistant to the drugs to which she was treated -- 4 ciprofloxacin, ceftriaxone and trimethoprim sulfa. So 5 she's admitted to the hospital and treated with 6 intravenous carbapenem therapy, which is the drug of 7 choice of ESBLs.</p> <p>8 So I think all these cases, while anecdotal 9 and sort of just individual cases, do sort of suggest 10 that these resistant pathogen infections are serious, 11 and they can happen and are happening. In the world 12 of clinical infectious disease, we often have less 13 data than we want. We do appreciate that the data on 14 infections at standard body sites like a urinary tract 15 infection are often the foundation on which we build. 16 But in our everyday life in clinical medicine, we have 17 to extrapolate a lot, and our patients don't always 18 present with sort of textbook, indication-based 19 infection. So we use data from a variety of sources 20 and a variety of observations to make these decisions.</p> <p>21 So that kind of brings us back to where are 22 we and how do we develop Drug X-1. And there's a</p>
<p style="text-align: right;">Page 386</p> <p>1 someone with unmet medical need. This is a 47-year- 2 old lady, schoolteacher, who came with pain on 3 urination and some lower abdominal pain. And she was 4 started again by her -- by the doctor at the clinic on 5 oral ciprofloxacin -- again, totally consistent with 6 the guidelines.</p> <p>7 Unfortunately, though, two days later, she 8 came back more ill with chills, nausea, back pain, and 9 she now has a high fever and flank pain on exam. She 10 still has evidence of infection in her urine and has 11 an elevated white blood cell count. So she now has a 12 kidney infection, and she's advanced to IV ceftriaxone 13 appropriately, got one dose of that and then sent home 14 because she looked otherwise healthy enough.</p> <p>15 So unfortunately, two days later again, now 16 four days after she first came in, she was much 17 sicker. Now she had a high fever, and she had a low 18 blood pressure. She wasn't able to eat or drink, and 19 she was vomiting.</p> <p>20 So now she's in the Emergency Room really 21 looking quite ill with, again, sort of evidence of a 22 urinary tract infection, a kidney infection, and she</p>	<p style="text-align: right;">Page 388</p> <p>1 little bit of a catch 22, I would submit, because we 2 hope to develop this drug before we actually have 3 enough drug-resistant <i>Pseudomonas</i> infections to do the 4 big Phase 3 program that Ed alluded to earlier.</p> <p>5 So you know, we never want to see so many 6 cases of resistant <i>Pseudomonas</i> that we can do that, 7 but then that brings us to this tension between the 8 desire for the high quality volume of data and the 9 challenges in generating those data. So the question 10 is how do we interpret murky data. And in these 11 studies that are going to have small numbers of 12 patients with MDR pathogens, how can we best manage 13 that so that we can make any judgments and 14 understanding that there's going to be limited 15 inferential testing?</p> <p>16 So again, as we talked about earlier, what's 17 the best path? Well, the best thing is to have all 18 adequate, well-controlled trials. And there are a 19 number of different types of adequate and well- 20 controlled trials that I think we'll discuss today.</p> <p>21 But there will be a continuum of what those datasets 22 will look like. So the dataset from the standard</p>

Page 389	Page 391
<p>1 randomized controlled trial with statistical testing</p> <p>2 all the way down to smaller datasets that might</p> <p>3 include externally controlled or even uncontrolled</p> <p>4 data if we come all the way down to the animal rule</p> <p>5 that Dr. Cox alluded to earlier.</p> <p>6 You know, well-controlled, randomized</p> <p>7 controlled trials will tell us a lot when done on a</p> <p>8 single indication and give us meaningful effectiveness</p> <p>9 data and also safety data. I think it's important to</p> <p>10 remember that, too. We get a lot of safety data from</p> <p>11 these trials.</p> <p>12 Externally controlled and even historically</p> <p>13 controlled data, I would submit, especially when we</p> <p>14 study patients with the most severe infections --</p> <p>15 those bloodstream infections, other pneumonias with</p> <p>16 high predictable mortality -- in those cases, we may</p> <p>17 be able to learn valuable data from externally</p> <p>18 controlled studies.</p> <p>19 Whichever path we go, I think it's important</p> <p>20 that they all have good preclinical PK/PD and adequate</p> <p>21 safety data. And I think in however -- again,</p> <p>22 whichever direction people choose to go, doing these</p>	<p>1 site of infection, and that population can be very</p> <p>2 well characterized. We'll also get safety data again</p> <p>3 in this kind of standard population. Those are all, I</p> <p>4 think, great strengths.</p> <p>5 The challenges, some of which we just talked</p> <p>6 about yesterday, are enrollment. These are a large</p> <p>7 number of patients, huge amount of resources that our</p> <p>8 industry colleagues showed us yesterday in terms of</p> <p>9 time and money in trying to enroll these patients. We</p> <p>10 have challenges about whether we treat empirically or</p> <p>11 we use targeted therapy. So do we wait until we know</p> <p>12 it's pseudomonas? Or do we enroll people at the onset</p> <p>13 of their disease? We'll be left, it appears, with</p> <p>14 small numbers of patients with that pathogen of</p> <p>15 interest even in a big trial.</p> <p>16 There are concerns and challenges about</p> <p>17 comparator choice in terms of what's the most</p> <p>18 effective comparator, what's the most accepted</p> <p>19 comparator in various parts of the world. And the</p> <p>20 non-inferiority margins might be wide, wider than we</p> <p>21 would hope.</p> <p>22 So if we contrast this to a more Tier C type</p>
Page 390	Page 392
<p>1 studies at sites with really good clinical trials,</p> <p>2 expertise -- and coming back to that discussion we had</p> <p>3 yesterday about the clinical trials network, being</p> <p>4 able to really know that these data were generated in</p> <p>5 the most rigorous sites by the most rigorous</p> <p>6 investigators -- will be very helpful. And then</p> <p>7 diagnostics to help us include patients who really</p> <p>8 have the disease would be extremely helpful.</p> <p>9 And I think we as clinicians have to be</p> <p>10 prepared to use the drugs developed on whichever type</p> <p>11 of adequate and well-controlled trials are selected.</p> <p>12 We have to be prepared to use them.</p> <p>13 So let's think about a couple of potential</p> <p>14 examples. So one example would be to use a Tier B</p> <p>15 approach, harkening back to Dr. Rex's sort of schema</p> <p>16 that he presented yesterday. So this is a randomized,</p> <p>17 active controlled study and standard indication, so</p> <p>18 complicated inter-abdominal infection, UTI, pneumonia</p> <p>19 for example.</p> <p>20 Those studies allow us to have inferential</p> <p>21 testing. The patients all have a standard kind of</p> <p>22 proven infection. We would generate PK data at a key</p>	<p>1 approach where we look at infection in multiple body</p> <p>2 sites, there are more considerations here. Is this a</p> <p>3 randomized study versus best available therapy? Is it</p> <p>4 versus external controls? Both of those would allow</p> <p>5 some type of superiority testing. Would there ever be</p> <p>6 a scenario where you do non-randomized studies? We</p> <p>7 heard a lot of arguments yesterday, I think, that were</p> <p>8 pretty compelling for the pitfalls of non-randomized</p> <p>9 studies, but I leave it here as something to consider.</p> <p>10 Here, we could potentially include patients</p> <p>11 who are the most seriously ill with the highest in</p> <p>12 predictable mortality. If this route is pursued, it's</p> <p>13 really important that strict definitions of infection,</p> <p>14 severity of illness scores, things like that, are used</p> <p>15 so that it's very clear that every patient has the</p> <p>16 infection that we care about as well as their outcome</p> <p>17 is just as rigorously defined. Things like</p> <p>18 adjudication committees and things may be very useful</p> <p>19 in this setting.</p> <p>20 And I think these studies do have some</p> <p>21 strengths. So the patients have proven infection.</p> <p>22 Their treatment course can be well characterized.</p>

<p style="text-align: right;">Page 393</p> <p>1 There is the ability to get PK data at these kind of 2 most interesting sites of infection like the blood, 3 the lung, even the bone and the brain. There's the 4 possibility to gain safety data. They might be less 5 resource-intensive, and I will probably spend some 6 time talking about that.</p> <p>7 Certainly, there are challenges in this Tier 8 C approach. So there's less ability to do statistical 9 testing and less -- especially if no randomization is 10 undertaken. And we heard yesterday about some of the 11 challenges with external controls. There are 12 challenges in adhering to strict diagnostic criteria, 13 especially in these infections. And I alluded earlier 14 to maybe an adjudication committee would help, but 15 there's controversy about that, too. And then if one 16 pursues this approach, there's likely going to be a 17 need for other safety as well as other kinds of data. 18 So in thinking about a whole program, that's an 19 important aspect.</p> <p>20 So in both of those approaches, the Tier B 21 and the Tier C type approaches, I think we're left 22 with some challenges that are shared by them,</p>	<p style="text-align: right;">Page 395</p> <p>1 with well-controlled, preclinical PK/PD in animal 2 studies, a clear understanding of the needed exposure 3 and how to dose, harkening back to Dr. Ambrose's talk 4 yesterday. Even a small amount of clinical efficacy 5 data and a reasonable safety database would all be 6 reasonable, I think.</p> <p>7 And so where does that bring us for this 8 Drug X-1? I think the minimum thing that we as 9 clinicians would hope to have in order to be able to 10 use it would be data from a well-controlled study and 11 the label -- efficacy data and safety data; and then 12 pharmacology and dosing information, including PK data 13 and, I would submit again as a clinician, from as many 14 body sites as possible and hopefully from patients who 15 are really, really sick with organ dysfunction and 16 critical illness; some information about age, gender 17 and drug interaction studies to help us, again, 18 extrapolate to the patients we see.</p> <p>19 And then there's sort of this notion of 20 secondary data, the data that would ideally be 21 available and easy to find that could come from that 22 less controlled or even uncontrolled data, that could</p>
<p style="text-align: right;">Page 394</p> <p>1 actually. So at the end of day, in either of these 2 approaches, we're left with relatively small numbers 3 of patients with the pathogen of interest treated with 4 X-1. So we're still looking at a smaller dataset. 5 There's a resource intensity in either one in terms of 6 human resources, time and money.</p> <p>7 There is probably less statistical power and 8 support than for the skin program that Dr. Cox alluded 9 to earlier. And then very importantly, other factors 10 impact outcome in these patients. So these are 11 patients who are critically ill and inter-abdominal 12 infection. They're having surgery. There are other 13 things. And so I think that those are all kind of in 14 the challenge or risk bucket that we have to consider, 15 whether you chose a Tier B or a Tier C type approach.</p> <p>16 And I think it's also important to say, as 17 those examples I presented show, there's also a risk 18 of not proceeding with either because, if we maintain 19 the status quo, we could be left with no options.</p> <p>20 So again, where would be like to be? We 21 like the perfect. But I think it's reasonable to 22 think that we could work with a program that ended up</p>	<p style="text-align: right;">Page 396</p> <p>1 include groups of patients or even individual patients 2 who had really severe infections treated with this 3 that could help inform our practice not in the same 4 way as the data from the well-controlled study, but 5 that could still be useful.</p> <p>6 So some ways to help do this, again, we 7 alluded a little bit yesterday to the LPAD mechanism. 8 And the PATH Act is the current act that's in the 9 Senate that establishes a limited population 10 antibacterial approval pathway that would be limited 11 to this population most at risk. So it would create 12 an option for the development of agents where only 13 limited data are possible.</p> <p>14 This legislation has a lot of safeguards to 15 ensure that the drugs are proven safe and effective 16 and used appropriately. And these include clear, 17 prominent labeling, that this drug is indicated only 18 for the limited population, FDA pre-review of 19 promotional materials and then for strict monitoring 20 of the drug use when it's approved. And we at IDSA 21 and others, many others, have been active in helping 22 to advocate for this legislation. And I think there's</p>

Facilitating Antibacterial Drug Development For Patients With Unmet Needs Volume II

<p style="text-align: right;">Page 397</p> <p>1 still good hope that we'll see that happen.</p> <p>2 So again, in sort of our efforts to use</p> <p>3 these drugs in the most effective way possible,</p> <p>4 stewardship is really, really important. And we're</p> <p>5 very encouraged that antibiotic stewardship programs</p> <p>6 have been proposed as a condition of participation for</p> <p>7 both hospitals and long-term care facilities in the</p> <p>8 United States. And stewardship programs would be the</p> <p>9 best vehicle to make sure that we use these drugs in</p> <p>10 the most appropriate way possible and preserve them</p> <p>11 for as long as possible and for as many patients as</p> <p>12 possible.</p> <p>13 So that sort of brings us back to where we</p> <p>14 started. You know, I think people are asking have we</p> <p>15 come to the pre-antibiotic area, and we didn't even</p> <p>16 get into sort of the most recent kind of scary news</p> <p>17 about MCR-1 and now MCR-2 and the potential of</p> <p>18 plasmin-mediated resistance to colistin and other</p> <p>19 drugs. And I think that is somewhat scary. The cases</p> <p>20 that we looked at certainly highlight the need for</p> <p>21 both parenteral and oral agents to treat specific</p> <p>22 pathogens.</p>	<p style="text-align: right;">Page 399</p> <p>1 useful, if possible. The LPAD mechanism can ensure</p> <p>2 use in this limited population with needed safeguards,</p> <p>3 and stewardship hopefully will ensure that we use</p> <p>4 these antibiotics in the best way possible for the</p> <p>5 patients who need them most.</p> <p>6 So with that, I'll thank the committee again</p> <p>7 as well as Amanda Jezek from IDSA and my colleagues</p> <p>8 here on the panel for the invitation. Thanks so much.</p> <p>9 (Applause)</p> <p>10 DR. COX: Thanks, Helen.</p> <p>11 And now our next speaker is John Tomayko.</p> <p>12 I'm sure many folks are familiar with John, currently</p> <p>13 chief medical officer at Spero Therapeutics and also a</p> <p>14 long history in the field of infectious disease</p> <p>15 development and is an infectious disease physician,</p> <p>16 also, too. John will be providing us his perspective</p> <p>17 from the standpoint of somebody from industry.</p> <p>18 So we appreciate your joining us here today,</p> <p>19 John.</p> <p>20 DR. TOMAYKO: Thank you, Ed.</p> <p>21 Thank you, Sumathi, for inviting me to talk</p> <p>22 a little bit about this important problem.</p>
<p style="text-align: right;">Page 398</p> <p>1 I think it's fair to assume that we're going</p> <p>2 to be forced to use these drugs with limited data, and</p> <p>3 the cases that -- where we have to use IV and inhaled</p> <p>4 colistin and fosfomycin for ESBL infections, which a</p> <p>5 lot of us have gotten very good at doing with very</p> <p>6 limited data -- tigesycline for MDR infections -- have</p> <p>7 all sort of highlighted this.</p> <p>8 It's very important that, obviously, we keep</p> <p>9 up our efforts on infection prevention and stewardship</p> <p>10 and surveillance. But for X-1, I think we hope to see</p> <p>11 adequate, well-controlled data emerge from either</p> <p>12 small, randomized controlled trials, perhaps with</p> <p>13 wider non-inferiority margins or even some really</p> <p>14 small Tier C type studies, perhaps with external</p> <p>15 controls.</p> <p>16 As we mentioned, you know, strong case</p> <p>17 definitions and the inclusion of the most severe</p> <p>18 infections, I think, are really important. High</p> <p>19 quality data, hopefully from clinical trial networks,</p> <p>20 could advance that.</p> <p>21 For clinicians, I think having information</p> <p>22 about infections at multiple body sites is very</p>	<p style="text-align: right;">Page 400</p> <p>1 These are my disclosures. And this is just</p> <p>2 my opinion. I don't know that I could represent all</p> <p>3 of industry.</p> <p>4 So the agenda is pretty basic. I'm going to</p> <p>5 just reflect a little bit on some of the success we've</p> <p>6 had in the past and maybe why we're successful. I'll</p> <p>7 review the case, and then I'll give you my perspective</p> <p>8 on how we might develop it. And the end result that</p> <p>9 I'm looking for is a regulatory approval. And since</p> <p>10 this is an FDA workshop, I'm looking for an approval</p> <p>11 in the U.S.</p> <p>12 So the past. I think if you look back you</p> <p>13 can pretty proud of what we've accomplished. We've</p> <p>14 had tremendous success in identifying a number of</p> <p>15 classes of antibiotics. There's two points here that</p> <p>16 I want to make. The first one's obvious because</p> <p>17 there's an arrow there. We haven't had a novel class</p> <p>18 of gram-negatives approved in the U.S., really, since</p> <p>19 the nalidixic acid story began in 1962 with</p> <p>20 fluoroquinolones.</p> <p>21 The other one is that these drugs were</p> <p>22 broad-spectrum agents. And you were able to actually</p>

<p style="text-align: right;">Page 401</p> <p>1 go out. Maybe the parameters of your trial might have 2 been different, but you could still recruit most of 3 the patients with -- that would be causing infections 4 at various body sites. So they were easier to 5 develop, perhaps, than some of the things we're 6 talking about today.</p> <p>7 In the present, we actually have a number of 8 drugs that are soon to be submitted for review and, 9 hopefully, approved. On the right, we have gram- 10 positive antibiotics that also have some respiratory 11 spectrum, such as H. flu and the atypicals. So these 12 drugs could be studied in community-acquired pneumonia 13 and skin infections. They could meet the statutory 14 requirements for approval, but they're not really 15 addressing what's considered an unmet medical need at 16 the moment, so they take in the traditional approach 17 to an approval.</p> <p>18 On the left, all of these drugs, for the 19 most part, set out to take advantage of what has been 20 described multiple times, the Tier B approach.</p> <p>21 In a not-so-distant future, I suspect novel 22 science is going to bring us a lot of interesting</p>	<p style="text-align: right;">Page 403</p> <p>1 challenge, and that's because antibiotics are really 2 amazing therapeutics. The treatment effect is so big. 3 As you could see, you could read any of the guidance 4 documents where FDA has tried to generate supportive 5 data for an M-1. And you could see that the treatment 6 effects are huge. So how much better can you be than 7 cured?</p> <p>8 And what you need to do -- and fortunately 9 we could do this with antibiotics. We have great 10 translational models. You need to create a clinical 11 equipoise argument, which really answers the question 12 that -- does the test therapeutic -- could it be as 13 good or better than a standard of care. And if it 14 could, you could conduct a non-inferiority study. And 15 I think that most of us throughout yesterday 16 recognized that a non-inferiority study, like we do in 17 Tier B, is probably the most tractable way to get a 18 drug approved.</p> <p>19 Test therapeutics that cannot make an 20 equipoise argument -- like most Mabs, anti-virulence 21 therapies, aerosolized antibiotics for VABP -- have to 22 be considered adjunctive. And although they could</p>
<p style="text-align: right;">Page 402</p> <p>1 approaches to managing infection. I can't go through 2 all of this. I'm sure my slides will be available. 3 But I mean, Spero Therapeutics is working on 4 potentiators. These are compounds that interact with 5 the gram-negative outer membrane and create passageway 6 that allows maybe drugs that couldn't access an 7 intracellular cytoplasmic target access to a gram- 8 negative. So that might be a nice strategy, probably 9 bring some challenges, and we hope to work that out.</p> <p>10 But there are others -- single pathogen 11 antimicrobials like our Drug X-1, monoclonal 12 antibodies -- we have license in development right 13 now; therapies that modify pathogen virulence -- the 14 literature is filled with ideas about how to do this; 15 novel delivery systems, including two programs where 16 we are trying to study aerosol antibiotics in VABP. 17 And then perhaps more bold would be can we modify the 18 host response and try to help patients in that manner.</p> <p>19 So this leads me to just touching on what 20 was brought up yesterday, the difference between an 21 antibiotic and an antibiotic adjunctive therapy. And 22 the adjunctive therapy really does present a</p>	<p style="text-align: right;">Page 404</p> <p>1 bring great advances, they might rescue patients who 2 would otherwise fail therapy or die. The development 3 is particularly challenging. You have to study these 4 in a superiority study. So here it's standard of care 5 plus a novel adjunct versus standard of care alone.</p> <p>6 And there are a number of compounds that are 7 facing some of these development challenges. The MvfR 8 inhibitor that Spero and Roche were working on has 9 presented a number of challenges, and the work is 10 diminishing there. But this is an anti-virulence 11 strategy. It would require an adjunctive approach as 12 would, I believe, any monoclonal antibodies, although 13 the MedImmune anti-pseudomonas antibody is still 14 looking for a superiority study. I think they're 15 going to pursue prophylaxis.</p> <p>16 The aerosol antibiotic therapies for VABP, 17 the studies are undergoing -- ongoing now. So we 18 should soon see whether or not there's any benefit 19 from an adjunctive. I know people use aerosolized 20 antibiotics all the time, and they'll probably 21 continue to use them until we either have one approved 22 with some good data or we have some conclusive data</p>

<p style="text-align: right;">Page 405</p> <p>1 that they're not beneficial. The only antibiotic here</p> <p>2 that I think could really meet that equipoise argument</p> <p>3 would be Polyphor, the cyclic peptide.</p> <p>4 So this is just an illustration taken from</p> <p>5 the comprehensive regulatory framework, kind of tiered</p> <p>6 development study that John Rex, myself and a number</p> <p>7 of industry colleagues published in 2013. And it just</p> <p>8 seems to me that as we address unmet need or take</p> <p>9 advantage of some of the new science, we're going to</p> <p>10 have to become more creative with clinical development</p> <p>11 and, in general, be conducting smaller studies and</p> <p>12 relying on more preclinical data and PK data.</p> <p>13 So Drug X-1 I don't need to tell you about</p> <p>14 since you've done your homework and Dr. Kim did a nice</p> <p>15 job reviewing this. So what I'll basically say is,</p> <p>16 really, the major weakness of what looks to be a</p> <p>17 promising therapeutic is how are we going to get it</p> <p>18 approved. And I don't think that there's a rapid</p> <p>19 diagnostic that's widely available, but we'll learn</p> <p>20 more about that in our discussions this afternoon.</p> <p>21 So let's look down at the bottom chart here,</p> <p>22 the frequency of pseudomonas, percent of all enrolled.</p>	<p style="text-align: right;">Page 407</p> <p>1 that's -- that was an enlightenment that I had as I</p> <p>2 put this together.</p> <p>3 And this kind of illustrates the situation.</p> <p>4 You know, if you have a typical endpoint with a 20</p> <p>5 percent failure rate and you use the typical</p> <p>6 parameters that we would like to use, 90 percent power</p> <p>7 in industry and you're stuck with a 10 percent margin,</p> <p>8 you've got a pretty decent study on your hands to</p> <p>9 conduct, 335 patients per arm. But now, if you have</p> <p>10 to only consider the evaluable population, culture-</p> <p>11 proven pseudomonas, if the rate's 22 percent, that</p> <p>12 goes up to 1,500 an arm. And you can see that it just</p> <p>13 gets progressively worse.</p> <p>14 So you might get a good safety database out</p> <p>15 of a study like this. But is it actually feasible to</p> <p>16 conduct? And that's a question that I'm going to come</p> <p>17 back to multiple times today because that's part of</p> <p>18 the thesis of our discussion this afternoon --</p> <p>19 feasibility.</p> <p>20 So for Drug X-1, what are some of the issues</p> <p>21 we should consider? I already said that this was a</p> <p>22 very drugable molecule, and there's clearly evidence</p>
<p style="text-align: right;">Page 406</p> <p>1 And this is interesting because I think we all</p> <p>2 recognize that pseudomonas is -- we consider it a</p> <p>3 common, nosocomial pathogen, and it is. But when you</p> <p>4 actually try to plan a clinical trial and you look in</p> <p>5 the literature or talk to your colleagues, you realize</p> <p>6 that very little pseudomonas is responsible for any</p> <p>7 single indication.</p> <p>8 Perhaps the most pseudomonas we'll see is in</p> <p>9 a nosocomial pneumonia, and that's even probably</p> <p>10 skewed towards VABP. And that probably ranges between</p> <p>11 10 and 20 percent, and it gets even lower as you look</p> <p>12 at this illustration.</p> <p>13 I've always loved this slide, and I think it</p> <p>14 first appeared as we were preparing that document.</p> <p>15 John Rex had presented this in several form, and I</p> <p>16 like the title, "The Painful Math." But it</p> <p>17 illustrates what we're up against.</p> <p>18 And I guess I should just digress for a</p> <p>19 second and say that if you follow my logic here, you</p> <p>20 might even come to the realization that I did, that a</p> <p>21 Tier C program could actually be bigger than a Tier B</p> <p>22 program but generate less substantial evidence. So</p>	<p style="text-align: right;">Page 408</p> <p>1 for clinical equipoise versus a standard antibiotic,</p> <p>2 albeit this only has a narrow spectrum. So non-</p> <p>3 inferiority is possible. But where would you study</p> <p>4 it? What site of infection? Or would you pool?</p> <p>5 You have to recognize, though, that if</p> <p>6 you're going to enroll patients empirically, you might</p> <p>7 not be right. Even with a diagnostic, they're not 100</p> <p>8 percent sensitive or specific, so you're going to have</p> <p>9 to provide coverage for the spectrum gaps that this</p> <p>10 agent has. What are your choices? You don't want to</p> <p>11 combine it with something that has activity against</p> <p>12 pseudomonas, which would further confound your</p> <p>13 analysis. So you're left with a few things.</p> <p>14 Tigecycline doesn't have good reliable pseudomonas or</p> <p>15 any, nor does ertapenem. So maybe those would be good</p> <p>16 things to combine it with.</p> <p>17 But you also have to face the reality of the</p> <p>18 VABP guidelines, which say you need to double cover</p> <p>19 patients that have VABP. And typically we use an</p> <p>20 aminoglycoside. So now you've compounded your</p> <p>21 analysis with some confounding coverage.</p> <p>22 I want to also point out that patients with</p>

<p style="text-align: right;">Page 409</p> <p>1 pseudomonas infections, it's not -- often not their 2 first nosocomial infection but their second. And they 3 get progressively debilitated in the hospital. So 4 there, they're typically sicker. They have higher 5 comorbidities. But as they become sicker and have 6 higher failure rates, that could lead to the need for 7 a larger sample size to really measure a treatment 8 effect. So maybe in the Analysis section, is 9 inferential testing even possible? I think we need to 10 really answer that question today.</p> <p>11 And about enrollability, you know, how long 12 will it take? How much will it cost? Would a rapid 13 diagnostic help us, and is the design going to be 14 something that investigators will actually be willing 15 to accept?</p> <p>16 So here, I'm going to provide just some 17 standard parameters, and I'll explain a few of those. 18 I think you heard a little bit about this yesterday, 19 but roughly speaking, a UTI and IAI study costs about 20 \$50,000 per patient. And a HABP/VABP is over 100. 21 And the costs are amplified as you have to go to more 22 centers. You could imagine having to visit those</p>	<p style="text-align: right;">Page 411</p> <p>1 Nobody's really mentioned investor fatigue. 2 And I'm actually going to emphasize this quite a bit 3 because, as I said, these are expensive studies and 4 they have to be paid for. And I've had two 5 experiences. Now I work for a small venture backed 6 company, but before this, I worked for 7 GlaxoSmithKline. Actually, at GlaxoSmithKline, maybe 8 it was a little easier to make the argument. There 9 were so many layers of management that at one point 10 somebody says do you really think we should do this. 11 And maybe somebody like Lynn Marks would say, yeah, I 12 do, and it would get funded. Maybe it's not the 13 experience that others have had.</p> <p>14 But with a venture group, you actually have 15 to explain what you're doing, and I don't think 16 they're going to be sensitive to or excited about a 17 three- or four- or five-year study. And they have 18 other choices to invest.</p> <p>19 Rapid diagnostics to the rescue. We all -- 20 we've mentioned this a lot, and I have actually had 21 some firsthand experience trying to use a rapid 22 diagnostic, which was approved in the United States.</p>
<p style="text-align: right;">Page 410</p> <p>1 centers, audit those centers, monitor those centers. 2 So the costs are amplified.</p> <p>3 The time is even more worrisome than the 4 cost. And I'm -- I'll just focus on HABP/VABP. It 5 takes, on average, about 12 centers actively screening 6 to recruit one patient per month. So you could turn 7 that around. And what does that tell you? That if 8 you have a good center, you might be lucky to get one 9 or two patients a year from that center.</p> <p>10 This leads to investigator fatigue. The 11 site staff has to work hard. And as Helen said, we 12 want to go to the best sites, sites that have a good 13 staff. But a good staff requires -- you know, the 14 fundamentals have to be in place. You have to be able 15 to pay for that staff. So these studies typically 16 compensate the sites when they recruit patients, when 17 they actually enroll a patient.</p> <p>18 So these sites that have good staff 19 typically do more than one study, and your study being 20 very, very challenging may actually get less attention 21 than a study, just because they have to pay the bills, 22 that is easier to enroll.</p>	<p style="text-align: right;">Page 412</p> <p>1 And I'll tell you that that experience isn't worth 2 getting into too much detail, but I think we have to 3 be careful about what we -- I think we'll accomplish 4 there.</p> <p>5 And I'll start with my aside. You know, I 6 do think a rapid diagnostic, if the economics get 7 worked out and if people use it, will be very valuable 8 with antibiotic stewardship and should lead to 9 improved outcome in patients that are in our 10 hospitals.</p> <p>11 But we have to remember diagnostics don't 12 create patients infected with the target pathogens. 13 Therefore, we could use them for enrichment. They may 14 allow us to save costs, but it's unlikely they're 15 going to help us save the time. And I pointed out 16 that time and risk is really what I'm focused on here. 17 I think that those are the elements that don't always 18 get the obvious attention. Cost -- you know, we have 19 a fairly good sense of what that is.</p> <p>20 Why do I feel that diagnostics aren't a 21 panacea? Well, they require hardware, and you have to 22 train people on how to use that hardware. You have to</p>

<p style="text-align: right;">Page 413</p> <p>1 get that hardware to the sites that you're doing your 2 clinical work, and then you have to service it. I 3 talked to a few diagnostic companies who feel that 4 their machines need servicing at least twice a year. 5 So you could imagine that if only a few 6 people can use that diagnostic, even if it's 7 relatively simple, that could impede your ability to 8 recruit patients who might present when those few 9 people aren't there. And the other thing I should 10 point out is the companies aren't working to your 11 clinical trial timelines, which means that they might 12 not be available to initiate your center, train them 13 and make sure everything is in operational condition 14 when you want that. 15 So moving forward, Drug X-1. I'll point 16 out, first of all, that no standalone Tier C programs 17 have been submitted for review, but we're going to see 18 standalone -- we're going to Tier C-like work in Tier 19 B presented. And I'm not saying that those aren't 20 important studies to conduct. But small samples may 21 not contain sufficient numbers of the target pathogens 22 to allow inferential testing even if we take advantage</p>	<p style="text-align: right;">Page 415</p> <p>1 So where does this substantial evidence come 2 from? I think we all know this. In Tier B, we rely 3 on a non-inferiority study against the usual drug- 4 resistant pathogens and the target pathogen study, 5 which I think is very important -- and we should find 6 ways of including that information in the label -- 7 becomes supportive evidence. 8 In Tier C, we don't have the UDR study, the 9 non-inferiority study. So now suddenly we have to 10 make that target pathogen study our substantial 11 evidence, and I think that that raises a lot of 12 questions. 13 So you know, fortunately, there's the Tier 14 D, or animal rule. And here, the target pathogen 15 study could remain your supportive evidence. It still 16 should be done. It'll generate the PK. It'll be very 17 important, but the statutory requirements could be met 18 by demonstrating substantial evidence of effectiveness 19 from animal studies. 20 So I'm really saying that I know that 21 pseudomonas is an important problem. It may be more 22 common than KPCs and NDMs in the U.S. and parts of</p>
<p style="text-align: right;">Page 414</p> <p>1 of wide non-inferiority margins and one-sided 2 significance testing. 3 Also, small samples from a sick population 4 may have this sample variability that we talked about. 5 With many comorbidities, we could get unpredictable 6 results, increasing our risk of failure. We've 7 already talked about what you can do, and I think you 8 need to do everything you can even for a narrow 9 spectrum drug. There's -- there is no reason to skip 10 the easy stuff, but what we're talking about is the 11 study required to generate the substantial evidence of 12 effectiveness. 13 So here's where my thesis comes in, that 14 with these feasibility challenges highlighted for Drug 15 X-1, can one expect that a clinical trial will meet 16 the requirements of substantial evidence of 17 effectiveness with any predictable certainty. 18 Remember, when you go ask for the funding, you're 19 going to have to say -- everybody's used to risk. But 20 you're going to have to tell them how you're going to 21 manage it and get people to believe that, you know, 22 what you're going to do is going to be successful.</p>	<p style="text-align: right;">Page 416</p> <p>1 Europe. There is strong supportive data for a drug 2 like Drug X-1. But I really think that the challenges 3 of recruiting a single pathogen Tier C-like study 4 carries a high degree of unmanageable risk. And I 5 don't know how I could put together an argument that 6 the results of a Tier C study, no matter how carefully 7 conducted, will favor a chance of supporting approval 8 versus condemning the drug to failure. 9 So we do need an alternate approach. At 10 least that's my thesis. And this is in the -- since 11 we're going to hear a lot more about the animal rule, 12 this is just a review of what you need to consider and 13 what the animal rule's all about. 14 But here, I've highlighted the word 15 feasible. If you cannot conduct an adequate and well- 16 controlled clinical study because it's infeasible and 17 you need to generate substantial evidence, could it be 18 -- could it come from an animal study? And first of 19 all, we have to agree that it's not feasible and 20 unlikely to work to do the clinical route. And then 21 we have to determine whether or not there's a 22 validated pseudomonas infection model that could</p>

<p style="text-align: right;">Page 417</p> <p>1 provide substantial evidence. And I'm not prepared to</p> <p>2 tell you that there is or there isn't.</p> <p>3 I'll just point out that there is this</p> <p>4 requirement for a field study. So if you're -- take</p> <p>5 advantage of the animal rule, say, for plague, when</p> <p>6 you submit your NDA, you have to provide a protocol</p> <p>7 that talks about a field study in the event that</p> <p>8 there's a plague outbreak. And you should be prepared</p> <p>9 to conduct that. I would argue that if you were to</p> <p>10 take an animal rule approach here, that there are</p> <p>11 questions that could be answered after approval and</p> <p>12 there are enough pseudomonas isolates out there that</p> <p>13 you might be able to do a selective study that might</p> <p>14 improve your benefit risk.</p> <p>15 So in conclusion, I think that we'll see</p> <p>16 promising narrow spectrum agents and that the -- but</p> <p>17 the development path is unclear. As the basic science</p> <p>18 advances, we'll see more translational changes.</p> <p>19 Adjunctive therapies will continue to be challenging</p> <p>20 to develop. I think the blending elements proposed</p> <p>21 under Tier C with the animal rule may allow FDA</p> <p>22 approval for select narrow spectrum therapeutics.</p>	<p style="text-align: right;">Page 419</p> <p>1 clinical utility for antibacterial drugs that are</p> <p>2 active against a single species. But we also</p> <p>3 recognize that such drugs are very difficult to study</p> <p>4 when the single species that the drug is active</p> <p>5 against occurs infrequently.</p> <p>6 This has been stated earlier. Pseudomonas</p> <p>7 is not really a rare cause of certain infections, but</p> <p>8 it just doesn't occur frequently enough. And so</p> <p>9 enrolling such patients in a clinical trial becomes</p> <p>10 particularly challenging. Certain infections like</p> <p>11 hospital-acquired pneumonia or ventilator-associated</p> <p>12 pneumonia, you're more likely to encounter pseudomonas</p> <p>13 aeruginosa. But such infections tend to be</p> <p>14 polymicrobial, necessitating the need for concomitant</p> <p>15 therapy. And this concomitant therapy often has</p> <p>16 overlapping spectrum of activity, which means it</p> <p>17 covers pseudomonas as well. So that really confounds</p> <p>18 our ability to assess treatment effect. You've heard</p> <p>19 a lot about rapid diagnostics, how they could help</p> <p>20 some but certainly will not solve all our problems.</p> <p>21 Again, Ed mentioned this this morning. So</p> <p>22 in contrast to other rare human diseases, we have</p>
<p style="text-align: right;">Page 418</p> <p>1 And I guess I'd hate to see us slip</p> <p>2 backwards to the -- a point where we don't have</p> <p>3 antibiotics to support important medical advances like</p> <p>4 bone marrow transplant, solid organ transplant and</p> <p>5 other things that have been mentioned. And I don't</p> <p>6 think we should rely on or hope for only broadly</p> <p>7 active, easier-to-develop antibacterial therapies.</p> <p>8 We're going to have to solve this problem.</p> <p>9 But thank you.</p> <p>10 (Applause)</p> <p>11 DR. COX: All right. Thank you, John.</p> <p>12 And now Sumathi Nambiar, who's the Director</p> <p>13 of the Division of Anti-Infective Products, will</p> <p>14 provide information on potential clinical pathways,</p> <p>15 some background information about the animal rule and</p> <p>16 then also describe some of the experiences with</p> <p>17 development of animal models that have been utilized</p> <p>18 in the area of plague.</p> <p>19 So Sumathi, thank you.</p> <p>20 DR. NAMBIAR: Good morning. So I think some</p> <p>21 of this was touched upon by Ed in his introductory</p> <p>22 talk. So we do recognize that there's a potential</p>	<p style="text-align: right;">Page 420</p> <p>1 unique challenges when we are trying to study acute</p> <p>2 bacterial infections. There is an urgent need to</p> <p>3 start therapy. Patients are sick. They need to lay</p> <p>4 an initiating effective therapy can impact outcome.</p> <p>5 There is diagnostic uncertainty at the time of</p> <p>6 presentation. Therapy tends to be empiric in most</p> <p>7 instances.</p> <p>8 It's difficult to identify such patients a</p> <p>9 priori ahead of time. So a lot of the other rare</p> <p>10 diseases, you can maintain a registry. You sort of</p> <p>11 know who your patients are and you can plan and</p> <p>12 conduct a trial. It's very different in this</p> <p>13 particular setting.</p> <p>14 And lastly, patients present at local</p> <p>15 healthcare facilities rather than at a special</p> <p>16 facility, and I think this, too, had come up in Dr.</p> <p>17 Rex's presentation yesterday.</p> <p>18 Some of the characteristics of X-1. I think</p> <p>19 overall, as was mentioned, by John Tomayko, this seems</p> <p>20 to be a promising candidate, appears to address an</p> <p>21 unmet need, has a novel mechanism of action.</p> <p>22 In vitro studies do not suggest a high</p>

Page 421	Page 423
<p>1 likelihood of resistance development. Safety profile 2 seems reasonable. We have identified hematologic and 3 hepatic toxicity, but both of them appear to be 4 monitorable. And at the proposed dose, we have a 5 safety margin for both toxicities. 6 There is evidence of antibacterial activity 7 in animal models of infection, so these are the 8 routine models that we do to assess if there's 9 activity. And they really don't rise to the level of 10 being efficacy studies that we'll talk later today. 11 There's a proof of concept study in a small 12 number of patients with non-CF-bronchiectasis. There 13 was evidence of log reduction, so there is some 14 evidence that the drug actually does impact the 15 organism. 16 Dosing rationale appears adequate, and 17 dosing has also been evaluated in patients with renal 18 impairment. So this will allow for patients in the 19 trial with renal dysfunction and, again, highlights 20 the importance of trying to enroll patients with 21 comorbidities, which tends to be more common in these 22 kinds of patients.</p>	<p>1 patients who only have pseudomonas aeruginosa for 2 specific phenol types. And all-comer pseudomonas 3 aeruginosa population would be acceptable. 4 You know, we'll go through some numbers, but 5 I think we all understand that it is difficult to 6 enroll an adequate number of patients with pseudomonas 7 in a standard non-inferiority trial. Availability of 8 the rapid diagnostic might help some, but really helps 9 with enrollment. It's really not going to change the 10 frequency with which the organism causes infection. 11 Again, this has been highlighted previously. 12 I touched upon this a little bit, and I 13 think it's going to come up a fair bit for discussion 14 this afternoon. I mean, two real difficult issues to 15 deal with -- one is the need for concomitant and 16 antibacterial drugs that treat other gram-negatives 17 because HABP/VABP is polymicrobial and X-1 is rarely 18 targeted only against pseudomonas. 19 So we've talked about ertapenem as a 20 potential option, and John mentioned this earlier. I 21 do want to note that it is not indicate it for 22 HABP/VABP. It has an indication for CAP. So we will</p>
Page 422	Page 424
<p>1 So we've certainly had a lot of discussion 2 on this within our group, and we've come up with four 3 options. Again, I'm sure there are other options out 4 there, and we look forward to the input during our 5 discussion period this afternoon. So this is not 6 meant to be an all-exhaustive list. 7 And I'll go through each one of them. But 8 broadly speaking, the first option hinges on doing a 9 non-inferiority trial. The second one is in 10 superiority trial. The third one is trying to do a 11 trial in a population that's at a high risk of 12 infection due to pseudomonas. And the last option, 13 again, has been discussed in earlier presentations, is 14 establishing efficacy under the animal rule. 15 So this is a first option. And here, I have 16 A and B which is an NI trial either at a single body 17 site or an NI trial pooling across body sites. So if 18 you look at an NI trial at a single body site, it's 19 potentially feasible if you're willing to accept a 20 greater degree of uncertainty, which translates to a 21 wider non-inferiority margin. 22 In such a trial, there is no need to enroll</p>	<p>1 need to do some work to find out if it will be 2 accepted or considered clinically okay to treat a sick 3 patient with HABP/VABP with ertapenem. 4 The second big issue that we have to deal 5 with is the dual therapy for pseudomonas aeruginosa. 6 Typically, for treatment of this condition due to 7 pseudomonas, a dual therapy is used. And again, this 8 has been -- has come up earlier. Now there -- the 9 treatment guidelines that were published just a few 10 days ago do suggest that monotherapy is acceptable. 11 They identify certain situations either based on the 12 local antibiograms and your institutional antibiogram 13 or the presence or absence of risk factors. 14 And if you go through the risk factors, it's 15 really hard to come up with too many that these 16 patients will not have by the time they develop 17 HABP/VABP. But still, there is some role for 18 monotherapy in a few patients. Again, we look forward 19 to discussing that this afternoon. 20 The other issue is, even if patients are 21 started on dual therapy, there is the option of 22 deescalating once you have the susceptibilities. And</p>

<p style="text-align: right;">Page 425</p> <p>1 what we've seen from clinical trials that have been 2 conducted in HABP/VABP, there's a great reluctance on 3 the part of investigators to deescalate. So in 4 effect, what happens is most patients get dual therapy 5 for just the entire duration of treatment. 6 So I'll just walk you through some numbers. 7 We looked at what a sample size might look like for a 8 HABP/VABP trial that uses all-cause mortality as a 9 primary endpoint with the following assumptions -- a 10 20 percent mortality rate, two-sided alpha of .05, 1- 11 to-1 randomization, 80 percent power. And I'll go 12 through a table review. The NI margins can go from 10 13 to 20 percent, and the prevalence of pseudomonas can 14 go from 10 to 20 percent. 15 And John Tomayko showed you some numbers. 16 In recent registrational trials, the prevalence has 17 been in the order of 10 to 15 percent. There are some 18 publications that do suggest that it may be closer to 19 the 20 percent or the low 20s. So we've tried to put 20 in some degree of variability and look at what sample 21 sizes might look like. 22 So if one is to do a standard NI trial with</p>	<p style="text-align: right;">Page 427</p> <p>1 And the other issue is -- again, it was 2 discussed yesterday -- is if you have efficacy only in 3 cUTI, how much comfort does that provide that it might 4 work in other body sites, especially the lung. 5 We've also thought it would burn some 6 surgical site infections because these tend to have 7 pseudomonas infections more commonly than other 8 organisms. But I think there are a lot of challenges. 9 These indications are very difficult to study. 10 They're not very common. We really need to figure out 11 what the endpoint or the trial design might look like. 12 Another option to do a non-inferiority trial 13 we thought is maybe pooling patients who have 14 HABP/VABP and/or bacteremia and use all-cause 15 mortality as the endpoint. It might help with the 16 numbers than if you did a trial in HABP/VABP alone. 17 But again, this was discussed. It's very difficult 18 when you combine a type -- different types of 19 infections and different sources of the bacteremia. 20 It might be difficult to discern if there's a deficit 21 in efficacy at one or more body site. And again, this 22 was mentioned yesterday. Decisive treatment effect</p>
<p style="text-align: right;">Page 426</p> <p>1 a 10 percent non-inferiority margin and a 10 percent 2 prevalence of pseudomonas, you can see that the sample 3 sizes are fairly large for the total number of 4 patients just to get about 500 patients who have 5 pseudomonas alone. The widest non-inferiority margin 6 would be, really, what M-1 is, based on what's in our 7 guidance with M-1 of 20 percent. And you're at about 8 1,200 patients. 9 If you're truly able to go to sites that 10 have a higher prevalence of pseudomonas and you're 11 more in the 20 percent range, it cuts your sample size 12 in half. And certainly, if you're willing -- if you 13 or we are willing to go with the wide non-inferiority 14 margin of 20 percent, which is all of M-1, then the 15 sample sizes seem to be in the feasible range. 16 The other body sites that we've considered 17 for where one can conduct a non-inferiority trial was 18 complicated UTI. It's certainly easier to study in 19 this indication because pseudomonas can be -- can 20 cause monomicrobial infection. However, the incidence 21 is still low, and we think that such a trial might not 22 be feasible.</p>	<p style="text-align: right;">Page 428</p> <p>1 does vary across the different indications. 2 So moving on to the second option, which is 3 to conduct the superiority trial, so here, we will 4 assess the superiority of Drug X-1 over best available 5 therapy. In such a trial, to be able to demonstrate 6 superiority, one would need to enroll patients with 7 pseudomonas aeruginosa, which is resistant to 8 currently available therapy. 9 You could enroll patients with different 10 types of infection. In such a trial, again, the 11 shortcomings of that we've already gone through. 12 Certainly, we wouldn't challenge the findings from 13 superiority trial. It's easy. It provides direct 14 evidence of treatment effect. 15 However, determining superiority over 16 existing therapy can be difficult. We saw some -- 17 went through one example yesterday from Dr. Friedland 18 where the challenges of doing such a superiority trial 19 were very clear. I think we've touched upon that, the 20 impact of pooling. And then it's also an issue of 21 sheer numbers which we will go through in the next few 22 slides.</p>

Page 429	Page 431
<p>1 So this was a recent study from JMI Labs</p> <p>2 where they looked at the prevalence of these different</p> <p>3 organisms. And they used the term PHP pneumonia in</p> <p>4 hospitalized patients, which essentially is everything</p> <p>5 other than VABP. So it's VABP and non-VABP patients.</p> <p>6 So of about 8,000 isolates, 21 percent was</p> <p>7 pseudomonas. Twenty-two percent of them were</p> <p>8 meropenem non-susceptible. They used a definition of</p> <p>9 MIC of four or greater, though the label breakpoint to</p> <p>10 the best of my understanding was eight.</p> <p>11 Among the meropenem non-susceptible</p> <p>12 pseudomonas, the incidence Amikacin resistance was 13</p> <p>13 percent. We're trying to do this, really, to see what</p> <p>14 is the likelihood of encountering a multidrug</p> <p>15 resistant, a band-resistant (ph) pseudomonas because</p> <p>16 that's the only opportunity you have then to</p> <p>17 demonstrate a superiority.</p> <p>18 And if you look at the incidence of what</p> <p>19 meropenem and Amikacin resistance in the overall</p> <p>20 population, so the first numbers are really if you're</p> <p>21 -- if you're only studying pseudomonas. Going into</p> <p>22 the study, you know, everybody has pseudomonas. But</p>	<p>1 if -- depending on what the mortality rate and the</p> <p>2 test control are ranging from 20 to 30 percent. So</p> <p>3 obviously the greater your treatment affect, the</p> <p>4 smaller your sample size would be.</p> <p>5 And the frequency of MDR, we range it from 5</p> <p>6 to 25. Going by the previous numbers, I think five</p> <p>7 would be your best-case scenario. But again, there</p> <p>8 are -- you know, that's one data set. Maybe other</p> <p>9 data sets will speak otherwise. But we just had --</p> <p>10 needed something to work with to go through this</p> <p>11 example.</p> <p>12 So if truly the frequency of MDR P --</p> <p>13 pseudomonas is only 5 percent and you have a 10</p> <p>14 percent improvement in the mortality rate with the</p> <p>15 test drug, your sample sizes are pretty impressive,</p> <p>16 whereas if you have a really good drug and your</p> <p>17 treatment benefit effect is at least 20 percent, even</p> <p>18 so you're in the 3,000-odd range.</p> <p>19 And we've heard over and over again just to</p> <p>20 do one all-comer HABP/VABP trial. The rate of</p> <p>21 enrollment is dismal and doing these trials is very</p> <p>22 challenging. But if your frequency of MDR PA is</p>
Page 430	Page 432
<p>1 if it's an all-comer HABP/VABP, the numbers are</p> <p>2 really, really small. So to find one patient with</p> <p>3 pseudomonas where the organism is non-susceptible to</p> <p>4 meropenem and resistant to Amikacin, you would need</p> <p>5 122 patients.</p> <p>6 And I just have to acknowledge, you know, we</p> <p>7 sort of average the numbers, but you can take a look</p> <p>8 at the paper. You know, there are differences whether</p> <p>9 you do U.S. sites versus X U.S. sites. There are</p> <p>10 differences in non-VABP and VABP. Certainly, in a</p> <p>11 VABP population, the prevalence of pseudomonas will be</p> <p>12 slightly higher, and the prevalence is also higher in</p> <p>13 X U.S. sites. In this study they did -- Europe,</p> <p>14 Mediterranean was one group; China; and then U.S.</p> <p>15 So what would the sample size look like if</p> <p>16 one were to try to do a superiority trial given some</p> <p>17 of these numbers I've shown you? These are our</p> <p>18 assumptions -- 1-to-1 randomization, 2-sided alpha</p> <p>19 .05, 80 percent power. We've estimated the control</p> <p>20 group mortality rate of 40 percent. And I'll go</p> <p>21 through numbers. I won't go through every one of</p> <p>22 them, but we've tried to provide three sets, you know,</p>	<p>1 really high, you're in the 25 percent range and your</p> <p>2 drug really works, then you might have a number that</p> <p>3 you can live with.</p> <p>4 So then moving on to the third option is</p> <p>5 really targeting a patient population where the</p> <p>6 prevalence of pseudomonas infections is much higher.</p> <p>7 So that could include patients with either cystic</p> <p>8 fibrosis or bronchiectasis. And we know that these</p> <p>9 patient -- this patient -- these patient populations</p> <p>10 tend to have pseudomonas more commonly than some of</p> <p>11 the other patient populations.</p> <p>12 But again, there's a lot of work to be done</p> <p>13 because we really need to identify what clinical</p> <p>14 condition we are going to treat in these patient</p> <p>15 population. Is it going to be treatment of pulmonary</p> <p>16 exacerbation? You're not going to use this product</p> <p>17 for preventing exacerbations.</p> <p>18 And a treatment of pulmonary exacerbation in</p> <p>19 this population really has similar issues as one</p> <p>20 encounters in treating HABP/VABP, whether it be</p> <p>21 concomitant therapy or identifying the organism. And</p> <p>22 then the other challenge, also, will be to extrapolate</p>

<p style="text-align: right;">Page 433</p> <p>1 efficacy from this patient population because they do 2 have unique characteristics to the wider population. 3 So that takes us to our last option, which 4 again Helen and John had mentioned in their 5 presentations which is using the animal rule. So I'll 6 go through some basics about the animal rule. I'll 7 walk you through an example of how an animal model was 8 developed for treatment of plague. I cannot go 9 through all the details, but I think just to give you 10 a flavor for what we are talking about when we mean 11 animal models to be able to use the animal rule. 12 So we have -- it's in the code of Federal 13 Regulations we have for drug and we have for 14 biologics. It's when we approve new drugs when human 15 efficacy studies are not ethical or feasible. 16 And it really applies to new products, you 17 know, which are being used to treat or prevent serious 18 or life-threatening conditions where definitive of 19 human efficacy studies cannot be conducted because it 20 would be unethical, so a slightly different situation 21 at hand here because, I think, as had been mentioned, 22 it's less about the study being unethical but more</p>	<p style="text-align: right;">Page 435</p> <p>1 support approval of the product. 2 And there are three additional requirements. 3 We heard about post-marketing studies, or field 4 studies, in John Tomayko's presentation. So there is 5 a requirement for post-marketing studies to provide 6 evaluation of the safety and benefit if circumstances 7 arise in which a study would be feasible and ethical, 8 like in a bio-threat situation. 9 There might be a need to restrict -- impose 10 restrictions to ensure safe use of the product. And 11 lastly, labeling must include information to patients 12 that explains that, for ethical or feasibility 13 reasons, the product was approved based on studies -- 14 efficacy studies conducted on animals. 15 So if we were to use the animal rule for our 16 product X-1, we will obtain efficacy data from 17 adequately characterized animal models. And this 18 could be supplemented with clinical data from patients 19 with a variety of infections caused by pseudomonas 20 aeruginosa. This could be one or more descriptive 21 study. 22 The plus to this approach is that, you know,</p>
<p style="text-align: right;">Page 434</p> <p>1 about the study not being feasible, given where we are 2 today. 3 So they want us to use an animal study to 4 establish effectiveness at a full criteria that have 5 to be met. And as I mentioned, there is animal rule 6 guidance that goes through these -- this in very 7 detail, and it's also outlined in the regulations. 8 So we have to have a reasonably well- 9 understood pathophysiologic mechanism for the disease. 10 The effect has to be demonstrated in more than one 11 animal species, and the animal species is expected to 12 react with a response which is predictive of humans. 13 The endpoint that we use in the animal study should be 14 clearly related to the desired benefit in humans, and 15 it's generally the enhancement of survival or 16 preventing major morbidity. 17 And we have to have adequate information, 18 the kinetics and pharmacodynamics of the drug in the 19 animals and humans so that we are able to select an 20 effective dose in humans. So all these criteria have 21 to be met for us to rely on the efficacy data from 22 animal studies to extrapolate -- or to be able to</p>	<p style="text-align: right;">Page 436</p> <p>1 if you're really not able to conduct an informative 2 efficacy trial, then this might provide us an option 3 to assess efficacy. However, again, as Ed had 4 mentioned in his presentation, we really don't have 5 any adequately characterized animal models, at least 6 not that we're aware of, for these particular 7 indications being considered. So a lot of work will 8 need to be done to develop well-characterized animal 9 models. 10 And unlike with bio-threat agents, it is 11 ethical to conduct these trials. I think the issue 12 here is really feasibility. 13 And unlike drugs approved for bio-threat 14 indication, if X-1 were to be approved, then it would 15 be used in a broader population and potentially on an 16 empiric basis. You're really not going to save it for 17 when an outbreak occurs as in a bio-threat scenario. 18 And then also raises questions about what 19 would the field trial look like because a field trial 20 is required when it's feasible and ethical. So if 21 you're able to conduct such a trial right after 22 approval, then it really invalidates the need to</p>

<p style="text-align: right;">Page 437</p> <p>1 approve the product under the animal rule.</p> <p>2 And the post-approval study would really</p> <p>3 face the same -- likely face the same challenges that</p> <p>4 you encountered pre-approval. And I think for us a</p> <p>5 bigger issue from a policy standpoint is what kind of</p> <p>6 a precedent we might set for other clinical conditions</p> <p>7 of low prevalence, so a lot of issues to work through</p> <p>8 but certainly an option worth discussing.</p> <p>9 Here's some examples of products. I just</p> <p>10 have the list of drugs. I don't have the list of</p> <p>11 biologics here that have been approved using the</p> <p>12 animal rule. For infectious diseases, we have three</p> <p>13 products approved for plague and three approved for</p> <p>14 inhalational anthrax. There are also other products</p> <p>15 available for non-infectious disease conditions, you</p> <p>16 know, products that might help for radiologic nuclear</p> <p>17 incident, cyanide poisoning or nerve gas poisoning.</p> <p>18 So next, I'll walk you through the plague</p> <p>19 example, you know, just sort of to, you know, let you</p> <p>20 know that this is -- it's really not that</p> <p>21 straightforward. But it's doable, I suppose, if we</p> <p>22 all decide this is the way we are going.</p>	<p style="text-align: right;">Page 439</p> <p>1 laboratory test standpoint, they had leukocytosis,</p> <p>2 abnormalities in the liver function test, coagulation</p> <p>3 abnormalities.</p> <p>4 The duration -- the onset of bacteremia was</p> <p>5 quite variable from 30 hours to 94 hours, and they had</p> <p>6 radiologic infiltrates as well. On histopath, there</p> <p>7 was evidence of fibrinosuppurative hemorrhagic</p> <p>8 pneumonia, so not really different from what one</p> <p>9 expects in animals.</p> <p>10 So here's -- in the next two or three tables</p> <p>11 I tried to compare how the disease looked like in the</p> <p>12 AGM compared to what we know about human pneumonic</p> <p>13 plague. So the challenge agent in the AGM model was</p> <p>14 Y. pestis CO92. In humans it's Y. pestis. The CO92</p> <p>15 strain was isolated from a human with pneumonic</p> <p>16 plague.</p> <p>17 The pathogenic determinants of the organism</p> <p>18 are the same monkey are to humans. The root of</p> <p>19 exposures in AGM was aerosol, had only exposure. In</p> <p>20 humans, it tends to be aerosol exposure as well,</p> <p>21 generally, when there's close contact with the --</p> <p>22 another individual with pneumonic plague are in the</p>
<p style="text-align: right;">Page 438</p> <p>1 So the African green monkey model of primary</p> <p>2 pneumonic plague was developed to provide a platform</p> <p>3 for testing various therapeutic intervention.</p> <p>4 Mortality outcome was assessed in AGMs with</p> <p>5 symptomatic disease, and this was done in more than</p> <p>6 one lab. The progression of the disease was</p> <p>7 described, and the potential triggers for therapeutic</p> <p>8 intervention were also evaluated.</p> <p>9 And we had some human data available. I</p> <p>10 mean, they were not perfect, so one could compare the</p> <p>11 disease in the AGMs with that in humans. So here,</p> <p>12 naïve -- experimentally naïve AGMs healthy male and</p> <p>13 female was studied. The Colorado 92 strain of</p> <p>14 Yersinia pestis was used, and this was the exposure</p> <p>15 target. The AGMs were monitored clinically, and</p> <p>16 laboratory tests were also monitored. And then the</p> <p>17 AGMs that succumbed to disease, pathology both gross</p> <p>18 and microscopic were assessed.</p> <p>19 So when these studies were done, the</p> <p>20 exposures did range a fair bit. AGMs clinically had</p> <p>21 fever, loss of appetite, respiratory distress,</p> <p>22 lethargy and increased respiratory secretions. From a</p>	<p style="text-align: right;">Page 440</p> <p>1 unfortunate setting of a bioweaponized aerosol.</p> <p>2 The exposures are quantified in the AGM. It</p> <p>3 ranged -- but as long as you got more than 20 LD50,</p> <p>4 the animals all succumbed. The infectious inoculum in</p> <p>5 humans varies. It depends on the contact and the</p> <p>6 degree of exposure.</p> <p>7 From a pathophysiology standpoint, there</p> <p>8 were a lot of similarities between the disease you saw</p> <p>9 in AGMs and humans. The time to onset of disease of</p> <p>10 condition ranged from one to three days, slightly</p> <p>11 longer duration in humans. Time to death, again, it's</p> <p>12 not very different.</p> <p>13 Signs and symptoms were fairly similar.</p> <p>14 There's fever, lethargy, tachypnea tachycardia. There</p> <p>15 was evidence of neutrophilic leukocytosis, coagulation</p> <p>16 abnormalities. Radiologic evaluation showed</p> <p>17 infiltrates. In humans, it's very similar --</p> <p>18 consolidation cavities bronchopneumonia and the</p> <p>19 pathologies hemorrhagic pneumonia in both.</p> <p>20 Both AGMs and humans are highly susceptible</p> <p>21 to the disease and uniformly fatal if untreated. The</p> <p>22 trigger to intervention in humans was based on them</p>

<p style="text-align: right;">Page 441</p> <p>1 having a certain degree of body temperature elevation 2 for a certain period of time. In humans, it certainly 3 varies. It depends on whether or not there's an index 4 of suspicion for plague being a possible etiology. 5 So based on all these, I think the four key 6 characteristics that we took into consideration 7 designing the animal efficacy study was that the 8 endpoint would be mortality. So the animal's dead or 9 alive. The timing of intervention is after the AGMs 10 had been febrile for a certain period of time and they 11 had met the threshold for the temperature elevation. 12 The test drug that was being evaluated for efficacy 13 was to -- was administered intravenously, and the 14 dosing regimens that the AGMs received were humanized 15 dosing regimens. 16 So I just picked one example for 17 levofloxacin, but there's information on the other 18 example -- on the other drugs as well in the public 19 domain. And also, a lot of discussion around how 20 these AGM models were developed if you're interested 21 was discussed at an advisory committee in 2012. So 22 all this information that I have presented and more is</p>	<p style="text-align: right;">Page 443</p> <p>1 summary thoughts here are that what we know so far 2 about Drug X-1, it certainly appears to address an 3 unmet medical need. It has a potential, so I think we 4 have to find a way forward to develop this drug. We 5 do acknowledge that under the current paradigm, 6 studying a drug such as X-1 that's only active against 7 a single species that occurs infrequently at any one 8 body site or even occurs infrequently across different 9 body sites can be very challenging. 10 I've gone through some potential development 11 options. Again, these are options that we've come up 12 with, but maybe there are others that we haven't 13 talked through. All the options I've discussed have 14 limitations, so none of them are perfect. And I don't 15 think any one of them is going to solve the problem 16 right away. 17 And even if we -- one were to lean towards 18 option four, which is to consider the animal rule, a 19 lot more work needs to be done to develop a specific 20 animal model, or models, for infection in which we can 21 assess the efficacy of either Drug X-1 or other 22 similar -- similarly situated products for the</p>
<p style="text-align: right;">Page 442</p> <p>1 available on the website if you look for an advisory 2 committee in 2012. 3 So if you'll -- if you take plague -- take 4 the levofloxacin, an example, a single placebo control 5 trial in AGMs was conducted. Now, at the time that 6 this indication was being sought in the study, these 7 study -- the study was being done. Levofloxacin was 8 already approved for other indications, which included 9 pneumonia, both community-acquired and nosocomial 10 pneumonia. 11 So we though a study in one species was 12 adequate. There was no requirement to evaluate it in 13 two different animal species. The AGMs were exposed 14 to a mean dose of 65 LD50 of the CO92 strain. And 15 they were randomized. They got either 10 days of 16 intravenous levofloxacin or placebo after they reached 17 the pre-specified trigger. And as you can see, 18 mortality in the levofloxacin was significantly lower 19 compared to that in the placebo, and you have a 20 significant P value. 21 So I know I walked you through a lot in the 22 short period of time. But you know, just my sort of</p>	<p style="text-align: right;">Page 444</p> <p>1 clinical conditions being considered for development. 2 Thank you. 3 (Applause) 4 DR. COX: Thanks, Sumathi. 5 Now we will have Marco Cavaleri from the 6 European Medicines Agency, where he's the head of 7 Anti-Infectives and Vaccines, will give a perspective 8 from the EMA on the challenges of developing a drug 9 that's targeting a single species. 10 Marco? 11 DR. CAVALERI: Thank you, Ed. 12 I think a lot has already been said. So 13 here, I will try to focus pretty much on some aspects 14 that are coming up based on our reflection on a case 15 like this one, which indeed is not an easy one. 16 So first of all, again, as stated yesterday, 17 I would stress that the preclinical and clinical 18 pharmacology package has to be thorough and exhaustive 19 as much as possible, including all the (inaudible) 20 aspects and drug-drug interaction; metabolism and 21 excretion; distribution in relevant body sites like 22 ELF; as said yesterday, the PK in ICU patient and with</p>

Page 445	Page 447
<p>1 augmented renal clearance should be started; the PK in 2 renal and hepatic impairment, too, and also with the 3 need of dose adjustment.</p> <p>4 And of course, we would expect to see an 5 adequate and robust PK/PD profiling, which is 6 essential and is expected to complement as much as 7 possible all the limitation that may derive from the 8 clinical efficacy data set. Exposure response 9 analysis are expected to be conducted in the efficacy 10 trials, even if here we have to recognize that is more 11 datasets we are talking about. And also, the 12 concomitant therapy will confirm a lot of this kind of 13 analysis.</p> <p>14 So some general reflection. We heard a bit 15 around the conduction of clinical trials what could be 16 the role of rapid diagnostic test in order to enrich 17 enrollment. And frankly, we've been struggling to 18 think how you can really avoid at least thinking about 19 using some experimental rapid diagnostic test in order 20 to conduct trials with such kind of drug.</p> <p>21 And of course, one of the goal will be to 22 try to reduce the amount of patient that are enrolled</p>	<p>1 into a careful site selection and try to go to sites 2 that are able to conduct trials in this -- with this 3 kind of drug in the (ph) pseudomonas.</p> <p>4 Now, I took the liberty of taking out one of 5 the table that was introducing the document that you 6 have seen and going back to the point of rapid 7 diagnostic test. And I noted that the specificity of 8 the test that was put in there was below 58 percent 9 and quite variable.</p> <p>10 So what I did was try to see if with the 11 specificity of 95 percent, which we may assume is not 12 so unrealistic, at least based on what we know in some 13 of the rapid diagnostic tests that are under 14 development for -- from negative pathogen and 15 pseudomonas, then what would be the PPV. And here, 16 you can see that if the prevalence of the illness is 17 15 percent and taking the sensitivity of 80 percent as 18 was initially proposed in the paper, then the PPV will 19 go up to 74 percent, which means that you will have to 20 enroll 135 patients in order to get 100 patient with 21 the illness or with a target pathogen.</p> <p>22 So clearly, there is some benefit in</p>
Page 446	Page 448
<p>1 empirically and which if on one side would add (ph) to 2 the safety database and the other will not be useful 3 for the sake of addressing efficacy evaluation. We 4 would allow 24 hours of previous antipseudomonal 5 therapy.</p> <p>6 And even if we are encouraging the use of 7 rapid diagnostic test, EMA will follow pragmatic 8 approach if these are using the context of clinical 9 trials. And therefore, for the recommendation in the 10 context of the SMPC will have to necessary not be 11 binding with respect to the use of the rapid 12 diagnostic test, and we will try to figure out what is 13 the best way forward in this in setting (ph).</p> <p>14 In consideration of the epidemiology for 15 this pathogen, at least in Europe, as you may know, in 16 certain countries the MDR pseudomonas aeruginosa 17 prevalence is very high. So at least try to enroll 18 some of these cases, considering that these 19 indications in the context of a limited use option. 20 But of course, here, we will not be overly demanding.</p> <p>21 And is said by others, it's very important 22 for conducting trials with this kind of drug to go</p>	<p>1 considering the use of rapid diagnostic test in terms 2 of clinical efficiency. At the same time, I do fully 3 recognize that, as also has been said before, that 4 this will not change the time you will take to run the 5 trials. It will not change the fact that you will 6 have to go broad with a large amount of size all over 7 the world and that the number that you have to screen 8 will be exactly the same, so very high.</p> <p>9 And also, we also do acknowledge that, as I 10 said, from an operational perspective, having a rapid 11 diagnostic test embedded in the clinical trials could 12 be problematic and not so straightforward.</p> <p>13 Nevertheless, it could be a good opportunity to try to 14 make the clinical development more efficient.</p> <p>15 So coming to what could be the options, and 16 here I would go along pretty much what I showed you 17 yesterday around what will be the examples that were 18 shown in our guidance document. So along those lines, 19 one option could be to conduct a randomized study in 20 HAP/VAP, which is the type of infection that is most 21 prevalent with pseudomonas aeruginosa. And we can 22 concede that that is a very good test for any drug.</p>

<p style="text-align: right;">Page 449</p> <p>1 Here, we will be open to consider enlarging</p> <p>2 the non-inferiority margin and also maybe to consider</p> <p>3 whether the alpha level could be relaxed somehow. And</p> <p>4 of course, all these elements will have to be</p> <p>5 discussed on a case-by-case basis and based on a</p> <p>6 specific proposal. But we are pretty open to talk</p> <p>7 about that.</p> <p>8 The primary endpoint will be clinical</p> <p>9 outcome as test of cure. And of course, this can be</p> <p>10 handled with different statistical analysis plan if</p> <p>11 the FDA requires all-course mortality. And it would</p> <p>12 be good to look into option for testing of nested</p> <p>13 superiority in subgroups or based on secondary</p> <p>14 clinical irrelevant endpoints.</p> <p>15 We do acknowledge that monotherapy's not</p> <p>16 possible, at least initially. And here, I think the</p> <p>17 proposal in the paper sound like a good approach and a</p> <p>18 valid starting point. But again, it would have to be</p> <p>19 discussed to what extent the use ertapenem would be</p> <p>20 possible in various parts of the world and whether the</p> <p>21 dose suggested would be accepted by most</p> <p>22 investigators.</p>	<p style="text-align: right;">Page 451</p> <p>1 Superiority is not demanding. But of</p> <p>2 course, it will be very important to try to explore</p> <p>3 option for nested superiority in subgroups and</p> <p>4 secondary relevant clinical endpoints as for the case</p> <p>5 before. And an even randomization can be considered</p> <p>6 for it to four-to-one (ph). What is important here is</p> <p>7 always to have even a small control group that would</p> <p>8 help us in order to understand that, for sensitivity</p> <p>9 purposes, to understand what we are seeing in the</p> <p>10 trial.</p> <p>11 Monotherapy is -- would not be possible at</p> <p>12 least initially, maybe with exception of UTI. But as</p> <p>13 I think already said by Sumathi, this is not very</p> <p>14 common, and so it can be very challenging to get a lot</p> <p>15 of cases with pseudomonas and UTI.</p> <p>16 Control therapy may be as well pretty fine</p> <p>17 or be best available therapy, and the same arguments</p> <p>18 as raised before will apply on the need of hierarchy</p> <p>19 if best available therapy is used.</p> <p>20 The last option will be an uncontrolled</p> <p>21 study, including the major indications as highlighted</p> <p>22 before with infection specific clinical outcome at</p>
<p style="text-align: right;">Page 450</p> <p>1 The control therapy may be a pretty fine</p> <p>2 single combination. And again, we're proposing the</p> <p>3 paper sounds (ph) as a good way forward. But again,</p> <p>4 in terms of feasibility, there might be a need to</p> <p>5 consider best available therapy.</p> <p>6 And of course, here we don't want to end up</p> <p>7 in a situation, as Mike was showing yesterday that</p> <p>8 there are 69 different best available therapy that can</p> <p>9 be considered. So it would be very important that</p> <p>10 there is a limitation to the number of best available</p> <p>11 therapy to be considered and according to a define --</p> <p>12 a predefined hierarchy (ph).</p> <p>13 And this could include option for cases of</p> <p>14 MDR isolate. For that specifically, an option could</p> <p>15 be to have an additional uncontrolled study that just</p> <p>16 is recruiting the MDR cases.</p> <p>17 Another option would be the all-comer</p> <p>18 studies, which would include the HAP/VAP, intra-</p> <p>19 abdominal, UTI and bacteremia. Again, infection</p> <p>20 specific in clinical outcome at test of cure is</p> <p>21 primary endpoint. We do not expect this study to be</p> <p>22 power for formal inferential testing.</p>	<p style="text-align: right;">Page 452</p> <p>1 test of cure as primary endpoint. And here, it would</p> <p>2 be essential to have adequate and convincing external</p> <p>3 and historical control.</p> <p>4 The same argument on the monotherapy will</p> <p>5 apply, of course. But of course, in light of the</p> <p>6 hurdles in the interpretation of the data which are</p> <p>7 expected to come up, adequate justifications will be</p> <p>8 provided that this is the only way forward or the only</p> <p>9 feasible approach. And here a convincing PK/PD</p> <p>10 package will be even more critical than in the other</p> <p>11 scenarios.</p> <p>12 So at the end of the day, the indication in</p> <p>13 line with what I told you yesterday will be for the</p> <p>14 treatment of infection due to pseudomonas aeruginosa</p> <p>15 in patients with limited treatment options. We</p> <p>16 referenced to other part of SMPC. And in particular,</p> <p>17 I would stress that in the Section 4.4, so the warning</p> <p>18 section, the limitation of the data will be explicitly</p> <p>19 stated, mentioning the relevance of population for</p> <p>20 which there are notable uncertainties as, for example,</p> <p>21 not sufficiently included or represented in the</p> <p>22 clinical studies, or for which PK data are not</p>

<p style="text-align: right;">Page 453</p> <p>1 available or not fully supported of activity at that</p> <p>2 specific body site.</p> <p>3 And I think I'll stop here. Thank you.</p> <p>4 (Applause)</p> <p>5 DR. REX: So, thanks to all four of our</p> <p>6 panelists. We're now going to take a break. Outside</p> <p>7 there is another handout. That handout is, in a</p> <p>8 sense, the reveal but it's also the basis for the</p> <p>9 debate. And I hope you've all come with some ideas.</p> <p>10 We've held back showing concrete solutions</p> <p>11 so you had all the time to sort of let your brains</p> <p>12 spin around and come up with the brilliant idea that</p> <p>13 none of us have thought of. That's what we're looking</p> <p>14 for.</p> <p>15 The -- we'll come back at 10:45 and talk to</p> <p>16 you soon.</p> <p>17 (Off the record.)</p> <p>18 DR. REX: -- towards getting started.</p> <p>19 So welcome back to Drug X-1.</p> <p>20 Maybe push that door shut. We'll deal with</p> <p>21 it in a second. So, yeah, if you would, thanks, it</p> <p>22 would be great.</p>	<p style="text-align: right;">Page 455</p> <p>1 And it -- and because it was chosen as a purely renal</p> <p>2 drug, you know, there's so much kind of known about</p> <p>3 what drugs like that do. But that's probably a good</p> <p>4 idea, is to develop some information like that. So,</p> <p>5 you know, yes you could do that.</p> <p>6 Other questions about the setup? John?</p> <p>7 DR. TOMAYKO: Yeah. I have a question for</p> <p>8 Marco. In your examples of the uncontrolled study and</p> <p>9 the across-body site study, what's the type of</p> <p>10 approval that that would get in the EMA?</p> <p>11 DR. CAVALERI: Yeah. Well, that will have</p> <p>12 to be discussed in light of the data and, you know, in</p> <p>13 light of the uncertainties that will emerge on the</p> <p>14 benefit tree.</p> <p>15 So one option might be exceptional</p> <p>16 circumstances. Another option might be a full</p> <p>17 approval if the data fully convincing and if external</p> <p>18 control, historical control can be pretty convincing</p> <p>19 in terms of demonstrating what is the effect of the</p> <p>20 drug. So I think we are keeping the options open and</p> <p>21 not ruling out what kind of approval will be most</p> <p>22 suitable.</p>
<p style="text-align: right;">Page 454</p> <p>1 So before we go on into the clinical case</p> <p>2 and how it got developed, are there any questions by</p> <p>3 anybody on the panel or in the audience about the</p> <p>4 setup, you know, for the sort of the background on X-</p> <p>5 1? You know, there -- one of the great things about a</p> <p>6 hypothetical drug is any data that I need I can invent</p> <p>7 in my microseconds. So if there's something you'd</p> <p>8 really like to know, we can tell you the answer to it.</p> <p>9 I realize things like, you know, what's the</p> <p>10 protein binding. Well, it didn't end there because --</p> <p>11 okay. It's 62. You know, you just did -- the math is</p> <p>12 adjusted somewhere buried down in there.</p> <p>13 So David (ph)?</p> <p>14 DAVID: Just something that Sumathi</p> <p>15 mentioned, is there Phase 1 data in seriously ill ICU</p> <p>16 patients in terms of PK?</p> <p>17 DR. REX: That's not listed in the book.</p> <p>18 That -- we haven't done it so you can add that to</p> <p>19 something you could go and dose some people with</p> <p>20 nosocomial pneumonia. What we did in the case was we</p> <p>21 said that we're going to assume the perimeter</p> <p>22 estimates -- are inflated from the healthy volunteers.</p>	<p style="text-align: right;">Page 456</p> <p>1 DR. CAVALERI: Okay. Thanks.</p> <p>2 And then I have one comment. Sumathi made</p> <p>3 this statement that if I proposed doing a field study</p> <p>4 right after I get an approval on the animal rule, then</p> <p>5 that kind of invalidates my feasibility argument. I</p> <p>6 just wanted to add some clarity to that.</p> <p>7 I'm looking for a little flexibility. I</p> <p>8 know that we don't have the pseudomonas animal model</p> <p>9 as of yet and there's probably some issues that have</p> <p>10 to be worked through. But what I think we might be</p> <p>11 able to do in a field study is answer questions that</p> <p>12 emerge during our clinical program, and their</p> <p>13 important clinical questions.</p> <p>14 As an example, what if we did have in our</p> <p>15 small clinical data a few of these patients with head</p> <p>16 trauma who had poor outcomes and we'd like to</p> <p>17 understand why. Maybe it's a PK issue, and maybe we</p> <p>18 should go to the centers where those patients are more</p> <p>19 likely to be studied and try to develop a better</p> <p>20 understanding and understand how perhaps to dose</p> <p>21 better. And all of this information only improves the</p> <p>22 benefit risk once you have the approval. So that's</p>

<p style="text-align: right;">Page 457</p> <p>1 what I meant about a field study.</p> <p>2 DR. NAMBIAR: Yeah. So I think the typical</p> <p>3 sense of the word, because you're looking at bio-</p> <p>4 threat and you talk about field study, it's really</p> <p>5 when you sort of have an event, a bio-threat event.</p> <p>6 So that's a little different than here.</p> <p>7 In here, I think the issue -- the reason one</p> <p>8 would -- when was thinking about using the animal rule</p> <p>9 is because it's really a feasibility issue, to be able</p> <p>10 to do an adequate well-controlled trial as we would</p> <p>11 like it. So even if one were to use the animal rule,</p> <p>12 we are certainly looking for some clinical data in</p> <p>13 humans, which should be available at the time that</p> <p>14 you're actually trying to approve the product based on</p> <p>15 animal rule.</p> <p>16 So yes. And if that is a across body sites</p> <p>17 and involves patients with various degrees of</p> <p>18 comorbidities, that site will all help us. But the</p> <p>19 basis for approval in that situation would be the</p> <p>20 animal rule. So that's the difference.</p> <p>21 DR. REX: It looks like Helen has a question</p> <p>22 and then Ed.</p>	<p style="text-align: right;">Page 459</p> <p>1 we get to that point.</p> <p>2 DR. COX: Maybe just following on this, too,</p> <p>3 one of the things I was wondering is, you know, if you</p> <p>4 think about it, if you're developing a drug, it may</p> <p>5 not be feasible to do, you know, a five-year trial</p> <p>6 that enroll an X number of patients.</p> <p>7 But you know, if the drug were approved, you</p> <p>8 know, could you then embark upon a longer clinical</p> <p>9 trial program that might get you to something that</p> <p>10 would actually be a controlled study that would help</p> <p>11 you to understand how the drug works that, you know --</p> <p>12 so in essence, I'm trying to figure out are there some</p> <p>13 things that might be feasible post-approval that you</p> <p>14 really just couldn't do preapproval?</p> <p>15 DR. TOMAYKO: Well, I'll just take a chance</p> <p>16 and try to highlight what comes to mind. You know,</p> <p>17 envision that you have a drug that's approved with</p> <p>18 very limited data such as animal data and some</p> <p>19 clinical data and you just convinced your investors to</p> <p>20 invest a substantial amount of money in doing that</p> <p>21 work. And yes, you'd love to be able to do anything,</p> <p>22 but you might not be selling much of that drug at that</p>
<p style="text-align: right;">Page 458</p> <p>1 DR. BOUCHER: So maybe I'll just follow up</p> <p>2 Sumathi.</p> <p>3 So in that scenario, what would the label</p> <p>4 look like?</p> <p>5 DR. NAMBIAR: Okay. So I'm not quite sure</p> <p>6 if we are at the label. But typically, for products</p> <p>7 that are approved under the animal rule, we describe</p> <p>8 the animal efficacy study that was the basis of</p> <p>9 approval in the clinical study section of the label.</p> <p>10 We don't have any human data other than safety, right?</p> <p>11 The one exception is in looking at these</p> <p>12 non-infectious disease-related labels, is for the</p> <p>13 cyanocobalamin. There was actually was some data in</p> <p>14 humans who sort of were exposed in -- I think they</p> <p>15 went into burning building or something, and it was</p> <p>16 actual cyanide exposure. So there is some human data</p> <p>17 that was available, and that is included in product</p> <p>18 labeling.</p> <p>19 But exactly what we would include, I mean,</p> <p>20 we really have to discuss. You know, the regulations</p> <p>21 do state you only include adequate well-controlled</p> <p>22 studies. But you know, we'd have to discuss that when</p>	<p style="text-align: right;">Page 460</p> <p>1 point. And you might not be able to raise the money</p> <p>2 to do anything huge. That's just the reality of the</p> <p>3 situation.</p> <p>4 I mean, if somebody were to come by and buy</p> <p>5 the drug and have greater resources and be willing to</p> <p>6 take that type of a thing on, great. But there's no</p> <p>7 easy solution to this problem, in my view.</p> <p>8 DR. COX: Yeah. And I realize, too, that,</p> <p>9 you know, the incidence of disease may still be very</p> <p>10 low. So it's -- that doesn't change. I'm just --</p> <p>11 something longer term, I'm just trying to figure out</p> <p>12 can you make -- you know, get something that would</p> <p>13 gather some clinical data that might help make sense</p> <p>14 of it.</p> <p>15 DR. BORIO: I mean, just to clarify Ed and</p> <p>16 Sumathi, that the field study is something that is</p> <p>17 very, very flexible and open and, you know, how you</p> <p>18 can collect the data. So it could include registries,</p> <p>19 reliance on electronic health records. It could</p> <p>20 include, you know, just a variety -- much more</p> <p>21 flexibility than what we'd expect as an adequate and</p> <p>22 well-controlled study for an investigational product.</p>

<p style="text-align: right;">Page 461</p> <p>1 DR. REX: Helen again.</p> <p>2 DR. BOUCHER: So to that end, some things</p> <p>3 that have been discussed as part of the carb effort</p> <p>4 have included, you know, improved monitoring of</p> <p>5 antibiotic use in general through the CDC and HSN and</p> <p>6 other mechanisms really directed at stewardship. But</p> <p>7 it may not be crazy to think that those types of</p> <p>8 mechanisms might work here where, you know, a new drug</p> <p>9 for very a specific special population came out and</p> <p>10 could be monitored in that way with some kind of</p> <p>11 feedback whereby, you know, it's more real world. And</p> <p>12 so the quality of the data, you know, it may not be</p> <p>13 exactly what you're looking for, but it would -- could</p> <p>14 be a way to monitor and understand more about the</p> <p>15 potential utility and/or risks of these new agents.</p> <p>16 DR. COX: And just thinking about things</p> <p>17 too, I mean, you know, there will be, you know, a fair</p> <p>18 -- you know, an animal rule-based approval does have,</p> <p>19 you know, a certain degree of uncertainty. And you</p> <p>20 know, those that have worked with animal models and,</p> <p>21 you know, how they're developed -- and they're sort of</p> <p>22 developed to actually show an affect. I mean, that's</p>	<p style="text-align: right;">Page 463</p> <p>1 Box, and I think it's self-explanatory for today.</p> <p>2 If you look at your handout, what we've done</p> <p>3 here is several of us have kind of collaborated on</p> <p>4 this. We've built up a series of approaches, and</p> <p>5 we're going to talk about, first, three scenarios that</p> <p>6 are an attempt to eke out a path to a non-inferiority-</p> <p>7 based approval. Just see what -- you know, what does</p> <p>8 it take. Kind of do a little wiggling around.</p> <p>9 And then Scenarios D and E are -- put you --</p> <p>10 sit down into a further corner where you just conclude</p> <p>11 that either you can't do it, or it's crazy for one</p> <p>12 reason or another. And then Scenario F is going to be</p> <p>13 that I'm looking for one of you guys to have a</p> <p>14 brilliant insight in the course of the day. Audience</p> <p>15 participation. What did we overlook? What else could</p> <p>16 we have done?</p> <p>17 In terms of timing, I'm going to use -- it's</p> <p>18 just now 11 o'clock. We're going to go till about</p> <p>19 12:15. I think that's probably going to be enough to</p> <p>20 walk through some of the Scenario A, basically. And</p> <p>21 then we will come back and walk through the remainder</p> <p>22 -- remaining stuff and have a moment for -- and along</p>
<p style="text-align: right;">Page 462</p> <p>1 sort of why you, you know, develop the animal model in</p> <p>2 the way that you do. So getting that sort of second</p> <p>3 component of predicting human efficacy, I mean, there</p> <p>4 is a degree of uncertainty.</p> <p>5 So the animal rule does have with it, you</p> <p>6 know, restrictions to ensure safe use. And it would</p> <p>7 seem that, you know, some of the conditions that are</p> <p>8 described might be very reasonable to consider in a</p> <p>9 circumstance like this because the drug would be --</p> <p>10 you know, patients are out there. They're having</p> <p>11 infections, you know, from day to day. And you know,</p> <p>12 the appropriate therapeutic role for such a product,</p> <p>13 you know, this may be an appropriate area to think</p> <p>14 about some of those restrictions and how the product</p> <p>15 would be used appropriately in order to balance, you</p> <p>16 know, what's the uncertainty the -- you know, so that</p> <p>17 the product is used safely out there in the real</p> <p>18 world, so.</p> <p>19 DR. REX: Any other questions for</p> <p>20 clarification sort of on the context in the setup?</p> <p>21 Okay. So let's move forward then.</p> <p>22 So I've always like this quote by George</p>	<p style="text-align: right;">Page 464</p> <p>1 the way it's very, very informal. So you can take off</p> <p>2 your tie.</p> <p>3 That's the other thing to know, okay? Yeah,</p> <p>4 I do tie it. If you can't tie it, you shouldn't wear</p> <p>5 it. Stop there.</p> <p>6 (Laughter)</p> <p>7 DR. REX: But I am -- with that said, it</p> <p>8 would going to be scary to go further. All right. So</p> <p>9 --</p> <p>10 AUDIENCE MEMBER: (inaudible - off mic).</p> <p>11 DR. REX: Yeah. No pressure here. It's</p> <p>12 just -- all right.</p> <p>13 So here are the constraints. So as we were</p> <p>14 developing this case and the approaches, the goal was</p> <p>15 to make this very real, okay? So you're not permitted</p> <p>16 any imaginary thing, so -- and also excluded sort of</p> <p>17 the BFMI solutions which is an acronym for me, brute</p> <p>18 force massive ignorance, okay? So enroll 10,000. No,</p> <p>19 we're not going to do that.</p> <p>20 We don't assume any kind of a perfect</p> <p>21 diagnostic. I don't have an instant susceptibility</p> <p>22 for all the pathogens in the sputum. I don't have</p>

<p style="text-align: right;">Page 465</p> <p>1 instant knowledge that only pseudomonas aeruginosa is 2 present. I don't have that. 3 We also presume that superiority via study 4 of just MDR pseudomonas is not possible, much too 5 rare. It would require well-timed outbreak, and I 6 don't ever want this -- I actually don't want it to be 7 possible. All right? That'd be bad. 8 Assumed at least in Scenario A that there 9 was enough money to do about 1,000 patients and they 10 kind of -- you know, so that sort of in the 60 to \$100 11 million range and that you can make an argument maybe 12 with some government support that you can sort of 13 somehow put that much money together. There's not 14 enough money for 3,000 patients. And also, you know, 15 it's not just money. 16 If you set off to do a BFMI program and you 17 decide I'm going to need the next 5,000 patients, what 18 does that mean for other drugs? You know, if there's 19 a clinical trial network, it means you've consumed it 20 for the next 10 years. I mean, no. You can't do 21 that. 22 We -- there's an implicit assumption just</p>	<p style="text-align: right;">Page 467</p> <p>1 And the difference between A and B -- A is 2 going to end up being a situation where the two study 3 arms end up being -- just the clinical results show 4 pretty close to similarities. So the difference 5 between them -- the delta between them is about zero, 6 but the confidence intervals are quite wide. 7 And there will be some confounding issues to 8 deal with. But overall, Scenario A is the easiest 9 scenario. In Scenario B, we're going to look at a 10 boundary case version of Scenario A. The difference - 11 - the delta will be made as wide as possible within 12 the constraints of already very wide margins. And 13 we're going to talk about that. 14 And then Scenario C, you'll find -- Scenario 15 C is a situation where we can't enrich and we don't 16 have very much pseudomonas. And so Scenario C winds 17 up with confidence intervals as bad as Scenario B. 18 That's part of the thing to watch for there, is they 19 sort of lock-step each other. 20 And then in D and E the pathogen is very 21 rare and it might no longer be pseudomonas. You know, 22 we quit kind of fussing so much about that at this</p>
<p style="text-align: right;">Page 466</p> <p>1 because it's not going to get discussed further, that 2 is that add-on therapy is not a viable strategy. And 3 it's hard to envision how standard of care plus X-1 4 would show superiority to standard of care plus 5 placebo. 6 I think that the clear blue water above that 7 when standard of care is active -- you know, when 8 standard of care is active, it's -- you know, it's 9 active. And as John Tomayko said, how much more cured 10 can you be than cured. 11 So in short, we -- the number required 12 miracles is kept at one -- at less than one in all the 13 solutions. I'm not going to reject a lot (ph), but I 14 simply will not plan on it. 15 So this table is in your handout. A, B and 16 C are all scenarios in which, as you'll see in a 17 minute, we're going to actually study -- end up 18 studying across three diseases, but principally across 19 nosocomial pneumonia and complicated intra-ab. They 20 all end up enrolling a little over 900 subjects. The 21 number with the pathogen falls as you go from B to C, 22 in particular.</p>	<p style="text-align: right;">Page 468</p> <p>1 point. But the end is very small, even though you 2 enroll a lot of subjects. And even if you were to 3 triple the size of the program, you're still barely 4 climbing up in terms of numbers to the size for the 5 pathogen of Scenario C. So that's sort of the logic 6 here, is to test at each step down the way. 7 What does it feel like in -- one, we were 8 joking just before it started. You know, we'd like 9 the sun and the moon and the stars, right? But when 10 you can't have that, how big of a flashlight would you 11 be willing to accept, you know? So that's kind of 12 what we're after here, is how much of a flashlight 13 will you settle for instead of the sun, the moon and 14 the stars. 15 So we're all now the sponsor. So let's just 16 do some thinking out loud. So safety database, what 17 do we have now? Well we've got about 40 in Phase 1 18 who've received the full dose over 14 days. It might 19 be a little higher. And then the 10 in the Phase 2 20 non-CF-bronchiectasis study. So that's 50 at full 21 dose and duration in theory. 22 What we know is the preclinical signals are</p>

<p style="text-align: right;">Page 469</p> <p>1 easily monitored. So what this suggests is we need --</p> <p>2 we need to get close to 300 for our safety database.</p> <p>3 There's not an absolute requirement for 300, but you</p> <p>4 heard yesterday the notion of the rule of three. You</p> <p>5 take your safety numbers, your end, divide it by</p> <p>6 three, and you're down to the level of which you're</p> <p>7 seeing all the -- all of the events within a 95</p> <p>8 percent confidence interval. So basically, at 300</p> <p>9 subjects you've seen all the -- you're likely to have</p> <p>10 seen all of the one -- the 1 percent events. And</p> <p>11 because it's pretty clean, monitor won't -- you know,</p> <p>12 provided nothing leaps out at us, it's, you know,</p> <p>13 somewhere between 250 and 300 cases on full dose and</p> <p>14 duration ought to be enough.</p> <p>15 It's pretty clear that the culture-positive</p> <p>16 rates, if they drift much below 15 percent, we're in</p> <p>17 deep trouble. And here are some simple numbers. At</p> <p>18 80 percent response, 85 percent power, 1-to-1</p> <p>19 randomization, you can see that you're really even</p> <p>20 with a pretty good size margin of 20 percent, your</p> <p>21 numbers are, you know, may not be even -- may not be</p> <p>22 feasible.</p>	<p style="text-align: right;">Page 471</p> <p>1 great.</p> <p>2 Let me emphasize that I'm not using this</p> <p>3 test as definitive. Patients, to get in the micro ITT</p> <p>4 population, which will be the population of interest,</p> <p>5 you're still going to have to have positive culture.</p> <p>6 The whole point is that this helps me more -</p> <p>7 - the people that enroll, if they're positive on this</p> <p>8 test, they're more likely to grow the organism. But</p> <p>9 I'm still not assuming that they become tremendously</p> <p>10 likely to grow the organism. It's just a little boost</p> <p>11 because you got to get to 25 percent in order to get</p> <p>12 under 1,000. I'm just going to warn you. When I did</p> <p>13 the math, I couldn't find a better way.</p> <p>14 Concomitant antibiotics are a problem. And</p> <p>15 that's an understatement. It is important to study</p> <p>16 nosocomial pneumonia. The guidelines often lead you</p> <p>17 to using two drugs. And Sumathi pointed at this, but</p> <p>18 let me show you the wording. This is the most</p> <p>19 recently published set of guidelines from IDSA. And</p> <p>20 I've clipped out three pieces of text.</p> <p>21 There's a place where they talk about what</p> <p>22 do you do for empiric therapy. "We suggest</p>
<p style="text-align: right;">Page 470</p> <p>1 So now for Scenario A, we envision -- we --</p> <p>2 I want -- fishing for a monoclonal. And very</p> <p>3 helpfully, if you look on page 8 -- which is page 2 of</p> <p>4 the handout afterwards, but it's page 8 as labeled --</p> <p>5 Point number 3, you'll see a citation to a paper by a</p> <p>6 guy named Pastels (ph). And they've actually invented</p> <p>7 a monoclonal against piocyan (ph) in a rather</p> <p>8 metabolite of piocyan.</p> <p>9 And if you know pseudomonas, this is a</p> <p>10 metabolite that this organism makes that others don't.</p> <p>11 And so if you've got a monoclonal against a</p> <p>12 metabolite, you can make one of those little</p> <p>13 immunochromatographic lateral flow things where you</p> <p>14 either get one line or two lines, depending on whether</p> <p>15 or not the metabolite of interest is present. It</p> <p>16 would be simple -- no batteries. It would be rugged,</p> <p>17 but I'm not pretending it's very good, okay?</p> <p>18 I'm just -- it's -- so we kind of invent</p> <p>19 this, and it's going to help us get a slightly higher</p> <p>20 rate of pseudomonas aeruginosa. If I had a better</p> <p>21 time or a better test and could get up to Marco's</p> <p>22 imaginary, you know, better sensitivity, that'd be</p>	<p style="text-align: right;">Page 472</p> <p>1 prescribing one antibiotic in patients without risk</p> <p>2 factors for antimicrobial resistance who are being</p> <p>3 treated at ICUs where less than 10 percent of gram-</p> <p>4 negative isolates are resistant to the agent being</p> <p>5 considered for monotherapy." I want to work there,</p> <p>6 okay? Where is this place? Okay.</p> <p>7 And then they say if -- now that you know</p> <p>8 it's pseudomonas, if you've got HAP/VAP and you're not</p> <p>9 in septic shock and you're not at high risk for death</p> <p>10 -- we'll come back to that in a second -- and for whom</p> <p>11 the subject test results are known, we say monotherapy</p> <p>12 is okay with one drug. And then they say however, if</p> <p>13 you're in septic shock or you're at high risk for</p> <p>14 death, then we suggest a combination.</p> <p>15 So let's see. Which patients aren't at high</p> <p>16 risk for death given that the mortality of this</p> <p>17 disease in untreated subjects is 60 or 70 percent and</p> <p>18 even with good therapy, it's 10 to 20 percent? So</p> <p>19 which one of you wants to say I'm not at high risk for</p> <p>20 death? I -- you know, again, I want to practice</p> <p>21 there.</p> <p>22 So what I conclude from this is that in a</p>

<p style="text-align: right;">Page 473</p> <p>1 study that I run as the sponsor where I have to get 2 people to sign up -- and I understand that's a little 3 different than what you might be able to do in an 4 academic investigation, but when -- but what I'm going 5 to do a study worldwide and convince a lot of 6 different sponsors to work on things, a lot of 7 different sites to work on stuff. I've got to come up 8 with something that meets, I'm not going to call it, 9 the lowest common denominator, but it meets a common 10 denominator.</p> <p>11 And so the assumption here is that, 12 inherently, the guidelines are really going to 13 basically say that most of the time for nosocomial 14 pneumonia in most patients, you got to give two drugs 15 at least empirically. Just take that as given. If 16 for some reason, you could get 10 or 20 percent where 17 you didn't have to give combination therapy, that's 18 upside. But for today's problem, I'm just sort of 19 assuming that the world says, really, you ought to do 20 this.</p> <p>21 You know, in two years from now, people 22 might really be saying it even more often. Other</p>	<p style="text-align: right;">Page 475</p> <p>1 of the concept here of these two trials.</p> <p>2 So just a little sidebar on entrapenem, 3 which is going to become very important. It's a 4 carbapenem that is stable to the ESPLs. It is 5 inactive for all intents and purposes versus 6 pseudomonas aeruginosa. It is indicated in 7 complicated intra-ab, skin, CAP and UTI, and I have 8 had a consultation with my PK-ologist. We've reviewed 9 the literature.</p> <p>10 There actually are ELF penetration data in 11 VABP patients with entrapenem that are published data. 12 It's in your -- it's cited in there somewhere that -- 13 and including free drug measurements in the ELF and in 14 the plasma simultaneously. And you look at that, and 15 that's the paper by -- on Page 9 by Boselli (ph). And 16 actually, you're hitting the -- well above the time 17 above requirements for entrapenem in the ELF.</p> <p>18 And then Artero (ph) and Bassetti (ph) just 19 before that, basically give you a little dab of 20 clinical data. So I'm not going to say this is great. 21 There are probably some more modeling that could be 22 done to get comfortable with it, you know, and also</p>
<p style="text-align: right;">Page 474</p> <p>1 information may've come out. You know, Paul Ambrose 2 is saying -- you know, talked about the fact that 3 variability in exposure suggests that it's favorable 4 for everybody to get two drugs just because, you know, 5 variability's there. But it's also important to get 6 some data using X-1 as monotherapy. So we got to do 7 both of these things in this program somehow.</p> <p>8 Helen has pointed out that it's valuable to 9 see data in more than one setting, and that seemed to 10 me to make a lot of sense. And so the sponsor said, 11 all right, I'm going to do two trials, but I'm going 12 to cover three indications in my two trials.</p> <p>13 The first trial will be a prospective, 14 blinded, as you'll see in a moment, randomized 15 controlled trial with separate sub-arms for nosocomial 16 pneumonia and complication intra-ab. And it's just 17 barely possible to kind of sort of eke out a non- 18 inferiority sign. And then there will be a study 19 called the Open Label LTO Study, open label and 20 limited treatment option patients. These are for 21 everybody else where you know it's pseudomonas and 22 you'd like to take a shot at it with X-1. That's sort</p>	<p style="text-align: right;">Page 476</p> <p>1 discovered along the way that entrapenem's actually 2 been studied at two grams a day as opposed to one, so 3 there's safety data from that. So you might even say 4 that we come back and look at 1 gram to (ph) 12, or 5 something with entrapenem. You know, it's sort of 6 more work for the site.</p> <p>7 But as it stands right now, it looks to me 8 like entrapenem for non-pseudomonas, gram-negative 9 nosocomial pneumonia, including VABP, is as well 10 validated as many other things. So I'm going to sort 11 of take that as an acceptable tool. So this is, you 12 know, number of miracles remains less than one.</p> <p>13 So here's the design for the randomized 14 control trial, separate sub-arms, but it's a common 15 protocol just for ease of implementation. And the two 16 arms are X-1 plus erta versus meropenem. In the 17 complicated intra-ab arm, you may add Amikacin. And 18 when you do so, it's blinded. So you've -- you write 19 an order for Amikacin, and it only gets given to the 20 meropenem arm. It does not given -- get given to the 21 X-1 arm. So it's Amikacin versus placebo.</p> <p>22 For nosocomial pneumonia, made the decision</p>

Page 477	Page 479
<p>1 to say you must give Amikacin. Just take the issue</p> <p>2 off the table. Everybody gets active drug. And you</p> <p>3 have to stop it as soon as you know your</p> <p>4 susceptibility, all right? And if by Day 4 you can't</p> <p>5 stop it or if it's -- or if the isolate is meropenem-</p> <p>6 resistant, you're out. You maybe go to the OL LTO</p> <p>7 study or something else, but no more on this, okay?</p> <p>8 Because otherwise, I can't keep you on a blinded</p> <p>9 therapy, all right?</p> <p>10 We'll discuss in a bit the notion of a</p> <p>11 different kind of a comparator. You know, I went -- I</p> <p>12 sort of went towards the bias of let's have a -- let's</p> <p>13 at least standardize the comparator to the extent we</p> <p>14 can because maybe we can.</p> <p>15 You can blind this. X-1 and meropenem are</p> <p>16 both Q8. Meropenem is supposed to be given over 30</p> <p>17 minutes. All you do is make its PK/PD better if you</p> <p>18 give it over an hour, so there's no reason not to give</p> <p>19 it, you know. So meropenem and X-1 can both be a Q8</p> <p>20 drug given over one hour.</p> <p>21 And then the ertapenem or placebo --</p> <p>22 everybody gets one dose of that a day because</p>	<p>1 subset that is positive for a baseline culture for</p> <p>2 pseudomonas. Being polymicrobial is not an exclusion.</p> <p>3 You can have pseudomonas and E. coli and Klebsiella.</p> <p>4 You've just got to have pseudomonas in there. The</p> <p>5 endpoint for clinical lab and for nosocomial are the</p> <p>6 ones that are the standard FDA-recommended ones.</p> <p>7 So it's clinical response for intra-ab and</p> <p>8 nosocomial pneumonia. It's 28-day all-cause</p> <p>9 mortality. And of course, you'd also put clinical</p> <p>10 response and nosocomial pneumonia, so you've got data</p> <p>11 for the EMA and the FDA. It's easily done. It's --</p> <p>12 you know -- we've recently done this, and there's just</p> <p>13 not a problem at all to collect both kinds of data.</p> <p>14 Now we come to an interesting one. What</p> <p>15 margin am I going to argue for? If you look in your</p> <p>16 handout, you'll see that the FDA-proposed M-2 for</p> <p>17 nosocomial pneumonia is 10 percent, and the -- for</p> <p>18 intra-ab, I think it is -- I know I wrote it down.</p> <p>19 Where is it? It's 10 percent. Right? Yes, it's 10</p> <p>20 percent. But if I look at those numbers a little more</p> <p>21 -- and the FDA said the M-1 for nosocomial pneumonia</p> <p>22 is 20 percent, and the M-1 for intra-ab is 14 percent.</p>
Page 478	Page 480
<p>1 ertapenem is a Q24 drug, so you know, really easy to</p> <p>2 set this up. And I didn't work out the dose</p> <p>3 adjustments for renal dysfunction. But, you know,</p> <p>4 we've invented X-1 as renally cleared, and I bet it</p> <p>5 would just sort of flow down with probably similar</p> <p>6 dose adjustments to the meropenem arm and come up with</p> <p>7 something.</p> <p>8 For both arms, if you want something for</p> <p>9 gram pauses, feel free. Put in some 1As. Look -- put</p> <p>10 in some vancomycin. It probably would specify</p> <p>11 something, but, you know, pick one.</p> <p>12 The inclusion -- standard rules for</p> <p>13 complicated intra-abdominal nosocomial pneumonia --</p> <p>14 I've already said that the other thing is we'd have</p> <p>15 this little lateral flow kit, and you need to -- or if</p> <p>16 you've recently grew pseudomonas, you can come in.</p> <p>17 You know, if you've got a belief that -- the baseline</p> <p>18 culture is going to have to be positive. You've got</p> <p>19 to have a reason to enroll them -- and no more than 24</p> <p>20 hours of prior effective therapy.</p> <p>21 So the stats will be -- the primary analysis</p> <p>22 will be in the microITT population. That is the</p>	<p>1 In theory, M-1 is the largest possible</p> <p>2 margin you could ever use. So if the nomenclature is</p> <p>3 not familiar to you, M-1 is the largest reliable</p> <p>4 treatment effect than anyone has agreed on.</p> <p>5 But if you look under the hood a little bit,</p> <p>6 the FDA's M-1 is actually calculated by doing some</p> <p>7 rounding down. So if you go into the actual data used</p> <p>8 to compute it and you use -- you apply and you look --</p> <p>9 they have two point estimates, treated and untreated -</p> <p>10 - and you look at the 95 percent confidence balance</p> <p>11 around those point estimates, the so-called 95-95</p> <p>12 rule, and you take the difference between those, you</p> <p>13 get 29 percent. So there's been a little rounding</p> <p>14 down that's been done to get to the FDA's M-1.</p> <p>15 I'm going to argue that, look, you know,</p> <p>16 unmet need, plausible agent, the Phase 2 data we're</p> <p>17 going -- that we've -- think -- talked about or will</p> <p>18 talk about again in a second -- 29 percent, round it</p> <p>19 to 30 percent, okay? I'm going to argue for 30</p> <p>20 percent. And maybe I'll go find some more data and</p> <p>21 I'll maybe -- and maybe I'll do with nosocomial</p> <p>22 pneumonia what I do with intra-ab, which is -- intra-</p>

<p style="text-align: right;">Page 481</p> <p>1 ab, the M-1 is incredibly conservative. I'm not going 2 to go through how it's calculated. It's written down 3 in the document. But it's very, very, very 4 conservative because it actually involved preventing 5 infection rather than treating infection as its basis. 6 So here I played Go Fish for some data in 7 the modern era where someone had suffered from an 8 outbreak of KPCs and documented the lack of response. 9 And I find a paper by Di Carlo, which there's the -- I 10 don't have the graph on the slide. I don't think I 11 do. No, I don't. But it's in your handouts on Page 12 4. And Di Carlo found 30 patients who developed 13 infections after open-abdominal surgery. They were in 14 Italy, and they had this outbreak of KPC-producing 15 Klebsiella. 16 And so they had 30 people who didn't get 17 effective therapy, basically. And -- or, rather, not 18 quite. So they started off and they were using 19 tigecycline and colistin at sort of what they called 20 ordinary doses, and they were doing terribly with it. 21 And so then they bumped the dose of both of them up, 22 and it -- and they do a whole lot better with it. And</p>	<p style="text-align: right;">Page 483</p> <p>1 -- very strong pre-clinical dose rationale. The 2 target exposure has been proven in the clinic -- and 3 by the way, we're going to do population PK in the 4 Phase 3 program, and I'm going to presume that it 5 comes out, more or less, in the zone. 6 We've got a Phase 1 study that shows that it 7 gets into the ELF. We've got a Phase 2 study in 8 people who are -- with non-CF-bronchiectasis 9 chronically colonized with pseudomonas. 10 By the way, there's literature on this. I 11 didn't invent that. I actually looked at some cases, 12 some little stories. And the idea of reducing most of 13 the group by about one log and about half of them by 14 two logs, that's entirely in the zone for an active 15 drug in the lung. So, you know, I found a series of 16 little papers like that. 17 It wasn't that it cured any of those folks. 18 You know, it didn't make them sterile. But the point 19 was that this study shows the drug gets into the lung, 20 and if pseudomonas is there, the drug can act on the 21 pseudomonas in the lung. So that was the whole reason 22 for that.</p>
<p style="text-align: right;">Page 482</p> <p>1 if you look in your handout -- should've put that on 2 the slide -- it's this little figure that's on the 3 lower right-hand corner of Page 4. 4 And so this is a Kaplan-Meier. This isn't a 5 clinical response. It's a KM of survival, okay? And 6 the upper line is the higher dose of tigecycline and 7 colistin, and the lower line is the lower dose. And 8 it's about 15 subjects in each arm. 9 And so I'm going to say, look, you know, 10 intra-ab is a real disease, and maybe I'll find some 11 other data. And I think your margin is too small, and 12 so I'm going to somehow come up with a 25 percent. 13 And if I can't get to 25 percent, we'll talk about the 14 consequences of that a little bit later on. 15 But you know, it's that kind of data because 16 you've actually -- can go look for some modern data to 17 tell you whether or not you've got a problem. That's 18 as close as I get to using a miracle. 19 So success would be defined as the 95 20 percent confidence interval of the differences within 21 margin in both sub-arms. And the logic for approval 22 now becomes the following pieces of data all together</p>	<p style="text-align: right;">Page 484</p> <p>1 And then this RCT has two disease where we 2 show an effect. And each one of them is flawed, 3 right? Nosocomial pneumonia is going to be confounded 4 by concomitant Amikacin. Complicated intra-ab is 5 partially confounded by surgery, but at least we get 6 some monotherapy data, right? So it's -- so the point 7 is not that any one of these pieces of data is the 8 answer, but each one of them kind of bangs around at a 9 different edge of the problem. 10 And then you assume that the unmet need 11 label will be in there, and it will only cover 12 patients with limited treatment options. I've not 13 talked about the open label companion study, but it 14 would give you some data in other settings. And I've 15 assumed that it is just an open-label study that you 16 get some data in. You could choose to randomize. And 17 I don't think I have that on the slide, but my sense 18 was there were not that many cases to begin with. And 19 so I'd rather have more exposure on X-1. 20 I'm trying to do it -- yeah, don't do that, 21 right. 22 So here's the actual study that, of course,</p>

<p style="text-align: right;">Page 485</p> <p>1 is imaginary that we invented. We powered 85 percent 2 and assume an 80 percent response rate in both arms, 3 and that's a simplification just -- you know, we've 4 got a pick a number. We're going to randomize it two- 5 to-one in both sub-arms. And I sat and played with 6 the math a little bit, and I came up with this balance 7 of cases. Assuming the margins of 30 percent for 8 nosocomial pneumonia and 25 percent for intra-ab, I 9 wanted to have something that -- where there was a 10 little bit of tolerance for heterogeneity, though, as 11 you'll see in a second, not a lot.</p> <p>12 So I put about one-third on nosocomial 13 pneumonia and two-thirds on intra-ab. And you can see 14 what that turns into for the X-1 cases and the control 15 arm cases. And from there, you see the math as to how 16 many you're going to get. And in the hand into the 17 setup, as I've talked about this hypothetical device, 18 I'm assuming about -- I'm getting a 25 percent 19 recovery rate for -- in nosocomial pneumonia, and 16 20 and a half percent for complicated intra-ab, which is 21 two-thirds better than you get by chance, okay? So 22 it's just arbitrary.</p>	<p style="text-align: right;">Page 487</p> <p>1 accrual rates drive you crazy.</p> <p>2 I'll -- you know, anyway, big study, I 3 think. And I think this is a minimum. And something 4 that's going to come out in a second is that I think 5 that the numbers I predicted to enroll have to be 6 inflated up some or for some other issues that are 7 going to come up along in a minute. But let's pretend 8 that we do the study and our PK-ologist consultant did 9 a great job with selecting our dose and our pop-PK 10 (ph) is bang, on target.</p> <p>11 And in the nosocomial pneumonia arm, the 12 people follow the directions, and pretty much 13 everybody gets a dose on Day 1. And -- but if falls 14 off pretty steadily. So they're -- you know, about 15 half the subjects only got two days. You know, it's, 16 you know, better than a sharp stick in the eye, as my 17 mother would say. And in the complicated intra-ab 18 study -- I didn't put it on the slide -- you know, 10 19 percent get Amikacin for a couple of days. Pick a 20 number. But it's not -- it's -- the majority don't 21 get it on intra-ab because you don't need it. And 22 with nosocomial pneumonia, the majority do get it, but</p>
<p style="text-align: right;">Page 486</p> <p>1 In Scenario C, the device is going to fail 2 and we're going to fall down to what happens only by 3 chance.</p> <p>4 So the actual study in Scenario A hits these 5 parameters. And how long did it take me to run this 6 study? Well, I did a little math here, and this is 7 what I came up with was that this might do it -- 36 8 months, 250 sites, screening nearly 2,000 subjects.</p> <p>9 Okay. Yes, Kenneth Hillin (ph), I'm having 10 to pick him up off the floor.</p> <p>11 So how did I get to this? Well, 36 times 12 250 is about 9,000 screening months' worth of work. I 13 looked at some comparables, like one that's -- I've 14 got some data from programs that we've run, and I took 15 a haircut on the enrollment rates that I was seeing in 16 recent studies. I'm sorted down two-thirds from that. 17 And I said what do I need. Okay?</p> <p>18 So I've not done super detailed feasibility 19 work. And those of you who have done feasibility work 20 know that it's, you know -- it's like George Box's 21 comments. All numbers are wrong. These are really 22 wrong. You know, the accrual rates -- predicted</p>	<p style="text-align: right;">Page 488</p> <p>1 I think it's not unreasonable to say that you'd know 2 within a day or two whether you could drop it down. 3 And so I'm just saying that by the end of day -- you 4 know, two days, most people get two days' worth. 5 After that, it tapers off pretty rapidly.</p> <p>6 So here are some numbers for a made-up 7 program. By the way, any questions about this so far? 8 Anybody want to ponder anything before I go forward?</p> <p>9 Yes, question.</p> <p>10 UNIDENTIFIED MALE SPEAKER: John, can you 11 run that by me again? You said you got 16 percent 12 (inaudible - off mic) study?</p> <p>13 DR. REX: Right, but we're using my device.</p> <p>14 UNIDENTIFIED MALE SPEAKER: Using the 15 device.</p> <p>16 DR. REX: Right. So the raw rate is 10 -- 17 the by-chance rate is 10 percent. And so this device 18 -- I'm saying it boosts you up two-thirds. It gets 19 you up to 16 and a half percent. So for intra-ab, it 20 takes you from 10 to 16 and a half. For nosocomial 21 pneumonia, it takes you from 15 to 25.</p> <p>22 UNIDENTIFIED MALE SPEAKER: But I'm</p>

<p style="text-align: right;">Page 489</p> <p>1 confused. How does the device increase the incidence?</p> <p>2 DR. REX: It doesn't. It just means I only</p> <p>3 enroll the ones who have pseudomonas -- of the people</p> <p>4 I enroll, they're more likely to have pseudomonas.</p> <p>5 Right. And you can argue about where is the cost.</p> <p>6 Actually, the cost isn't just in the enrolled</p> <p>7 patients. It's in the maintenance. You know, 250</p> <p>8 sites means I've got to visit 250 sites once or twice</p> <p>9 a year and replenish their IDP, and, oh my gosh, okay?</p> <p>10 It gets really expensive just to have 250 sites open</p> <p>11 for three years.</p> <p>12 That might -- I don't have a good -- if</p> <p>13 anybody has a good feel for the ratio of true per-</p> <p>14 patient to site running costs underneath -- you know,</p> <p>15 I've got a whole range of estimates from my group.</p> <p>16 I'm happy to have any ratios there you come up with,</p> <p>17 but that's the notion, okay? And, once again, why</p> <p>18 those particular numbers? Because it fits inside</p> <p>19 1,000 patients.</p> <p>20 You know, I have played exhaustively with</p> <p>21 this, and you can come up with other variations. I</p> <p>22 didn't go to one-to-one because I needed the safety</p>	<p style="text-align: right;">Page 491</p> <p>1 four weeks, so there are holes in it.</p> <p>2 AUDIENCE MEMBER: (inaudible - off mic).</p> <p>3 DR. REX: Sorry, say it one more time</p> <p>4 please.</p> <p>5 AUDIENCE MEMBER: (inaudible - off mic).</p> <p>6 DR. REX: No, because empirically, you don't</p> <p>7 know at moment zero on Day 0. So at Moment 0, Day 0,</p> <p>8 you randomize and you start Amikacin on everybody, so</p> <p>9 everybody is going to have had that in this design.</p> <p>10 Other questions? Question?</p> <p>11 AUDIENCE MEMBER: (inaudible - off mic).</p> <p>12 DR. REX: It's based on the cultures coming</p> <p>13 back. You know, by the end of the second day, you</p> <p>14 often have -- because what you all -- what you care</p> <p>15 about is the susceptibility of the pseudomonas.</p> <p>16 So if it grows on Day 1, then you'll have</p> <p>17 susceptibility by Day 2, and that happens with</p> <p>18 Pseudomonas, but it might also take to Day 2 and then</p> <p>19 Day 3 to get it. Pseudomonas is not a particularly</p> <p>20 slow-growing organism. It's not, you know -- it</p> <p>21 doesn't hide. And anything better than this or worse</p> <p>22 than, you know -- okay, so it's three days on average,</p>
<p style="text-align: right;">Page 490</p> <p>1 database on X-1, so I wanted more cases there.</p> <p>2 Didn't, you know -- one-to-one increases the -- it's -</p> <p>3 - your best statistical power is always at one-to-one.</p> <p>4 Any deviation from one-to-one costs you. But here I</p> <p>5 chose to accept that cost because I wanted the safety</p> <p>6 database, okay?</p> <p>7 AUDIENCE MEMBER: (inaudible - off mic).</p> <p>8 DR. REX: No, but they don't all get it for</p> <p>9 full dose and duration. So only the 48 and only the</p> <p>10 69 are going to stay on X-1 -- are -- because if you</p> <p>11 don't have pseudomonas, you come off the study. You</p> <p>12 know what? I didn't say that. That's a good point.</p> <p>13 You could leave them on the study if you wanted to and</p> <p>14 you learn about ertapenem. That's a good point.</p> <p>15 AUDIENCE MEMBER: (inaudible - off mic).</p> <p>16 DR. REX: Why not? Well, it's a good point.</p> <p>17 You could -- I'd implicitly assumed that,</p> <p>18 you know, if you didn't -- in terms of safety, you</p> <p>19 actually could have way more than enough safety here.</p> <p>20 It's a good point. Thank you. Thank you for the</p> <p>21 clarification.</p> <p>22 This case was busily invented over the last</p>	<p style="text-align: right;">Page 492</p> <p>1 you know.</p> <p>2 I -- but I sort of was thinking about what</p> <p>3 does it often feel like to me, and I often have some</p> <p>4 hint of it by the end of the second day. The morning</p> <p>5 of the third day, I can get rid of the Amikacin. You</p> <p>6 know, and maybe that's two and a half days, you know,</p> <p>7 that sort of thing. Good question.</p> <p>8 Yes, sir?</p> <p>9 AUDIENCE MEMBER: (inaudible - off mic).</p> <p>10 DR. REX: Sorry, say that one more time.</p> <p>11 I'm trying to repeat the questions, but it's tricky.</p> <p>12 UNIDENTIFIED MALE SPEAKER: All right. So</p> <p>13 the drop-off rate applies for the total MP population</p> <p>14 and not necessarily to the one who have pseudomonas,</p> <p>15 right, and get the test drug. So for those, let us</p> <p>16 say, to assess what the confounding effect of Amikacin</p> <p>17 on test track would be, those rates would be higher</p> <p>18 because those who have pseudomonas let's say probably</p> <p>19 4 or 5 days -- 80 percent right?</p> <p>20 DR. REX: What we're -- what I have assumed</p> <p>21 is that you're willing to drop down to monotherapy, so</p> <p>22 it goes a little bit against the IDSA guidelines.</p>

<p style="text-align: right;">Page 493</p> <p>1 You're willing to go down to monotherapy once you know 2 that the pseudomonas is susceptible to the test 3 agents. So that's an implicit assumption here, is 4 that by Day 2 or 3, you've got your culture, you've 5 got your susceptibility results. And you can say, 6 okay, it's meropenem susceptible. And for X-1, it's - 7 - you know, they're almost always susceptible, so that 8 says -- you know I'm going to take that as -- but you 9 may also be able to do the local test. And so you can 10 drop down to monotherapy.</p> <p>11 The idea here is you're dropping down to 12 monotherapy for the pseudomonas part. You may still 13 be continuing the ertapenem; you may still be 14 continuing the linezolid. You know, you can do other 15 stuff. Does that make sense?</p> <p>16 You know, I'm trying to say the Amikacin 17 doesn't -- if it goes on for a week in a quarter of 18 the patients, okay, it does. But everybody is going 19 to have had at least a couple of days.</p> <p>20 Yes, ma'am?</p> <p>21 UNIDENTIFIED FEMALE SPEAKER: How do you 22 account for the risk for CRE in the comparator arm?</p>	<p style="text-align: right;">Page 495</p> <p>1 control their outbreaks of CRE, so I think you can do 2 this and you can avoid the problem of CRE coming in 3 and being a big issue. So I think you can do that 4 where the pseudomonas is often -- well, that's not the 5 same as here. But the -- you -- so I think you could 6 probably have the meropenem be active against the 7 pseudomonas at least 80, 85 percent of the time.</p> <p>8 Other questions? Okay.</p> <p>9 So these are the data that were invented, 10 okay? And it's important to pay attention to both the 11 percent ratios and the absolute magnitude of things 12 like the denominator here. So the nosocomial 13 pneumonia arm, they're 48 and 24 in our microITT 14 analysis. And if you want to pitch them both at about 15 80 percent response -- in fact, 38 out of 48 would be 16 a little closer. I deliberately jittered that away a 17 tiny bit to get the -- to make the delta not so 18 boring. But you know, there's a result that, you know 19 -- it's 20 percent up and down around a delta of zero, 20 more or less.</p> <p>21 And there you have an intra-ab dataset. And 22 I left those numbers a little closer. You know, 80</p>
<p style="text-align: right;">Page 494</p> <p>1 DR. REX: You -- if we believed you had CRE, 2 you shouldn't come into this study, right? That would 3 be one part of it. And the -- if you identify it, 4 that's what I meant about meropenem resistance, you 5 know, if we spot it. You need to be in a center where 6 you would be comfortable using meropenem plus or minus 7 Amikacin as your empiric therapy about nosocomial 8 pneumonia. And so if you're at a center where that's 9 not true, then I can't put this study here.</p> <p>10 AUDIENCE MEMBER: (inaudible - off mic).</p> <p>11 DR. REX: Yeah, I'm with you. I want to 12 work there, too.</p> <p>13 But so -- but you know, we've recently done 14 a study like this where we did ceftazidime/avibactam 15 versus meropenem. And we were able to -- we actually 16 -- it was kind of hard. We didn't find CRE. You 17 know, even -- we were actively excluding it, but we 18 actually -- and we had another study where were 19 actively looking for it, and it was kind of harder to 20 get than you might imagine in prospective randomized 21 trials.</p> <p>22 Remember, the ICUs are trying very hard to</p>	<p style="text-align: right;">Page 496</p> <p>1 versus 80, for all intents and purposes. And then 2 there's an open label LTO study, and this is -- I 3 pitch this one to be -- to reflect our experience, as 4 well, with having done a study like this as part of 5 the CAZ-AVI program.</p> <p>6 You get a lot of UTI. And, you know, people 7 can find those. There's lots of urine to culture, you 8 know. They are identifiable. And it's harder to get 9 intra-abs and nosocomial pneumonias with highly 10 resistant pathogens. It's just harder to pick them up 11 in a way that makes sense.</p> <p>12 And so just completely fictitious numbers 13 here, just made up that this is what you managed to 14 accrue. And I want to emphasize that these patients 15 are going to be different qualitative than those in -- 16 qualitatively from those in the RCT. They're going to 17 have more comorbidities. You won't be really happy 18 with banging them together. In your handout, I add 19 them up if you happen to want to see an integrated 20 summary of efficacy, but I don't really recommend 21 doing that.</p> <p>22 And I'm guessing that here's a place where</p>

<p style="text-align: right;">Page 497</p> <p>1 you'll actually get some difficult pseudomonas because</p> <p>2 that -- why would you be in this? Because you've got</p> <p>3 a bad one, and so assuming that, you know, about 80</p> <p>4 percent -- it won't always be the reason, but let's</p> <p>5 just assume that we get a fair -- so this is a nice</p> <p>6 feature of this open label. You can say, well, it's</p> <p>7 an open-label study, how -- lots of complaints. But</p> <p>8 on the other hand, you know, here's at least, you</p> <p>9 know, 50 or 60 cases that you can look at and see what</p> <p>10 do you think happened.</p> <p>11 Safety. The N on full dose of duration,</p> <p>12 barring the comment from a moment ago where we could</p> <p>13 actually get a bigger N, if you just kept it down to</p> <p>14 those who grew pseudomonas, is about 240 -- 230, 240.</p> <p>15 You know, you get between 200 and 300 and you're</p> <p>16 getting really close to having enough for a reasonable</p> <p>17 safety database at this level of resolution. And</p> <p>18 unless a major new signal emerges, it's not bad. You</p> <p>19 know, you can come back to this question. How big of</p> <p>20 a flashlight do you want? So it's not bad.</p> <p>21 MR. DANE: John --</p> <p>22 DR. REX: Yes?</p>	<p style="text-align: right;">Page 499</p> <p>1 MS. BOUCHER: So Aaron, I agree. I think</p> <p>2 that's a great point, and I think many of us would</p> <p>3 expect perhaps lower successes in especially the</p> <p>4 HABP/VABP group and that open label extension. And so</p> <p>5 that comes back to that notion that we were talking</p> <p>6 about a little bit earlier, the idea that really</p> <p>7 looking at each one of those 10 individuals and seeing</p> <p>8 what was going on is going to be necessary. And we've</p> <p>9 seen similar examples in the antifungal space. And we</p> <p>10 saw it a little bit, as Ed alluded to yesterday, in</p> <p>11 the daptomycin experience of having to look in the</p> <p>12 cells of each diagnosis, each group, and try to</p> <p>13 understand what you can learn from what amounts to a</p> <p>14 collection of cases.</p> <p>15 But there may be things you could learn.</p> <p>16 And I don't think there's any shortcuts, and so you</p> <p>17 come back to the fact that -- was a diagnosis really</p> <p>18 well-established? Was the outcome really well-</p> <p>19 established? Do we have drug levels in any of those</p> <p>20 patients? You know, do we have any other data that</p> <p>21 might help us feel better or less okay with that</p> <p>22 message? But in many cases, you might end up with</p>
<p style="text-align: right;">Page 498</p> <p>1 MR. DANE: Just --</p> <p>2 DR. REX: So now we're going to do</p> <p>3 questions.</p> <p>4 MR. DANE: So -- and on the open label</p> <p>5 extension data -- I mean, in this example, that looks</p> <p>6 fairly supportive. The response rates are pretty</p> <p>7 high. Given the population we're dealing with, it's</p> <p>8 non-comparative small numbers. It might be worth</p> <p>9 discussing what would we do if those response rates</p> <p>10 were 30 percent or 40 percent, which may not be that</p> <p>11 outlandish. It's a small number, and it's a more</p> <p>12 severe patient population. So that might be, you</p> <p>13 know, another test case of -- well, how would we use</p> <p>14 that type of information then?</p> <p>15 DR. REX: I have no good answer to that. I</p> <p>16 deliberately pitched those response rates to be lower</p> <p>17 than in the RCT, just saying that I thought they were</p> <p>18 going to be more difficult cases. And you know,</p> <p>19 that's -- so let's open this up. And that's a good</p> <p>20 question. So open up for questions, comments, and</p> <p>21 critiques.</p> <p>22 So, Helen?</p>	<p style="text-align: right;">Page 500</p> <p>1 almost 50-50, or even a little less, in these really</p> <p>2 sick people.</p> <p>3 The other point I think here is that in the</p> <p>4 HABP/VABP population, or if you were lucky enough to</p> <p>5 have a group of people with bloodstream infection,</p> <p>6 that's a group where their outcome with pseudomonas</p> <p>7 infection is pretty clearly very bad in terms of</p> <p>8 mortality, and you could look at that data. Again,</p> <p>9 with all the caveats about the fact that these people</p> <p>10 die from other reasons, you know, all those things --</p> <p>11 and perhaps become either more comfortable or less</p> <p>12 comfortable with those data.</p> <p>13 DR. TOMAYKO: John, could I build on what</p> <p>14 Helen said? In HABP/VABP, I actually think that in</p> <p>15 this situation it could really illustrate one of the</p> <p>16 controversies or problems that people see with an all-</p> <p>17 cause mortality endpoint. And what I mean by that is</p> <p>18 there's two ways to fail in a -- in that analysis of -</p> <p>19 - like when you're comparing a non-inferiority type</p> <p>20 analysis with an all-cause mortality endpoint. You</p> <p>21 have to realize that untreated pseudomonas pneumonia</p> <p>22 has a pretty high morality, probably higher than maybe</p>

Page 501	Page 503
<p>1 some other pathogens. And that's crude mortality.</p> <p>2 And the reason we like the endpoint is</p> <p>3 because there's a lot of improvement you could</p> <p>4 demonstrate with a good antibiotic. And if you don't</p> <p>5 demonstrate enough, then you could look inferior, so</p> <p>6 there are potential to detect an inferior therapy, if</p> <p>7 you don't work as well as your comparator. But let's</p> <p>8 say you work as well. What are you left with? You're</p> <p>9 left with some of that crude mortality that you</p> <p>10 started with but you couldn't see because so much of</p> <p>11 it was buried in the pneumonia.</p> <p>12 So you've got this crude mortality and you</p> <p>13 have 24 patients on marrow and 48 on ertapenem, and</p> <p>14 you have to assume that you randomized that and that</p> <p>15 what's left over you're going to be able to really say</p> <p>16 that -- you know, this is a problem that I think</p> <p>17 people have with all-cause mortality because, at the</p> <p>18 end of the day, you have other things that are also</p> <p>19 responsible for those remaining deaths. And that</p> <p>20 might not be handled well here. I don't know if I</p> <p>21 said that clearly, if anybody has a better way of</p> <p>22 articulating it, but --</p>	<p>1 are going to be significantly lower than that. And --</p> <p>2 DR. REX: So feel free to knock them down.</p> <p>3 MR. LOUDIT: -- the point is how do you deal</p> <p>4 with that and put it into perspective? And I think</p> <p>5 Helen's points are exactly right.</p> <p>6 DR. REX: Yeah. And so, you know, keep in</p> <p>7 mind -- you know, if -- cut them in half if you'd</p> <p>8 like. They're deliberately pitched to be different</p> <p>9 and not as good. And that's sort of the concept here.</p> <p>10 DR. CAVALERI: I'm going to just come back</p> <p>11 before we go.</p> <p>12 So to John Tomayko's comment, I mean, it</p> <p>13 sounds like, too, I mean, you know, you're arguing</p> <p>14 that in a small group of patient you might not have</p> <p>15 really balanced things out with randomization and the</p> <p>16 impact that that might have on all-cause mortality.</p> <p>17 It could affect other endpoints too, yeah. So I just</p> <p>18 don't -- I mean, I don't know that that's exclusively</p> <p>19 a problem of all-cause mortality.</p> <p>20 And these are -- this is a patient</p> <p>21 population where there's a lot of other things going</p> <p>22 on, and, you know, some patients will succumb to other</p>
Page 502	Page 504
<p>1 DR. REX: Will the left-handed poodle owners</p> <p>2 be randomized? Right. Will the smokers be equally</p> <p>3 randomized? Will poodle ownership be equally</p> <p>4 randomized? You just have no clue.</p> <p>5 So Helen again.</p> <p>6 And there's somebody with a question on the</p> <p>7 mic. Yes?</p> <p>8 MR. LOUDIT: Yes, so this is Jeff Loudit</p> <p>9 (ph). So Helen and John are much smarter than I, so I</p> <p>10 was going to make the same comments. But so quick</p> <p>11 question, John. That is all-cause mortality that</p> <p>12 you're showing there with HABP/VABP or is that --</p> <p>13 DR. REX: Yes, the endpoint for HABP/VABP is</p> <p>14 all-cause mortality.</p> <p>15 MR. LOUDIT: That's survival that you're</p> <p>16 showing there.</p> <p>17 DR. REX: Excuse me, it's -- it is all-cause</p> <p>18 survival.</p> <p>19 MR. LOUDIT: Okay. So all-cause survival</p> <p>20 that we're showing there. All right. So I would</p> <p>21 agree, though, with John and Helen's comment that I</p> <p>22 think certainly in the open label trial, your numbers</p>	<p>1 conditions that they have. We just can't tell who's</p> <p>2 who and what the cause is for each of those two</p> <p>3 things.</p> <p>4 So, yeah, I just didn't want to -- I mean,</p> <p>5 so it's not exclusively mortality, but this is a</p> <p>6 problem that we run into with smaller numbers -- and,</p> <p>7 yeah, okay.</p> <p>8 DR. REX: David?</p> <p>9 DAVID: Yeah, so the issue that I'm</p> <p>10 struggling with is that we spend an awful lot of money</p> <p>11 studying an awful lot of patients for an extremely</p> <p>12 fragile result.</p> <p>13 DR. REX: I -- And that point is extremely</p> <p>14 well -- and we actually put up a slide that'll let you</p> <p>15 talk about this because if you look at -- there's a</p> <p>16 section, A45, that lists really big risks. And what</p> <p>17 you're pointing out is number 2 -- that N is tiny and</p> <p>18 there -- the risk of bouncing off that a little bit is</p> <p>19 notable.</p> <p>20 DAVID: Yeah, so I just don't think anybody</p> <p>21 is going to do this. I think bravo for going through</p> <p>22 this. I think that this was a really rigorous look at</p>

<p style="text-align: right;">Page 505</p> <p>1 the realities in a way of trying to design a trial</p> <p>2 like this, but nobody is going to do this.</p> <p>3 DR. REX: Well, so save that comment when we</p> <p>4 get to Scenario B because I think you'll maybe want to</p> <p>5 repeat the comment.</p> <p>6 MR. HOOFTMAN: Thank you.</p> <p>7 My name is Leon Hooftman (ph). I'm the</p> <p>8 chief medical officer, sometimes chief medical</p> <p>9 scapegoat, of a company that has something like this.</p> <p>10 So first of all, I would like to commend the</p> <p>11 panel and FDA and yourself, John, for doing all this</p> <p>12 work.</p> <p>13 You know, when you're in clinical trials, as</p> <p>14 you know, sometimes you're planning for success and</p> <p>15 always optimistic. Our -- we have done surveys in the</p> <p>16 Mediterranean area regarding incidence of pseudomonas</p> <p>17 positivity, and figures are a little bit more</p> <p>18 optimistic than the sobering statistic that you have</p> <p>19 presented us with this morning, which is good because</p> <p>20 often enough you -- you know, you've got the answer</p> <p>21 because of the hope not because of the fact that</p> <p>22 somebody says, no, this is not possible.</p>	<p style="text-align: right;">Page 507</p> <p>1 on that.</p> <p>2 I want to observe that the enrolled N</p> <p>3 probably needs to be 30 percent bigger, I think, and</p> <p>4 that there's going to be some unavailable. There's</p> <p>5 going to be some lost due to meropenem resistance. So</p> <p>6 if you want to maintain this blinded design, you know</p> <p>7 -- there are many sins in clinical trials. You could</p> <p>8 live without the blinded if you wanted to. That would</p> <p>9 be a best available therapy. But here, if you wanted</p> <p>10 to do it blinded, which I always like, then you've got</p> <p>11 to deal with that -- again, the small N with the</p> <p>12 pseudomonas. And we've not discussed pediatrics at</p> <p>13 all, so I'm just going to assume that you do something</p> <p>14 about generating PK data.</p> <p>15 I want to show this just because it's in the</p> <p>16 handout. Sometimes it is suggested that we use a</p> <p>17 larger alpha. Instead of an alpha of 0.05, we use an</p> <p>18 alpha of 0.1. It's a way of, you know, describing the</p> <p>19 idea of less certainty. So the mathematical</p> <p>20 equivalent of that is to use a 90 percent confidence</p> <p>21 interval. And so here I've recomputed it with 90</p> <p>22 percent confidence intervals.</p>
<p style="text-align: right;">Page 506</p> <p>1 And sorry to come back to the issue of</p> <p>2 feasibility, but that is the word, you know, with a</p> <p>3 capital that is high on this agenda. And I agree with</p> <p>4 the previous person who said this is still probably</p> <p>5 not feasible. If we would use our positivity data --</p> <p>6 and it's a survey, and I know you're going to shoot</p> <p>7 holes through it and it's mainly Mediterranean, you</p> <p>8 know, our hope would be to enrich the population in</p> <p>9 countries where this is more prevalent. But we</p> <p>10 shouldn't fool ourselves because, as you would say</p> <p>11 yourself, you know, the moment that you start the</p> <p>12 study, the incidence rates go down.</p> <p>13 DR. REX: I didn't say that. Louis Lasagna</p> <p>14 said that. It's a wonderful quote -- Lasagna's Law.</p> <p>15 So let me just point out these noteworthy</p> <p>16 risks and then we'll go to the next question -- or</p> <p>17 just so I've read through the slide. Erta at one gram</p> <p>18 -- I think I've talked about what I know about that.</p> <p>19 You know, it doesn't look dumb, but it needs some</p> <p>20 work. We've just now been talking about the small N</p> <p>21 Those margins -- and I would like to have a reflection</p> <p>22 from our colleagues -- the statistical and regulatory</p>	<p style="text-align: right;">Page 508</p> <p>1 And so the nice thing about it -- and the</p> <p>2 numbers were, of course, chosen to do this, right? I</p> <p>3 -- this -- everything about this is set up to give you</p> <p>4 the chance to meditate on this.</p> <p>5 So now the lower bound of the 95 -- 90</p> <p>6 percent confidence interval is minus 19, so it's</p> <p>7 inside of FDA's actual M-1 by 1 percent, okay? And</p> <p>8 ditto the negative 13.6. Okay. So it's inside</p> <p>9 negative 14 by 0.4 percent. Do you feel any better?</p> <p>10 MR. DANE: So, John, the other thing --</p> <p>11 DR. REX: These are the questions I want to</p> <p>12 be sure we cover, so.</p> <p>13 MR. DANE: Yeah, the other thing I would add</p> <p>14 on that last point, though, is that, although for a</p> <p>15 specific case when you observe the data, the</p> <p>16 confidence intervals shift by a few percent, and you</p> <p>17 could argue about whether that's important or not.</p> <p>18 Where it can be important is where you're designing</p> <p>19 the trial and having to figure out how big it's going</p> <p>20 to be and the feasibility. It can have an impact</p> <p>21 there as well. So that's where it can help as much as</p> <p>22 what the result looks like when you get to the end of</p>

<p style="text-align: right;">Page 509</p> <p>1 the study.</p> <p>2 DR. REX: Right --</p> <p>3 MR. HOOFTMAN: So it makes it --</p> <p>4 DR. REX: You're right. So this is powering</p> <p>5 versus actual data. So here a lot of the power</p> <p>6 questions are now gone at this point. We've invented</p> <p>7 some data. You know, we have what we have.</p> <p>8 MR. DANE: Yeah.</p> <p>9 DR. REX: Right. So I want to be sure we</p> <p>10 cover these questions, pros and cons from all</p> <p>11 perspectives. So we've got to talk about how to deal</p> <p>12 with two body sites. You know, what do you do there?</p> <p>13 Come back to concomitant therapy. Is there anything</p> <p>14 other than erta we could use? There's implicit</p> <p>15 approach to polymicrobial versus monomicrobial, just</p> <p>16 to double check. Any other thoughts on MDR</p> <p>17 pseudomonas and best available therapies? So we've</p> <p>18 kind of covered some of these, but if you're looking</p> <p>19 for a question to poke on, be sure we poke on one of</p> <p>20 these.</p> <p>21 So there was somebody holding their hand up</p> <p>22 a minute ago. Yeah, Tom?</p>	<p style="text-align: right;">Page 511</p> <p>1 is in whatever range is required, if you like. And on</p> <p>2 the design side, you can then ask what kind of a</p> <p>3 sample size would be needed if the true differences in</p> <p>4 a certain situation so that there's a high likelihood</p> <p>5 that that posterior probability will be sufficiently</p> <p>6 large. In other words, you can do -- you can reverse-</p> <p>7 engineer to do the design question, too.</p> <p>8 MR. DANE: Yeah, I mean, I would say on</p> <p>9 that, that's true. You still need -- a company going</p> <p>10 into a study and investing still needs to have an idea</p> <p>11 of what's going to be sufficient for approval, though.</p> <p>12 So, yeah, I agree with everything you say, but in some</p> <p>13 ways, whether it's an alpha level, whether it's a</p> <p>14 likelihood, that question still remains, is what's the</p> <p>15 acceptable regulatory risk in doing some of this in</p> <p>16 terms of incorrectly approving something.</p> <p>17 AUDIENCE MEMBER: (inaudible - off mic).</p> <p>18 DR. REX: Yeah. Well, and I think what</p> <p>19 you're saying is that we might need to spend some time</p> <p>20 as a community getting to where we understand -- what</p> <p>21 you're talking about, I can get a feel for it from a</p> <p>22 distance, but we'd actually have to be able to</p>
<p style="text-align: right;">Page 510</p> <p>1 DR. LOUIS: Tom Louis. Just to comment on</p> <p>2 the previous discussion on the 95 interval, the 90</p> <p>3 interval, it becomes endless. And here's a perfect</p> <p>4 case where, let's say, with uninformative priors on</p> <p>5 the underlying parameters -- or if you have some</p> <p>6 knowledge on baseline, just put it in. Compute the</p> <p>7 posterior probability that the difference in -- the</p> <p>8 true difference in the parameters is in the range that</p> <p>9 it needs to be in. I don't know what that number will</p> <p>10 be in this case, but it's far better than, oh, what</p> <p>11 about the 90, what about the 95. Just have a direct</p> <p>12 answer to that underlying question and --</p> <p>13 DR. REX: So you're getting at the -- a true</p> <p>14 posterior probability, or in terms that I understand,</p> <p>15 the likelihood?</p> <p>16 DR. LOUIS: Well, it would be based -- is if</p> <p>17 it were uninformative and being, if you like,</p> <p>18 frequentist, it would be based on the likelihood and</p> <p>19 would ask the question directly. It would say we</p> <p>20 don't see the parameters, but we -- there is a true</p> <p>21 difference. Let's build a model that computes the</p> <p>22 posterior probability, given the data, that the truth</p>	<p style="text-align: right;">Page 512</p> <p>1 understand it broadly enough that even if a pair who</p> <p>2 is being shown the data is -- you're able to say in a</p> <p>3 way that actually sort of conveys the feel for the</p> <p>4 strength of the information. And so that's something</p> <p>5 to work on. It's a new form of -- you know, because</p> <p>6 we haven't often -- we have never actually publicly in</p> <p>7 these conversations done anything other than standard</p> <p>8 frequentist statistics that we all learned in -- as</p> <p>9 freshmen in college, you know, that sort of thing. So</p> <p>10 it's a well-said point.</p> <p>11 MR. DANE: John, my other point on -- just</p> <p>12 related to that was that, you know, whether we talk</p> <p>13 about alpha levels or likelihoods, that the other</p> <p>14 point is that sometimes they can be useful rather than</p> <p>15 going to bigger and bigger non-inferiority margins</p> <p>16 that people become uncomfortable with because we say,</p> <p>17 well, we can have a margin of 40 percent, for example,</p> <p>18 because it's feasible. But who's going to be happy</p> <p>19 saying, well, we could be 40 percent worse, whereas</p> <p>20 something with a tighter margin -- but you're just</p> <p>21 saying, well, we've got a big more risk of what we're</p> <p>22 doing here might be a good balance and a better</p>

Page 513	Page 515
<p>1 balance than going that way.</p> <p>2 DR. REX: And so to say it back to you, in</p> <p>3 effect, that's what I did here. I made the confidence</p> <p>4 bound fit inside the margin by picking a different</p> <p>5 alpha. Actually, I did -- I set this up so that this</p> <p>6 would be true. But the point is that it's</p> <p>7 mathematically -- it's -- the underlying data are the</p> <p>8 same. It's the question of how do you talk about them</p> <p>9 and whether -- do you want to construe it as margin</p> <p>10 risk, or is it likelihood of making a certain kind of</p> <p>11 mistake risk. And -- but mathematically, it's the</p> <p>12 same. Am I saying it correctly? I mean you -- yeah,</p> <p>13 okay.</p> <p>14 AUDIENCE MEMBER: (inaudible - off mic).</p> <p>15 DR. REX: Well, see, I wanted this case to</p> <p>16 try to get at these debates. You're right.</p> <p>17 Okay, so Kenneth?</p> <p>18 MR. HILLIN: John, thanks.</p> <p>19 It's an extremely thoughtful and thought-</p> <p>20 provoking illustration, I think, that you're given</p> <p>21 here. And I guess there's lots that we could discuss</p> <p>22 and I'm sure that we will discuss. But as you take a</p>	<p>1 guidance document. And I think, you know, you're</p> <p>2 asking a question of how far can you stress M-1. I</p> <p>3 mean, if you really, you know, look at this very</p> <p>4 carefully and, you know, the 29 percent, versus the 20</p> <p>5 percent, versus the, you know, 10 or 12, 5, whatever</p> <p>6 it is --</p> <p>7 DR. REX: Use the microphone.</p> <p>8 DR. COX: Yeah, whatever it is in the</p> <p>9 situation that you're using it, you move from M-1 to</p> <p>10 M-2. I mean, it is a good question, and it's probably</p> <p>11 worth looking back at those numbers a little bit more</p> <p>12 and seeing, you know, how big things are. And then,</p> <p>13 you know, just to see, you know, where it is. Those</p> <p>14 numbers are pretty messy, though, from what I</p> <p>15 understand. And if I remember correctly, for</p> <p>16 complicated intra-abdominal, that was like -- I mean,</p> <p>17 it was not only sort of looking at the numbers, but</p> <p>18 there was also gymnastics involved in trying to work</p> <p>19 through that one because we didn't quite have the data</p> <p>20 that we needed. But we were able to get to something</p> <p>21 that told us about treatment effect, so --</p> <p>22 DR. REX: Well, I want to say the approach</p>
Page 514	Page 516
<p>1 step back and you look at this, I wonder if at some</p> <p>2 point during today's discussion we might take a vote</p> <p>3 in the room and ask people to put up their hands if</p> <p>4 they would be willing to run such a trial because I</p> <p>5 suspect, although I could be wrong, that they'll be</p> <p>6 very hands in the room that will go up. And so I just</p> <p>7 wanted to commend you for sharing this.</p> <p>8 DR. REX: Okay, well, thank you. We've had</p> <p>9 a good time putting it together. Lynn?</p> <p>10 DR. MARKS: Quick question. If you have a</p> <p>11 big issue (ph) non-inferiority margin and at the</p> <p>12 bottom of the inverted pyramid you have 20 MDRs in one</p> <p>13 arm and, I'll say, 25 and 17 and a half in the other</p> <p>14 arm and there's a descriptive but what some people</p> <p>15 would call medically interesting difference, would</p> <p>16 that be able to provide --</p> <p>17 DR. REX: I think that's upside, you know.</p> <p>18 I think, you know, that's helpful.</p> <p>19 DR. COX: And John, you were asking about</p> <p>20 this a little bit ago, and Sumathi and I talked some</p> <p>21 about this. And that is, you know, the margins and</p> <p>22 sort of setting them, the ones that are in the</p>	<p>1 that was -- so that you've heard it, the approach</p> <p>2 taken for intra-ab went as follows. There are no data</p> <p>3 on placebo therapy of complicated intra-abdominal</p> <p>4 infection. No one could find any. So something was</p> <p>5 found that's kind of like that, which is in the '60s</p> <p>6 and '70s there was a serious question about whether or</p> <p>7 not you needed antibiotic prophylaxis if you were</p> <p>8 about to have bowel surgery, so what we would call a</p> <p>9 clean contaminated procedure.</p> <p>10 I'm going to open you up. I'm going to</p> <p>11 transect your gut. So I'm going to spill bacteria.</p> <p>12 I'm going to sew you back up. Do you need prophylaxis</p> <p>13 to prevent -- so you didn't have an infection before.</p> <p>14 Do you develop one post-op?</p> <p>15 And so there were placebo-controlled studies</p> <p>16 of that done. What's the rate of preventing</p> <p>17 development of infections? So it didn't have an</p> <p>18 infection, didn't develop, versus didn't have and did</p> <p>19 develop with or without therapy.</p> <p>20 And so that -- and if you flip that -- so</p> <p>21 that's the closest anybody could come. And you flip</p> <p>22 that upside down and you can construe that to be the</p>

<p style="text-align: right;">Page 517</p> <p>1 rate of treating infections.</p> <p>2 So Mike Dudley is looking at me -- what does</p> <p>3 that mean? So in -- hypothetically, I've just cut</p> <p>4 through your wall of your bowel, and I've just created</p> <p>5 an infection. Let's pretend that I create a little</p> <p>6 baby infection right at that moment.</p> <p>7 So if I then put you on an antibiotic, I'm</p> <p>8 treating this itty bitty tiny infection. Or I don't</p> <p>9 put you on an antibiotic. I'm not treating it. And</p> <p>10 post-response will control some of them. Antibiotics</p> <p>11 will control some of the others.</p> <p>12 So that's how it was computed. And it</p> <p>13 actually showed that there is a benefit of</p> <p>14 perioperative antibiotics if I'm going to transect</p> <p>15 your gut wall. I very clearly show that, which, you</p> <p>16 know, is something we want to do.</p> <p>17 And you find that there is a difference</p> <p>18 between -- and you can actually -- the math -- so go</p> <p>19 read the guide. Now that you've heard the story, go</p> <p>20 read the guidance document again. You know, I thought</p> <p>21 it was a -- not a bad approach, and it, you know --</p> <p>22 show me something better. You guys -- like, all</p>	<p style="text-align: right;">Page 519</p> <p>1 treatment or your ertapenem isn't working. And how</p> <p>2 you can send for that in a situation of HBAP/VBAP to a</p> <p>3 patient where alternative treatments, which actually</p> <p>4 are approved, are available. So for me, that is one</p> <p>5 issue.</p> <p>6 The second issue is that even you have a</p> <p>7 fantastic new drug called X-1. Actually, that doesn't</p> <p>8 come for free. There will be safety issues. And some</p> <p>9 you raised and whatever they are. So you're going to</p> <p>10 treat 75 percent of the patients in that trial</p> <p>11 empirically with a useless drug. And they're exposed</p> <p>12 to safety issues.</p> <p>13 And you know, I'm 10 years plus chief</p> <p>14 medical officer of two companies. And I -- in an</p> <p>15 internal ethical committee, we would have a huge</p> <p>16 debate whether we would expose these patients to that</p> <p>17 risk and what type of warning we would give to them</p> <p>18 and how recruitable would be the study then at the end</p> <p>19 if you display that information to the participants.</p> <p>20 And so for me, it's not only a financial feasibility</p> <p>21 or an evidence issue, it is just an ethical</p> <p>22 feasibility to get all those patients on board and</p>
<p style="text-align: right;">Page 518</p> <p>1 models are flawed. You know, if you don't like this</p> <p>2 approach, you can't just criticize. You have to</p> <p>3 solve. So you know, my hat's off for somebody for</p> <p>4 having found a path.</p> <p>5 Question?</p> <p>6 UNIDENTIFIED MALE SPEAKER: Well, I think</p> <p>7 it's great work, and all the discussion focused on</p> <p>8 regulatory aspects and on statistical aspects and on</p> <p>9 evidence. I just want to shed a little bit of light</p> <p>10 on those patients who actually do not have pseudomonas</p> <p>11 infection in that study.</p> <p>12 So first of all, in the arm -- in the</p> <p>13 experimental arm that -- actually two experimental</p> <p>14 drugs because the drugs are approved, so probably you</p> <p>15 needed the DSMB on that arm. And what happens if that</p> <p>16 ertapenem actually is inferior in the non-PS, which is</p> <p>17 75 percent of the patients --</p> <p>18 DR. REX: That's a risk.</p> <p>19 UNIDENTIFIED MALE SPEAKER: What happens to</p> <p>20 the study? You're going to stop the study not because</p> <p>21 the PS isn't working, the pseudomonas. You'll</p> <p>22 probably stop the study because your adjunctive</p>	<p style="text-align: right;">Page 520</p> <p>1 telling them what their likelihood of benefit versus</p> <p>2 their likelihood of risk is in that arm.</p> <p>3 DR. REX: Yeah. Good point, and it actually</p> <p>4 makes Jeff Loudit's (ph) comment that you ought to</p> <p>5 keep them on the study more pointed. So if you know</p> <p>6 it's not pseudomonas, you ought to just keep on</p> <p>7 running it because now you're at least getting data on</p> <p>8 how well erta works. And so I had not thought about</p> <p>9 that aspect of it, but it's a very well -- one of the</p> <p>10 risks here is that erta is not an approved drug as the</p> <p>11 combination. But you know, look -- come up with a</p> <p>12 better solution. You know, I didn't like Tigecycline,</p> <p>13 so, you know, I came down on the side of ertapenem.</p> <p>14 Jeff and then Ian.</p> <p>15 MR. LOUDIT: So Dave asked -- Dave said no</p> <p>16 one would run this study, so I'm going to put my neck</p> <p>17 out here. I would run this study, Dave, with three</p> <p>18 caveats.</p> <p>19 DR. REX: Okay.</p> <p>20 MR. LOUDIT: One, it's somebody else's</p> <p>21 money. That would be --</p> <p>22 (Laughter)</p>

Page 521	Page 523
<p>1 MR. LOUDIT: So two -- the second caveat is</p> <p>2 that the FDA agreed to those non-inferiority modules.</p> <p>3 The third caveat, though, is the really</p> <p>4 important one to me, which is the rapid diagnostic</p> <p>5 test. So there are actually companies that are now</p> <p>6 developing almost by-the-bedside tests which can tell</p> <p>7 you within a very short period of time whether you</p> <p>8 have pseudomonas, acinetobacter, et cetera. And that</p> <p>9 significantly cuts down your costs of screening and</p> <p>10 enrollment.</p> <p>11 So I would be willing to do this study, and</p> <p>12 we're planning to do a similar study like this, Dave,</p> <p>13 in the near future with -- I guess it -- I don't have</p> <p>14 the second caveat agreed to yet.</p> <p>15 DR. REX: Well -- yeah, that's good. And</p> <p>16 the thing about the diagnostic, for our purposes, was</p> <p>17 we were assuming that it wasn't something that</p> <p>18 required a lot of maintenance. It didn't require a</p> <p>19 big site -- sort of a user manual at the site. It</p> <p>20 needed to be something -- because if money is no</p> <p>21 object, then you can do lots of things. But here,</p> <p>22 it's for something that you're going to be using</p>	<p>1 And likewise, ertapenem could make this drug more</p> <p>2 effective against pseudomonas. So I think if we think</p> <p>3 about this just as a regimen, we're evaluating the two</p> <p>4 drugs together.</p> <p>5 And at the end of the day, what you can say</p> <p>6 -- this is the safety and efficacy of this regimen,</p> <p>7 and that's the way the drug gets approved. It's in</p> <p>8 combination with ertapenem just as if we had put the</p> <p>9 two drugs together in a vial and said this is the</p> <p>10 product we're developing.</p> <p>11 DR. COX: Do you want me to comment on that?</p> <p>12 So, I mean, just one thing to think about, though,</p> <p>13 too, is I think, you know, this is the opportunity to</p> <p>14 test the efficacy of X-1. So you know, within that</p> <p>15 population of patients that are getting the drug,</p> <p>16 you'll want to be able to discern what was the effect</p> <p>17 of X-1. And oftentimes, I mean, one of the ways to</p> <p>18 think about this is suppose that your population of</p> <p>19 patients you enrolled, you know -- very few</p> <p>20 pseudomonas aeruginosa. You know, I think it becomes</p> <p>21 more difficult. So somewhere in there, you'll want to</p> <p>22 be able to figure out, you know, what X-1 is doing.</p>
Page 522	Page 524
<p>1 infrequently. You know, I wanted something without</p> <p>2 batteries.</p> <p>3 So Ian? And then --</p> <p>4 DR. FRIEDLAND: I also wanted --</p> <p>5 DR. REX: -- Paul's wiggling his fingers, so</p> <p>6 he's next.</p> <p>7 DR. FRIEDLAND: Thank you for going through</p> <p>8 this exercise because it is very useful to take a</p> <p>9 practical example and actually look at the numbers.</p> <p>10 There is a potential way to think about this</p> <p>11 a bit differently that could try and counter some of</p> <p>12 the points that are being made, and the one is to</p> <p>13 consider this a regimen. The regimen you're</p> <p>14 evaluating is ertapenem plus this drug. And you're</p> <p>15 not going to try and sort out what the one drug does</p> <p>16 and what the other drug does -- what the other one</p> <p>17 does. You know, one drug for one bug gets very</p> <p>18 complicated.</p> <p>19 We also don't know -- there could be a</p> <p>20 really positive interaction between the two drugs. It</p> <p>21 could be this could synergize with ertapenem and make</p> <p>22 ertapenem active against carbapenem-resistant strains.</p>	<p>1 DR. REX: But there is the intra-ab. You</p> <p>2 could take Ian's comment and say, well, in the intra-</p> <p>3 ab component, I get the monotherapy insight. And --</p> <p>4 but for nosocomial pneumonia, it's labeled as if it</p> <p>5 was a thing. I mean, I --</p> <p>6 DR. CAVALERI: Yeah.</p> <p>7 DR. REX: And I -- part of the assumption</p> <p>8 that was in the written version of the case was that</p> <p>9 the sponsor knows that something like that could come</p> <p>10 in the label, but why would I object to that being in</p> <p>11 the label, you know?</p> <p>12 DR. CAVALERI: Right. Yeah, and we have</p> <p>13 done that -- I mean, if -- some of the drugs that are</p> <p>14 used in combination with other drugs. But, you know,</p> <p>15 I'm just sort of saying that the test needs to be sort</p> <p>16 of a valid way to assess the effect of the drug and</p> <p>17 that the drug is used with other drugs is not</p> <p>18 necessarily a problem per se. But if it obscures the</p> <p>19 ability to assess the effect of the drug, then it gets</p> <p>20 a little more complicated, so.</p> <p>21 DR. REX: Okay. So let's look at these</p> <p>22 questions and be sure that we've -- sorry, Paul</p>

Page 525	Page 527
<p>1 Ambrose is waving his hand.</p> <p>2 Go for it, Paul. We really have plenty of</p> <p>3 time to discuss, and I don't want any idea to lie</p> <p>4 fallow.</p> <p>5 DR. AMBROSE: All right, I don't have an</p> <p>6 idea, I -- just a comment. Is there any concern that</p> <p>7 ertapenem is being picked here because -- well, it's</p> <p>8 being picked because we think its PK/PD will predict</p> <p>9 as active, right? It's got --</p> <p>10 DR. REX: Talk straight into the microphone.</p> <p>11 DR. AMBROSE: It's got no randomized</p> <p>12 clinical trial in nosocomial pneumonia. It's just</p> <p>13 being picked because the PK/PD for it -- forecasts</p> <p>14 it'll work. Is there any concern that we're comparing</p> <p>15 a new drug to something we don't really understand</p> <p>16 would work? For me, I mean, I really believe in the</p> <p>17 PK/PD as you -- I put a lot of weight in it, but it's</p> <p>18 an interesting precedent that you're setting up.</p> <p>19 DR. REX: I think that is a concern. And</p> <p>20 you know -- make another suggestion. You know, maybe</p> <p>21 as a community, we need to do an ertapenem --</p> <p>22 DR. FRIEDLAND: There actually is a clinical</p>	<p>1 DR. REX: Do you remember offhand if the</p> <p>2 mortalities were comparable in the two arms?</p> <p>3 DR. FRIEDLAND: No, I can't remember all the</p> <p>4 data. The main reason it wasn't submitted was because</p> <p>5 maybe it did too well, and at the time commercially</p> <p>6 they wanted to distinguish it from other carbapenems.</p> <p>7 They didn't want it to look as good as meropenem and</p> <p>8 ertapenem against, like, really sick patients. So it</p> <p>9 was a very strange reason why it was never actually</p> <p>10 promoted or --</p> <p>11 DR. REX: Well, it's -- so maybe there's a</p> <p>12 bit more data than we realize. And like I say, you</p> <p>13 know, the little bit I scrounged up, actually, it</p> <p>14 looks -- it looked as if it ought to work, you know.</p> <p>15 Sorry.</p> <p>16 MR. ARAKOFF: Dmitri Arakoff (ph),</p> <p>17 divisional and executive (ph) products of DE (ph).</p> <p>18 Since we have time for discussion, I'd like to address</p> <p>19 this question of immunotherapy versus dual therapy.</p> <p>20 Looking at the guidance, it seems that they deem</p> <p>21 immunotherapies acceptable as long as your drug is</p> <p>22 active against isolated pathogens. And the reason --</p>
Page 526	Page 528
<p>1 trial with ertapenem done in HABP and non-ventilated -</p> <p>2 - and early-onset VABP. It was just never submitted</p> <p>3 for reasons other than efficacy.</p> <p>4 DR. REX: You're kidding.</p> <p>5 DR. FRIEDLAND: But it actually was a trial.</p> <p>6 It was actually the very first trial I ever conducted</p> <p>7 in industry was a VABP -- a HABP/VABP trial with</p> <p>8 ertapenem. It is published. It was just never</p> <p>9 submitted for approval.</p> <p>10 DR. REX: Yeah.</p> <p>11 AUDIENCE MEMBER: (inaudible - off mic).</p> <p>12 DR. REX: So I was getting comments from two</p> <p>13 directions. So you're -- actually, I think -- find</p> <p>14 those data, you know. And, sir, did you say -- how</p> <p>15 did it do? I missed that part.</p> <p>16 DR. FRIEDLAND: It was -- you know, it was</p> <p>17 done back in 2000 --</p> <p>18 DR. REX: Back in the year aught, all right.</p> <p>19 DR. FRIEDLAND: So way -- non-inferiority</p> <p>20 margins were acceptable, but it was like a 350-patient</p> <p>21 study versus pip/tazo, and it fell within the non-</p> <p>22 inferiority margin of 15 percent to 20 percent of --</p>	<p>1 we give dual therapies to -- not to prevent</p> <p>2 resistance, but to make sure that at least one drug is</p> <p>3 active --</p> <p>4 DR. REX: Is active.</p> <p>5 MR. ARAKOFF: -- meaning that if you study a</p> <p>6 drug supposedly active against resistant pathogens,</p> <p>7 maybe this criteria not applicable to your product.</p> <p>8 And it's acceptable to use a new product, at least in</p> <p>9 this active arm.</p> <p>10 DR. REX: Yeah, so -- and I think if you</p> <p>11 felt like you could do that, that would be great</p> <p>12 upside. I considered the possibility for nosocomial</p> <p>13 pneumonia of saying -- of doing it the same way I did</p> <p>14 in complicated intra-ab, which is to say Amikacin is</p> <p>15 given, but it is blinded versus placebo. So the X-1</p> <p>16 arm gets a placebo Amikacin, and the meropenem arm</p> <p>17 gets real Amikacin. And you somehow blind even doing</p> <p>18 of levels and things like that. And I think you could</p> <p>19 do that. And if you could, that would certainly help</p> <p>20 clarify the dataset.</p> <p>21 I just chose for purposes of this discussion</p> <p>22 to make us deal with the possibility that there will</p>

<p style="text-align: right;">Page 529</p> <p>1 be a desire for two drugs. And the -- if you look at</p> <p>2 the IDSA guidelines, you know, what they've said is,</p> <p>3 oh, wrong way. They really are kind of wishy-washy on</p> <p>4 this, you know. They -- sometimes they still want two</p> <p>5 drugs, and so I don't assume to know where the logic</p> <p>6 is going to go in the future, but your point is really</p> <p>7 good.</p> <p>8 MR. ARAKOFF: Because what would be the</p> <p>9 argument to the second drug? This is my point if it's</p> <p>10 -- right.</p> <p>11 DR. REX: Yeah, well, and the argument might</p> <p>12 be -- you know, Paul Ambrose yesterday said, well,</p> <p>13 even with a single active drug, there's still a tail</p> <p>14 of exposures in some subjects. And so, you know,</p> <p>15 maybe it's nice for that reason. It's not about</p> <p>16 susceptibility. It's about exposure.</p> <p>17 Mike?</p> <p>18 But you're right. Part of this was about</p> <p>19 not picking -- not making everything always go our way</p> <p>20 in terms of the analysis. I really wanted stuff that</p> <p>21 -- to stretch the envelope.</p> <p>22 DR. DUDLEY: Yeah, I'd like to go back to a</p>	<p style="text-align: right;">Page 531</p> <p>1 pneumonia.</p> <p>2 So I just wanted to clarify would the</p> <p>3 labeling in this case -- would be used in combination</p> <p>4 with a carbapenem in the treatment of pneumonia or</p> <p>5 HABP/VABP. But -- he said yes.</p> <p>6 DR. REX: Whatever it is --</p> <p>7 DR. COX: Yeah, so, I mean, I think, you</p> <p>8 know, that we can do that. We've done that. I'm</p> <p>9 thinking of ceftolozane/tazobactam, where we added,</p> <p>10 you know, to the complicated intra-abdominal we said</p> <p>11 used in combination with metronidazole. So -- but</p> <p>12 that's, I mean -- so that's a very easily solvable</p> <p>13 issue.</p> <p>14 And it seems like -- and I'm -- in this</p> <p>15 trial where we're enrolling patients with pseudomonas</p> <p>16 aeruginosa, we've picked ertapenem because it's whole,</p> <p>17 and coverage is that it doesn't cover pseudomonas</p> <p>18 aeruginosa. It seems that what we're really trying to</p> <p>19 do is -- you know, within this regimen is to be able</p> <p>20 to test the role of X-1 by isolating it, if you will.</p> <p>21 And you know, the -- so I think -- you know, that's</p> <p>22 really what I think we're trying to learn out of this.</p>
<p style="text-align: right;">Page 530</p> <p>1 point I think Ian was making before, though, is what</p> <p>2 you really are is testing a regimen here. So this</p> <p>3 regimen is -- of ertapenem plus X-1 is a broad-</p> <p>4 spectrum regimen. And even though we've got sort of</p> <p>5 some enrichment or you've got your device and so</p> <p>6 forth, we're still treating with a broad-spectrum</p> <p>7 regimen.</p> <p>8 I'm curious about whether or not the</p> <p>9 labeling would be then specifying that it was -- you</p> <p>10 know, this drug is being used in combination with a</p> <p>11 carbapenem, and that what you really did test</p> <p>12 specifically was a carbapenem combination with this.</p> <p>13 And I think about -- for the -- the example</p> <p>14 that comes to mind is that piperacillin/tazobactam</p> <p>15 failed miserably as monotherapy in pseudomonas</p> <p>16 pneumonia in the initial trials -- miserably. And</p> <p>17 then when it was -- their trials were repeated in</p> <p>18 combination with an aminoglycoside, it worked because</p> <p>19 no -- it prevented resistance from emerging during</p> <p>20 therapy. So the actual label, I believe, actually</p> <p>21 states that it's indicated for use with an</p> <p>22 aminoglycoside and the treatment of pseudomonas</p>	<p style="text-align: right;">Page 532</p> <p>1 DR. REX: Right. It was all about --</p> <p>2 DR. COX: So we could say use it in</p> <p>3 combination with ertapenem --</p> <p>4 DR. REX: Coming at it from more than one</p> <p>5 direction.</p> <p>6 DR. COX: -- but we're really trying to</p> <p>7 figure out --</p> <p>8 AUDIENCE MEMBER: (inaudible - off mic).</p> <p>9 DR. REX: Oh, no, we're --</p> <p>10 DR. COX: Agree, yes.</p> <p>11 DR. REX: -- fully expecting E. colis and</p> <p>12 Klebsiellas and other things. Absolutely.</p> <p>13 DR. COX: And that's why the ertapenem is</p> <p>14 there. It's, you know -- there are other things.</p> <p>15 Either we're going to have patients that we don't</p> <p>16 culture. You know, it's going to take a while to get</p> <p>17 the culture back, just like the empiric Amikacin. But</p> <p>18 what I'm trying to get to is what the -- you know, the</p> <p>19 primary analysis, it would seem, would be on those</p> <p>20 patients that have pseudomonas aeruginosa, hopefully</p> <p>21 not too much concomitant Amikacin, not too much pre-</p> <p>22 study therapy, to try and isolate the effect of X-1</p>

<p style="text-align: right;">Page 533</p> <p>1 and figure out -- you know, it's only active against 2 pseudomonas aeruginosa to try and figure out how does 3 it perform against pseudomonas aeruginosa because, you 4 know, in subsequent trials in patients with 5 pseudomonas aeruginosa this drug will be used. And 6 this is the chance to figure out whether it works or 7 not. 8 DR. REX: And just for flow of time, we're 9 going to go until 12:15, another seven minutes. And 10 then we're going to take a break, come back at 1:00. 11 So just so you set expectations. 12 The lady right here in the yellow blouse had 13 a question and the gentleman at the mic. So I thought 14 -- you raised your hand. I thought I saw you raise 15 your hand. 16 UNIDENTIFIED FEMALE SPEAKER: Sorry, I'm at 17 the risk of belaboring a point that isn't necessarily 18 shared here. But I can't see how you could ethically 19 randomize a sick patient as was described to a regimen 20 that only included a single possibly active agent 21 against pseudomonas. Your test agent -- you have pre- 22 clinical data. The only clinical data you have are in</p>	<p style="text-align: right;">Page 535</p> <p>1 about it. I -- 2 DR. TOMAYKO: John, just to add, this is 3 what you're saying. You're rejecting the clinical 4 equipoise argument that would be made, and I'd take it 5 a step further, that that's -- would apply to a broad- 6 spectrum agent as well. It's -- 7 DR. REX: And so that's what I'm saying -- 8 DR. TOMAYKO: Yeah, it's not limited to a 9 single agent. And what you have to really believe in 10 is that, you know, you could generate PK data. You 11 could generate efficacy data in relevant pre-clinical 12 models, and that you've looked for resistance, that 13 you understand the likelihood that the patient will be 14 infected with the appropriate susceptible isolates and 15 hopefully that you're going to conduct a clinical 16 trial. We will be watching very closely. 17 Now, I will come back and say that I have 18 had the personal experience of a whole country 19 basically saying we're not going to let you do an 20 intra-abdominal study in our country because you've 21 never studied a novel agent in anything and we think 22 that population is too vulnerable and maybe you should</p>
<p style="text-align: right;">Page 534</p> <p>1 non-CF-bronchiectasis. 2 It's a very small study with limited, if 3 any, efficacy information. And you're going to 4 randomize a patient to ertapenem plus your 5 investigational agent when we know that the major 6 factor that predicts mortality, which already we know 7 is high, is being initially on appropriate therapy. I 8 just can't see how you could randomize patients to 9 that arm. 10 DR. REX: Well, I think you're asking a very 11 general question. How then can I develop any novel 12 antibiotic -- 13 UNIDENTIFIED FEMALE SPEAKER: Yep. 14 DR. REX: -- as monotherapy? And I think 15 that that question -- you know, we can -- we'll come 16 -- we can come back to that after lunch, if you'd like, 17 because there's a lot of thoughtful commentary in the 18 literature on that point. If you say that you can't -- 19 -- yeah, we do this, and this is how drugs get 20 advanced. And if you're not willing to do at least 21 this much, then we're at a dead stop in more than one 22 area. I mean, I don't know what else to tell you</p>	<p style="text-align: right;">Page 536</p> <p>1 go to a UTI study first. But you get a -- the 2 majority of countries were happy to initiate both an 3 IAI and a UTI study. 4 So it is an IRB or a personal kind of 5 determination that has to be made. But you should 6 generate the right data. 7 DR. COX: So just another thought -- and 8 this has come up in discussions, too. It is sometimes 9 when you're trying to advance a drug to treat patients 10 with, you know, more severe infections, with, you 11 know, higher mortality rates, you may try and do a 12 lesser -- less severe infection initially, something 13 with a lower mortality rate, something where there's 14 an opportunity to sort of test the drug and then sort 15 of advance up the scale of things that are more 16 severe. 17 But, I mean, your comment is also 18 interesting, too, in that if you think about what 19 we're talking about here, we're talking about the 20 highly controlled setting of a clinical trial and then 21 advancing a compound to be used out there in the real 22 world. So it also is a very sobering comment with</p>

<p style="text-align: right;">Page 537</p> <p>1 regards to the use of the drug out there. What types 2 of data would we have -- what types of information we 3 have, you know, that would allow us to be comfortable 4 in a clinical trial and what types of information we 5 want to have to be comfortable using this drug outside 6 of the highly controlled setting of a clinical trial 7 when it's out there in the real world? So ...</p> <p>8 DR. REX: Yeah, but you could run the IAI 9 component of this program for a year and have the DSMB 10 look at it and say, yes, it looks like it's working 11 out. Sort of you could eke -- you could ease your way 12 into it because the mortality in IAI -- you can sort 13 of salvage there. The mortality tends to be very low, 14 so a really good question. You know, I pitched it as 15 going together, but you certainly could stagger them.</p> <p>16 At the microphone?</p> <p>17 UNIDENTIFIED MALE SPEAKER: Yeah, so just to 18 touch on a point that's already been raised but it's 19 still not clear to me, you're just ignoring the ITT 20 population it seems here. So you have subjects who 21 are potentially being treated three or four days 22 before you come back with culture positivity. And you</p>	<p style="text-align: right;">Page 539</p> <p>1 you know, I mean, maybe they don't have an infection. 2 Maybe there's something masquerading as nosocomial 3 pneumonia here. It would be hard to test efficacy if 4 they don't have the pathogen of when -- which the drug 5 as active.</p> <p>6 Your point about the ITT, though, we do 7 always look at the ITT because if there's something 8 going in the wrong way, a safety issue, you know, in 9 the overall population, maybe there's something we 10 didn't anticipate or don't understand that's important 11 to know about in patients who are receiving this drug, 12 even though they don't have the target pathogen. So 13 an ITT that was, you know, for some reason going in 14 the wrong way would suggest there was something that 15 we didn't know about that we should know about.</p> <p>16 UNIDENTIFIED MALE SPEAKER: The reasons we 17 talked about, you know, that the study should be 18 replicating how it's going to be used in the clinic 19 and if what we'll be proposing is a substitution of X- 20 1, you know, into the regimen potentially with 21 ertapenem, if that's what the decision is and the way 22 that the labeling goes, so it is, you know, a broad</p>
<p style="text-align: right;">Page 538</p> <p>1 know, you're talking about the pseudomonas active 2 differential. How would that ITT result factor into 3 your interpretation then at this equivalency?</p> <p>4 And just -- some of my Merck colleagues are 5 here, too. I didn't work for Merck at the time, but 6 my recollection of ertapenem was there was a grave 7 concern about using that in the ICU because of the 8 lack of pseudomonas activity causing resistance to 9 carbapenems. I think that's why that decision was 10 made not to bring that forward.</p> <p>11 DR. REX: Yeah, you know, interesting. I 12 think that you would have -- the full ITT would be one 13 of your secondary analyses, and it would at least need 14 to not show anything wildly discrepant, something like 15 that.</p> <p>16 MR. DANE: Yeah -- go ahead. Go ahead.</p> <p>17 DR. COX: I was going to say, I mean, you 18 know, the reason we're looking at the MITT here is 19 because of the limited spectrum of the drug we're 20 testing -- if it's only active against pseudomonas 21 aeruginosa, you know, patients who don't have 22 pseudomonas aeruginosa that may have something else,</p>	<p style="text-align: right;">Page 540</p> <p>1 implication. Are you absolutely going to require the 2 diagnostic before you put them onto therapy? And then 3 it's not being used as it was in the study because 4 it's no longer being used more on an empiric basis but 5 on a confirmed diagnosis, so it's --</p> <p>6 DR. REX: I guess if I price it high enough, 7 you'll think really hard about using it.</p> <p>8 MR. DANE: I think the other thing to add 9 there is that in a non-inferiority study, if hardly 10 anybody has got the pathogen you're interested in, you 11 may well show non-inferiority and not have the 12 activity against pseudomonas. So I think you'd want 13 to understand it primary there and just make sure 14 nothing else was going wrong.</p> <p>15 DR. REX: Yeah, okay. It's 12:15. Let's go 16 have lunch and bring our glucose levels back up. Be 17 back at 1 o'clock, please.</p> <p>18 (Off the record.)</p> <p>19 DR. REX: Okay. The last few folks are kind 20 of drifting in. So I show a little after 1:00. My 21 guess is we're going to -- we'll use about the next 22 two hours, approximately. The stated end time is 4</p>

Page 541	Page 543
<p>1 o'clock. I just sort of -- my guess is it's going to</p> <p>2 be a couple hours of conversation. If it goes on much</p> <p>3 longer than that, we'll stop and take a break.</p> <p>4 So let me start by -- just look real quick</p> <p>5 at this list of questions and see if there are any</p> <p>6 other comments that anybody wants to make about the</p> <p>7 themes here -- pros and cons from a clinician's</p> <p>8 perspective, an investor's perspective, a regulator's</p> <p>9 perspective. You know, we've heard, you know, the</p> <p>10 notion that some randomization is better than none.</p> <p>11 That's where clinicians and regulators, investors very</p> <p>12 anxious about how big this program is -- since it's</p> <p>13 very inefficient, you're enrolling a lot of people to</p> <p>14 get out a very few.</p> <p>15 Though -- and there's also a risk embedded</p> <p>16 in this, if you're looking at Bullet 4, about</p> <p>17 ertapenem. You know, in effect, we're also testing</p> <p>18 ertapenem. But it -- but there may be more data on</p> <p>19 ertapenem than we've realized. And you need to dig</p> <p>20 that out and really test it.</p> <p>21 I think one of the takeaways I get from this</p> <p>22 is that really knowing the answer to ertapenem would</p>	<p>1 UNIDENTIFIED MALE SPEAKER: Hold it close.</p> <p>2 All right. That's great.</p> <p>3 DR. REX: Good.</p> <p>4 CURT: John, could you go back to the slide</p> <p>5 that had the two -- the data for the two body sites?</p> <p>6 DR. REX: Oh, sorry. You want, like, this -</p> <p>7 - like, one of these?</p> <p>8 CURT: Yeah, like that one.</p> <p>9 DR. REX: Like that one?</p> <p>10 CURT: Perfect.</p> <p>11 DR. REX: Okay.</p> <p>12 CURT: So you know, there are a couple ways</p> <p>13 you can go about this. You've got, effectively,</p> <p>14 separate analyses here. The nice thing that's</p> <p>15 reassuring is that the data seems consistent between</p> <p>16 the two body sites -- and it -- not necessarily even</p> <p>17 consistent on the mortality rates, but the fact that</p> <p>18 the treatment effect seems to be identical between the</p> <p>19 two body sites.</p> <p>20 You know, I often feel uncomfortable about</p> <p>21 pooling because if you say, a priori, I'm going to do</p> <p>22 a pooled analysis and then the data doesn't look like</p>
Page 542	Page 544
<p>1 be something that we ought to spend some time on</p> <p>2 because it could be that it's a valuable tool.</p> <p>3 Data on how to bring the two body sites</p> <p>4 together -- I've not heard specifically on that. So</p> <p>5 let's be sure we talk about that.</p> <p>6 We've talked a lot about concomitant</p> <p>7 therapy. So if I look at this list, the one that's</p> <p>8 not as obviously been covered is the data from two</p> <p>9 body sites. Again, one of our statistical colleagues'</p> <p>10 comment on approaches to dealing with that, you know,</p> <p>11 and keeping in mind that the margins are loose. But</p> <p>12 one of the things that I took some comfort from -- I</p> <p>13 think it's back here, like, on this slide -- was that,</p> <p>14 notionally, the program -- the logic for approval has</p> <p>15 all this stuff built into it, all these different</p> <p>16 steps, and that I -- the fact that you get a positive</p> <p>17 result in two subsets, to me, intuitively was</p> <p>18 attractive.</p> <p>19 But you want to comment on that particular</p> <p>20 question, Aaron, Tom?</p> <p>21 CURT: Sure. Is this --</p> <p>22 DR. REX: Curt (ph), oh, good.</p>	<p>1 it -- it does worse in HABP -- you can end up in a bad</p> <p>2 place.</p> <p>3 But this gets back to some of the stuff that</p> <p>4 I was talking about yesterday where if you had some</p> <p>5 kind of model that said you borrowed dynamically. So</p> <p>6 the model's set up in advance that if you get data</p> <p>7 like this, you do something. And I don't know whether</p> <p>8 it approaches pooling, but you borrow a lot of</p> <p>9 information between those groups and amplify the</p> <p>10 similarity. And if you get data that they're</p> <p>11 different, then you would have to rely on the separate</p> <p>12 analyses, and it would let that go. But it would get</p> <p>13 rid of a lot of the risk without pooling but still get</p> <p>14 you at 30, 40 percent effective sample size boost.</p> <p>15 MR. DANE: So Curt, how would that work in</p> <p>16 this type of example where you've only got two body</p> <p>17 sites? Because I know that performs better with three</p> <p>18 or more body sites.</p> <p>19 CURT: So we've done -- it makes a</p> <p>20 difference. So the more body sites that you have, you</p> <p>21 get a better idea of the body site variability. If</p> <p>22 you do it with two -- we've done this in the context</p>

<p style="text-align: right;">Page 545</p> <p>1 of devices where you have, say, two subsets or an old 2 and new device, and we've borrowed between them. Two 3 has more risks than three. But you can at least 4 quantify those in advance about what they are. And 5 you certainly still can do it. 6 And we'd have to say in advance, you know, 7 here are the datasets and here is the potential risk 8 to Type 1 error. And it would have to be agreed on in 9 advance. But you can do something like that. 10 DR. REX: Because otherwise, intuitively, if 11 you've got, like, three out of four pointing in the 12 right direction, that's nice. But if it's one out of 13 two, it's like -- kind of like you've thrown away the 14 one you didn't like and you kept the one you did like. 15 CURT: Well, and that's the purpose of -- 16 DR. REX: And then that's the problem, yeah. 17 CURT: -- is to say in advance when you're 18 going to do that so you can quantify the operating 19 characteristics. 20 DR. REX: Okay. 21 MR. DANE: John, it might be the role of the 22 -- what you do with this pool of combined data as</p>	<p style="text-align: right;">Page 547</p> <p>1 of pooling. It was more sort of if your eyeball can 2 see it, then -- the way I wrote it down was both have 3 to be inside their enormous margins, you know. But 4 having both of them inside is notionally correct. 5 I see Ian at the mic. 6 DR. FRIEDLAND: I have some reservation 7 about IAI as a test for activity against pseudomonas. 8 It's -- 9 DR. REX: So do I. 10 DR. FRIEDLAND: -- in the setting of 11 polymicrobial infections. You're not quite sure what 12 role the pseudomonas is playing. And I bet if you 13 looked at drugs that are not active against 14 pseudomonas like ertapenem, Tygeccline, and looked at 15 their activity against the pseudomonas, you might find 16 that you look as active as -- so I think there's just 17 some concern there. We need to know that this 18 actually is a good test of a -- 19 DR. REX: I think there's a confounding 20 issue with any microbials in general in intra-ab 21 that's not limited to just pseudomonas. So one of the 22 -- so part of the reason that I suggested doing the</p>
<p style="text-align: right;">Page 546</p> <p>1 well. So is this supportive to each individual body 2 site having a conclusion of non-inferiority as you've 3 got here? Or is that pool dataset the primary source 4 of -- 5 DR. REX: Yeah. 6 MR. DANE: -- confirmation? Yeah, so that 7 might make a difference to how you'd view it and how 8 risky it might for -- to Curt's point around the areas 9 you might be making. 10 DR. REX: You know, I think I was just 11 intuitively thinking that if I had, you know, two -- a 12 couple of different observations -- in this case, two 13 -- that were in the same direction, I'd feel good 14 about it. If one of them was really divergent, you 15 know, I'm not -- I -- to my mind, that might have been 16 a dead end for the drug and maybe it's not really 17 working so well. It also would sort of depend on 18 which one was divergent and why and which -- 19 MR. DANE: Yeah, and the different endpoints 20 as well that could well be here -- 21 DR. REX: All right. I recognize that. So 22 that's why I didn't really talk about any formal form</p>	<p style="text-align: right;">Page 548</p> <p>1 two body sites was so that you had two, each one of 2 which had a different flaw. You know, I couldn't 3 think of a better way to get -- you can always do 4 cUTI. But the numbers there -- we saw the numbers 5 again. There -- chasing (ph) pseudomonas there is 6 really hard. And so I took that one off. And I said, 7 well, just take these two with their flaws and see 8 where you get to. 9 Other questions or observations on this? So 10 anything else here that we could -- are there any -- 11 is there any options to ertapenem realistically? What 12 else could you do? A bunch of microbiologists in the 13 room -- give me something that has a pseudomonas-sized 14 hole in its coverage. 15 (Crosstalk) 16 DR. REX: That -- you know, that's actually 17 -- we should minute that. That's a really important 18 observation. 19 Was there somebody that raised their hand? 20 Todd (ph)? 21 TODD: What about ceftaroline? I mean, it 22 does have some enterobacteriaceae activity,</p>

Facilitating Antibacterial Drug Development For Patients With Unmet Needs Volume II

Page 549	Page 551
<p>1 pseudomonas --</p> <p>2 DR. REX: It does. It tips over on ESBLs.</p> <p>3 So you know, may -- this might have been a place for</p> <p>4 ceftaroline avibactam, which actually has never been</p> <p>5 developed. It's a developable drug, but it's never</p> <p>6 been developed. So okay. So but I don't think you</p> <p>7 can stand ceftaroline up on its own because the ESBLs</p> <p>8 knock it over.</p> <p>9 Other ideas?</p> <p>10 I mean, this for me was one of the harder</p> <p>11 things about it, was coming up with the fact that I</p> <p>12 could only find one choice that I was comfortable</p> <p>13 with. And I -- you know, so I did find the literature</p> <p>14 on it. And I'm just delighted here there's a study</p> <p>15 that's not published that might be helpful.</p> <p>16 On the panel, anybody else have comments on</p> <p>17 A, questions you want to get at?</p> <p>18 AUDIENCE MEMBER: (inaudible - off mic).</p> <p>19 DR. REX: So in the -- so use a quinolone.</p> <p>20 Use moxy -- so what's the -- I don't have that in my</p> <p>21 head -- rate of activity in moxy versus pseudomonas.</p> <p>22 Anybody know?</p>	<p>1 DR. COX: Oh, yeah, yeah. So I think what</p> <p>2 we're trying to do is we're trying to figure out, you</p> <p>3 know, X-1 and its activity against pseudomonas</p> <p>4 aeruginosa. So I mean -- so it would probably be</p> <p>5 something along the lines of, you know, X-1 is active</p> <p>6 in the treatment of or, you know, it can be used to</p> <p>7 treat the following infections when caused by</p> <p>8 pseudomonas aeruginosa.</p> <p>9 Now, if we take, you know, one of these more</p> <p>10 abbreviated pathways, it's going to have greater</p> <p>11 uncertainty around it. So I would expect, too, that</p> <p>12 it would also be a reserve this use for when you don't</p> <p>13 have anything else, you know, available.</p> <p>14 And then depending upon where we end up,</p> <p>15 because we've still got a lot more to discuss here as</p> <p>16 we work down these various different tiers, the degree</p> <p>17 of sort of, you know, reservation and whether there's</p> <p>18 any sort of formal program in place to preserve the</p> <p>19 drug, I think you'll see that, perhaps, as we start to</p> <p>20 work through some of these other scenarios where</p> <p>21 there's even greater uncertainty.</p> <p>22 So that's off the top of my head because we</p>
Page 550	Page 552
<p>1 (Crosstalk)</p> <p>2 DR. REX: Very high proportionate resistant.</p> <p>3 So that might -- it's a good extra thought. But is</p> <p>4 moxy, you know --</p> <p>5 AUDIENCE MEMBER: (inaudible - off mic.).</p> <p>6 DR. REX: Huh?</p> <p>7 AUDIENCE MEMBER: (inaudible - off mic.).</p> <p>8 DR. REX: But what about nosocomial</p> <p>9 pneumonia? No.</p> <p>10 (Crosstalk)</p> <p>11 DR. REX: Yeah. So you're in the same place</p> <p>12 you are with the erta, which is you've got -- I mean,</p> <p>13 you might know some -- this -- we can look at it. All</p> <p>14 right.</p> <p>15 UNIDENTIFIED FEMALE SPEAKER: John, my</p> <p>16 question -- or I guess maybe it's to the regulators --</p> <p>17 is how do they see data from this type of scenario.</p> <p>18 You develop your drug. What's getting in the label?</p> <p>19 DR. COX: It might be a little premature. I</p> <p>20 mean, we're trying to figure out, well --</p> <p>21 UNIDENTIFIED FEMALE SPEAKER: We're supposed</p> <p>22 to go and tell this to our management.</p>	<p>1 haven't even worked through all these yet. But if we</p> <p>2 can get to the -- you know, the information that will</p> <p>3 help us understand how the drug works, we'll be in a</p> <p>4 much better position to be able to figure this all</p> <p>5 out. And it's very hard. I mean, you know, you can</p> <p>6 see we're all struggling with trying figure out how do</p> <p>7 you actually discern the -- you know, the efficacy of</p> <p>8 the drug and then gather safety information.</p> <p>9 DR. REX: I couldn't imagine anything less</p> <p>10 than the wording around use in only patients with</p> <p>11 limited treatment options and get an expert to help</p> <p>12 you do it.</p> <p>13 DR. COX: Yeah. Yeah, because these are --</p> <p>14 I mean, this is really, I mean --</p> <p>15 DR. REX: Yeah.</p> <p>16 DR. COX: -- a very, very limited program.</p> <p>17 So it does seem like the indication would need to</p> <p>18 have, you know, reservations and maybe even a program</p> <p>19 around it.</p> <p>20 UNIDENTIFIED FEMALE SPEAKER: And what body</p> <p>21 sites are you describing?</p> <p>22 DR. REX: So --</p>

<p style="text-align: right;">Page 553</p> <p>1 AUDIENCE MEMBER: (inaudible - off mic).</p> <p>2 DR. COX: So the question is, is what body</p> <p>3 sites are you describing. And you know, we would want</p> <p>4 data in the body sites because, you know, at least our</p> <p>5 experience has been we've showed some of these, you</p> <p>6 know, past experiences that, you know, there are drugs</p> <p>7 that don't perform well in some body sites. And</p> <p>8 sometimes -- I mean, you know, Paul went through a</p> <p>9 very nice discussion sort of helping us to understand</p> <p>10 that a little bit more. But sometimes it seems like</p> <p>11 we find that in the clinical trial.</p> <p>12 So you know, not having at least some</p> <p>13 experience to be able to have some degree of</p> <p>14 understanding about what's going on in a body site</p> <p>15 would be difficult. And you know, I would think, you</p> <p>16 know, as part of this, too, as you work towards that</p> <p>17 body site, you're going to get preclinical information</p> <p>18 that's relevant to that body site to the extent</p> <p>19 possible. Understand, you know, tissue levels,</p> <p>20 whether it be blister fluid or ELF, those sorts of</p> <p>21 things, to help you sort of as you build, you know,</p> <p>22 towards doing the clinical trial. And those would be</p>	<p style="text-align: right;">Page 555</p> <p>1 information from each of the several body sites. So</p> <p>2 you might want to do -- you know, if you're going to</p> <p>3 do two, you might shoot for, like, 50/50. Or, you</p> <p>4 know, if you think one particular site be -- might be</p> <p>5 a little more difficult, maybe you do, you know,</p> <p>6 70/30, or something like that.</p> <p>7 But you wouldn't want to end up -- and we've</p> <p>8 seen this sometimes in the past with, you know, two</p> <p>9 patients in this site, three patients in this site,</p> <p>10 you know, 100 in this other site and then, you know,</p> <p>11 expect that you have sufficient information to be able</p> <p>12 to draw conclusions about the -- what we sort of refer</p> <p>13 to the onsie-tuosies in other sites where you really</p> <p>14 just don't have enough to be able to say too much of</p> <p>15 anything.</p> <p>16 So balancing it out across the sites of</p> <p>17 interest I think is a good way to think about this.</p> <p>18 Kenneth? And then we'll pop back over here.</p> <p>19 MR. HILLIN: I just wanted to make sure we</p> <p>20 did cover a topic. You specifically requested from an</p> <p>21 investor perspective. I'm not an investor. But --</p> <p>22 DR. REX: Well, then --</p>
<p style="text-align: right;">Page 554</p> <p>1 the sort of things you do anyways.</p> <p>2 DR. REX: Yeah, I should have put in a fake</p> <p>3 label. I was going to pitch for all three</p> <p>4 indications. That -- the -- that was, you know -- and</p> <p>5 in the sense that HAPB and the UTI -- and the intra-ab</p> <p>6 got nice RCT data, UTI, you've only got the open</p> <p>7 label. And I was going to sort of loosely make the</p> <p>8 analogy to like (ph) the as (ph) voriconazole approval</p> <p>9 where you've got a nice big randomized trial in one</p> <p>10 disease and a related setting, related organism</p> <p>11 mucormycosis where you've got some open label data.</p> <p>12 And you sort -- you line it up with urine</p> <p>13 concentrations being really high and show that, you</p> <p>14 know, the urine also became sterile and do some stuff</p> <p>15 like that.</p> <p>16 I mean, so I was going to pitch personally</p> <p>17 for all three indications. I should have said that.</p> <p>18 DR. COX: Yeah. And usually, too, I mean,</p> <p>19 we have -- you know, had some discussions around this,</p> <p>20 too. It seems like if -- you know, if you're going to</p> <p>21 do the multi-body site approach, you don't -- you want</p> <p>22 to have some, you know, representative amount of</p>	<p style="text-align: right;">Page 556</p> <p>1 MR. HILLIN: -- I've seen you give nice</p> <p>2 talks previously to CAC (ph). And I wonder if you</p> <p>3 could comment from maybe a pharma investor perspective</p> <p>4 if you think about the cost -- and you talked about</p> <p>5 that -- and the time and then you think of the</p> <p>6 probability of technical success, both of the</p> <p>7 executing the trial -- of the trial, demonstrating</p> <p>8 what you set up to demonstrate of the regulators</p> <p>9 approving it, so both the technical and the regulatory</p> <p>10 success versus the likely commercial return, how you -</p> <p>11 - when you integrate all those things because that's</p> <p>12 what an investor thinks about. Do you think that's</p> <p>13 going to be -- what kind of scenario will that paint?</p> <p>14 DR. REX: So very briefly, I'll answer one</p> <p>15 part of it now, defer the others.</p> <p>16 So can I get a return on this product if I</p> <p>17 had it developed? I think the answer to that is yes.</p> <p>18 This meets all the criteria for a new kind of fire</p> <p>19 extinguisher for which there should be a value. And</p> <p>20 I'm going to -- if I can get it developed at a</p> <p>21 reasonable price, I get I can make a reasonable return</p> <p>22 on this one. I'd be willing to make the case.</p>

Facilitating Antibacterial Drug Development For Patients With Unmet Needs Volume II

Page 557	Page 559
<p>1 The question of would I actually run --</p> <p>2 would actually spend the money, ask me that question</p> <p>3 after we've looked at Scenarios B and C. You know,</p> <p>4 let's get a little further along because I want to</p> <p>5 highlight a particular problem that we've pointed at,</p> <p>6 but I'm going to make it really painful.</p> <p>7 Have the mic? Go for it.</p> <p>8 UNIDENTIFIED MALE SPEAKER: Can I see the</p> <p>9 statistics again, please, the chart?</p> <p>10 DR. REX: Oh, sorry.</p> <p>11 UNIDENTIFIED MALE SPEAKER: So what --</p> <p>12 DR. REX: I keep going the wrong way. There</p> <p>13 you go.</p> <p>14 UNIDENTIFIED MALE SPEAKER: Yeah. So here</p> <p>15 in the HABP/VABP only, we cross the 20 percent margin</p> <p>16 by 2 percent, and that is already a wide margin. Now,</p> <p>17 what type of discussion would a sponsor face in front</p> <p>18 of, you know, NDA submitting these data and wanting a</p> <p>19 label for HABP/VABP and cIAI, given that only the</p> <p>20 pooled, or borrowed, matter, whatever, analysis meets</p> <p>21 the 20 percent margin but not the single ones with a</p> <p>22 numerical inferiority, which is just the patient,</p>	<p>1 drug that might be as much as 20 percent worse, okay,</p> <p>2 well, about -- or as much as 22 percent worse, can you</p> <p>3 have one that might be as much as 19 percent worse?</p> <p>4 Would you feel better about half a point? I just want</p> <p>5 you to be aware of the choices we're making</p> <p>6 numerically, all right?</p> <p>7 So I'm going to -- let's push on because I</p> <p>8 think we have covered these questions.</p> <p>9 So Scenario B, this one is chosen so the</p> <p>10 meropenem results have -- are unchanged. What's</p> <p>11 happened is that on the X-1 arm in both cases I've</p> <p>12 nudged the response rate down for X-1 as low as you</p> <p>13 can go and still have the computed 95 percent</p> <p>14 confidence bound to be within 30 for HABP/VABP and 25</p> <p>15 for intra-ab. And remember, it was 37. It actually</p> <p>16 would -- it would probably help to see. So it's 37</p> <p>17 and 55 is what gets you neutrality. 34 and 50 puts</p> <p>18 you in a worrisome place.</p> <p>19 So now, would you like to have this drug?</p> <p>20 Dr. Boucher?</p> <p>21 DR. BOUCHER: Is this --</p> <p>22 DR. REX: Yeah, you know, I -- let's say one</p>
Page 558	Page 560
<p>1 actually. But that is issue of small numbers.</p> <p>2 So what type of risk do we actually take as</p> <p>3 a sponsor? Also, imagine that probably only 36 or 48</p> <p>4 may respond. And then we're at 28, or whatever. You</p> <p>5 know, we're five over. So what type of discussion</p> <p>6 would we face for that indication then?</p> <p>7 DR. REX: And can I suggest --</p> <p>8 UNIDENTIFIED MALE SPEAKER: You know, what</p> <p>9 is the risk?</p> <p>10 DR. REX: -- the -- I'm going to -- let's</p> <p>11 hang on to that question because -- but did everybody</p> <p>12 hear what he just said? If we look at the numbers</p> <p>13 again, if that 37 over 48 becomes 38 over 48, then the</p> <p>14 difference -- because at 48, every one is worth 2</p> <p>15 percent. So now the delta goes down to, like, minus</p> <p>16 .1, and the confidence interval shrinks a teeny, tiny</p> <p>17 bit. And I will tell you that it comes in right at</p> <p>18 minus 20 -- deliberately done to make this point.</p> <p>19 So this is pitched to be out by the tiniest</p> <p>20 bit, and I can make that go away if you'd like by</p> <p>21 using a different alpha. And that was Aaron's point,</p> <p>22 was that if you're -- if you say, well, I can't have a</p>	<p>1 other thing. Look at the -- the HABP/VABP is all-cost</p> <p>2 survival, so -- the endpoint. So the mortalities are</p> <p>3 29.2 percent on the left and 20.8 percent on the</p> <p>4 right. That's 150 percent higher mortality on an</p> <p>5 absolute basis, okay?</p> <p>6 Now Dr. Boucher?</p> <p>7 DR. BOUCHER: So this really comes back to</p> <p>8 what we talked about earlier. The issue will become</p> <p>9 what is going on. It's five patients who have moved</p> <p>10 here now. And the data are the data, right? We have</p> <p>11 numerically lower survival and success in this</p> <p>12 scenario. And so we're going to have to understand as</p> <p>13 well as we can what's going on there.</p> <p>14 And I think it's quite possible that there's</p> <p>15 a real problem that suggests that there is a drug</p> <p>16 either efficacy or safety. I think, really</p> <p>17 importantly, what if there's a toxicity, either</p> <p>18 something we could have predicted or something we</p> <p>19 might not have predicted, playing a role or an</p> <p>20 apparent lack of efficacy -- efficaciousness, I should</p> <p>21 say, based on serum concentrations in these patients</p> <p>22 or other things we could ascertain. But it's going to</p>

<p style="text-align: right;">Page 561</p> <p>1 take a look at all 48 and 24 HABP/VABP patients and 69</p> <p>2 and 34 cIAI patients. And it will come back to how</p> <p>3 strong -- how clear are we in what was going on in all</p> <p>4 of those individuals.</p> <p>5 So there's really no room for poor quality</p> <p>6 data. There's no room for question about what --</p> <p>7 whether the diagnosis is what we thought it was or</p> <p>8 whether the outcome is what we think it is. But it's</p> <p>9 a risk.</p> <p>10 DR. REX: So Dr. Tomayko, you're an ID doc</p> <p>11 at the mic. You talk --</p> <p>12 DR. TOMAYKO: Yeah.</p> <p>13 DR. REX: -- talk to me about these data.</p> <p>14 DR. TOMAYKO: I guess if I was still out in</p> <p>15 the field I'd be less interested in understanding</p> <p>16 everything here than in the last example. But still,</p> <p>17 now that I have the added experience of working for a</p> <p>18 company and looking at data, you know, the first thing</p> <p>19 I would do is focus on the word you have up there,</p> <p>20 which is the punch line and the message that I had in</p> <p>21 my presentation.</p> <p>22 The first thing I would do is I would, like,</p>	<p style="text-align: right;">Page 563</p> <p>1 define wee, I suppose.</p> <p>2 Since you were just about to talk yourself</p> <p>3 into X-1 not being a very good drug when I just showed</p> <p>4 you the bottom scenario, is X-1 a superior agent in</p> <p>5 the top scenario?</p> <p>6 Kenneth?</p> <p>7 MR. HILLIN: This is -- and it's relatively</p> <p>8 straightforward. This is just a tyranny of small</p> <p>9 numbers --</p> <p>10 DR. REX: Tyranny of the dichotomous mind.</p> <p>11 MR. HILLIN: -- and the ability of</p> <p>12 randomization in the scenario to take care of the</p> <p>13 imbalances which are inherent in the kind of design</p> <p>14 you have here.</p> <p>15 So I think it's -- when you get down to</p> <p>16 small (ph) end (ph) streams, things happen.</p> <p>17 So and as Helen said, actually, then you're</p> <p>18 driven by the individual characteristics of every</p> <p>19 single patient when you get down to small numbers. So</p> <p>20 it would be a statistical --</p> <p>21 DR. REX: Well --</p> <p>22 MR. HILLIN: -- question, though, I think --</p>
<p style="text-align: right;">Page 562</p> <p>1 sit down and look at a bunch of HABP/VABP studies and</p> <p>2 bring a statistician and say how much heterogeneity is</p> <p>3 in there and are these just sample variation issues.</p> <p>4 And if they are, then, you know, we're really stuck</p> <p>5 with a big problem, you know, I mean, as I think we're</p> <p>6 all trying to illustrate. If you can't reliably do a</p> <p>7 small sample and get an answer that tells you that</p> <p>8 this is a good drug, then you have a problem. And</p> <p>9 that's --</p> <p>10 DR. REX: So --</p> <p>11 DR. TOMAYKO: -- what I think we're looking</p> <p>12 at here.</p> <p>13 DR. REX: So I didn't call up a statistician</p> <p>14 to do that, but I did do the study a second time. And</p> <p>15 this time, the results came out like this. So now X-</p> <p>16 1's -- X-1 and meropenem have basically traded places.</p> <p>17 I'm going to put them side by side on the next slide.</p> <p>18 But notice that they've now basically traded places.</p> <p>19 And so here they are side by side. At the</p> <p>20 top is the tilt to the right. X-1 looks a wee bit</p> <p>21 better. And at the bottom is the tilt to the left.</p> <p>22 X-1 looks a wee bit worse. It depends on how you</p>	<p style="text-align: right;">Page 564</p> <p>1 MR. DANE: Well, I would just add it's not</p> <p>2 just imbalances. It could be perfectly balanced and</p> <p>3 you could still see this just from random variability.</p> <p>4 So --</p> <p>5 AUDIENCE MEMBER: (inaudible - off mic.)</p> <p>6 MR. DANE: So I mean, in some ways, you</p> <p>7 can't avoid that. You can't magic up more precision</p> <p>8 than you've got, you know. And I mean, that's the</p> <p>9 risk with these programs, as far as I can see, unless</p> <p>10 you can supplement it with something else.</p> <p>11 MR. HILLIN: I think they -- what would be</p> <p>12 criminal would be if you had a great drug that was</p> <p>13 truly superior and you didn't observe it and the drug</p> <p>14 was never approved. That's what we want to -- also</p> <p>15 one of the things we want to -- we don't want to miss</p> <p>16 if it turns out we have a better drug and we can't</p> <p>17 figure out how to get it approved.</p> <p>18 DR. REX: Yeah. And this is one of the</p> <p>19 places where my decision to do two-to-one was</p> <p>20 beginning to bite me because now the meropenem arm,</p> <p>21 every movement of one is almost 4 percent. And so</p> <p>22 that -- you know, it's painful, right? You know, I --</p>

<p style="text-align: right;">Page 565</p> <p>1 it was -- you know, I had a reason for doing the two-</p> <p>2 to-one. But now it's biting me in the tail.</p> <p>3 And so you know -- and you look at how</p> <p>4 little the numbers have to move for this sort of a</p> <p>5 shift to occur. And I found that to be disturbing.</p> <p>6 So sort of the same sorts of questions, you</p> <p>7 know, because, you know, Kenneth, you asked the</p> <p>8 question how do I feel about the risk. Now Tom's</p> <p>9 going to come to the microphone and give me some</p> <p>10 insight.</p> <p>11 DR. LOUIS: Question on the numbers changing</p> <p>12 only a little, two points -- one is, properly done,</p> <p>13 the confidence interval knows that. We all know that,</p> <p>14 that it tries to reflect exactly that. But maybe a</p> <p>15 point that does directly relate to the -- if you only</p> <p>16 were to change one number is the strong need for high-</p> <p>17 quality data and that any kind of miscodes or anything</p> <p>18 like that can also be tilting this balance, especially</p> <p>19 in a small setting.</p> <p>20 DR. REX: And also, if you would really like</p> <p>21 to -- I don't know how to maximize bacteremias and so</p> <p>22 forth, but you'd like to have a sort of maximum</p>	<p style="text-align: right;">Page 567</p> <p>1 to ascribe those patients to failure. So now, this is</p> <p>2 all spilling over into your other endpoints as well.</p> <p>3 So it becomes a real issue.</p> <p>4 DR. REX: Right. Sort of the same questions</p> <p>5 -- and as -- let me see if I can back up to this. So</p> <p>6 the questions for the -- to be sure we discussed on B</p> <p>7 are the same as for A, basically.</p> <p>8 And does anybody see anything up there that</p> <p>9 they, you know -- I think the big one for me was about</p> <p>10 the investor perspective because this was the, you</p> <p>11 know -- I was thinking about that question as I built</p> <p>12 these scenarios. And you know, John Tomayko's phrase</p> <p>13 was, you know, it's okay to understand risk. How do I</p> <p>14 manage risk? And if the drug fails, you know, that's</p> <p>15 the deal. The drugs fail. But if it fails for</p> <p>16 reasons that don't have anything to do with the drug,</p> <p>17 then, you know, you're unhappy.</p> <p>18 And here, where it's -- you know, this is</p> <p>19 really pushing the limits, particularly since our</p> <p>20 endpoints are dichotomous, not continuous. We</p> <p>21 actually are -- you know, there's not anything else,</p> <p>22 really, to look at.</p>
<p style="text-align: right;">Page 566</p> <p>1 severity of cases. And I -- you know, you could</p> <p>2 arbitrarily seek people with APACHEs course (ph) about</p> <p>3 some threshold, I suppose. That would just further</p> <p>4 shrink your pool. You know, every one of these</p> <p>5 choices just gets -- digs you a different kind of a</p> <p>6 hole.</p> <p>7 Yes, ma'am?</p> <p>8 UNIDENTIFIED FEMALE SPEAKER: Yeah, I'm just</p> <p>9 thinking about the previous comment by Tom --</p> <p>10 DR. REX: Into the microphone. Sorry.</p> <p>11 UNIDENTIFIED FEMALE SPEAKER: Sorry. Just</p> <p>12 about the previous comment by Tom, yes, you -- it --</p> <p>13 there is definitely a huge component of quality. But</p> <p>14 especially with the point you're making, John, as you</p> <p>15 move up in the severity index, as these patients get</p> <p>16 sicker, then their comorbidities start to come into</p> <p>17 play. And not only do you see what John Tomayko was</p> <p>18 talking about with that affecting all-cause mortality</p> <p>19 as your endpoint, but you -- it also starts to play</p> <p>20 over into your other endpoints, right, because you're</p> <p>21 not going to call a patient a clinical cure from their</p> <p>22 cUTI or their cIAI if they died. You're going to have</p>	<p style="text-align: right;">Page 568</p> <p>1 Any other wisdom or -- Marco looks like he's</p> <p>2 about to say something.</p> <p>3 DR. CAVALERI: Yeah. Well, I think I agree</p> <p>4 with the previous comment that, at the end, with such</p> <p>5 small datasets, you would need to look at the data one</p> <p>6 by one, subgroup and try to understand what is</p> <p>7 happening. So it's not just merely into the</p> <p>8 statistical analysis of the entire dataset -- so it's</p> <p>9 -- because we acknowledge that there is this risk that</p> <p>10 the statistic might not tell us exactly the whole</p> <p>11 truth about the product.</p> <p>12 So it's very important to look at this data</p> <p>13 really capillary (ph), looking at the patient of the</p> <p>14 subgroup, try to understand what would be the</p> <p>15 imbalance at baseline and any other factor that could</p> <p>16 have contributed to showing a difference. And that's</p> <p>17 what we would do, and that's also why sometimes in the</p> <p>18 small dataset running after, you know, inferential</p> <p>19 testing might not be helpful at the end of the day.</p> <p>20 And that's why we're open to alternative approaches.</p> <p>21 And so it's the entirety of the evidence</p> <p>22 that matters. And we have to look at all aspects.</p>

<p style="text-align: right;">Page 569</p> <p>1 DR. REX: Yeah. And if you could maybe do a</p> <p>2 Paul Ambrose-ish pharmacometric analysis and see if</p> <p>3 you felt like there was a response in there that you</p> <p>4 could identify.</p> <p>5 MR. DANE: Yeah, John, because -- to me,</p> <p>6 scenario where you -- or Scenario B, the investor</p> <p>7 aspect is the same in the investor aspects at the</p> <p>8 start before you've even done the study. And I think</p> <p>9 it's all about the risks you've got that you're not</p> <p>10 going to be able to support what you're trying to do</p> <p>11 because you've got more uncertainty and you don't</p> <p>12 quite know where you're going to end up. And yes,</p> <p>13 that stays somehow captured in the confidence. It's</p> <p>14 for -- but you know, it's got more potential to move</p> <p>15 around.</p> <p>16 DR. REX: Yeah, I just spent a year raising</p> <p>17 \$60 million for a drug where the story was not nearly</p> <p>18 this hard to understand. And that -- I -- that year</p> <p>19 was hard work.</p> <p>20 Okay. So Scenario C. So what's happened</p> <p>21 here is that the -- or excuse -- back up. I want you</p> <p>22 to lock something into your brain. Lower bound --</p>	<p style="text-align: right;">Page 571</p> <p>1 lower bounds are kind of like in B but with the deltas</p> <p>2 being centered on zero. I mean, it is -- so this is -</p> <p>3 - you know, you didn't even get the high quality of A</p> <p>4 because you couldn't get your device to work. So this</p> <p>5 is the problem of -- you know, and we take -- instead</p> <p>6 of enrolling 1,000, you'd have to enroll 1,600 in</p> <p>7 order to get at this if the device just flat out</p> <p>8 failed.</p> <p>9 Comments on this? Because this, for me,</p> <p>10 really amplifies the investor concern. I don't know</p> <p>11 how this device is going to work. I -- if I've had to</p> <p>12 invent this device for my trial, goodness gracious,</p> <p>13 you know, I have no idea how it's really going to</p> <p>14 work.</p> <p>15 MR. DANE: John, I think the thing I would</p> <p>16 say is that, although it may -- when you get -- this</p> <p>17 is what the data could look like. It might not be any</p> <p>18 worse. The time you've got an issue is that if your</p> <p>19 diagnostic doesn't work and you get this many fewer</p> <p>20 patients, your power is 50 percent, not 85 percent</p> <p>21 because what this is telling you is you've got 50/50</p> <p>22 chance of showing something like that even if the two</p>
<p style="text-align: right;">Page 570</p> <p>1 look at the left scenario. Lower bound is minus 29</p> <p>2 and minus 24.5, so just inside my hypothetical -- huge</p> <p>3 margins, right?</p> <p>4 So in Scenario C, the selection device has</p> <p>5 failed, and you get just the natural rate of</p> <p>6 pseudomonas. You get 10 percent on intra-ab, and you</p> <p>7 get 15 percent in nosocomial pneumonia. And the</p> <p>8 sponsor sees this coming because, you know, you can</p> <p>9 have blinded -- a blinded rate of pseudomonas as</p> <p>10 you're -- you can know that about the trial. But</p> <p>11 there's no more money. You know, we've just got to</p> <p>12 take what we get, okay?</p> <p>13 So now we do -- so we run it, and it comes</p> <p>14 out like this. And now this is assuming the two drugs</p> <p>15 really match very, very tightly. And I've got a minus</p> <p>16 29 up top and a minus 20.8 on the bottom. Now, look</p> <p>17 at that for a second and notice that it is 22</p> <p>18 successes and 34 successes.</p> <p>19 I'm sorry. Where did it go? Excuse me.</p> <p>20 That's going to come in a minute. It's a different</p> <p>21 analysis.</p> <p>22 So this one, the margins are the -- the</p>	<p style="text-align: right;">Page 572</p> <p>1 drugs are actually the same.</p> <p>2 DR. REX: Now, every movement of -- on the -</p> <p>3 - in HABP/VABP arm of one patient is 3 percent on the</p> <p>4 X-1 arm and 6 percent in the meropenem arm. It's</p> <p>5 enormous. Move one patient, and those number -- so</p> <p>6 this just gyrates like crazy if you start to play with</p> <p>7 it.</p> <p>8 Other insights or comments?</p> <p>9 Okay. So we've now done A, B and C in</p> <p>10 which, you know, you can kind of sort of see, if you</p> <p>11 look sideways, a non-inferiority study buried in here.</p> <p>12 And there are other variants. You could put more</p> <p>13 energy into the nosocomial pneumonia arm and just sort</p> <p>14 of focus there.</p> <p>15 But that actually -- Amy's question before</p> <p>16 the break was are you really comfortable doing that,</p> <p>17 right? And so -- and also, you'd like to have --</p> <p>18 you'd like to un-confound where you can. And so I</p> <p>19 liked having the intra-ab as part of this program,</p> <p>20 even though it, too, has its flaws. As Ian pointed</p> <p>21 out, you know, it's very, you know -- inter-ab is</p> <p>22 confounded by surgery. And yet there is -- there's</p>

<p style="text-align: right;">Page 573</p> <p>1 some sort of an effect there.</p> <p>2 So let's go on to Scenario D. So inhale,</p> <p>3 exhale because now it gets awful. The culture-</p> <p>4 positive rate is now about 5 percent, and there's</p> <p>5 absolutely nothing I can do about it. You know, I</p> <p>6 just -- that's it.</p> <p>7 So the program size explodes. At a 30</p> <p>8 percent margin and one-to-one, I might get down to</p> <p>9 1,276 for any one indication in order to get the same</p> <p>10 kind of crummy margins that we were getting in</p> <p>11 Scenario C. So you understand, that's -- that -- it</p> <p>12 would take 1,300 patients to get at data as bad as</p> <p>13 Scenario C.</p> <p>14 If I bring the margin down at all, the sizes</p> <p>15 go up north of 2,000 patients. And maybe I could</p> <p>16 really enrich (ph) for high-reach cases -- for high-</p> <p>17 risk cases such as renal failure and more co-</p> <p>18 morbidities. But this, I think, is where the animal</p> <p>19 rule question becomes of interest.</p> <p>20 So Sumathi and I went back and forth on this</p> <p>21 a little bit. And this model doesn't exist. But</p> <p>22 there's no reason to believe you couldn't do it, which</p>	<p style="text-align: right;">Page 575</p> <p>1 .005. And then we do the Phase 3 in nosocomial</p> <p>2 pneumonia alone, so just picking one indication,</p> <p>3 picking the most -- the important one. And we assume</p> <p>4 the things that are shown there that I won't read to</p> <p>5 you.</p> <p>6 And at the end of the day, I get, after</p> <p>7 enrolling, 726 subjects. I have 24 and 12 on X-1 in</p> <p>8 control with my target pathogen. And there are my</p> <p>9 made-up results. And if I want -- if I'm using a</p> <p>10 boundary of negative 30 as my margin -- isn't that</p> <p>11 what I said? Where -- did I write a margin down?</p> <p>12 UNIDENTIFIED MALE SPEAKER: Thirty-five.</p> <p>13 DR. REX: Thirty-five. Right. If I move</p> <p>14 one patient -- instead of it being 19 to 24, it's 18</p> <p>15 to 24 -- I actually exceed the 35 percent non-</p> <p>16 inferiority margin. Sorry I didn't write it down. So</p> <p>17 -- and I'm not doing inferential statistics. I'm</p> <p>18 signing up for no math, okay -- none. Instead, I'm</p> <p>19 signing up for the P of .005.</p> <p>20 So now the discussion. Do these things</p> <p>21 together create Tier C minus or D plus? Discuss.</p> <p>22 DR. TOMAYKO: John, is there any chance that</p>
<p style="text-align: right;">Page 574</p> <p>1 is you can take a large enough mammal -- a piglet or a</p> <p>2 rabbit -- you can put it on a ventilator and give it</p> <p>3 nosocomial pneumonia. You know, I've got to assume</p> <p>4 that I could create something that looks a little like</p> <p>5 the human disease. But you know, Tom Walsh (ph) has</p> <p>6 been doing rabbits like this for years, and they</p> <p>7 produce a very human-like pattern. I don't really</p> <p>8 have reason to believe you can't do it. And then you</p> <p>9 actually get into the notion of the clinical trial</p> <p>10 being, effectively, a field trial. And you -- maybe</p> <p>11 you can throw in some informational (ph) control data.</p> <p>12 So here's the results. We've -- we did it.</p> <p>13 Sumathi and I got together and did a ventilated piglet</p> <p>14 model somehow.</p> <p>15 UNIDENTIFIED MALE SPEAKER: You've been</p> <p>16 busy.</p> <p>17 DR. REX: Yeah, I'll tell you what. We've</p> <p>18 been busy. It's been a -- we've had a busy month</p> <p>19 since she suggested that I write this case. All</p> <p>20 right.</p> <p>21 So in the ventilated piglet model, 18 to 20</p> <p>22 survival with X-1 and 0/10 with placebo, P equals</p>	<p style="text-align: right;">Page 576</p> <p>1 you would be able to tell us whether or not target</p> <p>2 attainment was achieved?</p> <p>3 DR. REX: Oh, well, absolutely. The desired</p> <p>4 exposures were hit. And so it's like in Scenario A.</p> <p>5 You know, we hired a really good PK-ologist, and we</p> <p>6 nailed it in our clinical program. And maybe we --</p> <p>7 it's picking up on the idea that we actually dosed a</p> <p>8 couple of people with HABP, with VABP with single</p> <p>9 doses before we started the program just to be sure</p> <p>10 that we were comfortable with our exposures. You</p> <p>11 know, you can do all those things. It's all right.</p> <p>12 Absolutely, the drug -- and the drug gets</p> <p>13 into the ELF, might or might not be able to do the</p> <p>14 non-CF bronchiectasis study, depending on -- like, if</p> <p>15 we're doing acinetobacter, I don't think I've ever</p> <p>16 seen acinetobacter colonize in that. It might not be</p> <p>17 a study, like, that you can do. But I can sure enough</p> <p>18 do an ELF.</p> <p>19 DR. TOMAYKO: But you're basically saying</p> <p>20 that all of these folks for the MIC of pseudomonas,</p> <p>21 which is I think going to be something less than one,</p> <p>22 all the achieve (ph), the target exposure that they</p>

Page 577	Page 579
<p>1 needed --</p> <p>2 DR. REX: Let's assume that.</p> <p>3 DR. TOMAYKO: Okay.</p> <p>4 DR. REX: Let's assume that we've got a good</p> <p>5 exposure and that Paul Ambrose puts up one of those</p> <p>6 plots like the other day and says, you know, it looks</p> <p>7 like it's in the right spot, you know. It's not a</p> <p>8 guarantee, but it looks like it's in the right spot.</p> <p>9 I think you must assume that.</p> <p>10 David (ph)?</p> <p>11 DAVID: I just think -- I mean, again, it's</p> <p>12 a huge amount of work, and you're amazing for having</p> <p>13 done it. But I think it shows that you can't do non-</p> <p>14 inferiority for this sort of indication. The data</p> <p>15 just become too fragile at the end of the day, and the</p> <p>16 risk is too high. So I would reject the non-</p> <p>17 inferiority design for this sort of program.</p> <p>18 DR. REX: And so let me be clear that I'm</p> <p>19 not actually going to propose a statistical</p> <p>20 hypothesis. I'm just going to say it's a control and</p> <p>21 it's small. And I'll bring you some external</p> <p>22 controls, and I'll show you that people in the past</p>	<p>1 DAVID: But so I think what you -- yeah, I</p> <p>2 think what you'd have to do -- I mean, I could go</p> <p>3 through kind of a design that we went through thinking</p> <p>4 about this particular sort of drug a while ago if this</p> <p>5 is the right time to do that. Or I could wait until</p> <p>6 later or not --</p> <p>7 DR. REX: Oh, no. There's no better time</p> <p>8 than now. So go ahead.</p> <p>9 DAVID: Okay. So what we were thinking</p> <p>10 about was a superiority design where you had your</p> <p>11 drug, X-1. And this would -- could either be combined</p> <p>12 with ertapenem or even meropenem, depending the</p> <p>13 sensitivity of your investigators to a new drug for a</p> <p>14 dangerous infection like pseudomonas. And I can tell</p> <p>15 you that you do get pushback from investigators when</p> <p>16 you go out and talk to them about this in real life.</p> <p>17 So and you treat these patients. You try</p> <p>18 and enroll patients with pseudomonas. You do all-</p> <p>19 comers if you like. I would do all-comers. And</p> <p>20 within that population of pseudomonas -- and you have</p> <p>21 to be careful about what centers you pick because if</p> <p>22 you do the trial in centers where there are very high</p>
Page 578	Page 580
<p>1 with pseudomonas died a lot.</p> <p>2 DAVID: I think -- but again, I think if you</p> <p>3 put in the context of a different design approach,</p> <p>4 then it gets a lot easier in a way -- in some ways.</p> <p>5 DR. REX: What is that design?</p> <p>6 DAVID: A superiority approach using</p> <p>7 external controls and other controls, again, not</p> <p>8 necessarily powered at P .05.</p> <p>9 DR. REX: Well, let me be sure I've heard</p> <p>10 what you said because you said use the external</p> <p>11 control to show superiority. So I can do that right</p> <p>12 now because I can tell you that, in the historical</p> <p>13 data, people with untreated nosocomial pneumonia or</p> <p>14 incorrectly treated nosocomial pneumonia have a all-</p> <p>15 cause survival of about 30 to 40 percent.</p> <p>16 DAVID: Yeah. So --</p> <p>17 DR. REX: So I -- so it's -- so that's</p> <p>18 buried down deep in here. And I bet I could do that</p> <p>19 with contemporaneous controls.</p> <p>20 DAVID: Right.</p> <p>21 DR. REX: I bet I could that with some --</p> <p>22 like, the Di Carlo data --</p>	<p>1 rates of carbapenem resistance, then everybody gets</p> <p>2 put on colistin. So you actually don't want to do</p> <p>3 your trial there.</p> <p>4 You want to do your trial where you have UDR</p> <p>5 rates of carbapenem resistance, which is on the order</p> <p>6 of 15 to 20 percent kind of globally, and their</p> <p>7 physicians are still using carbapenem mostly to treat</p> <p>8 pseudomonas aeruginosa infections.</p> <p>9 So you then look -- so you treat everybody</p> <p>10 with your drug plus ertapenem or your drug plus</p> <p>11 carbapenem. But you specifically look from among that</p> <p>12 group --</p> <p>13 DR. REX: This is open label --</p> <p>14 DAVID: It's open label, yeah.</p> <p>15 DR. REX: This is open label, one arm.</p> <p>16 DAVID: Yeah, it's one label, one arm and</p> <p>17 historically controlled. And I'm going to get to this</p> <p>18 controls because you have to do a lot of work on the</p> <p>19 controls up front to make this all work. And I</p> <p>20 actually don't know the numbers because nobody's ever</p> <p>21 done the work that I'm -- that I have in mind.</p> <p>22 But you treat everybody up front with this</p>

<p style="text-align: right;">Page 581</p> <p>1 combination. And then your historical control should</p> <p>2 be contemporaneous. It could either be done by a</p> <p>3 retrospective analysis similar to what the medicines</p> <p>4 company people did. It should be done in centers that</p> <p>5 are going to participate in your trial. And it should</p> <p>6 be done using the inclusion-exclusion criteria that</p> <p>7 you plan to use for your trial, which I would argue</p> <p>8 would have to be fairly broad.</p> <p>9 Then what you would need -- so that would</p> <p>10 give your control. What you're looking for is the</p> <p>11 control levels of response of people initially treated</p> <p>12 with carbapenems who have carbapenem resistant</p> <p>13 pseudomonas aeruginosa. That's the control number you</p> <p>14 want to get.</p> <p>15 And then what you have to do --</p> <p>16 DR. REX: So to play it back, what you're</p> <p>17 going to do is seek people who would have met the</p> <p>18 inclusion-exclusions of this trial.</p> <p>19 DAVID: Yeah.</p> <p>20 DR. REX: You didn't actually ask them to</p> <p>21 consent. But at least on paper, they could have</p> <p>22 consented. And then you're going to look for the</p>	<p style="text-align: right;">Page 583</p> <p>1 of MDR pseudomonas in a group that meet inclusion-</p> <p>2 exclusions. And now you're doing the real trial. And</p> <p>3 you either observe people who didn't go into your</p> <p>4 trial, or you do a very disproportionate</p> <p>5 randomization.</p> <p>6 DAVID: Right.</p> <p>7 DR. REX: So --</p> <p>8 DAVID: The idea is to try and get numbers</p> <p>9 to support the historical control that you started</p> <p>10 with, so to avoid the Ellenburg effect of having</p> <p>11 inadequate historical controls, if you like.</p> <p>12 DR. REX: Okay.</p> <p>13 DAVID: So that was kind of the design in a</p> <p>14 nutshell of what we looked at for a drug like this.</p> <p>15 And the problem that you run into is that when you</p> <p>16 actually get crunch -- start crunching numbers,</p> <p>17 depending on what those controls look like, you might</p> <p>18 get down to a point where you don't have an adequate</p> <p>19 inferential test at .05. So it might have to be .1 or</p> <p>20 .2 or something, and you might have to use additional</p> <p>21 data. You'd have to rely very heavily on PK/PD data</p> <p>22 both in people and in animals.</p>
<p style="text-align: right;">Page 582</p> <p>1 response rate in the carbapenem resistance subset --</p> <p>2 DAVID: Yes.</p> <p>3 DR. REX: -- of that group.</p> <p>4 DAVID: Right. Right. So then the other</p> <p>5 issue is monotherapy or where, you know, are you going</p> <p>6 to add Amikacin. The centers that we talked -- when</p> <p>7 we talked about this would have added Amikacin. So</p> <p>8 you'd probably have to do that so you don't answer</p> <p>9 that you're still stuck with that. But again, looking</p> <p>10 at the carbapenem resistant group gives you at least a</p> <p>11 look at the activity you want to look at.</p> <p>12 So then what you have to do is you actually</p> <p>13 have to validate your previously constructed control</p> <p>14 group during your trial. And you can do that in two</p> <p>15 ways, or both ways, one of which is you do a</p> <p>16 prospective observational study of people who don't</p> <p>17 get enrolled. Again, and/or -- and/or -- you have</p> <p>18 something like a four-to-one randomization in your</p> <p>19 trial.</p> <p>20 DR. REX: So to play it back, what you're</p> <p>21 saying is that after you've constructed this</p> <p>22 hypothetical -- your developed data on a response rate</p>	<p style="text-align: right;">Page 584</p> <p>1 But I believe that that sort of program all</p> <p>2 together might provide a way forward for the smaller</p> <p>3 patient populations. And it avoids a lot of the</p> <p>4 issues that you run into in the non-inferiority</p> <p>5 designs.</p> <p>6 DR. REX: So Ian Friedland, where are you?</p> <p>7 You're summoned to the microphone.</p> <p>8 So help us out here. This sounds -- so just</p> <p>9 sort of feel your way into this. It -- you know, in</p> <p>10 many ways, this is a little like what you did, though</p> <p>11 -- I mean, there are clear differences. But you are -</p> <p>12 - this is about seeking the super-resistant bugs. And</p> <p>13 Sumathi did the math to suggest that 1 in 122</p> <p>14 pseudomonases would be resistant to two drugs, which</p> <p>15 would --</p> <p>16 DAVID: No.</p> <p>17 DR. REX: No? Sorry. One -- no, it's the</p> <p>18 rate of dual resistance --</p> <p>19 DAVID: These organisms are only resistant</p> <p>20 to the carbapenem. They don't have to be resistant to</p> <p>21 Amikacin in the study. You accept -- you do the same</p> <p>22 thing you did in your study. So --</p>

Facilitating Antibacterial Drug Development For Patients With Unmet Needs Volume II

<p style="text-align: right;">Page 585</p> <p>1 DR. REX: Okay.</p> <p>2 DAVID: -- patients are treated for --</p> <p>3 DR. REX: But they have to have been treated</p> <p>4 -- but in order to get a control group, it has to be</p> <p>5 those treated only with the carbapenem in order to get</p> <p>6 the response rate for carbapenem-resistant</p> <p>7 pseudomonas.</p> <p>8 DAVID: Most of the patients that you'll</p> <p>9 find when you do your little study are going to get</p> <p>10 carbapenem plus an aminoglycoside for pseudomonas --</p> <p>11 DR. REX: So they will have actually had --</p> <p>12 so I guess I say again if I want to get a placebo</p> <p>13 response rate, I have to find people who didn't get an</p> <p>14 active drug.</p> <p>15 DAVID: No, what you want is a control rate</p> <p>16 that matches the controls that you'll have in your --</p> <p>17 DR. REX: But I have to beat the control.</p> <p>18 So if the controls --</p> <p>19 DAVID: Yeah.</p> <p>20 DR. REX: -- have gotten an active drug, why</p> <p>21 am I going to be superior to an active drug?</p> <p>22 DAVID: Because Amikacin alone is not very</p>	<p style="text-align: right;">Page 587</p> <p>1 DR. REX: All right. So that's an idea that</p> <p>2 fits into Scenario F of an approach that wasn't</p> <p>3 considered and which I -- we're going to come to that</p> <p>4 in a minute. We're looking for other ideas.</p> <p>5 Can I get a little more conversation on the</p> <p>6 animal rule-ish support for this? So it's not the</p> <p>7 sun, the moon and the stars. And it's a pretty small</p> <p>8 flashlight.</p> <p>9 Dr. Boucher?</p> <p>10 DR. BOUCHER: I mean, I think again we'll</p> <p>11 work with what we have to work with. And if this was</p> <p>12 a drug Scenario D that worked in acinetobacter or some</p> <p>13 new place where we're really up against it, I think</p> <p>14 it's possible to work with that. You know, ideally, a</p> <p>15 little more clinical data would be nice.</p> <p>16 And so in -- I sort of hesitate to say this.</p> <p>17 But from the clinical perspective, it still would be</p> <p>18 helpful to see those patients with the worst -- you</p> <p>19 know, with the blood stream infections or, you know,</p> <p>20 some places where clinically, even if it's individual</p> <p>21 cases, there was some evidence that the drug was</p> <p>22 effective.</p>
<p style="text-align: right;">Page 586</p> <p>1 good is what we find.</p> <p>2 DR. REX: I -- boy howdy. Okay. I'm now</p> <p>3 not buying the risk, but --</p> <p>4 AUDIENCE MEMBER: (inaudible - off mic.)</p> <p>5 DR. FRIEDLAND: I agree. The concern would</p> <p>6 be the Amikacin because, if you treated just Amikacin</p> <p>7 alone, maybe you would, but they're not going to do</p> <p>8 that. As soon as they get the ceftaroline (ph),</p> <p>9 they're going to switch to another drug. So they're</p> <p>10 going to give you an Amikacin plus an active drug. So</p> <p>11 it's basically the 24, 48 hours in which maybe they're</p> <p>12 not covered with a --</p> <p>13 DAVID: That's --</p> <p>14 DR. FRIEDLAND: -- effective butolactam (ph)</p> <p>15 or some other --</p> <p>16 DAVID: Right. But that's why the controls</p> <p>17 are mainly -- it's historical or external controls.</p> <p>18 So that's -- so you're not -- so the four-to-one</p> <p>19 randomization, you would have to deal with this</p> <p>20 confounding issue. Or you do the prospective</p> <p>21 observational study where, again, you're not treating</p> <p>22 the control group.</p>	<p style="text-align: right;">Page 588</p> <p>1 DR. REX: So --</p> <p>2 DR. FRIEDLAND: I'll comment on the animal -</p> <p>3 -</p> <p>4 DR. REX: And -- well, actually, the two of</p> <p>5 you -- Ed asked the question of me a second ago, and</p> <p>6 I'm going to phrase it because I'd like the two of you</p> <p>7 to respond to this. How will you use this drug in the</p> <p>8 clinic? How often do you think you'll use it? Why</p> <p>9 will you use it? Because that goes in to the question</p> <p>10 of risk, benefit and labeling.</p> <p>11 Ed, do you want to amplify it all in a</p> <p>12 question for them before we let them loose on it?</p> <p>13 DR. COX: Yeah. I know we're still</p> <p>14 struggling. And this is why I asked John. I said is</p> <p>15 it too early to ask this question.</p> <p>16 But you know, we're struggling with trying</p> <p>17 to figure out how we evaluate the efficacy of this</p> <p>18 drug. And at the end of the day, I mean, there's</p> <p>19 going to be tremendous uncertainty around this. And</p> <p>20 you know, maybe this drug is active against baumannii,</p> <p>21 and maybe other drug is active against pseudomonas</p> <p>22 aeruginosa.</p>

Facilitating Antibacterial Drug Development For Patients With Unmet Needs Volume II

Page 589	Page 591
<p>1 I mean, it would be interesting if folks</p> <p>2 have insights. You know, how would this drug actually</p> <p>3 be used in the clinical arena. I mean, would it be,</p> <p>4 you know, your institution had some tremendous problem</p> <p>5 with resistance among pseudomonas aeruginosa in</p> <p>6 patients. And could you identify risk factors? Or</p> <p>7 you know, there's an outbreak of acinetobacter</p> <p>8 baumannii in your ICU and, you know, available --</p> <p>9 based on what you know about resistance testing from</p> <p>10 the first case or the first couple of cases, you don't</p> <p>11 have good options. So you're -- you know, that --</p> <p>12 this is going to be the instance where you, you know,</p> <p>13 reach for an alternative.</p> <p>14 I'm just trying to figure out where does</p> <p>15 this fit or how does this -- how would it be used.</p> <p>16 Any thoughts or insights on that?</p> <p>17 DR. TOMAYKO: I'll take a stab. I -- as I</p> <p>18 said yesterday, I'm pretty impressed with the</p> <p>19 surviving SES (ph), this experience where we really</p> <p>20 learn to pay very careful attention to infections and</p> <p>21 manage them appropriately, be it source control or be</p> <p>22 it rapid onset of appropriate therapy.</p>	<p>1 aeruginosa so it would be empiric use, given the</p> <p>2 importance of initial therapy. So it could be a fair</p> <p>3 volume of usage that this drug would see --</p> <p>4 DR. TOMAYKO: Well --</p> <p>5 DR. COX: -- within your institution. Is</p> <p>6 that --</p> <p>7 DR. TOMAYKO: I think you're getting to the</p> <p>8 point. I'm not arguing that.</p> <p>9 DR. COX: Yeah, I'm not being --</p> <p>10 DR. TOMAYKO: Let me tell you --</p> <p>11 DR. COX: I'm just trying to figure it out.</p> <p>12 DR. TOMAYKO: Let me tell you that we have</p> <p>13 some safety data on the drug, and we have a lot of</p> <p>14 preclinical safety data. I mean, that equation might</p> <p>15 change dramatically if the drug was like colistin or</p> <p>16 worse. But if it was better than colistin in terms of</p> <p>17 safety and the data was supportive, then I'm thinking,</p> <p>18 well, the big problem here is that the efficacy isn't</p> <p>19 good enough, but I don't have anything else, or I have</p> <p>20 colistin. I'd have to make a decision there. That</p> <p>21 animal data might look better. I wonder if you could</p> <p>22 study colistin in that model and see what that looks</p>
Page 590	Page 592
<p>1 And I believe Anon Kumar (ph) has now</p> <p>2 followed up on his database. And he's no longer just</p> <p>3 looking at one-hour intervals increasing mortality by</p> <p>4 7 percent. I think he's got it down to 15 minutes.</p> <p>5 So you know, I would take -- if I had a</p> <p>6 problem in my institution and I was in my ICU and my</p> <p>7 patient was in septic shock -- because that's what he</p> <p>8 studied -- and I was concerned about pseudomonas, I'd</p> <p>9 give them whatever I had to treat pseudomonas before</p> <p>10 this drug was approved. And then I'd add this on it.</p> <p>11 And if I came back just like I do with my</p> <p>12 Amikacin in the clinical program and found out that</p> <p>13 everything else is there and I have great evidence,</p> <p>14 then I would drop the drug X-1. If I didn't, I'd be</p> <p>15 gathering data to submit to the company that was kind</p> <p>16 enough to invest in the program and say hey, your X-1</p> <p>17 really made a difference today.</p> <p>18 DR. COX: And I'm not being critical. I'm</p> <p>19 just trying to understand a little bit more.</p> <p>20 So if I'm understanding correctly, you would</p> <p>21 use this as part of your empiric regimen in the ICU</p> <p>22 for sick patients that you suspected pseudomonas</p>	<p>1 like.</p> <p>2 So there's a lot of information that you</p> <p>3 could craft together. I'm kind of interested to see</p> <p>4 what Helen would say. But I would not be afraid to</p> <p>5 start the drug in a person where it could make a huge</p> <p>6 difference and I could actually advance our</p> <p>7 understanding of whether or not the drug could have an</p> <p>8 impact if it could make that difference. If nothing</p> <p>9 else was treating that patient and that patient in</p> <p>10 septic shock got better, I think you'd want to hear</p> <p>11 that data.</p> <p>12 DR. COX: Yeah. So before -- and just</p> <p>13 because this is helpful to me, let me just -- so I'm</p> <p>14 assuming, John, sort of there's two cases that are</p> <p>15 coming to mind. Within your institution, it sounds</p> <p>16 like you have, you know, patients who are infected</p> <p>17 with pseudomonas aeruginosa that, you know, have, you</p> <p>18 know, very resistant organisms. So that's sort of one</p> <p>19 situation. The other situation I'm thinking about is</p> <p>20 the situation that Paul mentioned, which is the</p> <p>21 variability and exposure.</p> <p>22 So I mean, I'm trying to figure out if you</p>

<p style="text-align: right;">Page 593</p> <p>1 only were to use it in situation where the institution</p> <p>2 had a significant rate of resistance to, you know,</p> <p>3 available therapies, you know, that would be a more</p> <p>4 restricted population. If there's concern more</p> <p>5 generally about, you know, patients where there's</p> <p>6 going to be significant variability of exposure -- so</p> <p>7 this is, in essence, a third agent being added in --</p> <p>8 then the use of the drug could be quite significant, I</p> <p>9 would think. Fair?</p> <p>10 DR. TOMAYKO: I don't know. It's been a</p> <p>11 while. How many patients in my ICU are in septic</p> <p>12 shock and have some of the risk factors that would</p> <p>13 predispose them to pseudomonas? How many of the units</p> <p>14 on my hospital have this? And again, you know, if I</p> <p>15 don't need it, I'm going to stop it.</p> <p>16 But the other place I would use it is when</p> <p>17 for some reason I got it wrong but the patient's still</p> <p>18 alive and I want to rescue them. So I would</p> <p>19 definitely use it there. But you know, you're going</p> <p>20 to have the biggest impact on an infection if you</p> <p>21 start antibiotics early. And I think that it's really</p> <p>22 what we're trained to do.</p>	<p style="text-align: right;">Page 595</p> <p>1 DR. COX: Do tell.</p> <p>2 DR. TOMAYKO: Well, I mean, if the drug's</p> <p>3 approved and I want to do something that's meaningful,</p> <p>4 then I get a protocol out there and, you know, figure</p> <p>5 out how to get it disseminated. I think if it's an ID</p> <p>6 program, I'd have a lot of support from my IDSA</p> <p>7 colleagues. And I would make it a pragmatic-type</p> <p>8 protocol, and I would collect rigorous data, including</p> <p>9 PK data, on this population of patients in septic</p> <p>10 shock where I could manage a real-time significant</p> <p>11 effect. And then I would pull that together and do</p> <p>12 what I can with it and submit it.</p> <p>13 DR. COX: No, that's fair. I mean, you</p> <p>14 know, and I think, you know, one of the things we</p> <p>15 talked about this some during the preparation of the</p> <p>16 cases, is that, you know, if the overall rate of</p> <p>17 infections caused by pseudomonas aeruginosa doesn't</p> <p>18 really change, you may end up with a very large "ITT"</p> <p>19 population. You may learn something important there.</p> <p>20 You could certainly get PK, and PK would be valuable.</p> <p>21 And then you know, it's also -- and I was</p> <p>22 thinking about this a little bit. I was sort of</p>
<p style="text-align: right;">Page 594</p> <p>1 One last comment, on that animal data that</p> <p>2 John showed, I'd certainly want to know whether or not</p> <p>3 Paul saw anything in the exposures in the animals that</p> <p>4 might not make the data look pretty robust because it</p> <p>5 did look pretty robust. You know, it was a lethal</p> <p>6 model, and the drug had a profound effect in that</p> <p>7 study, so.</p> <p>8 DR. COX: Yeah, and I don't disagree with</p> <p>9 that. I'm just trying to figure out, you know, the</p> <p>10 development program, what the, you know, clinical data</p> <p>11 are that you accrue during that program and then what</p> <p>12 usage might look like for such a drug that was really</p> <p>13 based on a database that had a fair degree of</p> <p>14 uncertainty. And I don't disagree with what you're</p> <p>15 saying.</p> <p>16 DR. TOMAYKO: No --</p> <p>17 DR. COX: I'm just trying to anticipate what</p> <p>18 this might look like because I think that's important</p> <p>19 for us to understand.</p> <p>20 DR. TOMAYKO: No, this is important, too,</p> <p>21 because you just gave me a great idea for a field</p> <p>22 study.</p>	<p style="text-align: right;">Page 596</p> <p>1 asking, you know, are there studies that you could do</p> <p>2 after a drug is approved that might become somewhat</p> <p>3 more feasible. And it sounds like you're hinting at</p> <p>4 that may be something that, in fact, would be true.</p> <p>5 And I'm -- there, I'm focusing on the MITT population</p> <p>6 and recognizing that the patients were probably</p> <p>7 getting a variety of other drugs that may make it</p> <p>8 difficult to evaluate the test drug unless there are</p> <p>9 certain resistant -- certain resistance profiles that</p> <p>10 allow you to isolate that. But there may be</p> <p>11 opportunities to try and figure out how to study the</p> <p>12 drug.</p> <p>13 So I'm just trying to think through it.</p> <p>14 DR. DUDLEY: Yeah. Mike Dudley. The</p> <p>15 medicine's coming out.</p> <p>16 John, you sort of flipped the card that I</p> <p>17 think I was thinking of as well. And the new</p> <p>18 commissioner actually made some comments a few weeks</p> <p>19 ago about use of registries in the post-approval smart</p> <p>20 process and really was encouraging use of that kind of</p> <p>21 information.</p> <p>22 So I -- where I thought David was going to</p>

<p style="text-align: right;">Page 597</p> <p>1 go and which I think was on the superiority side is --</p> <p>2 is that you may -- what we may want to be thinking</p> <p>3 about, in fact, the multi-drug-resistant situation</p> <p>4 here, not for inferential testing and -- but perhaps</p> <p>5 for trying to see signals of superiority because if</p> <p>6 the drug has a big enough treatment effect, that's</p> <p>7 probably the population where you're going to be</p> <p>8 seeing that.</p> <p>9 So I never thought I'd see myself arguing</p> <p>10 for a superiority, but I do think that if the</p> <p>11 properties that were described in the case, that of</p> <p>12 being able to go where you think the biggest treatment</p> <p>13 effect may be.</p> <p>14 And then thirdly, I was thinking about the</p> <p>15 population. And you know, the anti-PCR (ph) antibody</p> <p>16 work that's been done with pseudomonas, the trials</p> <p>17 that were done in 40 hospitals in France enrolled 30</p> <p>18 patients with pseudomonas infections in nine months.</p> <p>19 And so perhaps maybe specifying a patient population</p> <p>20 that's particularly high risk, which they identified</p> <p>21 as having tracheal bronchitis, might be a population</p> <p>22 where we could go and see that treatment effect.</p>	<p style="text-align: right;">Page 599</p> <p>1 known infections because this dataset is small. And</p> <p>2 that's something that our community looks at when we</p> <p>3 decide to bring these drugs in.</p> <p>4 And then perhaps -- the next place I could</p> <p>5 see early use would be in -- if, God forbid, there was</p> <p>6 an ICU kind of problem where we had a particularly</p> <p>7 nasty organism that we knew about that was</p> <p>8 circulating, you know, that that would be another</p> <p>9 place where -- thank Heavens I haven't had to do that</p> <p>10 -- but we -- where you could envision tapping into</p> <p>11 something like this.</p> <p>12 But we'd want to see more clinical data,</p> <p>13 whether that's Phase 4 -- you know, however we got it</p> <p>14 before we moved on. And I think that's largely what's</p> <p>15 happening, at least in our hands and in those around</p> <p>16 the country with the two new agents, even though</p> <p>17 they're kind of relatives of drugs we know well with</p> <p>18 the ceftolozane/tazo and the ceftazidime/avibactam.</p> <p>19 You know, we're using them in individual cases with</p> <p>20 the best susceptibility testing we can get and getting</p> <p>21 experience with them before we think about broader use</p> <p>22 -- in stewardship programs, you know, in a very kind</p>
<p style="text-align: right;">Page 598</p> <p>1 But I vote for the animal rule.</p> <p>2 DR. COX: You know, I would vote against it.</p> <p>3 DR. REX: Sorry. So sort of Helen and then</p> <p>4 David. Sorry. We're going to go back and forth.</p> <p>5 DR. BOUCHER: Okay. So I would just say as</p> <p>6 much as I agree with a lot of what John said, from a</p> <p>7 clinical perspective, especially in Scenario D, I</p> <p>8 think that the way the drug would be used would be in</p> <p>9 those settings like my first patient that we talked</p> <p>10 about where we know that we've got nothing else to</p> <p>11 offer, or we know that --</p> <p>12 DR. REX: Okay. But you're talking about</p> <p>13 your first patient from your presentation --</p> <p>14 DR. BOUCHER: From my presentation.</p> <p>15 DR. REX: -- from this morning.</p> <p>16 DR. BOUCHER: The lady with the MDR</p> <p>17 Klebsiella that was resistant to everything except</p> <p>18 colistin, including the two new agents, where this</p> <p>19 drug might offer something that's potentially</p> <p>20 tolerable to this woman for whom colistin really</p> <p>21 wasn't an option and that, through our stewardship</p> <p>22 program, we would gain some experience in people with</p>	<p style="text-align: right;">Page 600</p> <p>1 of -- in a way that probably our sponsor colleagues</p> <p>2 don't like to hear. But that is what's happening, I</p> <p>3 would say.</p> <p>4 So I think the answer to your question on</p> <p>5 the prior example maybe is a little more difficult.</p> <p>6 But I find it hard to imagine in 2016 with the way</p> <p>7 things are working where I work that we would be able</p> <p>8 to think about using this stuff empirically at this</p> <p>9 point.</p> <p>10 DR. COX: So that's helpful, Helen. So that</p> <p>11 sounds like situations where culture results tell you</p> <p>12 that you essentially don't have options or in the</p> <p>13 setting of ICU outbreaks with the particularly</p> <p>14 problematic organisms circulate around where you have</p> <p>15 a resistance profile that tells you you don't have</p> <p>16 other options or you have very, very, very few what --</p> <p>17 other options.</p> <p>18 Okay. Thank you.</p> <p>19 DR. REX: We need to talk about the</p> <p>20 economics of that at some point.</p> <p>21 So David?</p> <p>22 DAVID: Yeah, I was just going to Ed's</p>

Facilitating Antibacterial Drug Development For Patients With Unmet Needs Volume II

<p style="text-align: right;">Page 601</p> <p>1 question about how it would be used. So I work in a 2 70-bed hospital. I think 70 percent of U.S. hospitals 3 are under 200 beds. Most of those small hospitals 4 don't have big resistance problems. In the four years 5 that I've been working there, we had our first case of 6 VAP just last year. And it was pseudomonas aeruginosa 7 but a susceptible strain.</p> <p>8 So if you extrapolate that across the United 9 States, I don't think there's going to be a huge 10 amount of empiric use. It'll be mainly in academic 11 centers where resistance is going to be a problem.</p> <p>12 So I don't -- and also, the -- in order for 13 anyone to make money on this, which I think is 14 someplace John was going to go, the price in the 15 United States is going to have to be pretty high. And 16 stewardship programs are going to clamp down pretty 17 hard on people who use very expensive drugs 18 empirically for no good reason, so.</p> <p>19 DR. REX: Right (ph), go ahead, please. And 20 introduce yourself.</p> <p>21 MR. WARREN: So Travis Warren (ph) from the 22 U.S. Army.</p>	<p style="text-align: right;">Page 603</p> <p>1 pseudomonas models that are out there. But it's been 2 alluded to that there's not a good animal model that's 3 out there. And I don't want especially sponsors who 4 were considering potentially using this type of thing 5 to think if there's not already -- if there's not a 6 model that's already out there -- it's not a plug-and- 7 play system where you choose the species you're 8 interested in and the pathogen you're interested in 9 and put them together and, voila, you've got the 10 disease that's indicative of the human disease.</p> <p>11 So it's -- I think that if this is -- as 12 sponsors are thinking about potentially using this 13 pathway, it seems possible that there would be as much 14 regulatory interaction just around validation and 15 trying to have -- give the FDA confidence in that 16 animal model because they're going to be scrutinizing 17 those data very, very carefully, I would anticipate.</p> <p>18 DR. REX: I want to say thank you for 19 standing up and saying that. That's something I -- it 20 was on my list to comment on. And Dr. Nambiar will.</p> <p>21 DR. NAMBIAR: Yeah, I thank you for your 22 comment. And that's what's probably (ph) was the last</p>
<p style="text-align: right;">Page 602</p> <p>1 Could you go back to the previous slide from 2 this one? It's the one where you introduced the 3 animal model.</p> <p>4 DR. REX: I think it's this one.</p> <p>5 MR. WARREN: Next one.</p> <p>6 DR. REX: Yeah. Well, so I've got some 7 made-up data with the animal model here.</p> <p>8 MR. WARREN: Okay. So well -- so it was --</p> <p>9 DR. REX: And so -- and by the way, this is 10 --</p> <p>11 MR. WARREN: There was the one --</p> <p>12 DR. REX: -- kind of like the animal model - 13 -</p> <p>14 MR. WARREN: There was a bullet point about 15 the -- generating the validated pig model. And so I 16 think there's a possibility you may have violated your 17 requirement for the miracle less than one on that one. 18 And you know, I --</p> <p>19 DR. REX: Oops.</p> <p>20 MR. WARREN: -- I say that tongue in cheek. 21 But it's an important point because I think it's 22 important to emphasize that I'm not familiar with the</p>	<p style="text-align: right;">Page 604</p> <p>1 point on my slide as well. Even though the animal 2 model seems like an approach, there is a lot of work 3 to be done between now and getting to it. And then 4 certainly we're talking about one model. But ideally, 5 we need more than one model. And the disease in the 6 animal has to be reflective of human disease.</p> <p>7 And I think your comment is right. There's 8 a lot of interaction, a lot of back and forth before 9 we get to a model that we are comfortable with to 10 decide the trigger and I think, as I mentioned, what's 11 the inoculum, what's the organism. With bio-threat 12 agents, it is -- it was easier because we used one 13 strain of Y. pestis. You know, with pseudomonas, I 14 mean, we have a lot more issues.</p> <p>15 So even though there's an appeal to the 16 animal rule, I think it's fair to say that it's a lot 17 of work done. And the years and time spent in getting 18 that to fruition, you might be able to do clinical 19 trials. I think we have to keep that in mind.</p> <p>20 DR. REX: And Lu to -- so Ed -- Lu and then 21 Ed.</p> <p>22 DR. BORIO: And I know you asked the</p>

<p style="text-align: right;">Page 605</p> <p>1 question, John. But I'll ask a question to Sumathi, 2 which is, you know, if you two can comment on the 3 appropriateness of a placebo in the control arm in 4 this model, you see a very dramatic treatment effect. 5 But the control is based on a placebo. Can you 6 comment on that? When was the last time you had an 7 animal rule in a pivotal -- the efficacy studies that 8 relied on a placebo control? 9 DR. NAMBIAR: It will -- so I think the 10 approval for levofloxacin was levofloxacin versus 11 placebo. 12 DR. REX: So was the answer that you 13 typically do it this way? 14 DR. NAMBIAR: Yeah. 15 DR. REX: Right, since this is the model you 16 made up. So I was -- 17 DR. NAMBIAR: Like -- 18 DR. REX: -- hoping it was -- 19 DR. NAMBIAR: -- in humans. 20 DR. REX: -- correct. 21 DR. NAMBIAR: This is not good, you know. 22 DR. REX: Well, and the -- and you know, it</p>	<p style="text-align: right;">Page 607</p> <p>1 where the safety and efficacy, essentially, were -- 2 you know, whether it was balance of benefit risk and 3 then also thinking about how do you gather more data 4 to figure out what is going on with the product. Is 5 it -- you know, is it working well in the situation 6 out there in the real world? Or have we uncovered 7 something that we didn't anticipate from the premarket 8 data in that -- you know, either with regards to 9 safety or efficacy? So -- 10 DR. BOUCHER: So Ed, I agree 100 percent. I 11 think that, you know, tying it in to sort of the 12 overall strategies that we're working on in the carb 13 efforts, you know, the stewardship kind of being more 14 universal in the United States as well as monitoring 15 of antibiotic use in general but especially for these 16 type of antibiotics seems like a very appropriate and 17 timely kind of systems-type measure to help with this. 18 And that's something that, you know, in our carb 19 efforts there's a lot going on in this area. And more 20 hospitals are using the NHSN antibiotic module 21 already. That's capturing all the antibiotics that we 22 use.</p>
<p style="text-align: right;">Page 606</p> <p>1 -- the example that you showed in the real-world 2 example of the African green monkey, you kind of had 3 data like this at the end of the day. 4 DR. NAMBIAR: Yeah. I think maybe off by a 5 couple of numbers, but it was -- 6 DR. REX: Or less. Right. 7 Ed? 8 DR. COX: Yeah. I just wanted to thank the 9 folks that were daring enough to postulate or 10 speculate on how the drug might be used. 11 And you know, the reason I'm asking is I 12 think that, you know, everyone recognizes that there's 13 tremendous uncertainty around this data. And so you 14 know, if it -- you know, if we think about, you know, 15 managing the risk of a product out there, it seems 16 like there would need to be some sort of program or 17 some sort of restriction on use. And just -- it helps 18 to have some insights into how the product might be, 19 you know, envisioned being used to help to understand, 20 you know, how you might put some sort of program in 21 place to, you know, restrict the use to certain 22 settings where it was appropriate to use it, you know,</p>	<p style="text-align: right;">Page 608</p> <p>1 So that's a system that exists. Now, it may 2 not be 100 percent acceptable for all the need. But 3 it's a -- it's evidence that there is a U.S.-based 4 systematic approach to all antibiotic use, but 5 especially for these really precious agents. 6 DR. TOMAYKO: And I just want to say that 7 there are settings where we've done things in the past 8 under a protocol. So that's what you were getting at. 9 Maybe there should be restrictions on how the drug is 10 used in the general sense based on that data. But 11 maybe it really is. 12 I was kind of thinking on the fly. But 13 maybe it really does become kind of a registry or a 14 field study. And you know, we make it -- take 15 advantage of diagnostics to try to minimize any issues 16 and whatever. But collecting that data is critical. 17 DR. COX: Yeah, and I agree, John. I think 18 we're all thinking on the fly today, and that's part 19 of what makes this interesting. But yeah, you know, I 20 appreciate everybody's comments and willingness to 21 hazard an opinion on this as we try and work through 22 it -- very helpful.</p>

Facilitating Antibacterial Drug Development For Patients With Unmet Needs Volume II

<p style="text-align: right;">Page 609</p> <p>1 DR. REX: So I want to be sure that we've</p> <p>2 thought about what this means economically. So what</p> <p>3 does it cost to run the plant that makes an injectable</p> <p>4 antibiotic 100,000 doses a year? My number is \$20</p> <p>5 million.</p> <p>6 UNIDENTIFIED MALE SPEAKER: Is that a</p> <p>7 combination product of two --</p> <p>8 DR. REX: Well --</p> <p>9 UNIDENTIFIED MALE SPEAKER: -- of different</p> <p>10 types --</p> <p>11 DR. REX: It's --</p> <p>12 UNIDENTIFIED MALE SPEAKER: I mean, what --</p> <p>13 DR. REX: This is a general -- I asked my</p> <p>14 guys for a general number for having a facility. And</p> <p>15 it definitely went just like this. Yeah, if you're</p> <p>16 making a monoclonal, it's more expensive. It sort of</p> <p>17 is. This was a general number, all in. And it</p> <p>18 doesn't mean -- it doesn't assume you have had to be -</p> <p>19 - it assumes you don't have to build your own</p> <p>20 facility. You can actually work in somebody else's,</p> <p>21 you know, shed, so to speak.</p> <p>22 But to have the staff to make -- to have the</p>	<p style="text-align: right;">Page 611</p> <p>1 base exist so that Helen can do her experiment? I</p> <p>2 mean, I -- ouch. I just want to observe that.</p> <p>3 So this -- you know, this is why I spend a</p> <p>4 lot of time on the pool models. I would want to treat</p> <p>5 this as a better fire extinguisher and argue that some</p> <p>6 countries should pay a certain access fee to guarantee</p> <p>7 that the drug exists in the pharmacy so that you can</p> <p>8 have it on an as-needed fire extinguisher-like basis.</p> <p>9 But you know, I look this, and I wonder</p> <p>10 could I convince somebody to pay for this fire</p> <p>11 extinguisher. You know, and I'm not saying that I</p> <p>12 like my answer when I say that. You know, it doesn't</p> <p>13 make me happy. But this is the problem -- this was</p> <p>14 the reason for the case.</p> <p>15 I don't see any hands go. So let me just</p> <p>16 show the very last slide. So this is Scenario E.</p> <p>17 It's like in Scenario D. But the animal model is --</p> <p>18 I've pointed out it's hard. I don't know that I can</p> <p>19 do one. Well, so we tried, and it -- couldn't do one.</p> <p>20 Absolutely. The pseudomonas, piglets, rabbits -- none</p> <p>21 of it really looked like human beings.</p> <p>22 So now we're down to can't do it, can never</p>
<p style="text-align: right;">Page 610</p> <p>1 runs to, you know, sort of take it in and out of</p> <p>2 production, that's the warm-based kind of a minimum</p> <p>3 cost if kind of the wind is to your back.</p> <p>4 It can be more expensive than that depending</p> <p>5 -- it still depends on how much you want to make. You</p> <p>6 know, the actual physical cost of each vial begins to</p> <p>7 be relevant after a while. You know, making 100,000</p> <p>8 vials or something even at 5 bucks, you know, that's</p> <p>9 half a million dollars right there -- boom, done. And</p> <p>10 that's -- it doesn't count stuff that goes in and out</p> <p>11 of date. And the occasional run, you know, sterile</p> <p>12 injectable manufacturing -- oh, my God, well, at least</p> <p>13 once a year, some batch blows apart and you lose</p> <p>14 50,000 vials. And you -- everybody just goes bananas.</p> <p>15 So the part -- the difficulty with what we</p> <p>16 just discussed is that if the drug is being used in</p> <p>17 the United States 100 times a year and in Europe -- so</p> <p>18 Europe -- the population of Europe is three times all</p> <p>19 of your -- even whether you -- it's in or out, it's a</p> <p>20 little over three times the United States.</p> <p>21 So let's pretend 500 courses a year. What</p> <p>22 do I have to charge for each course to have the warm</p>	<p style="text-align: right;">Page 612</p> <p>1 do it. What do -- and yet X-1, honestly, looks like</p> <p>2 it ought to be of some value. I mean, honestly, it</p> <p>3 does.</p> <p>4 So discuss. I told you the cases were going</p> <p>5 to get harder. Everybody take a deep breath.</p> <p>6 MR. DANE: You know, I guess it ranks (ph)</p> <p>7 to some of the earlier discussion, John, is that when</p> <p>8 we're in this situation, it's -- yeah, it's hard</p> <p>9 whatever we do. And in one way, the idea of open</p> <p>10 label trials with external control may sound</p> <p>11 appealing, but the trouble is are they really</p> <p>12 comparable. And you'd have to do a lot of work to be</p> <p>13 sure they were unless you had a very big effect. So</p> <p>14 if you had a very big effect, you could be a bit more</p> <p>15 confident that, actually, you had the benefit.</p> <p>16 Otherwise, it's just all getting mixed up in noise.</p> <p>17 But at the same time, yeah, it normally</p> <p>18 (ph)randomize. But if you've got a small number of</p> <p>19 heterogeneous cases, does it really help you? So it</p> <p>20 avoids the bias of treatment choice, but it doesn't</p> <p>21 necessarily give you balance in your groups.</p> <p>22 So I'm not sure I've given any answers there</p>

Page 613	Page 615
<p>1 other than more problems. But I think it was -- it's</p> <p>2 just the caution around this idea of external controls</p> <p>3 can solve all our problems. We just have to be a big</p> <p>4 careful with that and make sure that's sufficiently</p> <p>5 comparable to be able to do something with that.</p> <p>6 DR. REX: So let's talk a little more about</p> <p>7 external controls. I mean, I -- you're right. I'm</p> <p>8 teasing you a little bit to -- the -- no, you didn't</p> <p>9 help me at all there. So I'm still stuck. Okay.</p> <p>10 So I've got this thing. And the -- really,</p> <p>11 the best thing I can imagine is I'm going to go find</p> <p>12 folks who they've grown it. And now I'm going to --</p> <p>13 maybe it's acinetobacter, you know, right? Now I can</p> <p>14 kind of do this with acinetobacter, that, well, you</p> <p>15 see one of those, pretty high frequency of I don't</p> <p>16 have any drug at all that works. And I could do an</p> <p>17 open label case series.</p> <p>18 What about -- you know, David Shlaes was</p> <p>19 pointing at the idea of some sort of a contemporaneous</p> <p>20 control group. I mean, is there anything -- and I</p> <p>21 know there are strong allergies to external controls</p> <p>22 because previous datasets have been really messy.</p>	<p>1 You know, I've talked some with my</p> <p>2 colleagues in oncology, and I asked them about, you</p> <p>3 know, the situations where they've used historical</p> <p>4 controls. And you know, they'll sometimes say to me</p> <p>5 so, like, you know, tumors just don't get smaller on</p> <p>6 their own. They just don't do that. So if you have</p> <p>7 something that makes tumors get smaller on their own,</p> <p>8 you know, that as a surrogate (ph) endpoint, helps us</p> <p>9 to understand that we think we have an active drug.</p> <p>10 And then some other studies can happen, you know,</p> <p>11 longer term that tells us more about the effect of the</p> <p>12 drug clinically.</p> <p>13 So when you -- so there are some infectious</p> <p>14 disease conditions where, you know, the progression is</p> <p>15 invariable and, you know, unfortunately, I mean, it's,</p> <p>16 you know, the really bad diseases. And you know, we</p> <p>17 have used historical controls in those sort of</p> <p>18 circumstances where we think we've got a situation</p> <p>19 where, you know, progression will be essentially</p> <p>20 relentless if you don't have an active drug.</p> <p>21 And I think the last time we did something</p> <p>22 like that was for isavuconazole, which is approved for</p>
Page 614	Page 616
<p>1 Marco's smiling at me fixedly. And Ed and</p> <p>2 Sumathi are in deep debate.</p> <p>3 So opine on agents approved based solely on</p> <p>4 external controls.</p> <p>5 DR. COX: So yeah, we were talking about</p> <p>6 something else.</p> <p>7 (Laughter)</p> <p>8 DR. NAMBIAR: Well, I can reveal what that</p> <p>9 is, is I was asked to find another job.</p> <p>10 (Laughter)</p> <p>11 DR. REX: Well, at least we all share the</p> <p>12 pain here. That's the good thing.</p> <p>13 DR. COX: So yes, I mean, we do use external</p> <p>14 controls and historical controls. And the times we</p> <p>15 use them are in situations where, you know, the</p> <p>16 outcome is -- you know, I like to use the term -- you</p> <p>17 saw it on my slides today -- lights on, lights off,</p> <p>18 for it's -- you know, it's dependable. It happens all</p> <p>19 the time, and it doesn't really change that much. And</p> <p>20 you're not quite as susceptible, you know, within the</p> <p>21 group that you're looking at to variability with</p> <p>22 regard to outcomes.</p>	<p>1 invasive aspergillosis and also for mucormycosis. And</p> <p>2 we focused in on that -- in that application. You</p> <p>3 know, it was very helpful to have data from the</p> <p>4 invasive aspergillosis study. And then you know, we</p> <p>5 recognize these are different agents, and I mean the</p> <p>6 agent causing the infection.</p> <p>7 But with mucormycosis, we were able to look</p> <p>8 at patients with hematologic malignancies, a group</p> <p>9 that we thought would have, essentially, relentless</p> <p>10 progression if they didn't see an effective antifungal</p> <p>11 agent. And you know, we looked at that group of</p> <p>12 patients and saw something that we thought wouldn't</p> <p>13 have happened absent an effective antifungal drug.</p> <p>14 So there are scenarios where such an</p> <p>15 approach is, I think, informative. There are, you</p> <p>16 know, many other scenarios where, you know, the</p> <p>17 outcome and can change tremendously. You know, the</p> <p>18 variability and outcome may be as large as the</p> <p>19 treatment effect that you might expect, depending upon</p> <p>20 who gets in the trial, what their, you know, baseline</p> <p>21 conditions and comorbidities are. And when you're in</p> <p>22 that scenario, it can be very difficult to,</p>

<p style="text-align: right;">Page 617</p> <p>1 essentially, you know, sort out, you know, what --</p> <p>2 whether the drug is having an effect or not.</p> <p>3 And you know, we've seen situations, too,</p> <p>4 where, you know, despite thinking that we understand</p> <p>5 the factors that impact upon outcomes, you know, the</p> <p>6 patients that actually end up in a clinical trial do</p> <p>7 better. And that's not just us, but that's an ICHE</p> <p>8 (ph) tend that essentially says that, you know,</p> <p>9 patients that end up in a control group within a</p> <p>10 historic -- within a clinical trial typically do</p> <p>11 better than their historical counterparts.</p> <p>12 So I mean, that's what makes it really hard,</p> <p>13 is when there is this variability. If it's lights on,</p> <p>14 lights off, something that never happens, then</p> <p>15 historical controls, you know, can be a good and</p> <p>16 reliable way to do this. If it -- if there's a lot of</p> <p>17 variability and it's hard to understand all the</p> <p>18 factors that impact upon that variability, it can be</p> <p>19 really tough.</p> <p>20 DR. REX: Have you ever seen anybody do what</p> <p>21 David described, which isn't -- it isn't just the last</p> <p>22 50 cases with X, but rather, they've been filtered.</p>	<p style="text-align: right;">Page 619</p> <p>1 possible so that you're reducing the likelihood that</p> <p>2 your historical control is not, you know, related --</p> <p>3 is not comparable to your patients that you're</p> <p>4 actually getting your therapeutic.</p> <p>5 And we've also heard a couple of times, I</p> <p>6 think, from our statistical colleagues the idea of</p> <p>7 having, if at all possible, some concurrent controls,</p> <p>8 even if the randomization is disproportionate so that</p> <p>9 you can do some techniques to try and understand who's</p> <p>10 in the trial and how they might relate to the external</p> <p>11 controls, too.</p> <p>12 So I mean -- so external controls, I think,</p> <p>13 you know, are useful in certain situations.</p> <p>14 Understand the characteristics of a particular disease</p> <p>15 that you're studying. But you also do have to be</p> <p>16 careful of situations where they may not be, you know,</p> <p>17 as helpful as you might hope they would be.</p> <p>18 DR. REX: Yeah. And Jack (ph) then one made</p> <p>19 -- once made the observation to me about people with</p> <p>20 cryptococcal meningitis that got into the early</p> <p>21 protocols. He said they were unusual because they</p> <p>22 lived long enough to make it to the NIH. You know,</p>
<p style="text-align: right;">Page 618</p> <p>1 And at least you've looked at them at the level of I</p> <p>2 think they could have been enrolled in the trial had I</p> <p>3 been in that hospital at the right time. Have you</p> <p>4 ever seen that done?</p> <p>5 DR. COX: So I don't know that we've seen</p> <p>6 exactly what David's described. But we have seen</p> <p>7 people make a fairly valiant effort to pull together</p> <p>8 historical controls. And you know, it usually -- it -</p> <p>9 - this is not the way to do it. But usually, it's</p> <p>10 done sort of after the fact, and it's sort of, you</p> <p>11 know, where can I go and sort of pick through a</p> <p>12 collection of patient records and find some patients</p> <p>13 that I think, you know, could have been enrolled in my</p> <p>14 trial and trying to get to something similar. And</p> <p>15 it's -- that is very, very difficult.</p> <p>16 So I think, I mean, you know -- and</p> <p>17 everybody, you know, who I think advises on what you</p> <p>18 ought to be doing if you're trying to put together an</p> <p>19 external control will be talking about, you know,</p> <p>20 trying to be in the same institutions, trying to have</p> <p>21 the same protocol, trying to do it at a similar time</p> <p>22 period to get patients that are as comfortable as</p>	<p style="text-align: right;">Page 620</p> <p>1 and so they were a selected subset.</p> <p>2 Marco, do you have any comment?</p> <p>3 DR. CAVALERI: Well, I think, yeah, indeed,</p> <p>4 as Ed said, in the antifungal space, we had a number</p> <p>5 of cases, isavuconazole as being the last one for us,</p> <p>6 too. And you know, at the end, we went positive as</p> <p>7 well for mucormycosis, despite we were not really</p> <p>8 overenthusiastic about how historical control were put</p> <p>9 together. So it could have been better, frankly.</p> <p>10 Yeah, I think, indeed, there is a lack of</p> <p>11 this idea of setting up robust external or historical</p> <p>12 control that could be used for the sake of</p> <p>13 interpreting, you know, single on (ph) trials. And</p> <p>14 that is a matter where maybe there is a need to think</p> <p>15 about what could be the option. And now we can do it</p> <p>16 better in order to make them useful in a setting like</p> <p>17 this one.</p> <p>18 MR. DANE: I do wonder is whether there's --</p> <p>19 I'm not sure this is even feasible. But could you set</p> <p>20 something off prospectively that? And, yes, under a</p> <p>21 similar type of trial program that a sponsor would</p> <p>22 conduct, you have something that runs, you know, maybe</p>

Page 621	Page 623
<p>1 a bit more like a network so that you -- you're 2 generating data an on ongoing basis. Then it's all 3 under the same protocol. And the prospectives, you've 4 got those issues of comparability still. But at least 5 you're doing it all under the same banner, if you 6 like, rather than going back and trying to do it.</p> <p>7 DR. COX: Right. You know, thanks, Aaron. 8 Yeah, you know, this is -- I mean, we've 9 talked some about this. But the idea of a clinical 10 trial network, I think, is sort of an ideal sandbox to 11 try and work through some of these questions. You 12 know, if you just slightly change, you know, the 13 inclusion-exclusion criteria within a trial, if you 14 change the institutions where the trial is taking 15 place, if the comparator drug changes over time, you 16 know, we may not sort of fully take that into 17 consideration when we're looking at the outcomes of 18 Trial A to Trial B to Trial C.</p> <p>19 So it is possible that if you had a clinical 20 trial network this would -- you know, where you've got 21 a protocol that's stable, you're at similar or the 22 same institutions over time, it might give you some</p>	<p>1 But then you get into that small numbers 2 part because in the -- and you have so much belief 3 that the one that's in the real trial is the real 4 number. So if it deviates in the wrong way from this 5 larger body of data, sometimes, you know, your mind 6 goes to the fact, well, those were just sort of the 7 fake controls and this is the real control and one 8 person in that kind of disproportionate stuff. So I'm 9 not sure it makes you -- it makes a heck of a lot of 10 difference.</p> <p>11 Now, if everything goes in the right way, 12 then life's good. And then you have these kind of 13 trials because most of the time we've focused on the 14 non-inferiority downside as opposed to the non- 15 inferiority upside. But then again, since I'm up 16 here, I'll say I have a hard time thinking of that 17 non-inferiority drug because that's not how I was 18 planning on using the drug in the real world to what 19 you guys talked about. I mean, this is something 20 that's on top of something else to make sure that your 21 percent susceptibility or that difficult to treat or 22 that outbreak or that scenario's there rather than</p>
Page 622	Page 624
<p>1 important insights into what -- you know, what is 2 happening with regards to patient outcomes and 3 whether, you know, I mean, what is the degree of 4 variability. We see the variability. I'm not sure we 5 fully understand it.</p> <p>6 And the question is, is could -- I mean, 7 could you, using, you know, those sorts of -- if -- I 8 don't know -- using a network, could you figure that 9 out in a way that, you know, you could convince 10 yourself that things were sufficiently consistent and 11 sufficiently reliable over time that they didn't 12 change. I think it's a good question and one where, 13 you know, data would help us through that. And a 14 clinical trial network could help tremendously.</p> <p>15 DR. REX: Lynn? 16 DR. MARKS: We talked a good bit about what 17 I think -- I don't know what the right term is -- but 18 augmented control arms so that you do have a small 19 randomization number -- let's -- I'll make it up -- 10 20 to 1. So it's very disproportionate. And then you 21 run in the same time frame, same institution, et 22 cetera, to get that baseline.</p>	<p>1 just I've got something else I'm going to add in. 2 MR. DANE: So on the augmented control, I 3 don't know if maybe Kert wants to make a comment, but 4 I would agree that in this setting -- so when we -- we 5 tend to look at that when you've got a few hundred 6 patients and then you've still got a reasonable amount 7 and a reasonable amount of precision to compare with 8 your external dataset, whereas here, if you're only 9 talking -- I mean, in that example, it was 12. And if 10 you did a more extreme randomization ratio, it's less. 11 So it seems a lot more difficult to actually do 12 something that formal. Yeah, exactly.</p> <p>13 UNIDENTIFIED MALE SPEAKER: John, going back 14 to the estimate that you were saying where we are 15 treating 100 patients in the U.S. and maybe 500 in 16 Europe, I just cannot fit it with some statistics that 17 I've seen. So CDC estimates that there are 51,000 18 total cases of so the --</p> <p>19 DR. REX: Oh, sorry. But wait. I'm sorry. 20 In D and E, I've drifted -- pseudomonas is 21 definitely more frequent than this. So like, maybe 22 this is acinetobacter. Maybe this is</p>

Facilitating Antibacterial Drug Development For Patients With Unmet Needs Volume II

Page 625	Page 627
<p>1 stenotrophomonas, you know, something that's even less</p> <p>2 common. So it's no longer pseudomonas, necessarily.</p> <p>3 UNIDENTIFIED MALE SPEAKER: Okay. Okay. So</p> <p>4 you were not --</p> <p>5 DR. REX: Is that --</p> <p>6 UNIDENTIFIED MALE SPEAKER: -- talking about</p> <p>7 pseudomonas.</p> <p>8 DR. REX: No, because we know we can get --</p> <p>9 we know we got the slightly higher numbers. And so I</p> <p>10 made this -- and I suppose you could --</p> <p>11 UNIDENTIFIED MALE SPEAKER: No, no. I was</p> <p>12 talking about the scenario --</p> <p>13 DR. REX: No, no. You are correct.</p> <p>14 Pseudomonas is definitely more frequent than that --</p> <p>15 but acinetobacter, stenotrophomonas, things of</p> <p>16 interest.</p> <p>17 UNIDENTIFIED MALE SPEAKER: Fine.</p> <p>18 DR. REX: Thank you.</p> <p>19 UNIDENTIFIED MALE SPEAKER: Bye.</p> <p>20 UNIDENTIFIED MALE SPEAKER: Hi. At the risk</p> <p>21 of going really sideways here, instead --</p> <p>22 DR. REX: Well, actually, let me say this is</p>	<p>1 UNIDENTIFIED MALE SPEAKER: We know that</p> <p>2 exposure is associated with a certain level of</p> <p>3 efficacy.</p> <p>4 DR. REX: Right. And we -- it's tied into</p> <p>5 the animal responses, and it's tied into the risk</p> <p>6 factors and familiarity (ph), you know, and the</p> <p>7 changes in PK due to underlying diseases.</p> <p>8 And so Dr. Cox?</p> <p>9 DR. TOMAYKO: That's the animal rule, isn't</p> <p>10 it? You know, you do the good animal data to show</p> <p>11 it's an antibiotic. And then you know what the target</p> <p>12 exposure has to be. And then you show in the target</p> <p>13 population that you achieve those exposures in a</p> <p>14 certain percentage of the population. I think that's</p> <p>15 -- that sounds great. That's what I'm advocating for.</p> <p>16 UNIDENTIFIED MALE SPEAKER: It's the human -</p> <p>17 -</p> <p>18 DR. TOMAYKO: It's the human version of it,</p> <p>19 yeah.</p> <p>20 DR. COX: So I think --</p> <p>21 DR. REX: It's the large animal rule.</p> <p>22 DR. COX: So I think, you know, John, when</p>
Page 626	Page 628
<p>1 the time to go sideways because we're to Scenario F</p> <p>2 and you're the first up.</p> <p>3 What else?</p> <p>4 UNIDENTIFIED MALE SPEAKER: Right. So we</p> <p>5 know some standard drug works, at least to some -- at</p> <p>6 a level of efficacy that we like, right? Maybe it's</p> <p>7 meropenem against pseudomonas. It has a certain</p> <p>8 probability of hitting an effective exposure, does it</p> <p>9 not? So why not compare for our new drug, new</p> <p>10 regimen, its probability of hitting those effective</p> <p>11 exposures? And that's where comparing those exposure</p> <p>12 distributions, knowing that, for the drug we know,</p> <p>13 that exposure distribution is tied to an efficacy</p> <p>14 level that we like. And that's really what we're</p> <p>15 making our comparison on.</p> <p>16 DR. REX: So if I play it back, you're</p> <p>17 proposing approval on the basis of adequate PK with</p> <p>18 the definition of adequate being really pretty</p> <p>19 sophisticated. It's tied into an exposure --</p> <p>20 UNIDENTIFIED MALE SPEAKER: But we know that</p> <p>21 --</p> <p>22 DR. REX: -- response curve.</p>	<p>1 you're bringing up -- you know, one of the criteria</p> <p>2 for the animal rule is when you have the outcome in</p> <p>3 the animal model. And then what you're trying to do</p> <p>4 is to, you know, link the exposure from the animal to</p> <p>5 the exposure in the human. If you look at our animal</p> <p>6 rule guidance document, it actually recommends, you</p> <p>7 know, that you try and exceed that exposure with the</p> <p>8 human exposure that would exceed the animal exposure</p> <p>9 by some multiple, if at all possible, recognizing that</p> <p>10 sometimes we run into safety issues.</p> <p>11 And I think, Paul -- so what you're</p> <p>12 describing is -- so you've got -- and I'm going to say</p> <p>13 you've another carbapenem and you have an idea of what</p> <p>14 your exposure target is for carbapenem. And you're</p> <p>15 trying to -- so you've now got another drug from the</p> <p>16 same class. And you're trying to, essentially,</p> <p>17 achieve a similar target for this new agent that's</p> <p>18 also from the same class, if I understood correctly.</p> <p>19 Is that fair?</p> <p>20 UNIDENTIFIED MALE SPEAKER: They could be</p> <p>21 from the same class or a different class,</p> <p>22 theoretically.</p>

Facilitating Antibacterial Drug Development For Patients With Unmet Needs Volume II

<p style="text-align: right;">Page 629</p> <p>1 DR. COX: If you get to a different class, 2 it gets a little tougher, though, doesn't it, because 3 you don't actually have -- you don't actually know 4 exactly where you're going. 5 UNIDENTIFIED MALE SPEAKER: Yeah, but you do 6 know that, you know, your chances of curing the 7 pneumonia go up with killing bacteria. So you're 8 picking an exposure threshold target that's associated 9 with a certain -- 10 DR. COX: Okay. 11 UNIDENTIFIED MALE SPEAKER: -- killing of 12 cells. 13 DR. COX: Okay. So you're picking the 14 target from other drugs, yeah. 15 I mean, so I don't know that I would replace 16 what it is that we're talking about here, trying to 17 replace a clinical outcome. But I think what you're 18 describing could be very helpful in deciding, you 19 know, what dose to use. Fair? 20 UNIDENTIFIED MALE SPEAKER: I'm not saying 21 replace. 22 DR. COX: Okay.</p>	<p style="text-align: right;">Page 631</p> <p>1 examples from yesterday I thought were particularly 2 striking and really underscored the importance of 3 doing that. 4 And I think, you know, to your point of will 5 we still be stressed if the clinical outcome data 6 looks a little bit lower. I think our stress will 7 continue. But I don't think that takes away anything 8 from the importance of, you know, trying to do the 9 best you can with the PK. 10 DR. REX: Mike? 11 MIKE: Yeah. So you -- maybe it was covered 12 in Scenario XY, or something, and may -- as on the 13 cutting room floor. But I'm curious. I was trying to 14 think about dose response as a form of control and has 15 been used for some programs. But I was trying to come 16 up with whether or not that's more efficient than 17 using sort of a simultaneous control but perhaps in 18 the setting of the external controls, which I think 19 everyone sort of is feeling is a little bit more 20 doable. 21 So it -- maybe you could talk a little bit 22 about dose response control, where there we're not</p>
<p style="text-align: right;">Page 630</p> <p>1 UNIDENTIFIED MALE SPEAKER: You've got this 2 study in which you show one at 74 percent in a couple 3 fistfuls of patients and the other at 77. And you're 4 worried that it's -- that there's not enough evidence 5 there. 6 DR. COX: Yeah. 7 UNIDENTIFIED MALE SPEAKER: Well, maybe 8 because we know so many other factors cause failures 9 in this disease state that you've all pointed out, 10 right -- their protein status, all the other things 11 that we all know -- 12 DR. COX: Right. 13 UNIDENTIFIED MALE SPEAKER: -- and you're 14 worried that the new regimen looks a little bit lower 15 than the old regimen, and it's stressing you out. I 16 think the way to not be stressed is to look at the 17 exposures you achieved and are you hitting things you 18 know. 19 DR. COX: Yeah. So I mean, I think, you 20 know, throughout all the discussions, you know, I 21 think the importance of PK and getting the dose right 22 is, you know, clearly there. I -- some of the</p>	<p style="text-align: right;">Page 632</p> <p>1 trying to meet certain margins. Or what are the 2 criteria where in a dose response control are you -- 3 you're not looking for necessarily statistically 4 significant differences between groups? Or are you? 5 And obviously, we would pick our doses to be 6 informed by PK/PD so we're not unnecessarily exposing 7 patients at risk to sub-therapeutic doses just to 8 squeak out a control group. 9 DR. COX: Do you want to do this one, John? 10 DR. REX: Oh, I just -- I was going to 11 suggest we -- my comment is I left dose response out 12 deliberately because I don't tend to see how I can 13 choose two doses, both of which are going to be 14 efficacious, and have them be meaningful different 15 because my general sense is I have to -- doses have to 16 be quite different going (ph). One mg per kg versus 17 five mgs per kg will get really separate exposures. 18 One mg per kg versus one and a half, you know, the -- 19 MIKE: Yeah, maybe like -- 20 DR. REX: And -- sorry. The last thing is 21 the one mg per kg has to be acceptable. 22 MIKE: Yeah. So let me clarify a little</p>

Page 633	Page 635
<p>1 bit.</p> <p>2 So I think what you're -- what you want to</p> <p>3 do is you want to be -- there's going to be</p> <p>4 variability. So what the dose response curve</p> <p>5 essentially does is it spreads your exposure response</p> <p>6 out over a greater period -- a greater number of</p> <p>7 exposures. Obviously, you could have somebody in the</p> <p>8 high-dose arm be among those patients that had</p> <p>9 actually the lowest exposures because of variability.</p> <p>10 So I think the dose response is, more or</p> <p>11 less, just sort of spread the field. You'd obviously</p> <p>12 not be wanting to choose the lowest dose that would be</p> <p>13 getting you 90 percent of your patients having a sub-</p> <p>14 therapeutic exposure --</p> <p>15 DR. REX: No, I just said that I --</p> <p>16 MIKE: -- but it would be --</p> <p>17 DR. REX: -- would not be willing to sign on</p> <p>18 to the one -- to even the one mg per kg having a low</p> <p>19 target attainment because that sets me up for public</p> <p>20 shaming. You know, I --</p> <p>21 MIKE: Well, I --</p> <p>22 DR. REX: -- I'm just not willing to do</p>	<p>1 different way? Because yesterday, Paul presented a</p> <p>2 number of examples. And I think some of them were</p> <p>3 related to pseudomonas -- the doripenem (ph) data, the</p> <p>4 Ceftobiprole data, maybe some Tigecycline data. And</p> <p>5 if you do a pharmacometric analysis and you see that</p> <p>6 when you achieve exposure, if you have those failures</p> <p>7 already and you could make an argument that those</p> <p>8 failures are dose-related, well, it just basically</p> <p>9 says I didn't have an antibiotic here.</p> <p>10 So you can get a pretty good estimate of</p> <p>11 what it's like not to treat one of these patients. I</p> <p>12 mean, is that not correct, Paul? I mean, do you --</p> <p>13 DR. AMBROSE: Yeah, I think what you're --</p> <p>14 what you may be referring to is when you model the</p> <p>15 exposure response and you can basically use the</p> <p>16 intercept of the no exposure as kind of your</p> <p>17 equivalent placebo by extrapolating back to that.</p> <p>18 That then allows you to estimate the magnitude of the</p> <p>19 treatment effect.</p> <p>20 UNIDENTIFIED MALE SPEAKER: And between what</p> <p>21 Paul -- I guess I'm taking it one step further. He</p> <p>22 showed it -- made the point in a number of different</p>
Page 634	Page 636
<p>1 that.</p> <p>2 MIKE: I don't think it has to be -- you</p> <p>3 know, again, I don't think it has to be, you know, low</p> <p>4 target attainment. As I've -- as we've talked about</p> <p>5 before, we always -- we put our doses up to get 100</p> <p>6 percent target --</p> <p>7 DR. REX: Right.</p> <p>8 MIKE: -- attainment. So --</p> <p>9 DR. REX: But then you're --</p> <p>10 MIKE: So I think you could --</p> <p>11 DR. REX: -- Paul and -- but Paul -- what</p> <p>12 Paul said was that I'm picking them both to be</p> <p>13 efficacious. I mean, I -- it's -- you're asking for</p> <p>14 both sides of this simultaneously.</p> <p>15 MIKE: But again, the objective of trying to</p> <p>16 get, you know, information about safety as well as</p> <p>17 efficacy in that population having dose response or</p> <p>18 exposure response as the ultimate analysis plan, that</p> <p>19 would do that compared to a simultaneous external</p> <p>20 control group. What are the thinking about dose</p> <p>21 response or exposure responses in control?</p> <p>22 DR. TOMAYKO: Mike, can I just ask a</p>	<p>1 programs. And FDA probably has a number of different</p> <p>2 databases where maybe we could even fortify that</p> <p>3 learning. And that could be useful information, and</p> <p>4 it may be better than an external control.</p> <p>5 UNIDENTIFIED MALE SPEAKER: Yeah. Well, I</p> <p>6 think you use -- you may be able to use the intercept</p> <p>7 if you're doing that intercept pharmacometric method</p> <p>8 to be able to compare that to the external control</p> <p>9 data just to sort of see where you are in terms of</p> <p>10 your treatment effect.</p> <p>11 DR. REX: Ed. Sorry. We kind have been</p> <p>12 going around.</p> <p>13 DR. COX: Yeah. So I think our experience</p> <p>14 has been, you know, similar to the debate that you and</p> <p>15 John were having, which is, you know, most folks going</p> <p>16 into the serious infection, you know, the dose that</p> <p>17 they pick is going to be one that's going to be</p> <p>18 ideally on the flat part of the curve. So I think</p> <p>19 that's one part of it. I understand you're asking</p> <p>20 about a second part.</p> <p>21 So the -- you know, the idea of doing a</p> <p>22 second dose, I mean, and most -- it seems like most</p>

Facilitating Antibacterial Drug Development For Patients With Unmet Needs Volume II

Page 637	Page 639
<p>1 people would be shooting for that flat part of the</p> <p>2 curve where the likelihood of showing it -- an effect</p> <p>3 is going to be, you know, not so great.</p> <p>4 Now, if there's equipoise and you pick two</p> <p>5 doses and you get the degree of variability that Paul</p> <p>6 shows with your low dose, that's -- you know, there's</p> <p>7 equipoise for doing that and you happen to find a</p> <p>8 difference there for those two dose groups, then I</p> <p>9 mean, you've got something that, you know, suggests --</p> <p>10 I mean, you've got, essentially, a superiority design</p> <p>11 where you've shown a clear effect.</p> <p>12 Obviously, with serious diseases, you want</p> <p>13 to have a DSMB in place. I mean, you couldn't -- I</p> <p>14 don't think -- you couldn't plan to do this, is what</p> <p>15 I'm thinking. You can't plan to give patients with</p> <p>16 serious infections sub-therapeutic doses.</p> <p>17 So is that -- that's part one of your</p> <p>18 question, I think, right?</p> <p>19 UNIDENTIFIED MALE SPEAKER: I think that's</p> <p>20 right. I mean, I think that what Paul's data showed</p> <p>21 vividly there --</p> <p>22 DR. COX: Yeah.</p>	<p>1 couldn't tell if you were getting to sort of, you</p> <p>2 know, exposure response, what happens in the trial and</p> <p>3 trying to sort through that. Is that your other</p> <p>4 question?</p> <p>5 UNIDENTIFIED MALE SPEAKER: Yeah, I think I</p> <p>6 --</p> <p>7 DR. COX: Okay.</p> <p>8 UNIDENTIFIED MALE SPEAKER: But I think it's</p> <p>9 more of --</p> <p>10 DR. COX: And John, you're going to have to</p> <p>11 cut us off in a moment because I think some other</p> <p>12 folks might want to ask some questions.</p> <p>13 UNIDENTIFIED MALE SPEAKER: -- more of like,</p> <p>14 you know, can we use -- I think Paul's getting at</p> <p>15 this, was the exposure response --</p> <p>16 UNIDENTIFIED MALE SPEAKER: Yeah.</p> <p>17 UNIDENTIFIED MALE SPEAKER: -- relationship</p> <p>18 that would come as part of a dose ranging trial. I</p> <p>19 absolutely agree that, you know, you're not going to</p> <p>20 try and sign this. We all have limitations. I mean,</p> <p>21 I haven't seen very many 10-gram doses of carbapenems,</p> <p>22 although I know a 10-gram dose of carbapenem would</p>
Page 638	Page 640
<p>1 UNIDENTIFIED MALE SPEAKER: -- in the best</p> <p>2 laid plans --</p> <p>3 DR. COX: Right.</p> <p>4 UNIDENTIFIED MALE SPEAKER: -- there are</p> <p>5 still going to be patients who have low exposures</p> <p>6 and/or higher (inaudible - off mic) ranges.</p> <p>7 DR. COX: Right.</p> <p>8 UNIDENTIFIED MALE SPEAKER: So unless you're</p> <p>9 doing a concentration control trial because you're --</p> <p>10 that's the only way that you're ever going to prevent</p> <p>11 that.</p> <p>12 DR. COX: Right. And you know, it's hard</p> <p>13 because, as you start to learn that, you have to push</p> <p>14 the dose because you have this concern that with this</p> <p>15 variability you're going to have some patients that</p> <p>16 are sub-therapeutic. It becomes hard not to try and</p> <p>17 push the dose to get to something that's on the flat</p> <p>18 part of the curve, you know, to, essentially, create a</p> <p>19 scenario where the likelihood of showing this</p> <p>20 difference is going to decrease to some extent.</p> <p>21 Is that fair? Have I answered your</p> <p>22 question? Or was there another part to it? I</p>	<p>1 clearly get concentrations where we need it. So --</p> <p>2 DR. COX: Right.</p> <p>3 UNIDENTIFIED MALE SPEAKER: -- there's</p> <p>4 always limitations that you're always going to have on</p> <p>5 these things.</p> <p>6 But I think that's the nature of the trials,</p> <p>7 are going to give you an exposure response curve. And</p> <p>8 therefore, by modeling that effect, is that evidence</p> <p>9 of a treatment effect, therefore, when reflected</p> <p>10 against external controls, that give you evidence of</p> <p>11 efficacy?</p> <p>12 DR. COX: Right. So --</p> <p>13 UNIDENTIFIED MALE SPEAKER: And so --</p> <p>14 DR. COX: And you said dose ranging trial,</p> <p>15 which again makes me think you're talking about going</p> <p>16 in with different doses.</p> <p>17 UNIDENTIFIED MALE SPEAKER: Yeah. I --</p> <p>18 DR. COX: Okay.</p> <p>19 UNIDENTIFIED MALE SPEAKER: I would say that</p> <p>20 we would pick doses that --</p> <p>21 DR. COX: Yeah.</p> <p>22 UNIDENTIFIED MALE SPEAKER: -- are above,</p>

<p style="text-align: right;">Page 641</p> <p>1 based upon the Phase 1 data that are above the</p> <p>2 expected therapeutic effect. One, you know, is at</p> <p>3 therapeutic effect and then some multiple of that,</p> <p>4 knowing that we're going to have variability and</p> <p>5 exposures in those patients and in ELF if we're doing</p> <p>6 a HABP/VABP trial. And therefore, we would de-</p> <p>7 convolute that as part of the analysis plan and then</p> <p>8 be able to show then those exposure response or</p> <p>9 evidence of an --</p> <p>10 DR. REX: So to play it back, you might</p> <p>11 deliberately use a range of doses in order to ensure</p> <p>12 that you got a reasonably broad range of actual</p> <p>13 exposures and then hope that you have enough cases to</p> <p>14 fill in some of the cells at the lower end of the</p> <p>15 exposure, which gets into how many of those you've got</p> <p>16 to have, which might -- makes to be a reasonably good-</p> <p>17 sized program, which maybe you could do something</p> <p>18 else.</p> <p>19 So I -- good. So we're -- so --</p> <p>20 DR. COX: Maybe just one last quick comment</p> <p>21 and then I'll stop.</p> <p>22 It's just the issue of -- I mean, if you</p>	<p style="text-align: right;">Page 643</p> <p>1 DR. COX: Yeah. I mean, are the patients</p> <p>2 that, you know, are hyper-metabolizers that clear the</p> <p>3 drug more quickly? Are there -- is that somehow</p> <p>4 associated with a worse outcome?</p> <p>5 UNIDENTIFIED MALE SPEAKER: Yeah,</p> <p>6 biologically.</p> <p>7 DR. COX: Yeah, yeah, yeah.</p> <p>8 DR. REX: Because the exposure is --</p> <p>9 DR. COX: Yeah, and you say there's no data</p> <p>10 for that.</p> <p>11 UNIDENTIFIED MALE SPEAKER: Not really --</p> <p>12 DR. COX: Okay.</p> <p>13 UNIDENTIFIED MALE SPEAKER: But --</p> <p>14 DR. REX: Yes, ma'am?</p> <p>15 DR. COX: All right. So a topic for a</p> <p>16 longer discussion.</p> <p>17 DR. REX: All right. So I've accumulated on</p> <p>18 my list for Scenario F things like think about</p> <p>19 exposure response, the Shlaes case control model. And</p> <p>20 I've also jotted down Bayesian prior.</p> <p>21 So yes, ma'am? On to you.</p> <p>22 UNIDENTIFIED FEMALE SPEAKER: Okay. So the</p>
<p style="text-align: right;">Page 642</p> <p>1 were, you know, allocating patients to different dose</p> <p>2 groups, then you've got comparisons between dose</p> <p>3 groups and you're trying to show superiority of one</p> <p>4 group to the other. If the exposures happen, you</p> <p>5 know, and you're trying to look at the exposures that</p> <p>6 actually happen to patients compared to outcome. You</p> <p>7 know, there's always the question of is the reason</p> <p>8 that the exposure is low in a particular patient also</p> <p>9 something that's associated with the poor outcome.</p> <p>10 And that's the difficult question.</p> <p>11 DR. REX: The exposure --</p> <p>12 DR. COX: So the de-convolution is very</p> <p>13 difficult.</p> <p>14 DR. REX: So we're going to move on.</p> <p>15 UNIDENTIFIED MALE SPEAKER: We've heard that</p> <p>16 argument before, and there's not a lot of evidence</p> <p>17 that have that because you're going to be able to de-</p> <p>18 convolute that. There is --</p> <p>19 DR. COX: So you -- so --</p> <p>20 UNIDENTIFIED MALE SPEAKER: So you're saying</p> <p>21 that are there patients that are at greater risk for a</p> <p>22 bad outcome that just have goofy pharmacokinetics.</p>	<p style="text-align: right;">Page 644</p> <p>1 difference between X-1 and some of the other things</p> <p>2 that we're looking at to treat multidrug-resistant</p> <p>3 organisms is that X-1 and a couple of other things</p> <p>4 that some of us are more familiar with don't have any</p> <p>5 effect on other organisms. And that's makes the</p> <p>6 challenge because if you've got something like</p> <p>7 isavuconazole, you have got clinical data and you've</p> <p>8 got something to base your efficacy on.</p> <p>9 DR. REX: Right.</p> <p>10 UNIDENTIFIED FEMALE SPEAKER: If you have</p> <p>11 new aminoglycosides, if you have new versions of</p> <p>12 classes which are expanding, they are completely</p> <p>13 different from what we're looking at with X-1.</p> <p>14 Now, what I am going to suggest, which might</p> <p>15 be that we could look at the sort of thing with --</p> <p>16 that we did with isavuconazole where we looked at</p> <p>17 Fungiscope, which is a registry of rare fungus</p> <p>18 diseases where we got the data from that we used for a</p> <p>19 lot of the case controls.</p> <p>20 And I'm just going to ask if -- particularly</p> <p>21 from Helen -- whether actually we ought to be keeping</p> <p>22 a registry of these difficult cases like the first</p>

<p style="text-align: right;">Page 645</p> <p>1 case you presented because that's exactly what we do 2 with things like Fungiscope. We collect these cases. 3 We track them. We look at the outcome. Obviously, 4 with fungal infections like mucor, they're much longer 5 conditions. 6 But perhaps that's what we should be doing 7 and not trying to get our safety and clinical data 8 separately in more conventional trials for those 9 programs and look at using external controls from the 10 data that, perhaps, those kind of registries could be 11 set up so that we're not trying to push the envelope 12 and spend an awful lot of money looking at the edges 13 of very good drugs in other ways but actually have 14 been expanded a little. 15 For those things that are -- have no other 16 activity, I think we should be going to John looking 17 at what they bring in addition to what is there 18 already, which is the adjunctive elements of those 19 projects. So I kind of think we should be looking at 20 this rather differently, looking at what we're trying 21 to achieve in terms of the clinical things with the 22 established products that we can get data on other</p>	<p style="text-align: right;">Page 647</p> <p>1 would say, healthy debate about the benefit of 2 registries. I mean, I think in a lot of ways, I mean, 3 academic. You know, I love to learn about these thing 4 -- you know, there's a lot of upside to learning about 5 the natural history of these diseases. And I think 6 groups in the IMI and other places are taking little 7 pieces of this in the ARLG here in the U.S. 8 But the consensus that I've heard has been 9 that a registry, per se, wouldn't meet the criteria 10 that we need for the external control, necessarily. 11 So that's been part of the reason for the lack of 12 enthusiasm in funding. It's very expensive. 13 So the question would come down to, well, 14 who pays for this. The NIH? You know, it gets to -- 15 the sponsor has an interest for his or her compound 16 for that period of time, but not in perpetuity. 17 DR. TOMAYKO: So Helen, you mentioned IMI. 18 And before I left GSK, I was working with Jesus 19 Rodriguez-Bano. And I've presented this before. And 20 IMI was sponsoring and designing and, I presume, still 21 executing a study that was -- it was looking at a very 22 sophisticated way of collecting the natural history</p>
<p style="text-align: right;">Page 646</p> <p>1 areas. And for those that are completely novel, look 2 at the adjunctive programs in a completely different 3 way because we are looking there. I think we can't 4 get away from superiority studies against placebo and 5 normal control because we are trying to do something 6 different to support those patients. 7 So I would advocate the registry element if 8 Helen thinks that's viable. 9 DR. REX: A long-term registry after the 10 fashion of Fungiscope. Okay. 11 MR. DANE: So I suppose my only question 12 comes back to the external control again. Is it 13 comparable or not? So and it comes back to whether 14 you just (ph) pay a big benefit over that external 15 group, I think. 16 DR. BOUCHER: You know, there's been a lot 17 of discussion over the years. So Ed and I go back to 18 the voriconazole days and caspofungin, which was 19 approved on 61 cases with historical control. So you 20 know, we've come full circle in some ways. 21 But in discussions both in the fungal space 22 and the antibiotic space, there's been a lot of, I</p>	<p style="text-align: right;">Page 648</p> <p>1 data of carbapenem resistance in Europe. 2 And my hope was, is that that could be, you 3 know, initiated and completed before the natural 4 history or the natural -- the management changes 5 dramatically. I'm sure they'll figure out ways of 6 incorporating what -- what's changed from polymyxin- 7 based therapies to Avycaz when it becomes available 8 and some of the other products we've heard of. 9 But I think combining all of these things, I 10 mean, thinking Bayesian. You know, if you have the 11 exposure response data that Paul's already presented, 12 you know what, you know, a placebo effect might look 13 like from a pharmacometric approach with some of this 14 stuff. The data -- the understanding probably gets 15 strong and stronger. And then maybe it helps us if 16 the treatment effect, as Aaron said, is big enough, 17 which we would think it might be with an antibiotic -- 18 that was what makes adjunctive work so hard -- you 19 know, maybe you could get comfortable with small 20 datasets if you could start to believe what all this 21 other data is telling you. 22 MR. DANE: Yeah, it might help you</p>

<p style="text-align: right;">Page 649</p> <p>1 understand the area rather than be a direct 2 comparator. That's what I could imagine. So you -- 3 yeah, you understand your risk factors and things like 4 that. It's that comparison, that direct comparison, 5 that becomes more challenging. 6 DR. REX: Kenneth? 7 Sorry. Did you have a follow-up? No, you 8 didn't. Okay. 9 Kenneth? 10 MR. HILLIN: I think one of the things 11 that's become very clear to me is that, for these 12 types of drugs, you won't have evidence of -- 13 substantial evidence of safety and efficacy for these 14 drugs for the purposes of approval. And I have lots 15 of questions about the animal model and even how 16 biologics and small molecules might behave differently 17 in those models which are intrinsically human. 18 So if we can't get to the stage where we 19 have substantial evidence of safety and efficacy, is 20 there a different way to get these drugs approved and 21 available so that we can study them further? In the 22 oncology world and in many other places, you have, for</p>	<p style="text-align: right;">Page 651</p> <p>1 it's actually only these centers that would be 2 eligible for this drug based on the resistance levels. 3 You know, I don't exactly know how that 4 would work, but perhaps a two-stage approval process 5 because we can't get to substantial evidence of safety 6 and efficacy as part of the statute. 7 DR. REX: So both Ed and Marco should 8 comment. 9 DR. COX: Yeah. So you know, the 10 accelerated approval still is substantial evidence of 11 efficacy, but it's based on the surrogate marker. So 12 and I see, Kenneth, I mean, you're already recognizing 13 that. 14 So you know, and usually, it's used in 15 situations where the clinical outcome for the disease 16 is sometime removed. So you may see something like, 17 you know, a reduction in tumor size or, you know, a 18 decrease in HIV viral load or hepatitis C viral load, 19 whatever the case may be. And you know, some of these 20 surrogates are, you know, very, very well correlated 21 with the clinical outcome that may happen many years 22 down the road.</p>
<p style="text-align: right;">Page 650</p> <p>1 example -- it would be different from this -- but 2 accelerated approval. And I lived through the pain of 3 Avastin being approved for breast cancer based on PFS 4 and then having to be -- that label be withdrawn for 5 breast cancer. So I know it doesn't always work out 6 well. 7 But I wonder if there would be a way to have 8 a two-step approval based on a minimal dataset. And 9 that could be defined relatively well. It could, you 10 know, include preclinical as well as clinical data so 11 you actually have some safety data. And then there 12 will be a commitment. And I think this in the world 13 of anti-infectives would have to be in conjunction 14 with the government in some ways. So perhaps that 15 clinical trial network actually continues to help to 16 study the drug beyond then. And then a further 17 dataset would be brought back to the FDA for, perhaps, 18 a full approval. 19 So it would be a two-stage process. And you 20 would put in place restrictions both in terms of the 21 label and also the use, perhaps even the types of 22 centers. Maybe the CDC, based on the monitoring, says</p>	<p style="text-align: right;">Page 652</p> <p>1 You want to amend your question, I see. 2 MR. HILLIN: Well, I was actually -- we did 3 -- at Genentech, we did lots of analysis about the 4 correlation between PFS and overall survival. And 5 actually, I think killing the pathogen is actually a 6 much better surrogate than reduction and shrinkage of 7 a tumor, so. 8 AUDIENCE MEMBER: (inaudible - off mic). 9 DR. COX: Which is? We'll give Marco a 10 chance to talk in just a minute. 11 AUDIENCE MEMBER: (inaudible - off mic). 12 DR. COX: Sorry? 13 MR. HILLIN: We're choosing a way what is 14 the standard for anti-infectives in Europe, which is 15 test of cure, which is basically looking at the 16 microbiological response, which could be - 17 DR. COX: Most tests of cures are a clinical 18 response. The patient's better. 19 AUDIENCE MEMBER: (inaudible - off mic). 20 DR. COX: It's a clinical response. Yeah, 21 yeah. Okay. 22 So just to clarify that issue, so usually,</p>


Page 653	Page 655
<p>1 with accelerated approval, you're looking at a</p> <p>2 surrogate. And oftentimes, the diseases that you're</p> <p>3 using those surrogates in are outcomes that have been</p> <p>4 some time removed.</p> <p>5 So if you think about what happens in an</p> <p>6 acute bacterial disease, you may have, you know, a</p> <p>7 particular biomarker that you're looking at. But you</p> <p>8 also usually have the clinical outcome staring you</p> <p>9 right in the face before you. And you don't -- I</p> <p>10 mean, you know, there's not necessarily a one-to-one</p> <p>11 correlation with these two events. And so you end up</p> <p>12 in the somewhat awkward scenario of saying I believe</p> <p>13 the biomarker, but I don't believe the clinical</p> <p>14 outcome.</p> <p>15 And I know it's tough because there are</p> <p>16 patients, obviously, that succumb to their underlying</p> <p>17 illness. And the issue becomes it's difficult to</p> <p>18 understand, you know, in whom that's true and in whom</p> <p>19 that's not true. So it creates a little bit of an</p> <p>20 issue.</p> <p>21 So I'm not -- you know, so that's why we</p> <p>22 have not -- you know, in acute bacterial diseases</p>	<p>1 so, I think, described it very in a sort of</p> <p>2 heartbreaking way, the patients that she sees.</p> <p>3 And so is there a way to have options</p> <p>4 available in a controlled way until such time as we do</p> <p>5 gather more data in the future. That was my point.</p> <p>6 Could we come up with a new way, not called</p> <p>7 accelerated approval, but specific for anti-bacterials</p> <p>8 targeting pathogens, particularly from multidrug</p> <p>9 resistance.</p> <p>10 DR. COX: Right. So it sounds like, you</p> <p>11 know -- I mean, everybody feels the urgency. That's</p> <p>12 why we're trying to figure out ways to do this.</p> <p>13 There's no question about that. It sounds like what</p> <p>14 you're almost describing -- and David Shlaes I see</p> <p>15 back there. We talked about this not too long ago.</p> <p>16 And he brought up the idea many years ago and, you</p> <p>17 know, I -- you know, the idea of some sort of gray</p> <p>18 approval or some sort of conditional approval.</p> <p>19 And you know, right now, I mean, the options</p> <p>20 that we have are sort of standard, full approval,</p> <p>21 accelerated approval using a surrogate marker,</p> <p>22 availability under IND, you know, usually not the</p>
Page 654	Page 656
<p>1 where you achieve the clinical outcome within a -- you</p> <p>2 know, within a couple of weeks or, you know, you're</p> <p>3 looking at Day 28 mortality, we haven't looked so much</p> <p>4 at, you know, clearance of biomarkers or, you know, a</p> <p>5 microbiologic endpoints alone because if there is a</p> <p>6 discord and you're going to let the biomarker trump</p> <p>7 the clinical outcome, it's a little bit of a -- you</p> <p>8 know, it's a little bit of an odd scenario in some</p> <p>9 ways.</p> <p>10 MR. HILLIN: No, thanks. And I appreciate a</p> <p>11 lot of that. I actually wasn't advocating for</p> <p>12 accelerated group. It would be a new mechanism</p> <p>13 because accelerated approval is absolutely on a</p> <p>14 surrogate, as you spoke about.</p> <p>15 But in some ways, if you think about it, why</p> <p>16 do we approve things for accelerated approval when you</p> <p>17 could actually just wait until the outcomes mature for</p> <p>18 overall survival, wait two years, find out the</p> <p>19 outcome? It's because of the feeling in oncology of</p> <p>20 the urgency to have these new therapies be made</p> <p>21 available for patients who have few options. And</p> <p>22 we're in the scenario where we have patients, as Helen</p>	<p>1 scenario here that we're talking about, but, you know,</p> <p>2 in the setting of, you know, a national emergency --</p> <p>3 we've got emergency use authorization. But that</p> <p>4 really doesn't seem to fit here either.</p> <p>5 So could somebody do this? Yeah, somebody</p> <p>6 could do this, I mean, you know, change the way you</p> <p>7 look at approvals and such. And I think that's what</p> <p>8 you're getting at. You're getting at more sort of a</p> <p>9 conditional sort of situation.</p> <p>10 And it -- given that's what you're asking</p> <p>11 about, maybe Marco wants to make some comments.</p> <p>12 DR. CAVALERI: Yeah. Indeed, as I explained</p> <p>13 yesterday, we have tools in Europe for this early</p> <p>14 access regulatory route. And of course, the condition</p> <p>15 marginalization (ph) is the lead one, indeed, where we</p> <p>16 stayed, that the benefit of having other drug</p> <p>17 available earlier outweighs any risk associated with</p> <p>18 the uncertainties that will derive from the data that</p> <p>19 will be initially submitted. So that is pretty clear</p> <p>20 and is a pathway that could be used.</p> <p>21 Of course, it is very important to see what</p> <p>22 can come next because the condition of marginalization</p>

<p style="text-align: right;">Page 657</p> <p>1 is it's quite serious, you know, requiring that post- 2 approval specific obligation are committed to and that 3 dataset are provided. And if we are in a situation 4 that then these data are not provided or delayed or 5 even come out with negative result, that is a big 6 problem and could put us in a very difficult 7 situation. But of course, it's a tool that is not 8 being used for antibacterial so far. And maybe it's 9 the time to think about whether there are situation 10 for which it can be used.</p> <p>11 The alternative, of course, will be the 12 exceptional circumstances which may be fitting into 13 situation for which the new drug is supposed to be 14 working just in rare populations. So why not also 15 considering that? And on top of that, also, as said, 16 we have the new pharmaco-regional (ph) legislation 17 which allows us to pose even in the context of a full 18 marginalization to the sponsor to conduct post- 19 authorization safety or efficacy study. And I think 20 the receptor (ph) is a good case because, you know, we 21 received recently positive opinion from the CHMP. And 22 there was a post-authorization efficacy study imposed,</p>	<p style="text-align: right;">Page 659</p> <p>1 then put in the word V -- V as in Victor, O-S-S-E-N. 2 It's a man's name -- Vander (ph) Vossen. It's a 3 lovely paper about four drugs that got approved under 4 exceptional circumstances and about how miserably they 5 did in the marketplace. And that's the story. 6 So John and then Dave. 7 UNIDENTIFIED MALE SPEAKER: So I guess it 8 was kind of getting at my question. But I was going 9 to ask about the role of an expanded access program 10 and as far as generation of data and what that could 11 ultimately -- how that can be looked at. 12 And secondly, how the -- potentially the 13 clinical trials network could be involved because know 14 -- so Helen, when I looked at your -- when I think of 15 your patients, I think of the patient that you sent to 16 hospice because you had nothing else available. And 17 if there was something that was being developed 18 clinically, if there -- if you could utilize that in 19 whatever outcome and how that could be utilized 20 because I think back to, putting back my clinical hat 21 on, when we were developing these problems when you 22 had a patient like that, what you did was go around</p>
<p style="text-align: right;">Page 658</p> <p>1 which essentially is the (inaudible) nosocomial 2 pneumonia study. 3 So we have a lot of tools to look into 4 having more data come in the post-authorization phase. 5 And we should look seriously about how can we improve 6 these mechanisms so that new drugs that have a 7 potential of addressing on a need (ph) can reach 8 patient needs earlier with enough certainty about what 9 it can do, but then supplement it after authorization 10 (ph) with other data that could bring us to a full 11 understanding of the benefit risk. 12 And registries, of course, are an important 13 area. And I think they should be disease or pathogen 14 registries. And it would be very important to think 15 about a mechanism worldwide, or at least in the U.S. 16 and in Europe, about setting up this registry because 17 this will be extremely useful information for 18 everybody, including sponsors. 19 DR. REX: So we're going to try to wrap up 20 in about the next 15 minutes. And before we leave 21 this one, everybody should look up marketing 22 authorizations under exceptional circumstances. And</p>	<p style="text-align: right;">Page 660</p> <p>1 fishing to all these different pharmaceutical 2 companies that were doing something and trying to find 3 someone who had something to be able to give this 4 patient the chance. 5 If there was an opportunity to go to a 6 network of people who are -- all knew all the 7 different studies that were ongoing and if you could 8 figure out a way to get that patient tapped in, 9 generate some data but then, most importantly, how 10 that data could be utilized. 11 DR. REX: Well, I have lived that. Expanded 12 access programs -- you can't ask for clinical data as 13 a condition of receiving the drug. You just can't. 14 And so you end up -- and the problem then is also drug 15 supply and having to give away drug supply that you 16 need to actually run your Phase III program. It's 17 less useful than you think. And it's really better to 18 have an open label study that you stick people in so 19 you can gather data. 20 UNIDENTIFIED MALE SPEAKER: Yeah, but the 21 problem, I guess, becomes, is that if it's an open 22 label study in an institution, what happens is you get</p>

<p style="text-align: right;">Page 661</p> <p>1 the phone call from the hospital that's not 2 participating in your study. 3 DR. REX: So we put a study kit in a box, 4 and we hired a company called Clinigen to have depots 5 around the world so that we can actually do that in 24 6 to 48 hours, any country in the world. 7 So Dave? 8 DR. COX: To your second point, too, about a 9 clinical trial network, I mean, it may -- I think it - 10 - I would expect it would help. And I think it would 11 push forth the threshold of what it is that is 12 achievable. And you would be able to study things 13 that, you know, were on the cusp previously. And it - 14 - you know, it may also be a mechanism, too, if 15 there's the need to do studies after a drug is 16 approved to be able to further understand how the drug 17 is performing. 18 So and I agree completely -- 19 DR. REX: Yeah. 20 DR. COX: -- with John on the expanded 21 access part. It's -- you know, it's hard to do much 22 of anything there. But the clinical trial network is</p>	<p style="text-align: right;">Page 663</p> <p>1 always ask for more data and another review. 2 So that would be one -- I would think one 3 way maybe you could ask. I guess the question is 4 would that be one way. Is that an option for you? 5 And then I was going to ask -- the other 6 issue is if one went to Europe and got a conditional 7 approval in Europe, gathered more data, then that 8 would bolster the dataset you could then present to 9 the FDA, I would think. So -- 10 DR. COX: So maybe just to an overall 11 comment, which is, you know, most of the time what we 12 end up doing in the U.S. pretty much mirrors what 13 happens in Europe. And you know, Marco was talking 14 about ceftazidime and avibactam and, you know, similar 15 circumstances, similar approaches, similar outcomes 16 for that application here. 17 You know, the reason that we're talking 18 through all this today and trying to figure out how to 19 handle these difficult situations is a recognition 20 that it's going to be hard to get much data here. And 21 you know, we can look at substantial evidence in terms 22 of, you know, the degree of unmet need, what we can</p>
<p style="text-align: right;">Page 662</p> <p>1 promising. 2 DR. REX: Yeah. That's actually one of my 3 summary points, is that if you have this warm base 4 network running, you drop a diagnostic in and you 5 start playing go fish for the cases of pseudomonas. 6 Then it's efficient to be looking for pseudomonas at 7 all these sites. And the investigators have other 8 things to do. 9 Dave? 10 DAVID: I just wanted to go back to this 11 idea of conditional approval and the differences 12 between Europe and the U.S. and see if there are ways 13 we could think about this. 14 So along the lines of what Marco was 15 suggesting, actually, so going back to that 16 conversation that we had, which was 15 years ago now, 17 I think, but I think we talk -- more recently talking 18 about this, the idea would be that you would do a full 19 approval based on small datasets. You would require 20 some post-market studies. But then you would pre- 21 specify some review, which could be an advisory 22 committee review, or something. I mean, you can</p>	<p style="text-align: right;">Page 664</p> <p>1 actually, you know, accrue. 2 And so I think that there are ways to work, 3 you know, with what we are -- you know, with what we 4 have, the tools, you know, to be able to evaluate a 5 product, recognizing the limitations of what's 6 achievable. 7 And then, you know, I think, David, you're 8 asking about -- you know, and we've talked some about 9 how a drug might be utilized. There may be some sort 10 of program about its availability and a recognition 11 for the need for additional data, which can be done 12 through post-marketing commitments, post-marketing 13 requirements. 14 So there are ways to gather additional data 15 and -- you know, after a drug is approved for its 16 initial indication. And it's -- you know, I mean, I'm 17 -- you guys already know this because you're the ones 18 doing it for the most part. And that is, is that, you 19 know, oftentimes, a drug will get an initial 20 indication, but further study will follow to further 21 understand the therapeutic role of the drug, whether 22 it be in other indications.</p>

<p style="text-align: right;">Page 665</p> <p>1 And with regards to opportunities to look at</p> <p>2 a drug at some later point in time, you know, have an</p> <p>3 advisory committee discussion, I mean, sure. I mean,</p> <p>4 those things could be an option. I mean, obviously,</p> <p>5 once a drug is out there and it's approved, you know,</p> <p>6 it is an approved agent. It can be used. And you</p> <p>7 know, I think Kenneth, who's now left was talking some</p> <p>8 about, you know, some of the experiences with Avastin.</p> <p>9 So we won't get into the -- those situations.</p> <p>10 But you know, the hope is, is that, you</p> <p>11 know, if a drug gets out there, there's further study,</p> <p>12 it will help to further characterize its safety and</p> <p>13 efficacy. We hope that everything looks good. And</p> <p>14 you know, the usual scenario, at least in the</p> <p>15 antibiotics base, has been when a drug -- when the new</p> <p>16 data becomes available about an indication or an agent</p> <p>17 that, you know, has safety problems that are, you</p> <p>18 know, significant or major or significant efficacy</p> <p>19 issues are uncovered in a subsequent study, usually,</p> <p>20 that leads to either that indication going away or</p> <p>21 that drug going away because there's mutual</p> <p>22 recognition that there's a problem here and it's not</p>	<p style="text-align: right;">Page 667</p> <p>1 pharmacology and PK understanding and that you're just</p> <p>2 going to have to presume that you're going to have to</p> <p>3 do a lot more work there than at other times in the</p> <p>4 past.</p> <p>5 The third thing is that a clinical trial</p> <p>6 network doing ordinary studies could be the foundation</p> <p>7 that enables us to study less common things. So I</p> <p>8 could fully imagine running a HABP/VABP clinical trial</p> <p>9 network, having a diagnostic running for</p> <p>10 acinetobacter. And it's not efficient to search for</p> <p>11 those rare cases of acinetobacter and put them into a</p> <p>12 clinical program that could accrue with reasonable</p> <p>13 efficiency. And I think it's -- suggest to me it's</p> <p>14 possible.</p> <p>15 The fourth thing I've learned is there's no</p> <p>16 easy way out of this. The animal rule is really --</p> <p>17 you look at D and E, and you go, wow, that would be a</p> <p>18 tough sell. And the open labels with external or</p> <p>19 historical controls or external contemporaneous</p> <p>20 controls, you know, that, too, causes a great sucking</p> <p>21 in of breath and is not satisfactory. You know, it's</p> <p>22 -- somehow we have to get at least a little clinical</p>
<p style="text-align: right;">Page 666</p> <p>1 an appropriate agent for being out there, so.</p> <p>2 DR. REX: All right. So I've got six things</p> <p>3 that I'd like to offer as a summary of stuff I've</p> <p>4 learned today. And then I'd like to turn it over to</p> <p>5 Ed to talk about what's kind of the next step in this</p> <p>6 conversation.</p> <p>7 So actually, first, is thanks to all of you</p> <p>8 for participating in this. We had no idea how this</p> <p>9 was going to work out. The fact that you've all been</p> <p>10 so energized and bring so many ideas, I'm really</p> <p>11 grateful for it.</p> <p>12 So the first thing I learned is that all</p> <p>13 approaches that we've discussed are flawed, including</p> <p>14 the approach of not having an approach. And that's</p> <p>15 actually a really important thing to say, is that it -</p> <p>16 - that not having an approach is as flawed as</p> <p>17 everything else. And actually, it could hurt us over</p> <p>18 time. But you know, that's -- sometimes you have to</p> <p>19 point stuff out like that to make it clear why we have</p> <p>20 to make some other tradeoffs.</p> <p>21 The second thing I've learned is that</p> <p>22 everything is going to be based on having fabulous</p>	<p style="text-align: right;">Page 668</p> <p>1 data.</p> <p>2 Number five is we need to validate</p> <p>3 ertapenem. Somebody needs to help me figure out how</p> <p>4 to do that.</p> <p>5 And number six is we have got to get the</p> <p>6 pool incentives working so that people will pay for</p> <p>7 these things as fire extinguishers because paying for</p> <p>8 them on a per-use basis, that's going to be \$100,000 a</p> <p>9 course in order to make it make sense. And that's not</p> <p>10 going to fly.</p> <p>11 So those are my six quick observations from</p> <p>12 today.</p> <p>13 So again, thanks to all of you for your</p> <p>14 participation.</p> <p>15 Ed?</p> <p>16 DR. COX: Thanks, John.</p> <p>17 And thanks to everybody who joined us. And</p> <p>18 you know, we really do appreciate, you know, the</p> <p>19 continued attention to development in this area. We</p> <p>20 think it's an important area. There's patient needs</p> <p>21 out there that need to be met currently, and we expect</p> <p>22 that will continue to be the case in the future, just</p>

<p style="text-align: right;">Page 669</p> <p>1 given what we know about microbes and their ability to 2 evade our therapeutics. So many thanks. 3 Many thanks, too, to all the panelists who 4 gave up their time both before the meeting and during 5 the meeting and to the many, many people who made the 6 meeting possible. 7 In particular, I want to thank Sonita (ph), 8 too, who also helped us tremendously with our workshop 9 and getting it together. 10 You know, this is a difficult problem. I 11 mean, the easy problems we don't bring to you because 12 we can solve those. So we bring you the difficult 13 ones because we're having, you know, significant 14 challenges we -- as we work through them. 15 I -- somebody asked me yesterday what did I 16 think about the workshop. And I said I thought it was 17 going to be good, but it exceeded my expectations. 18 And I find the same here today, too. I mean, these 19 are difficult discussions, and I appreciate 20 everybody's willingness to express their opinions and 21 to, you know, offer suggestions and ideas. 22 We're all working through this, you know, at</p>	<p style="text-align: right;">Page 671</p> <p>1 So you know, we're committed to continue to 2 work on this to get to the point of, you know, having 3 a pathway and trying to figure out exactly how this 4 will work. And you know, some of this will need to 5 continue to be worked out because we had some 6 discussions about how would such a product be 7 available. How do people see this product being used 8 clinically? 9 And I think it's important that we also 10 think about, you know, how the product would be 11 available -- you know, restrictions for use, those 12 sorts of things, which seem commensurate with a 13 product that this degree of uncertainty, which is 14 considerable but also is some way to essentially have 15 such products have a pathway for developing. 16 And clearly, you know, as we work through 17 the science, I mean, if the -- and I'm sure all of my 18 fellow panelists are somewhat tired and probably more 19 tired -- humbled by the science and what the biology 20 continues to teach us day to day as we continue to 21 work through these difficult problems. 22 So I want to thank everybody. And we will</p>
<p style="text-align: right;">Page 670</p> <p>1 this present time. So not everything has been 2 completely figured out. But the willingness to sort 3 of talk about things I think helped us to move the 4 field forward. 5 You know, this is clearly an important area 6 of development. You know, there are folks out there 7 with compounds. The ability to not destroy the -- you 8 know, the normal flora of the GI tract and the 9 consequences that can result thereafter seems like, 10 you know, a very important therapeutic area to try and 11 explore and develop products. 12 You know, we -- this is really sort of the 13 first real public discussion we've had about these, 14 you know, more narrow-spectrum drugs, you know, drugs 15 targeting a single species. And clearly, you know, 16 our goal here is to get to a pathway so that there is 17 a pathway for development. And we recognize, too, 18 that the problem is, you know, not so much in areas 19 where -- you know, the example I used in my slides, 20 staph aureus and skin infections -- it's typically for 21 gram-negative rods and more serious infections like 22 HAPB/VABP, complicated -- abdominal-complicated UTI.</p>	<p style="text-align: right;">Page 672</p> <p>1 continue to work on this. If you have a product and 2 you're targeting something, you know, like, you know, 3 a species that occurs rarely, please do come in and 4 talk to us. The particular cases in hand help us to 5 sort of work through these situations. 6 You know, we will continue to try and, you 7 know, have discussions within our group and look 8 forward, perhaps to additional public meetings and/or, 9 you know, putting out, you know, pathways on how you 10 might approach this situation because there clearly is 11 a need. And to the extent that we can get to, you 12 know, approaches that have been, you know, described 13 and articulated, I think that's the best situation for 14 everybody. It helps everybody to sort of know where 15 they're going. 16 So thank you very much for participating in 17 the challenging discussion that we've had over the 18 last day and the day prior. 19 And with that, any final words, John? Or -- 20 all right. 21 We will close the meeting. And thank you. 22 And we wish you all safe travels back to home and look</p>

<p style="text-align: right;">Page 673</p> <p>1 forward to seeing everybody again sometime soon.</p> <p>2 So thank you.</p> <p>3 (Proceedings concluded at 3:15 p.m.)</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p>	<p style="text-align: right;">Page 675</p> <p>1 CERTIFICATE OF TRANSCRIBER</p> <p>2</p> <p>3 I, Karynn Willman, do hereby certify that this</p> <p>4 transcript was prepared from audio to the best of my</p> <p>5 ability.</p> <p>6</p> <p>7 I am neither counsel for, related to, nor</p> <p>8 employed by any of the parties to this action, nor</p> <p>9 financially or otherwise interested in the outcome of</p> <p>10 this action.</p> <p>11</p> <p>12</p> <p>13</p> <p>14 07/27/2016 Karynn Willman</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p>
<p style="text-align: right;">Page 674</p> <p>1 CERTIFICATE OF NOTARY PUBLIC</p> <p>2 I, Michael Farkas, the officer before whom the</p> <p>3 foregoing proceeding was taken, do hereby certify that</p> <p>4 the proceedings were recorded by me and thereafter</p> <p>5 reduced to typewriting under my direction; that said</p> <p>6 proceedings are a true and accurate record to the best</p> <p>7 of my knowledge, skills, and ability; that I am</p> <p>8 neither counsel for, related to, nor employed by any</p> <p>9 of the parties to the action in which this was taken;</p> <p>10 and, further, that I am not a relative or employee of</p> <p>11 any counsel or attorney employed by the parties</p> <p>12 hereto, nor financially or otherwise interested in the</p> <p>13 outcome of this action.</p> <p>14</p> <p>15</p> <p>16 </p> <p>17 Michael Farkas</p> <p>18 Notary Public in and for the</p> <p>19 State of Maryland</p> <p>20 My commission expires: 6/27/18</p> <p>21 Notary Registration No.: 256324</p> <p>22</p>	

&	562:16,20,22 563:3	15 425:17 447:17	20s 425:19
& 358:21,21 360:7	563:4 572:4 574:22	469:16 482:8	21 429:6
0	575:7 579:11	488:21 526:22	22 388:1 407:11
0 491:7,7,7	583:19 584:13	570:7 580:6 590:4	559:2 570:17
0.05 507:17	590:14,16 612:1	658:20 662:16	230 497:14
0.06 376:19	622:20 641:1 644:1	150 560:4	24 446:4 478:19
0.1. 507:18	644:3,13	16 485:19 488:11,19	495:13 501:13
0.4 508:9	1's 562:16	488:20	561:1 575:7,14,15
0/10 574:22	1,000 465:9 471:12	17 514:13	586:11 661:5
005 575:1,19	489:19 571:6	18 574:21 575:14	24.5 570:2
05 425:10 430:19	1,200 426:8	19 356:9 384:21	240 497:14,14
578:8 583:19	1,276 573:9	385:18 508:6 559:3	25 377:3 379:2
07/27/2016 675:14	1,300 573:12	575:14	431:6 432:1 471:11
1	1,500 407:12	1962 400:19	482:12,13 485:8,18
1 375:18,19 376:1	1,600 571:6	1:00 533:10 540:20	488:21 514:13
376:18,22 377:6,9	10 370:2,3 379:7,12	1as 478:9	559:14
377:13 378:3,4,9,12	379:13 406:11	2	250 469:13 486:8,12
378:15,20 379:1,7	407:7 425:12,14,17	2 362:3,7 378:3	489:7,8,10
379:11 380:21	426:1,1 431:13	379:4,12 397:17	256324 674:20
387:22 394:4 395:8	442:15 465:20	430:18 468:19	28 479:8 558:4
397:17 398:10	468:19 472:3,18	470:3 479:16	654:3
402:11 403:5	473:16 479:17,19	480:16 483:7	29 480:13,18 515:4
405:13 407:20	479:19 487:18	491:17,18 493:4	570:1,16
413:15 414:15	488:16,17,20 499:7	504:17 515:10	29.2 560:3
416:2 420:18	515:5 519:13 570:6	557:16 558:14	3
423:17 425:10,11	622:19 639:21,22	583:20	3 388:4 470:5 483:4
426:6,7,14 428:4	10,000 464:18	2,000 486:8 573:15	491:19 493:4 572:3
430:18,18 435:16	100 378:10 408:7	20 369:17 406:11	575:1
436:14 443:2,6,21	409:20 447:20	407:4 425:10,13,14	3,000 431:18 465:14
453:19 454:5,15	465:10 555:10	425:19 426:7,11,14	30 370:7 431:2
466:3 468:17	607:10 608:2	431:2,17 440:3	439:5 477:16
469:10,18,18 474:6	610:17 624:15	469:20 472:18	480:19,19 481:12
474:22 476:4,16,21	634:5	473:16 479:22	481:16 485:7
477:15,19 478:4	100,000 387:1 609:4	495:19 514:12	498:10 507:3
479:21,22 480:1,3,6	610:7 668:8	515:4 526:22	544:14 559:14
480:14 481:1 483:6	10903 356:15	557:15,21 558:18	573:7 575:10
484:19 485:14	10:45 453:15	559:1 574:21 580:6	578:15 597:17
487:13 490:1,10	11 377:9 463:18	609:4	300 469:2,3,8,13
491:16 493:6 508:7	12 410:5 476:4	20.8 560:3 570:16	497:15
508:7 515:2,9 519:7	515:5 575:7 624:9	200 497:15 601:3	335 407:9
523:14,17,22	122 430:5 584:13	2000 526:17	34 559:17 561:2
528:15 530:3	12:15 463:19 533:9	2012 382:7 441:21	570:18
531:20 532:22	540:15	442:2	35 575:15
539:20 540:17	13 429:12	2013 405:7	350 526:20
545:8 551:3,5	13.6. 508:8	2016 356:9 600:6	36 486:7,11 558:3
558:16 559:11,12	135 447:20	20993 356:16	362 361:3
	14 379:5 468:18		
	479:22 508:9		

37 558:13 559:15,16 375 361:4 38 495:15 558:13 380 361:5 399 361:6 3:15 673:3	6	559:13	515:20 523:16,22
	6 572:4 6/27/18 674:19 60 370:6,7 465:10 472:17 497:9 569:17 60s 516:5 61 646:19 62 454:11 65 442:14 69 450:8 490:10 561:1	95-95 480:11 99 377:5	531:19 552:4 553:13 555:11,14 569:10 576:1,13 597:12 600:7 604:18 613:5 616:7 636:6,8 641:8 642:17 660:3 661:12,16 664:4 abnormalities 439:2 439:3 440:16
4	7	a	abs 496:9
4 376:20 379:13 477:4 481:12 482:3 492:19 540:22 541:16 564:21 599:13 4.4 452:17 40 370:7,8 378:11 378:15 379:1 430:20 468:17 498:10 512:17,19 544:14 578:15 597:17 418 361:7 445 361:8 453 361:9 47 386:1 48 373:3 490:9 495:13,15 501:13 558:3,13,13,14 561:1 586:11 661:6	7 590:4 70 472:17 601:2,2 70/30 555:6 70s 516:6 71 382:5 726 575:7 74 447:19 630:2 75 518:17 519:10 77 630:3	a.m. 356:10 a45 504:16 aaron 358:4 363:21 363:22 499:1 542:20 621:7 648:16 aaron's 558:21 ab 466:19 474:16 475:7 476:17 479:7 479:18,22 480:22 481:1 482:10 484:4 485:8,13,20 487:17 487:21 488:19 495:21 516:2 524:1 524:3 528:14 547:20 554:5 559:15 570:6 572:19,21 abbreviated 551:10 abdominal 365:22 386:3 390:18 394:11 450:19 478:13 481:13 515:16 516:3 531:10 535:20 670:22 ability 381:6,13 393:1,8 413:7 419:18 524:19 563:11 669:1 670:7 674:7 675:5 able 369:10 372:14 373:2,6,7,19 386:18 389:17 390:4 395:9 400:22 410:14 417:13 426:9 428:5 433:11 434:19,22 436:1,21 447:2 456:11 457:9 459:21 460:1 473:3 493:9 494:15 501:15 511:22 512:2 514:16	absence 424:13 absent 616:13 absolute 469:3 495:11 560:5 absolutely 532:12 540:1 573:5 576:3 576:12 611:20 639:19 654:13 academia 365:4 379:16 381:2 academic 380:7 473:4 601:10 647:3 accelerated 650:2 651:10 653:1 654:12,13,16 655:7 655:21 accept 409:15 422:19 468:11 490:5 584:21 acceptable 423:3 424:10 476:11 511:15 526:20 527:21 528:8 608:2 632:21 accepted 391:18 424:2 449:21 access 402:6,7 611:6 656:14 659:9 660:12 661:21 accomplish 412:3 accomplished 400:13 account 493:22 accrual 486:22 487:1
5	8		
5 377:3 431:5,13 492:19 515:5 573:4 610:8 5,000 465:17 50 468:20 497:9 559:17 571:20 617:22 50,000 409:20 610:14 50-50 500:1 50/50 555:3 571:21 500 426:4 610:21 624:15 51,000 624:17 55 559:17 58 447:8	8 470:3,4 8,000 429:6 80 425:11 430:19 447:17 469:18 485:2 492:19 495:7 495:15,22 496:1 497:3 85 469:18 485:1 495:7 571:20 8:30 356:10 362:5		
	9		
	9 379:11 475:15 9,000 486:12 90 370:1,3 377:5 378:13,16 407:6 507:20,21 508:5 510:2,11 633:13 900 466:20 92 438:13 94 439:5 95 447:11 469:7 480:10 482:19 508:5 510:2,11		

accrue 496:14 594:11 664:1 667:12 accumulated 643:17 accurate 674:6 achaogen 358:13 achievable 661:12 664:6 achieve 369:10 576:22 627:13 628:17 635:6 645:21 654:1 achieved 576:2 630:17 acid 400:19 acinetobacter 521:8 576:15,16 587:12 589:7 613:13,14 624:22 625:15 667:10,11 acknowledge 430:6 443:5 448:9 449:15 568:9 acquired 401:12 419:11 442:9 acronym 464:17 act 396:8,8 483:20 acting 357:6 359:4 364:7 action 376:1 420:21 674:9,13 675:8,10 active 366:4,7,21 367:3 376:18 380:8 390:17 396:21 418:7 419:2,4 443:6 466:7,8,9 477:2 483:14 495:6 522:22 525:9 527:22 528:3,4,6,9 529:13 533:1,20 538:1,20 539:5 547:13,16 551:5 585:14,20,21 586:10 588:20,21 615:9,20 actively 410:5 494:17,19	activity 371:20 372:1 373:9 375:20 375:21 377:10,11 379:9 408:11 419:16 421:6,9 453:1 538:8 540:12 547:7,15 548:22 549:21 551:3 582:11 645:16 acts 376:1 actual 458:16 480:7 484:22 486:4 508:7 509:5 530:20 610:6 641:12 acute 369:13 382:15 420:1 653:6,22 add 446:1 454:18 456:6 466:2 476:17 496:18 508:13 535:2 540:8 564:1 582:6 590:10 624:1 added 531:9 561:17 582:7 593:7 addition 645:17 additional 378:19 435:2 450:15 583:20 664:11,14 672:8 address 405:8 420:20 443:2 527:18 addressing 401:15 446:3 658:7 adequate 388:18,19 389:20 390:11 398:11 416:15 421:16 423:6 434:17 442:12 445:5 452:2,7 457:10 458:21 460:21 583:18 626:17,18 adequately 435:17 436:5 adhering 393:12 adjudication 392:18 393:14	adjunct 357:14,16 404:5 adjunctive 402:21 402:22 403:22 404:11,19 417:19 518:22 645:18 646:2 648:18 adjusted 454:12 adjustment 378:18 445:3 adjustments 478:3 478:6 administered 441:13 administration 356:13 admitted 387:5 advance 398:20 536:9,15 544:6 545:4,6,9,17 592:6 advanced 359:5 386:12 534:20 advances 404:1 417:18 418:3 advancing 536:21 advantage 401:19 405:9 413:22 417:5 608:15 adverse 379:13 advice 384:20 advises 618:17 advisory 362:18 441:21 442:1 662:21 665:3 advocate 396:22 646:7 advocating 627:15 654:11 aerosol 402:16 404:16 439:19,20 440:1 aerosolized 403:21 404:19 aeruginosa 368:20 375:21 376:2,18 377:14 379:10 419:13 423:1,3 424:5 428:7 435:20	446:16 448:21 452:14 465:1 470:20 475:6 523:20 531:16,18 532:20 533:2,3,5 538:21,22 551:4,8 580:8 581:13 588:22 589:5 591:1 592:17 595:17 601:6 affairs 357:13 affect 431:3 461:22 503:17 afraid 592:4 african 438:1 606:2 afternoon 363:5,9 405:20 407:18 422:5 423:14 424:19 age 395:16 agency 357:21 364:10 444:6 agenda 363:2,10 400:4 506:3 agent 367:20 368:17 368:19 408:10 439:13 472:4 480:16 533:20,21 534:5 535:6,9,21 563:4 593:7 616:6 616:11 628:17 665:6,16 666:1 agents 374:17 396:12 397:21 400:22 417:16 436:10 461:15 493:3 598:18 599:16 604:12 608:5 614:3 616:5 aggressive 383:3 agm 439:12,13,19 440:2 441:20 agms 438:4,11,12 438:15,17,20 440:9 440:20 441:9,14 442:5,13 ago 382:6 424:10 497:12 509:22
--	---	--	---

514:20 579:4 588:5 596:19 655:15,16 662:16 agree 416:19 499:1 502:21 506:3 511:12 532:10 568:3 586:5 598:6 607:10 608:17 624:4 639:19 661:18 agreed 480:4 521:2 521:14 545:8 ahead 420:9 538:16 538:16 579:8 601:19 albeit 408:2 alive 441:9 593:18 allergies 613:21 allocating 642:1 allow 362:19 390:20 392:4 412:14 413:22 417:21 421:18 446:4 537:3 596:10 allows 371:22 402:6 635:18 657:17 alluded 381:10 388:4 389:5 393:13 394:8 396:7 499:10 603:2 alpha 425:10 430:18 449:3 507:17,17,18 511:13 512:13 513:5 558:21 alternate 416:9 alternative 519:3 568:20 589:13 657:11 amanda 399:7 amazing 403:2 577:12 ambrose 357:3 474:1 525:1,5,11 529:12 569:2 577:5 635:13 ambrose's 395:3 amend 652:1	americas 357:13 amikacin 429:12,19 430:4 476:17,19,21 477:1 484:4 487:19 491:8 492:5,16 493:16 494:7 528:14,16,17 532:17,21 582:6,7 584:21 585:22 586:6,6,10 590:12 aminoglycoside 408:20 530:18,22 585:10 aminoglycosides 644:11 amount 381:14 385:6 391:7 395:4 445:22 448:6 459:20 554:22 577:12 601:10 624:6,7 amounts 499:13 amplified 409:21 410:2 amplifies 571:10 amplify 544:9 588:11 amy's 572:15 analogy 554:8 analyses 538:13 543:14 544:12 analysis 408:13,21 409:8 445:9,13 449:10 478:21 495:14 500:18,20 529:20 532:19 543:22 557:20 568:8 569:2 570:21 581:3 634:18 635:5 641:7 652:3 anecdotal 387:8 animal 371:4,6,10 371:15,16,21 372:3 372:6,7 373:4,8,14 373:15,21 374:4,8 377:13 381:12 389:4 395:1 415:14 415:19 416:11,13	416:18 417:5,10,21 418:15,17 421:7 422:14 433:5,6,7,11 433:11 434:3,5,11 434:11,13,22 435:15,17 436:5,8 437:1,12 441:7 442:13 443:18,20 456:4,8 457:8,11,15 457:20 458:7,8 459:18 461:18,20 462:1,5 573:18 587:6 588:2 591:21 594:1 598:1 602:3,7 602:12 603:2,16 604:1,6,16 605:7 611:17 627:5,9,10 627:21 628:2,3,4,5 628:8 649:15 667:16 animal's 441:8 animals 372:16 373:18 434:19 435:14 439:9 440:4 583:22 594:3 anon 590:1 answer 381:6 409:10 454:8 456:11 484:8 498:15 505:20 510:12 541:22 556:14,17 562:7 582:8 600:4 605:12 611:12 answered 417:11 638:21 answers 403:11 612:22 anthrax 437:14 anti 357:20 359:2 359:16 364:12 375:7,19 403:20 404:10,13 418:13 444:7 597:15 650:13 652:14 655:7 antibacterial 356:4 356:6 358:20	362:15 367:18 370:18 371:20 375:16,20 396:10 418:7 419:1 421:6 423:16 657:8 antibiogram 424:12 antibiograms 424:12 antibiotic 397:5,15 402:21,21 404:16 405:1 408:1 412:8 461:5 472:1 501:4 516:7 517:7,9 534:12 607:15,20 608:4 609:4 627:11 635:9 646:22 648:17 antibiotics 370:21 384:1 399:4 400:15 401:10 402:16 403:1,9,21 404:20 418:3 471:14 517:10,14 593:21 607:16,21 665:15 antibodies 402:12 404:12 antibody 404:13 597:15 anticipate 539:10 594:17 603:17 607:7 antifungal 499:9 616:10,13 620:4 antifungals 358:21 antimicrobial 358:2 472:2 antimicrobials 402:11 antipseudomonal 446:4 anxious 541:12 anybody 454:3 488:8 489:13 501:21 504:20 516:21 540:10 541:6 549:16,22 567:8 617:20
---	--	--	---

anyway 487:2 anyways 554:1 apaches 566:2 apart 610:13 apparent 372:12 560:20 apparently 382:17 appeal 604:15 appealing 612:11 appear 421:3 appeared 406:14 appears 391:13 420:20 421:16 443:2 appetite 438:21 applause 379:19 399:9 418:10 444:3 453:4 applicable 528:7 application 616:2 663:16 applies 433:16 492:13 apply 451:18 452:5 480:8 535:5 appreciate 380:5 387:13 399:18 608:20 654:10 668:18 669:19 approach 384:10 390:15 392:1 393:8 393:16 394:15 401:16,20 404:11 416:9 417:10 435:22 446:8 449:17 452:9 509:15 515:22 516:1 517:21 518:2 554:21 578:3,6 587:2 604:2 608:4 616:15 648:13 666:14,14,16 672:10 approaches 374:3 393:20,21 394:2 402:1 463:4 464:14 542:10 544:8 568:20 663:15	666:13 672:12 appropriate 397:10 462:12,13 534:7 535:14 589:22 606:22 607:16 666:1 appropriately 386:13 396:16 462:15 589:21 appropriateness 605:3 approval 396:10 400:9,10 401:14,17 416:7 417:11,22 435:1 436:22 437:2 437:4 455:10,17,21 456:4,22 457:19 458:9 459:13 461:18 463:7 482:21 511:11 526:9 542:14 554:8 596:19 605:10 626:17 649:14 650:2,8,18 651:4,10 653:1 654:13,16 655:7,18,18,20,21 657:2 662:11,19 663:7 approvals 656:7 approve 433:14 437:1 457:14 654:16 approved 396:20 400:18 401:9 403:18 404:21 405:18 411:22 435:13 436:13,14 437:11,13,13 442:8 458:7 459:7,17 518:14 519:4 520:10 523:7 564:14,17 590:10 595:3 596:2 614:3 615:22 646:19 649:20 650:3 659:3 661:16 664:15 665:5,6	approving 511:16 556:9 approximately 378:21 379:1 540:22 arakoff 527:16,16 528:5 529:8 arbitrarily 566:2 arbitrary 485:22 area 362:12 365:13 397:15 418:18 462:13 505:16 534:22 607:19 649:1 658:13 668:19,20 670:5,10 areas 372:5 546:8 646:1 670:18 arena 589:3 argue 417:9 479:15 480:15,19 489:5 508:17 581:7 611:5 arguing 503:13 591:8 597:9 argument 403:11,20 405:2 411:8 416:5 452:4 456:5 465:11 529:9,11 535:4 635:7 642:16 arguments 392:7 451:17 arlg 647:7 arm 407:9,12 476:17,20,21 478:6 482:8 485:15 487:11 493:22 495:13 514:13,14 518:12,13,15 520:2 528:9,16,16 534:9 559:11 564:20 572:3,4,4,13 580:15 580:16 605:3 633:8 arms 467:3 474:15 476:14,16 478:8 482:21 485:2,5 527:2 622:18 army 601:22 arrow 400:17	artero 475:18 articulated 672:13 articulating 501:22 ascertain 560:22 ascribe 567:1 asia 357:13 aside 412:5 asked 520:15 565:7 588:5,14 604:22 609:13 614:9 615:2 669:15 asking 397:14 514:19 515:2 534:10 596:1 606:11 634:13 636:19 656:10 664:8 asm 366:19 aspect 393:19 520:9 569:7 aspects 444:13,20 518:8,8 568:22 569:7 aspergillosis 616:1 616:4 assess 419:18 421:8 428:4 436:3 443:21 492:16 524:16,19 assessed 379:9 438:4,18 associate 357:9 358:19 associated 376:6 377:18 385:3 419:11 627:2 629:8 642:9 643:4 656:17 assume 398:1 447:11 454:21 464:20 484:10 485:2 497:5 501:14 507:13 529:5 574:3 575:3 577:2,4,9 609:18 assumed 465:8 484:15 490:17 492:20 assumes 609:19
---	--	--	---

assuming 471:9 473:19 485:7,18 497:3 521:17 570:14 592:14 assumption 465:22 473:11 493:3 524:7 assumptions 425:9 430:18 astrazeneca 359:22 364:14 attainment 378:17 576:2 633:19 634:4 634:8 attempt 463:6 attention 410:20 412:18 495:10 589:20 668:19 attorney 674:11 attractive 542:18 atypicals 401:11 audience 454:3 463:14 464:10 490:7,15 491:2,5,11 492:9 494:10 511:17 513:14 526:11 532:8 549:18 550:5,7 553:1 564:5 586:4 652:8,11,19 audio 675:4 audit 410:1 ought 526:18 augmented 445:1 622:18 624:2 aureus 365:16,18 670:20 authority 359:5 authorization 656:3 657:19,22 658:4,9 authorizations 658:22 availability 371:8 423:7 655:22 664:10 available 363:4 366:15 374:8 392:3 395:21 402:2 405:19 413:12	428:4,8 437:15 438:9 442:1 450:5,8 450:10 451:17,19 453:1 457:13 458:17 507:9 509:17 519:4 551:13 589:8 593:3 648:7 649:21 654:21 655:4 656:17 659:16 665:16 671:7,11 avastin 650:3 665:8 avenue 356:15 average 410:5 430:7 491:22 avi 496:5 avibactam 384:3 494:14 549:4 599:18 663:14 avoid 367:12 445:18 495:2 564:7 583:10 avoids 584:3 612:20 avycaz 648:7 aware 436:6 559:5 awful 504:10,11 573:3 645:12 awkward 653:12 b b 390:14 393:20 394:15 401:20 403:17 406:21 413:19 415:2 422:16 466:15,21 467:1,9,17 505:4 557:3 559:9 567:6 569:6 571:1 572:9 621:18 baby 517:6 back 362:6 380:21 381:19 382:7,14 383:15,16 386:8,8 387:21 390:2,15 395:3 397:13 400:12 407:17 447:6 453:10,15,19 463:21 472:10 476:4 491:13	497:19 499:5,17 503:10 506:1 509:13 513:2 514:1 515:11 516:12 526:17,18 529:22 532:17 533:10 534:16 535:17 537:22 540:16,17 542:13 543:4 544:3 555:18 560:7 561:2 567:5 569:21 573:20 581:16 582:20 590:11 598:4 602:1 604:8 610:3 621:6 624:13 626:16 635:17 641:10 646:12,13 646:17 650:17 655:15 659:20,20 662:10,15 672:22 backed 411:5 background 418:15 454:4 backwards 418:2 bacteremia 427:14 427:19 439:4 450:19 bacteremias 565:21 bacteria 516:11 629:7 bacterial 368:6 369:13 375:17 377:18 420:2 653:6 653:22 bacterials 655:7 bacteriology 358:6 bad 370:1 465:7 467:17 497:3,18,20 500:7 517:21 544:1 573:12 615:16 642:22 balance 462:15 480:10 485:6 512:22 513:1 565:18 607:2 612:21 balanced 503:15 564:2	balancing 555:16 bananas 610:14 band 429:15 bang 487:10 banging 496:18 bangs 484:8 banner 621:5 bano 647:19 barda 359:6 barely 468:3 474:17 barn 366:19 barring 497:12 base 611:1 644:8 662:3 665:15 based 377:15,17 378:9,18 387:18 424:11 426:6 435:13 440:22 441:5 444:14 447:12 449:5,13 457:14 461:18 463:7 491:12 510:16,18 560:21 589:9 594:13 605:5 608:3,10 610:2 614:3 641:1 648:7 650:3,8,22 651:2,11 662:19 666:22 baseline 478:17 479:1 510:6 568:15 616:20 622:22 basic 400:4 417:17 basically 405:15 463:20 469:8 473:13 475:19 481:17 535:19 562:16,18 567:7 576:19 586:11 635:8,15 652:15 basics 433:6 basis 436:16 449:5 453:8 457:19 458:8 481:5 540:4 560:5 611:8 621:2 626:17 668:8 bassetti 475:18 batch 610:13
---	--	---	--

batteries 470:16 522:2	bet 478:4 547:12 578:18,21	biologics 433:14 437:11 649:16	bloodstream 389:15 500:5
baumannii 588:20 589:8	better 403:6,13 456:19,21 470:20 470:21,22 471:13 477:17 481:22 485:21 487:16 491:21 499:21 501:21 508:9 510:10 512:22 517:22 520:12 541:10 544:17,21 548:3 552:4 559:4 562:21 564:16 579:7 591:16,21 592:10 611:5 617:7 617:11 620:9,16 636:4 652:6,18 660:17	biology 671:19 biomarker 653:7,13 654:6 biomarkers 654:4 biomedical 359:5 biomerieux 357:14 biostatistics 359:9 360:2 bioweaponized 440:1 bit 362:9 364:17 372:9 380:21 381:17 388:1 396:7 399:22 400:5 409:18 411:2 423:12,13 438:20 445:14 477:10 480:5 482:14 485:6 485:10 492:22 495:17 499:6,10 504:18 505:17 514:20 515:11 518:9 522:11 527:12,13 553:10 558:17,20 562:20 562:22 573:21 590:19 595:22 612:14 613:8 621:1 622:16 630:14 631:6,19,21 633:1 653:19 654:7,8	bloomberg 359:9 blouse 533:12 blows 610:13 blue 466:6 board 519:22 body 387:14 392:1 395:14 398:22 401:4 422:16,17,18 426:16 427:4,21 441:1 443:8,9 444:21 453:2 455:9 457:16 509:12 542:3,9 543:5,16,19 544:16,18,20,21 546:1 548:1 552:20 553:2,4,7,14,17,18 554:21 555:1 623:5
believe 363:2 404:12 414:21 525:16 530:20 535:9 573:22 574:8 584:1 590:1 648:20 653:12,13	beyond 650:16 bfmi 464:17 465:16 bias 477:12 612:20 big 388:4 391:15 403:2 424:4 468:10 487:2 495:3 497:19 504:16 508:19 512:21 514:11 515:12 521:19 541:12 554:9 562:5 567:9 591:18 597:6 601:4 612:13,14 613:3 646:14 648:16 657:5	bold 402:17 bolster 663:8 bone 393:3 418:4 book 454:17 boom 610:9 boost 471:10 544:14 boosts 488:18 boring 495:18 borio 357:6 364:7,7 460:15 604:22 borrow 544:8 borrowed 544:5 545:2 557:20 boselli 475:15 bottom 405:21 514:12 562:21 563:4 570:16 boucher 357:8 361:5 364:2,2 379:22 380:12 458:1 461:2 499:1 559:20,21 560:6,7 587:9,10 598:5,14 598:16 607:10 646:16	
believed 494:1 beneficial 405:1 benefit 373:5 404:18 417:14 431:17 434:14 435:6 447:22 455:14 456:22 517:13 520:1 588:10 607:2 612:15 646:14 647:1 656:16 658:11 benefits 373:10 berry 360:8 best 371:1 381:6 388:12,17,17 392:3 397:9 399:4 410:12 428:4 429:10 431:7 446:13 450:5,8,10 451:17,19 490:3 507:9 509:17 599:20 613:11 631:9 638:1 672:13 674:6 675:4	bigger 406:21 437:5 497:13 507:3 512:15,15 biggest 593:20 597:12 bills 410:21 bimodal 376:19 binary 374:5,10 binding 446:11 454:10 bio 366:20 435:8 436:10,13,17 457:3 457:5 604:11 biologically 643:6	bite 564:20 biting 565:2 bitty 517:8 blending 417:20 blind 477:15 528:17 blinded 474:14 476:18 477:8 507:6 507:8,10 528:15 570:9,9 blister 553:20 block 384:2 blood 382:20 385:1 386:11,18 393:2 587:19	boosts 488:18 boring 495:18 borio 357:6 364:7,7 460:15 604:22 borrow 544:8 borrowed 544:5 545:2 557:20 boselli 475:15 bottom 405:21 514:12 562:21 563:4 570:16 boucher 357:8 361:5 364:2,2 379:22 380:12 458:1 461:2 499:1 559:20,21 560:6,7 587:9,10 598:5,14 598:16 607:10 646:16 bouncing 504:18 bound 508:5 513:4 559:14 569:22 570:1

boundary 467:10 575:10	brute 464:17	called 474:19	375:4,8,16 380:20
bounds 571:1	bucket 394:14	480:11 481:19	384:15,16,21
bowel 516:8 517:4	bucks 610:8	519:7 655:6 661:4	398:16 400:7 431:7
box 463:1 661:3	bug 522:17	campus 356:14	444:14 449:5,5
box's 486:20	bugs 584:12	cancer 382:6 384:12	451:4 454:1,20
boy 586:2	build 375:9 387:15	650:3,5	464:14 467:10
bozzette 357:12	500:13 510:21	candidate 420:20	490:22 498:13
brain 393:3 569:22	553:21 609:19	can't 477:4,8	508:15 510:4,10
brains 453:11	building 458:15	482:13 494:9 504:1	513:15 524:8 531:3
branch 358:7	built 463:4 542:15	518:2 527:3 533:18	546:12 556:22
bravo 504:21	567:11	534:8,18	574:19 589:10
break 453:6 533:10	bullet 541:16	cap 423:22 475:7	597:11 601:5
541:3 572:16	602:14	capillary 568:13	611:14 613:17
breakpoint 429:9	bumped 481:21	capital 356:22 506:3	643:19 644:19
breast 650:3,5	bunch 548:12 562:1	captured 569:13	645:1 651:19
breath 612:5 667:21	buried 454:12	capturing 607:21	657:20 668:22
briefly 556:14	501:11 572:11	carb 461:3 607:12	cases 382:3,3
brilliant 453:12	578:18	607:18	384:20 387:8,9
463:14	burn 427:5	carbapenem 383:20	388:6 389:16
bring 363:10 395:7	burning 458:15	387:6 475:4 522:22	397:19 398:3
401:22 402:9 404:1	busily 490:22	530:11,12 531:4	446:18 450:13,16
538:10 540:16	business 359:22	580:1,5,7,11 581:12	451:15 469:13
542:3 562:2 573:14	busy 574:16,18,18	582:1,10 584:20	483:11 484:18
577:21 599:3	butolactam 586:14	585:5,6,10 628:13	485:7,14,15 490:1
645:17 658:10	buy 460:4	628:14 639:22	497:9 498:18
666:10 669:11,12	buying 586:3	648:1	499:14,22 559:11
bringing 628:1	bye 625:19	carbapenemase	566:1 573:16,17
brings 368:22	c	382:22 383:14	587:21 589:10
387:21 388:7	c 357:1 361:1 362:1	carbapenems 527:6	592:14 595:16
397:13	367:9 391:22 393:8	538:9 581:12	599:19 612:4,19
broad 400:22 448:6	393:21 394:15	639:21	617:22 620:5
530:3,6 535:5	398:14 406:21	card 596:16	624:18 641:13
539:22 581:8	413:16,18 415:8	care 384:11 392:16	644:22 645:2
641:12	416:3,6 417:21	397:7 403:13 404:4	646:19 662:5
broader 436:15	466:16,21 467:14	404:5 466:3,4,7,8	667:11 672:4
599:21	467:15,16 468:5	491:14 563:12	caspofungin 646:18
broadly 418:6 422:8	486:1 557:3 569:20	career 380:4	catch 388:1
512:1	570:4 572:9 573:11	careful 412:3 447:1	category 385:22
bronchiectasis	573:13 575:21	579:21 589:20	catheter 385:4,4
379:6 421:12 432:8	621:18 651:18	613:4 619:16	cause 419:7 425:8
468:20 483:8 534:1	cac 556:2	carefully 416:6	426:20 427:14
576:14	calculated 480:6	515:4 603:17	479:8 500:17,20
bronchitis 597:21	481:2	carlo 481:9,12	501:17 502:11,14
bronchopneumonia	california 357:16	578:22	502:17,19 503:16
440:18	call 473:8 514:15	carolina 357:18	503:19 504:2
brought 402:20	516:8 562:13	carries 416:4	566:18 578:15
650:17 655:16	566:21 661:1	case 364:18,22	630:8
		365:2,5,6,11 366:2	

caused 435:19 551:7 595:17	424:11 441:1,2,10 446:16 461:19	485:21 486:3 488:17 508:4 533:6	chose 394:15 490:5 528:21
causes 365:20 423:10 667:20	511:4 513:10 596:9 596:9 606:21 611:6	571:22 575:22 652:10 660:4	chosen 455:1 508:2 559:9
causing 401:3 538:8 616:6	619:13 626:7 627:2 627:14 629:9 632:1	chances 629:6	chronic 382:16
caution 613:2	certainly 368:1	change 377:8 423:9 448:4,5 460:10	chronically 483:9
cavaleri 357:20 361:8 364:9,9 444:5 444:11 455:11 456:1 503:10 524:6 524:12 568:3 620:3 656:12	381:2 384:13 393:7 397:20 419:20 422:1 426:12,18 428:12 430:10 437:8 441:2 443:2 457:12 502:22 528:19 537:15 545:5 594:2 595:20 604:4	565:16 591:15 595:18 614:19 616:17 621:12,14 622:12 656:6	ciai 557:19 561:2 566:22
caveat 521:1,3,14	certainty 414:17 507:19 658:8	changed 648:6	ciprofloxacin 386:5 387:4
caveats 500:9 520:18	certificate 674:1 675:1	changes 417:18 621:15 627:7 648:4	circle 646:20
cavities 440:18	certify 674:3 675:3	changing 565:11	circulate 600:14
caz 496:5	cetera 521:8 622:22	characteristics 368:6 420:18 433:2 441:6 545:19 563:18 619:14	circulating 599:8
cdc 461:5 624:17 650:22	cf 421:12 468:20 483:8 534:1 576:14	characterize 665:12	circumstance 462:9
cder 358:2,17 359:2 359:16 360:2 364:12	challenge 368:2 394:14 403:1 428:12 432:22 439:13 644:6	characterized 391:2 392:22 435:17 436:5,8	circumstances 435:6 455:16 615:18 657:12 658:22 659:4 663:15
ceftaroline 548:21 549:4,7 586:8	challenges 362:21 370:17 388:9 391:5 391:10,16 393:7,11 393:12,22 402:9 404:7,9 414:14 416:2 420:1 427:8 428:18 437:3 444:8 669:14	charge 610:22	citation 470:5
ceftazidime 384:3 494:14 599:18 663:14	challenging 362:9 362:12 366:1 367:14 368:7 369:12 370:11 371:14 373:11 404:3 410:20 417:19 419:10 431:22 443:9 451:14 649:5 672:17	chart 405:21 557:9	cited 475:12
ceftobiprole 635:4	chance 364:19 416:7 459:15	chasing 548:5	clamp 601:16
ceftolozane 384:3 531:9 599:18		check 509:16	clarification 462:20 490:21
ceftriaxone 386:12 387:4		cheek 602:20	clarify 460:15 528:20 531:2 632:22 652:22
cell 386:11		chemo 382:7	clarity 366:3 456:6
cells 499:12 629:12 641:14		chief 357:6 358:6,13 359:21 360:4 364:6 364:7 399:13 505:8 505:8 519:13	class 400:17 628:16 628:18,21,21 629:1
center 370:9 380:2 410:8,9 413:12 494:5,8		chills 386:8	classes 400:15 644:12
centered 377:3 571:2		china 430:14	clean 469:11 516:9
centers 409:22 410:1,1,1,5 456:18 579:21,22 581:4 582:6 601:11 650:22 651:1		chloramphenicol 385:15	clear 373:18 392:15 395:2 396:16 428:19 466:6 469:15 537:19 561:3 577:18 584:11 637:11 643:2 649:11 656:19 666:19
certain 372:17 373:19 419:7,10		chmp 657:21	clearance 445:1 654:4
		choice 366:5 387:7 391:17 549:12 612:20	cleared 478:4
		choices 408:10 411:18 559:5 566:5	clearer 370:4
		choose 389:22 484:16 603:7 632:13 633:12	clearly 370:3 407:22 434:14 447:22 500:7 501:21
		choosing 652:13	

517:15 630:22 640:1 670:5,15 671:16 672:10 climbing 468:4 clinic 386:4 483:2 539:18 588:8 clinical 357:4 358:20 359:13 366:12 367:13 369:3,11 370:13 371:2 373:5,9 374:4 374:9 376:3,17 378:2 381:14 387:12,16 390:1,3 395:4 398:19 403:10 405:10 406:4 408:1 413:2 413:11 414:15 416:16,20 418:14 419:1,9 425:1 432:13 435:18 437:6 444:1,17 445:8,15 446:8 448:2,11,14 449:8 449:14 450:20 451:4,22 452:22 454:1 456:12,13,15 457:12 458:9 459:8 459:19 460:13 465:19 467:3 475:20 479:5,7,9 482:5 483:1 505:13 507:7 525:12,22 533:22,22 535:3,11 535:15 536:20 537:4,6 553:11,22 566:21 574:9 576:6 587:15,17 589:3 590:12 594:10 598:7 599:12 604:18 617:6,10 621:9,19 622:14 629:17 631:5 644:7 645:7,21 650:10,15 651:15,21 652:17 652:20 653:8,13 654:1,7 659:13,20 660:12 661:9,22	667:5,8,12,22 clinically 374:16 424:2 438:15,20 587:20 615:12 659:18 671:8 clinician 380:10 395:13 clinician's 541:7 clinicians 366:15 390:9 395:9 398:21 541:11 clinigen 661:4 clipped 471:20 close 373:20 439:21 467:4 469:2 482:18 497:16 543:1 672:21 closely 535:16 closer 425:18 495:16,22 closest 516:21 clue 502:4 cmv 358:21 co92 439:14,14 442:14 coagulation 439:2 440:15 code 433:12 coli 479:3 colis 532:11 colistin 383:3 384:10 385:9 397:18 398:4 481:19 482:7 580:2 591:15,16,20,22 598:18,20 colitis 367:10 collaborated 463:3 colleagues 391:8 399:7 405:7 406:5 506:22 538:4 542:9 595:7 600:1 615:2 619:6 collect 460:18 479:13 595:8 645:2 collecting 608:16 647:22	collection 499:14 618:12 college 512:9 colonization 367:7,9 colonize 576:16 colonized 483:9 colony 377:15 colorado 438:13 combination 384:10 450:2 472:14 473:17 520:11 523:8 524:14 530:10,12,18 531:3 531:11 532:3 581:1 609:7 combinations 383:3 385:12 combine 408:11,16 427:18 combined 545:22 579:11 combining 648:9 come 381:19,20 389:4 395:21 397:15 406:20 407:16 415:1 416:18 420:16 422:2 423:13 424:8 424:15 443:11 452:7 453:9,12,15 460:4 463:21 472:10 473:7 474:1 476:4 478:6,16 479:14 482:12 487:4,7 489:16,21 490:11 494:2 497:19 499:17 503:10 506:1 509:13 516:21 519:8 520:11 524:9 533:10 534:15,16 535:17 536:8 537:22 561:2 565:9 566:16 570:20 587:3 631:15 639:18 646:20 647:13 655:6 656:22 657:5 658:4	672:3 comer 423:2 430:1 431:20 450:17 comers 579:19,19 comes 370:16 383:16 414:13 459:16 483:5 499:5 530:14 558:17 560:7 570:13 646:12,13 comfort 427:3 542:12 comfortable 362:20 475:22 494:6 500:11,12 537:3,5 549:12 572:16 576:10 604:9 618:22 648:19 coming 390:2 444:14 448:15 491:12 495:2 532:4 549:11 570:8 592:15 596:15 commend 505:10 514:7 commensurate 671:12 comment 363:6 371:15 456:2 497:12 502:21 503:12 505:3,5 510:1 520:4 523:11 524:2 525:6 536:17 536:22 542:10,19 556:3 566:9,12 568:4 588:2 594:1 603:20,22 604:7 605:2,6 620:2 624:3 632:11 641:20 651:8 663:11 commentary 534:17 comments 363:14 486:21 498:20 502:10 526:12 541:6 549:16 571:9 572:8 596:18 608:20 656:11
---	--	--	---

commercial 556:10	compare 438:10	computed 517:12	417:9 420:12
commercially 527:5	439:11 624:7 626:9	559:13	426:17 428:3 436:1
commission 674:19	636:8	computes 510:21	436:11,21 445:20
commissioner	compared 439:12	concede 448:22	447:2 448:19
596:18	442:19 634:19	concentration 379:1	535:15 620:22
commitment 650:12	642:6	638:9	657:18
commitments	comparing 500:19	concentrations	conducted 356:8
664:12	525:14 626:11	377:20 554:13	379:5 416:7 425:2
committed 657:2	comparison 626:15	560:21 640:1	433:19 435:14
671:1	649:4,4	concept 379:4	442:5 445:9 526:6
committee 362:19	comparisons 642:2	421:11 475:1 503:9	conducting 405:11
393:14 399:6	compelling 392:8	concern 379:14	446:22
441:21 442:2	compensate 410:16	525:6,14,19 538:7	conduction 445:15
519:15 662:22	complaints 497:7	547:17 571:10	confidence 467:6,17
665:3	complement 445:6	586:5 593:4 638:14	469:8 480:10
committees 392:18	completed 378:2,4	concerned 590:8	482:20 507:20,22
common 406:3	648:3	concerning 376:10	508:6,16 513:3
415:22 421:21	completely 496:12	concerns 391:16	558:16 559:14
427:10 451:14	644:12 646:1,2	conclude 463:10	565:13 569:13
473:9,9 476:14	661:18 670:2	472:22	603:15
625:2 667:7	complicated 365:21	concluded 673:3	confident 612:15
commonly 427:7	365:22 382:13	conclusion 417:15	confirm 445:12
432:10	385:17 390:18	546:2	confirmation 546:6
community 401:12	426:18 466:19	conclusions 555:12	confirmed 540:5
442:9 511:20	475:7 476:17	conclusive 404:22	conflict 363:1
525:21 599:2	478:13 484:4	concomitant 370:18	confound 408:12
comorbidities 409:5	485:20 487:17	419:14,15 423:15	572:18
414:5 421:21	515:16 516:3	432:21 445:12	confounded 484:3,5
457:18 496:17	522:18 524:20	471:14 484:4	572:22
566:16 616:21	528:14 531:10	509:13 532:21	confounding 408:21
companies 413:3,10	670:22,22	542:6	467:7 492:16
519:14 521:5 660:2	complication	concrete 453:10	547:19 586:20
companion 484:13	474:16	concurrent 619:7	confounds 419:17
company 356:22	component 462:3	condemning 416:8	confused 489:1
358:11 411:6 505:9	524:3 537:9 566:13	condition 397:6	conjunction 650:13
511:9 561:18 581:4	compound 365:16	413:13 424:6	cons 374:3 509:10
590:15 661:4	536:21 647:15	432:14 440:10	541:7
comparability	compounded	656:14,22 660:13	consensus 362:18
621:4	408:20	conditional 655:18	647:8
comparable 527:2	compounds 365:14	656:9 662:11 663:6	consent 581:21
612:12 613:5 619:3	366:17,21 374:14	conditions 371:7	consented 581:22
646:13	374:20 402:4 404:6	433:18 437:6,15	consequences
comparables 486:13	670:7	444:1 462:7 504:1	482:14 670:9
comparative 498:8	comprehensive	615:14 616:21	conservative 481:1
comparator 391:17	405:5	645:5	481:4
391:18,19 477:11	compute 480:8	conduct 368:13	consider 385:22
477:13 493:22	510:6	403:14 407:9,16	392:9 394:14 406:2
501:7 621:15 649:2		413:20 416:15	407:10,21 416:12

443:18 449:1,2 450:5 462:8 522:13 considerable 671:14 consideration 441:6 446:14 621:17 considerations 392:2 considered 401:15 403:22 424:2 426:16 436:7 444:1 450:9,11 451:5 472:5 528:12 587:3 considering 446:18 448:1 603:4 657:15 consisted 379:5 consistent 383:12 386:5 543:15,17 622:10 consolidation 440:18 constitutional 382:17 constraints 464:13 467:12 constructed 582:13 582:21 construe 513:9 516:22 consultant 364:1 487:8 consultants 360:8 consultation 475:8 consulting 358:4 consumed 465:19 contact 439:21 440:5 contain 413:21 contaminated 516:9 contemporaneous 578:19 581:2 613:19 667:19 context 381:18 446:8,10,19 462:20 544:22 578:3 657:17 continue 375:8 404:21 417:19 631:7 668:22 671:1	671:5,20 672:1,6 continued 668:19 continues 650:15 671:20 continuing 493:13 493:14 continuous 567:20 continuum 388:21 contrast 391:22 419:22 contributed 568:16 control 430:19 431:2 442:4 450:1 451:7,16 452:3 455:18,18 476:14 485:14 495:1 517:10,11 574:11 575:8 577:20 578:11 581:1,10,11 581:13 582:13 583:9 585:4,15,17 586:22 589:21 605:3,5,8 612:10 613:20 617:9 618:19 619:2 620:8 620:12 622:18 623:7 624:2 631:14 631:17,22 632:2,8 634:20,21 636:4,8 638:9 643:19 646:5 646:12,19 647:10 controlled 388:18 388:20 389:1,3,6,7 389:12,13,18 390:11,17 395:1,10 395:22 396:4 398:11,12 416:16 457:10 458:21 459:10 460:22 474:15 516:15 536:20 537:6 580:17 655:4 controls 392:4 393:11 398:15 577:22 578:7,7,19 580:18,19 583:11 583:17 585:16,18 586:16,17 613:2,7	613:21 614:4,14,14 615:4,17 617:15 618:8 619:7,11,12 623:7 631:18 640:10 644:19 645:9 667:19,20 controversies 500:16 controversy 393:15 conventional 645:8 conventions 369:10 conversation 541:2 587:5 662:16 666:6 conversations 512:7 conveys 512:3 convince 473:5 611:10 622:9 convinced 459:19 convincing 452:2,9 455:17,18 convolute 641:7 642:18 convolution 642:12 copd 382:8 corner 463:10 482:3 correct 547:4 605:20 625:13 635:12 correctly 363:10 513:12 515:15 590:20 628:18 correlated 651:20 correlation 652:4 653:11 cost 409:12 410:4 412:18 489:5,6 490:5 556:4 560:1 609:3 610:3,6 costs 409:19,21 410:2 412:14 489:14 490:4 521:9 cough 382:15 couldn't 501:10 counsel 674:8,11 675:7 count 386:11 610:10 counter 522:11	counterparts 617:11 countries 446:16 506:9 536:2 611:6 country 384:20 535:18,20 599:16 661:6 couple 382:3,6 390:13 487:19 493:19 541:2 543:12 546:12 576:8 589:10 606:5 619:5 630:2 644:3 654:2 course 363:12 375:9 380:4 383:12 392:22 445:4,21 446:20 449:4,9,11 450:6 451:2 452:5,5 463:14 479:9 484:22 508:2 566:2 610:22 656:14,21 657:7,11 658:12 668:9 courses 610:21 cover 408:18 474:12 484:11 508:12 509:10 531:17 555:20 coverage 408:9,21 531:17 548:14 covered 509:18 542:8 559:8 586:12 631:11 covers 419:17 cox 356:8 358:1 361:3 362:2 364:15 379:18,20 381:10 389:5 394:8 399:10 418:11 444:4 459:2 460:8 461:16 514:19 515:8 523:11 531:7 532:2 532:6,10,13 536:7 538:17 550:19 551:1 552:13,16 553:2 554:18 588:13 590:18
---	---	--	--

591:5,9,11 592:12 594:8,17 595:1,13 598:2 600:10 606:8 608:17 614:5,13 618:5 621:7 627:8 627:20,22 629:1,10 629:13,22 630:6,12 630:19 632:9 636:13 637:22 638:3,7,12 639:7,10 640:2,12,14,18,21 641:20 642:12,19 643:1,7,9,12,15 651:9 652:9,12,17 652:20 655:10 661:8,20 663:10 668:16 craft 592:3 crazy 461:7 463:11 487:1 572:6 cre 493:22 494:1,16 495:1,2 create 396:11 402:5 403:10 412:12 517:5 574:4 575:21 638:18 created 517:4 creates 653:19 creative 405:10 criminal 564:12 criteria 371:18 393:12 434:4,20 528:7 556:18 581:6 621:13 628:1 632:2 647:9 critical 395:16 452:10 590:18 608:16 critically 394:11 criticize 518:2 critiques 498:21 cross 557:15 crosstalk 548:15 550:1,10 crude 501:1,9,12 crummy 573:10 crunch 583:16	crunching 583:16 cryptococcal 619:20 csr 356:21 cubist 380:4 culture 387:1 407:10 469:15 471:5 478:18 479:1 493:4 496:7 532:16 532:17 537:22 573:3 600:11 cultures 491:12 cure 369:16 449:9 450:20 452:1 566:21 652:15 cured 382:8 384:12 403:7 466:9,10 483:17 cures 652:17 curing 629:6 curious 530:8 631:13 current 380:1 396:8 443:5 currently 399:12 428:8 668:21 curt 542:21,22 543:4,8,10,12 544:15,19 545:15 545:17 curt's 546:8 curve 626:22 633:4 636:18 637:2 638:18 640:7 cusp 661:13 cut 368:20 503:7 517:3 639:11 cuti 427:3 548:4 566:22 cuts 426:11 521:9 cutting 631:13 cyanide 437:17 458:16 cyanocobalamin 458:13 cyclic 405:3 cystic 379:6 432:7 cytoplasmic 402:7	d d 362:1 415:14 463:9 467:20 573:2 575:21 587:12 598:7 611:17 624:20 667:17 dab 475:19 dan 360:1 dane 358:4 363:22 363:22 497:21 498:1,4 508:10,13 509:8 511:8 512:11 538:16 540:8 544:15 545:21 546:6,19 564:1,6 569:5 571:15 612:6 620:18 624:2 646:11 648:22 danestat 358:4 dangerous 579:14 daptomycin 499:11 daring 606:9 data 369:8 370:13 370:22 371:5 373:13 374:4,5,9 378:9,19 381:10,15 387:13,13,19 388:8 388:9,10 389:4,9,9 389:10,13,17,21 390:4,22 391:2 393:1,4,17 395:5,10 395:11,11,12,20,20 395:22 396:4,13 398:2,6,11,19 403:5 404:22,22 405:12 405:12 416:1 431:8 431:9 434:21 435:16,18 438:9 445:8 452:6,18,22 454:6,15 455:12,17 456:15 457:12 458:10,13,16 459:18,18,19 460:13,18 461:12 474:6,9 475:10,11 475:20 476:3 479:10,13 480:7,16	480:20 481:6 482:11,15,16,22 484:6,7,14,16 486:14 495:9 498:5 499:20 500:8,12 506:5 507:14 508:15 509:5,7 510:22 512:2 513:7 515:19 516:2 520:7 526:14 527:4,12 533:22,22 535:10 535:11 536:6 537:2 541:18 542:3,8 543:5,15,22 544:6 544:10 545:22 550:17 553:4 554:6 554:11 557:18 560:10,10 561:6,13 561:18 565:17 568:5,12 571:17 573:12 574:11 577:14 578:13,22 582:22 583:21,21 587:15 590:15 591:13,14,17,21 592:11 594:1,4,10 595:8,9 599:12 602:7 603:17 606:3 606:13 607:3,8 608:10,16 616:3 621:2 622:13 623:5 627:10 631:5 635:3 635:4,4 636:9 637:20 641:1 643:9 644:7,18 645:7,10 645:22 648:1,11,14 648:21 650:10,11 655:5 656:18 657:4 658:4,10 659:10 660:9,10,12,19 663:1,7,20 664:11 664:14 665:16 668:1 database 381:17 395:5 407:14 446:2 468:16 469:2 490:1 490:6 497:17 590:2 594:13
---	--	---	--

databases 636:2	491:22 492:6,19	definitely 566:13	610:4 616:19
dataset 388:22	493:19 537:21	593:19 609:15	depends 440:5
394:4 495:21	646:18	624:21 625:14	441:3 562:22 610:5
528:20 546:3 568:8	days' 488:4	definition 429:8	depots 661:4
568:18 599:1 624:8	de 527:17 641:6	626:18	deputy 359:4
650:8,17 657:3	642:12,17	definitions 392:13	derive 445:7 656:18
663:8	dead 441:8 534:21	398:17	describe 418:16
datasets 388:21	546:16	definitive 433:18	458:7
389:2 445:11 545:7	deal 423:15 424:4	471:3	described 401:20
568:5 613:22	453:20 467:8 503:3	degree 416:4 422:20	438:7 462:8 533:19
648:20 662:19	507:11 509:11	425:20 440:6 441:1	597:11 617:21
date 610:11	528:22 567:15	461:19 462:4	618:6 655:1 672:12
dave 520:15,15,17	586:19	551:16 553:13	describing 507:18
521:12 659:6 661:7	dealing 375:5 498:7	594:13 622:3 637:5	552:21 553:3
662:9	542:10	663:22 671:13	628:12 629:18
david 454:13,14	death 440:11 472:9	degrees 370:15	655:14
504:8,9,20 577:10	472:14,16,20	378:17 457:17	descriptive 435:20
577:11 578:2,6,16	deaths 501:19	delayed 657:4	514:14
578:20 579:1,9	debate 453:9 519:16	deliberately 495:16	design 409:13
580:14,16 581:19	614:2 636:14 647:1	498:16 503:8	427:11 476:13
582:2,4 583:6,8,13	debates 513:16	558:18 632:12	491:9 505:1 507:6
584:16,19 585:2,8	debilitated 409:3	641:11	511:2,7 563:13
585:15,19,22	december 382:14	delighted 549:14	577:17 578:3,5
586:13,16 596:22	decent 407:8	delivery 402:15	579:3,10 583:13
598:4 600:21,22	decide 437:22	delta 467:5,11	637:10
613:18 617:21	465:17 599:3	495:17,19 558:15	designing 441:7
655:14 662:10	604:10	deltas 571:1	508:18 647:20
664:7	decided 384:11	demanding 446:20	designs 584:5
david's 618:6	deciding 629:18	451:1	desire 388:8 529:1
day 362:3,7 363:12	decision 374:5,10	demonstrate 428:5	desired 434:14
364:17 379:5	476:22 538:9	429:17 501:4,5	576:3
383:12 394:1	539:21 564:19	556:8	despite 617:4 620:7
452:12 462:11,11	591:20	demonstrated	destroy 670:7
463:14 476:2 477:4	decisions 387:20	434:10	detail 365:10 412:2
477:22 479:8	decisive 427:22	demonstrating	434:7
487:13 488:2,3	decrease 638:20	415:18 455:19	detailed 486:18
491:7,7,13,16,17,18	651:18	556:7	details 371:11,17
491:19 492:4,5	deem 527:20	dennis 358:6	433:9
493:4 501:18 523:5	deep 385:19 469:17	denominator 473:9	detect 501:6
568:19 575:6 577:6	578:18 612:5 614:2	473:10 495:12	determinants
577:15 588:18	deescalate 425:3	department 359:8	439:17
606:3 654:3 671:20	deescalating 424:22	depend 546:17	determination
671:20 672:18,18	defer 556:15	dependable 614:18	536:5
days 373:7,7,7	deficit 427:20	dependent 376:5	determine 416:21
380:10 386:7,15,16	define 450:11 563:1	depending 369:17	determining 428:15
424:10 440:10	defined 392:17	370:8 431:1 470:14	develop 365:15
442:15 468:18	482:19 650:9	551:14 576:14	366:6,8 372:5
487:15,19 488:4		579:12 583:17	387:22 388:2 400:8

401:5 417:20 418:7 424:16 436:8 443:4 443:19 455:4 456:19 462:1 516:14,18,19 534:11 550:18 670:11 developable 549:5 developed 384:22 390:10 433:8 438:2 441:20 454:2 461:21,22 481:12 549:5,6 556:17,20 582:22 659:17 developing 356:6 362:14 366:22 374:14 380:8 444:8 459:4 464:14 521:6 523:10 659:21 671:15 development 356:5 359:5 365:7 372:7 374:20 379:15 381:4 396:12 399:15 402:12 404:2,7 405:6,10 417:17 418:17 421:1 443:10 444:1 447:14 448:14 516:17 594:10 668:19 670:6,17 deviates 623:4 deviation 490:4 device 485:17 486:1 488:13,15,17 489:1 530:5 545:2 570:4 571:4,7,11,12 devices 545:1 di 481:9,12 578:22 diagnosis 499:12,17 540:5 561:7 diagnostic 368:1,8 382:18 393:12 405:19 408:7 409:13 411:22 412:6 413:3,6 420:5 423:8 445:16,19 446:7,12 447:7,13	448:1,11 464:21 521:4,16 540:2 571:19 662:4 667:9 diagnostics 366:10 390:7 411:19 412:11,20 419:19 608:15 dichotomous 563:10 567:20 didn't 478:2 481:16 483:11,18 487:18 489:22 490:2,12,18 494:16 504:4 506:13 515:19 516:13,17,18,18 520:12 521:18 527:7 538:5 539:10 539:15 die 404:2 500:10 died 566:22 578:1 diego 357:16 diff 367:10 difference 402:20 457:20 467:1,4,10 480:12 510:7,8,21 514:15 517:17 544:20 546:7 558:14 568:16 590:17 592:6,8 623:10 637:8 638:20 644:1 differences 430:8,10 482:20 511:3 584:11 632:4 662:11 different 362:8 365:4 366:18 369:18 374:3 385:22 388:19 401:2 420:12 427:18,19 428:1,9 429:2 433:20 439:8 440:12 442:13 443:8 449:10 450:8 457:6 473:3,6,7 477:11 484:9 496:15 503:8 513:4 542:15 544:11	546:12,19 548:2 551:16 558:21 566:5 570:20 578:3 609:9 616:5 628:21 629:1 632:14,16 635:1,22 636:1 640:16 642:1 644:13 646:2,6 649:20 650:1 660:1 660:7 differential 538:2 differentiate 371:19 differently 373:18 522:11 645:20 649:16 difficult 368:13,16 372:11 384:19 419:3 420:8 423:5 423:14 427:9,17,20 428:16 497:1 498:18 523:21 553:15 555:5 596:8 600:5 616:22 618:15 623:21 624:11 642:10,13 644:22 653:17 657:6 663:19 669:10,12,19 671:21 difficulty 610:15 dig 541:19 digging 385:19 digress 406:18 digs 566:5 diminishing 404:10 direct 428:13 510:11 649:1,4 directed 461:6 direction 389:22 532:5 545:12 546:13 674:5 directions 487:12 526:13 directly 510:19 565:15 director 357:8 358:1,4,16 359:4,15 360:7 364:11	418:12 disagree 594:8,14 discern 427:20 523:16 552:7 discharged 383:11 disclosures 363:1 380:16 400:1 discord 654:6 discovered 476:1 discrepant 538:14 discuss 362:20 388:20 458:20,22 477:10 513:21,22 525:3 551:15 575:21 612:4 discussed 362:10 377:12 422:13 427:2,17 441:21 443:13 449:5,19 455:12 461:3 466:1 507:12 567:6 610:16 666:13 discusses 373:22 discussing 370:13 375:15 424:19 437:8 498:9 discussion 362:11 362:17 384:6 390:2 407:18 422:1,5 423:13 441:19 510:2 514:2 518:7 527:18 528:21 553:9 557:17 558:5 575:20 612:7 643:16 646:17 665:3 670:13 672:17 discussions 405:20 536:8 554:19 630:20 646:21 669:19 671:6 672:7 disease 358:10 364:3,5 368:6 372:8 380:1 387:12 390:8 391:13 399:14,15 434:9 437:15 438:5 438:6,11,17 439:11 440:8,9,21 458:12
---	--	--	--

460:9 472:17	documented 481:8	468:18,21 469:13	510:1,13,16 511:18
482:10 484:1	documents 403:4	477:22 478:2,6	513:2,15 514:8,10
554:10 574:5	doesn't 489:2	481:21 482:6,7	514:17,19 515:7,8
603:10,10 604:5,6	491:21 493:17	483:1 487:9,13	515:22 518:18
615:14 619:14	506:19 519:7	490:9 497:11	520:3,19 521:15
630:9 651:15 653:6	531:17 571:19	629:19 630:21	522:4,5,7 523:11
658:13	dogs 376:5	631:14,22 632:2,11	524:1,6,7,12,21
diseases 357:8	doing 383:15 389:22	633:4,8,10,12	525:5,10,11,19,22
364:14 367:18	398:5 411:15 413:1	634:17,20 635:8	526:4,5,10,12,16,18
368:7 369:13 372:2	422:8 428:18	636:16,22 637:6,8	526:19 527:1,3,11
419:22 420:10	431:21 456:3	638:14,17 639:18	528:4,10 529:11,22
437:12 466:18	459:20 480:6	639:22 640:14	531:6,7 532:1,2,4,6
615:16 627:7	481:20 496:21	642:1,2	532:9,10,11,13
637:12 644:18	505:11 511:15	dosed 576:7	533:8 534:10,14
647:5 653:2,22	512:22 523:22	doses 376:7 481:20	535:2,7,8 536:7
dismal 431:21	528:13,17 547:22	576:9 609:4 632:5,7	537:8 538:11,17
display 519:19	553:22 565:1	632:13,15 634:5	540:6,15,19 542:22
disproportionate	572:16 574:6	637:5,16 639:21	543:3,6,9,11 545:10
583:4 619:8 622:20	575:17 576:15	640:16,20 641:11	545:16,20 546:5,10
623:8	583:2 618:18 621:5	dosing 395:12	546:21 547:6,9,10
disseminated 595:5	631:3 636:7,21	421:16,17 441:14	547:19 548:16
distance 511:22	637:7 638:9 641:5	441:15	549:2,19 550:2,6,8
distant 401:21	645:6 660:2 663:12	double 408:18	550:11,19 551:1
distinguish 527:6	664:18 667:6	509:16	552:9,13,15,16,22
distress 438:21	dollars 610:9	downside 623:14	553:2 554:2,18
distribution 376:19	domain 441:19	dr 362:2 363:16	555:22 556:14
377:2 444:21	don't 465:6 481:10	364:2,4,7,9,11,13	557:10,12 558:7,10
626:13	481:10,11 484:17	364:15 375:14	559:20,21,22 560:6
distributions	484:20 487:20,21	379:18,20 380:12	560:7 561:10,10,12
626:12	489:12 490:8,11	380:12,13 381:10	561:13,14 562:10
disturbing 565:5	491:6 496:20	389:5 390:15 394:8	562:11,13 563:10
ditto 508:8	499:16 501:4,7,20	395:3 399:10,20	563:21 564:18
divergent 546:14,18	503:18,18 504:20	405:14 418:11,20	565:11,20 566:10
divide 469:5	510:9,20 517:8	420:16 428:17	567:4 568:3 569:1
division 359:1,15	518:1 521:13	444:4,11 453:5,18	569:16 572:2
364:12 375:6	522:19 525:3,5,15	454:17 455:7,11	574:17 575:13,22
418:13	529:5 532:15	456:1 457:2,21	576:3,19 577:2,3,4
divisional 527:17	534:22 538:21	458:1,5 459:2,15	577:18 578:5,9,17
dixon 358:6	539:1,4,10,12	460:8,15 461:1,2,16	578:21 579:7
dmitri 527:16	door 453:20	462:19 464:7,11	580:13,15 581:16
doable 437:21	doripenem 635:3	488:13,16 489:2	581:20 582:3,20
631:20	dose 376:5,12,14,16	490:8,16 491:3,6,12	583:7,12 584:6,17
doc 561:10	377:20 378:18	492:10,20 494:1,11	585:1,3,11,17,20
doctor 386:4	379:8 381:14	497:22 498:2,15	586:2,5,14 587:1,9
document 373:21	386:13 395:3 421:4	500:13 502:1,13,17	587:10 588:1,2,4,13
406:14 447:5	434:20 442:14	503:2,6,10 504:8,13	589:17 590:18
448:18 481:3 515:1	445:3 449:21	505:3 506:13	591:4,5,7,9,10,11
517:20 628:6	454:19 456:20	508:11 509:2,4,9	591:12 592:12

593:10 594:8,16,17 594:20 595:1,2,13 596:14 598:2,3,5,12 598:14,15,16 600:10,19 601:19 602:4,6,9,12,19 603:18,20,21 604:20,22 605:9,12 605:14,15,17,18,19 605:20,21,22 606:4 606:6,8 607:10 608:6,17 609:1,8,11 609:13 613:6 614:5 614:8,11,13 617:20 618:5 619:18 620:3 621:7 622:15,16 624:19 625:5,8,13 625:18,22 626:16 626:22 627:4,8,9,18 627:20,21,22 629:1 629:10,13,22 630:6 630:12,19 631:10 632:9,10,20 633:15 633:17,22 634:7,9 634:11,22 635:13 636:11,13 637:22 638:3,7,12 639:7,10 640:2,12,14,18,21 641:10,20 642:11 642:12,14,19 643:1 643:7,8,9,12,14,15 643:17 644:9 646:9 646:16 647:17 649:6 651:7,9 652:9 652:12,17,20 655:10 656:12 658:19 660:11 661:3,8,19,20 662:2 663:10 666:2 668:16 dramatic 605:4 dramatically 591:15 648:5 draw 374:11 555:12 drift 469:16 drifted 624:20 drifting 540:20	drink 386:18 drive 487:1 driven 563:18 drop 370:2,7 488:2 492:13,21 493:10 590:14 662:4 dropping 493:11 drug 356:4,13 365:7 366:4,7,8,13,14 367:3,13 368:21 369:8 370:18 371:8 371:20 372:22 373:3,18 375:17,19 376:17 377:9,13,19 378:7,7,15,20,21,21 379:1,7 380:8 385:15 387:6,22 388:2,3 395:8,17 396:17,20 402:11 403:18 405:13 407:20 413:15 414:9,14 415:3 416:1,2,8 419:4 421:14 428:4 431:15,16 432:2 433:13 434:18 441:12 443:2,4,6,21 444:8,20,20 445:20 446:22 447:3 448:22 453:19 454:6 455:2,20 459:4,7,11,17,22 460:5 461:8 462:9 472:12 475:13 477:2,20 478:1 483:15,19,20 492:15 499:19 519:7,11 520:10 522:14,15,16,17 523:1,7,15 524:16 524:17,19 525:15 527:21 528:2,6 529:9,13 530:10 533:5 536:9,14 537:1,5 538:19 539:4,11 546:16 549:5 550:18 551:19 552:3,8	559:1,19 560:15 562:8 563:3 564:12 564:13,16 567:14 567:16 569:17 576:12,12 579:4,11 579:13 580:10,10 583:14 585:14,20 585:21 586:9,10 587:12,21 588:7,18 588:20,21 589:2 590:10,14 591:3,13 591:15 592:5,7 593:8 594:6,12 596:2,8,12 597:3,6 598:8,19 606:10 608:9 610:16 611:7 613:16 615:9,12,20 616:13 617:2 621:15 623:17,18 626:5,9,12 628:15 643:3 650:16 651:2 656:16 657:13 660:13,14,15 661:15,16 664:9,15 664:19,21 665:2,5 665:11,15,21 drug's 595:2 drugable 407:22 drugs 356:6 358:16 362:15 367:1 374:21 381:4,14,22 385:13 387:3 390:10 396:15 397:3,9,19 398:2 400:21 401:8,12,18 402:6 419:1,3 423:16 433:14 436:13 437:10 441:18 455:3 465:18 471:17 473:14 474:4 518:14,14 522:20 523:4,9 524:13,14 524:17 529:1,5 534:19 547:13 553:6 567:15 570:14 572:1 584:14 596:7 599:3	599:17 601:17 629:14 645:13 649:12,14,20 658:6 659:3 670:14,14 dsmb 518:15 537:9 637:13 dual 424:5,7,21 425:4 527:19 528:1 584:18 dudley 358:9 517:2 529:22 596:14,14 due 385:1 422:12 424:6 452:14 507:5 627:7 dumb 506:19 duration 425:5 439:4 440:11 468:21 469:14 490:9 497:11 dying 384:12 dynamically 544:5 dysfunction 395:15 421:19 478:3
e			
e 357:1,1 361:1 362:1,1 463:9 467:20 479:3 532:11 611:16 624:20 659:1 667:17 earlier 381:11 388:4 388:16 389:5 393:13 394:9 419:6 422:13 423:20 424:8 499:6 560:8 612:7 656:17 658:8 early 526:2 588:15 593:21 599:5 619:20 656:13 ease 476:15 537:11 easier 401:4 410:22 411:8 418:7 426:18 578:4 604:12 easiest 467:8 easily 469:1 479:11 531:12			

east 357:13	626:8,10	532:15 560:16,17	601:18
easy 395:21 414:10	effectively 543:13	579:11 581:2 583:3	employed 674:8,11
428:13 444:15	574:10	607:8 656:4 665:20	675:8
460:7 478:1 667:16	effectiveness 389:8	eke 463:6 474:17	employee 674:10
669:11	414:12,17 415:18	537:11	enables 667:7
eat 386:18	434:4	electronic 460:19	encounter 384:14
economically 609:2	effects 403:6	element 646:7	419:12
economics 357:14	efficacious 632:14	elements 412:17	encountered 382:4
412:6 600:20	634:13	417:20 449:4	437:4
ed 375:14 380:12	efficaciousness	645:18	encountering
388:4 399:20	560:20	elevated 386:11	429:14
418:21 419:21	efficacy 369:6 371:4	elevation 441:1,11	encounters 432:20
436:3 444:11	371:16,22 372:6,15	elevations 376:11	encouraged 397:5
457:22 460:15	373:21 381:15	elf 378:5,22 444:22	encouraging 446:6
499:10 588:5,11	395:4,11 421:10	475:10,13,17 483:7	596:20
604:20,21 606:7	422:14 427:2,21	553:20 576:13,18	ended 394:22
607:10 614:1 620:4	433:1,15,19 434:21	641:5	endless 510:3
636:11 646:17	435:14,16 436:2,3	eligible 651:2	endpoint 407:4
651:7 666:5 668:15	441:7,12 443:21	elimination 378:19	425:9 427:11,15
ed's 600:22	445:8,9 446:3 458:8	ellenburg 583:10	434:13 441:8 449:8
edge 484:9	462:3 496:20 523:6	else's 609:20	450:21 452:1 479:5
edges 645:12	523:14 526:3 534:3	else's 520:20	500:17,20 501:2
edward 356:8 358:1	535:11 539:3 552:7	ema 365:5 379:16	502:13 560:2
361:3	560:16,20 588:17	444:8 446:7 455:10	566:19 615:8
effect 367:4 403:2	591:18 605:7 607:1	479:11	endpoints 449:14
409:8 419:18 425:4	607:9 626:6,13	embark 459:8	451:4 503:17
427:22 428:14	627:3 634:17	embarked 384:9	546:19 566:20
431:17 434:10	640:11 644:8	embedded 448:11	567:2,20 654:5
455:19 480:4 484:2	649:13,19 651:6,11	541:15	ends 377:4
492:16 513:3	657:19,22 665:13	emerge 398:11	energized 666:10
515:21 523:16	665:18	455:13 456:12	energy 572:13
524:16,19 532:22	efficiency 448:2	emergency 383:11	engineer 372:19
541:17 543:18	667:13	386:20 656:2,3	511:7
573:1 583:10 594:6	efficient 448:14	emerges 497:18	england 380:2
595:11 597:6,13,22	631:16 662:6	emerging 384:17	enhancement
605:4 612:13,14	667:10	530:19	434:15
615:11 616:19	effort 461:3 618:7	emphasize 411:2	enlarging 449:1
617:2 635:19	efforts 372:5 397:2	471:2 496:14	enlightenment
636:10 637:2,11	398:9 607:13,19	602:22	407:1
640:8,9 641:2,3	eight 376:13,16	empiric 367:18	enormous 547:3
644:5 648:12,16	378:10 429:10	420:6 436:16	572:5
effective 374:15	either 363:7,16	471:22 494:7	enrich 445:16
377:14 391:18	367:8 394:1,5,18	532:17 540:4	467:15 506:8
396:15 397:3 420:4	398:11 404:21	590:21 591:1	573:16
434:20 478:20	422:16 424:11	601:10	enrichment 412:13
481:17 523:2	432:7 442:15	empirically 391:10	530:5
544:14 586:14	443:21 463:11	408:6 446:1 473:15	enroll 369:4 370:9
587:22 616:10,13	470:14 500:11	491:6 519:11 600:8	391:9,12 408:6

410:17,22 421:20 422:22 423:6 428:6 428:9 446:17 447:20 459:6 464:18 468:2 471:7 478:19 487:5 489:3 489:4 571:6 579:18 enrollability 409:11 enrolled 405:22 445:22 489:6 507:2 523:19 582:17 597:17 618:2,13 enrolling 419:9 466:20 531:15 541:13 571:6 575:7 enrollment 391:6 423:9 431:21 445:17 486:15 521:10 ensure 396:15 399:1 399:3 435:10 462:6 641:11 enterobacteriaceae 375:22 548:22 enthusiasm 647:12 entire 425:5 568:8 entirely 383:7 483:14 entirety 568:21 entrapenem 475:2 475:11,17 476:5,8 entrapenem's 476:1 envelope 529:21 645:11 envision 459:17 466:3 470:1 599:10 envisioned 606:19 enzyme 376:10 enzymes 376:6 epidemiology 446:14 equal 376:22 377:5 378:11,16 equally 502:2,3 equals 574:22 equation 591:14 equipoise 403:11,20 405:2 408:1 535:4	637:4,7 equivalency 538:3 equivalent 507:20 635:17 er 383:16 era 481:7 error 545:8 erta 476:16 506:17 509:14 520:8,10 550:12 ertapenem 408:15 423:19 424:3 449:19 477:21 478:1 490:14 493:13 501:13 518:16 519:1 520:13 522:14,21 522:22 523:1,8 525:7,21 526:1,8 527:8 530:3 531:16 532:3,13 534:4 538:6 539:21 541:17,18,19,22 547:14 548:11 579:12 580:10 668:3 esbl 387:2 398:4 esbls 387:7 549:2,7 especially 389:13 393:9,13 427:4 499:3 565:18 566:14 598:7 603:3 607:15 608:5 espls 475:4 essence 369:2 459:12 593:7 essential 445:6 452:2 essentially 429:4 600:12 607:1 615:19 616:9 617:1 617:8 628:16 633:5 637:10 638:18 658:1 671:14 establish 434:4 established 499:18 499:19 645:22	establishes 396:9 establishing 422:14 estimate 624:14 635:10,18 estimated 430:19 estimates 369:6 378:14 454:22 480:9,11 489:15 624:17 et 521:8 622:21 ethical 433:15 435:7 435:12 436:11,20 519:15,21 ethically 533:18 etiology 441:4 europe 416:1 430:13 446:15 610:17,18,18 624:16 648:1 652:14 656:13 658:16 662:12 663:6,7,13 european 357:21 364:9 444:6 evade 669:2 evaluable 407:10 evaluate 368:18 371:4 442:12 588:17 596:8 664:4 evaluated 374:22 382:18 421:17 438:8 441:12 evaluating 371:16 522:14 523:3 evaluation 435:6 440:16 446:3 event 417:7 457:5,5 events 379:13 469:7 469:10 653:11 everybody 362:3,5 429:22 474:4,21 477:2,22 487:13 491:8,9 493:18 558:11 580:1,9,22 610:14 612:5 618:17 655:11 658:18,21 668:17 671:22 672:14,14	673:1 everybody's 414:19 608:20 669:20 everyday 384:19 387:16 evidence 376:15 386:10,21 406:22 407:22 414:11,16 415:1,7,11,15,18 416:17 417:1 421:6 421:13,14 428:14 439:7 440:15 518:9 519:21 568:21 587:21 590:13 608:3 630:4 640:8 640:10 641:9 642:16 649:12,13 649:19 651:5,10 663:21 exacerbation 432:16,18 exacerbations 432:17 exactly 448:8 458:19 461:13 503:5 565:14 568:10 618:6 624:12 629:4 645:1 651:3 671:3 exam 386:9 example 390:14,19 428:17 431:11 433:7 437:19 441:16,18 442:4 452:20 456:14 498:5 512:17 522:9 530:13 544:16 561:16 600:5 606:1 606:2 624:9 650:1 670:19 examples 390:14 394:17 437:9 448:17 455:8 499:9 631:1 635:2 exceed 575:15 628:7 628:8 exceeded 669:17
---	---	--	---

exception 451:12 458:11 exceptional 455:15 657:12 658:22 659:4 excited 411:16 excluded 464:16 excluding 494:17 exclusion 479:2 581:6 621:13 exclusions 581:18 583:2 exclusively 503:18 504:5 excreted 378:15 excretion 444:21 excuse 502:17 569:21 570:19 executing 556:7 647:21 executive 527:17 exercise 522:8 exhale 573:3 exhaustive 422:6 444:18 exhaustively 489:20 exist 573:21 611:1 existing 428:16 exists 608:1 611:7 expanded 645:14 659:9 660:11 661:20 expanding 644:12 expect 362:10 369:11 414:15 445:4 450:21 460:21 499:3 551:11 555:11 616:19 661:10 668:21 expectations 533:11 669:17 expected 434:11 445:6,9 452:7 641:2 expecting 532:11 expects 439:9 expensive 411:3 489:10 601:17	609:16 610:4 647:12 experience 373:1 380:3 411:13,21 412:1 496:3 499:11 535:18 553:5,13 561:17 589:19 598:22 599:21 636:13 experiences 411:5 418:16 553:6 665:8 experiment 611:1 experimental 445:19 518:13,13 experimentally 438:12 expert 552:11 expertise 390:2 expires 674:19 explain 409:17 411:15 explained 656:12 explains 435:12 explanatory 463:1 explicitly 452:18 explodes 573:7 explore 451:2 670:11 expose 519:16 exposed 442:13 458:14 519:11 exposing 632:6 exposure 373:20 381:13 395:2 438:14 439:19,20 440:6 445:8 458:16 474:3 483:2 484:19 529:16 576:22 577:5 592:21 593:6 626:8,11,13,19 627:2,12 628:4,5,7 628:8,8,14 629:8 633:5,14 634:18,21 635:6,15,16 639:2 639:15 640:7 641:8 641:15 642:8,11 643:8,19 648:11	exposures 438:20 439:19 440:2 529:14 576:4,10 594:3 626:11 627:13 630:17 632:17 633:7,9 638:5 641:5,13 642:4,5 express 669:20 extension 498:5 499:4 extent 449:19 477:13 553:18 638:20 672:11 external 392:4 393:11 398:14 452:2 455:17 577:21 578:7,10 586:17 612:10 613:2,7,21 614:4,13 618:19 619:10,12 620:11 624:8 631:18 634:19 636:4,8 640:10 645:9 646:12,14 647:10 667:18,19 externally 389:3,12 389:17 extinguisher 556:19 611:5,8,11 extinguishers 668:7 extra 550:3 extrapolate 372:21 387:17 395:18 432:22 434:22 601:8 extrapolating 635:17 extreme 624:10 extremely 390:8 504:11,13 513:19 658:17 eye 487:16 eyeball 547:1	fabulous 666:22 face 362:22 408:17 437:3,3 557:17 558:6 653:9 facilitating 356:4 facilities 397:7 420:15 facility 420:16 609:14,20 facing 404:7 fact 374:7 384:7 448:5 474:2 495:15 499:17 500:9 505:21 542:16 543:17 549:11 596:4 597:3 618:10 623:6 666:9 factor 534:6 538:2 568:15 factors 369:14,18 394:9 424:13,14 472:2 589:6 593:12 617:5,18 627:6 630:8 649:3 fail 404:2 486:1 500:18 567:15 failed 530:15 570:5 571:8 failing 383:17 fails 567:14,15 failure 382:12,16 383:10 407:5 409:6 414:6 416:8 567:1 573:17 failures 630:8 635:6 635:8 fair 364:17 372:9 398:1 423:13 438:20 461:17 497:5 591:2 593:9 594:13 595:13 604:16 628:19 629:19 638:21 fairly 362:10 412:19 426:3 440:13 498:6 581:8 618:7 fake 554:2 623:7
		f	
		f 463:12 587:2 626:1 643:18	

fall 486:2 fallow 525:4 falls 466:21 487:13 familiar 399:12 480:3 602:22 644:4 familiarity 627:6 family 384:6,10 fancier 385:13 fantastic 519:7 far 363:20 443:1 488:7 510:10 515:2 564:9 657:8 659:10 farkas 356:21 674:2 674:16 fashion 646:10 fatal 440:21 fatigue 410:10 411:1 favor 416:7 favorable 367:8 474:3 fda 357:6 358:2,17 359:2,16 360:2 364:7,12 365:5 379:16 396:18 400:10 403:4 417:21 449:11 479:6,11,16,21 505:11 521:2 603:15 636:1 650:17 663:9 fda's 480:6,14 508:7 feasibility 407:19 414:14 435:12 436:12 450:4 456:5 457:9 486:18,19 506:2 508:20 519:20,22 feasible 365:19 371:3 407:15 416:15,19 422:19 426:15,22 433:15 434:1 435:7 436:20 452:9 459:5,13 469:22 506:5 512:18 596:3 620:19	feature 497:6 febrile 441:10 federal 433:12 fee 611:6 feedback 461:11 feel 362:19 363:15 412:20 413:3 468:7 478:9 489:13 492:3 499:21 503:2 508:9 511:21 512:3 543:20 546:13 559:4 565:8 584:9 feeling 631:19 654:19 feels 655:11 fell 526:21 fellow 671:18 fellowship 357:9 felt 528:11 569:3 female 438:13 493:21 533:16 534:13 550:15,21 552:20 566:8,11 643:22 644:10 fever 382:11,17 383:18 386:9,17 438:21 440:14 fewer 369:4 571:19 fiber 377:21 fibrinosuppurative 439:7 fibrosis 379:6 432:8 fictitious 496:12 field 399:14 417:4,7 435:3 436:19,19 456:3,11 457:1,4 460:16 561:15 574:10 594:21 608:14 633:11 670:4 figure 367:21 372:13 427:10 446:12 459:12 460:11 482:2 508:19 523:22 532:7 533:1,2,6 550:20 551:2 552:4 552:6 564:17	588:17 589:14 591:11 592:22 594:9 595:4 596:11 607:4 622:8 648:5 655:12 660:8 663:18 668:3 671:3 figured 670:2 figures 505:17 fill 641:14 filled 402:14 filtered 617:22 final 672:19 financial 519:20 financially 674:12 675:9 find 369:5 382:19 395:21 415:5 424:1 430:2 443:4 467:14 471:13 480:20 481:9 482:10 494:16 496:7 516:4 517:17 526:13 547:15 549:12,13 553:11 585:9,13 586:1 600:6 613:11 614:9 618:12 637:7 654:18 660:2 669:18 finding 373:8 findings 428:12 fine 450:1 451:16 625:17 fingers 522:5 fire 556:18 611:5,8 611:10 668:7 first 365:1 372:2 379:21 380:17 382:5 386:16 400:16 406:14 409:2 413:16 416:18 422:8,15 429:20 444:16 463:5 474:13 505:10 518:12 526:6 536:1 561:18 561:22 589:10,10 598:9,13 601:5 626:2 644:22 666:7	666:12 670:13 firsthand 411:21 fish 481:6 662:5 fishing 470:2 660:1 fistfuls 630:3 fit 513:4 589:15 624:16 656:4 fits 489:18 587:2 fitting 657:12 five 373:7 383:12 411:17 431:6 459:5 558:5 560:9 575:12 575:13 632:17 668:2 fixedly 614:1 flank 382:11 383:18 386:9 flashlight 468:10,12 497:20 587:8 flat 571:7 636:18 637:1 638:17 flavor 433:10 flaw 548:2 flawed 484:2 518:1 666:13,16 flaws 548:7 572:20 flexibility 456:7 460:21 flexible 460:17 flip 516:20,21 flipped 596:16 floor 486:10 631:13 flora 367:5,6 374:18 670:8 flow 470:13 478:5 478:15 533:8 flowing 362:11 flu 401:11 fluid 553:20 fluoroquinolones 400:20 fly 608:12,18 668:10 focal 376:8,12 focus 410:4 444:13 561:19 572:14 focused 412:16 518:7 616:2 623:13
---	--	--	---

focusing 366:3 596:5 folks 362:6,13,19 363:3,14 364:16 365:4,12,15 371:13 374:13 379:22 399:12 483:17 540:19 576:20 589:1 606:9 613:12 636:15 639:12 670:6 follow 406:19 446:7 458:1 487:12 649:7 664:20 followed 590:2 following 369:20 425:9 459:2 482:22 551:7 follows 516:2 food 356:13 fool 506:10 forbid 599:5 force 464:18 forced 398:2 forecasts 525:13 foregoing 674:3 form 406:15 512:5 546:22 616:3 631:14 formal 450:22 546:22 551:18 624:12 forming 377:15 forth 530:6 565:22 573:20 598:4 604:8 661:11 fortify 636:2 fortunately 403:8 415:13 forward 368:2 371:11 413:15 422:4 424:18 443:4 446:13 450:3 452:8 462:21 488:8 538:10 584:2 670:4 672:8 673:1 fosfomycin 398:4	found 481:12 483:15 516:5 518:4 565:5 590:12 foundation 387:15 667:6 four 373:7 376:11 386:16 411:17 422:2 429:9 441:5 443:18 451:6 453:5 491:1 537:21 545:11 582:18 586:18 601:4 659:3 fourth 667:15 fragile 504:12 577:15 frame 622:21 framework 405:5 france 597:17 frankly 445:17 620:9 free 362:11 363:15 377:19 475:13 478:9 503:2 519:8 frequency 377:7 405:22 423:10 431:5,12,22 613:15 frequent 624:21 625:14 frequentist 510:18 512:8 frequently 419:8 freshmen 512:9 friedland 358:13 428:17 522:4,7 525:22 526:5,16,19 527:3 547:6,10 584:6 586:5,14 588:2 front 363:3 557:17 580:19,22 fruition 604:18 full 434:4 455:16 468:18,20 469:13 490:9 497:11 538:12 646:20 650:18 655:20 657:17 658:10 662:18	fully 448:2 453:1 455:17 532:11 621:16 622:5 667:8 function 439:2 fundamentals 410:14 funded 411:12 funding 414:18 647:12 funga 367:9 645:4 646:21 fungiscope 644:17 645:2 646:10 fungus 644:17 further 368:15,21 408:12 463:10 464:8 466:1 535:5 557:4 566:3 635:21 649:21 650:16 661:16 664:20,20 665:11,12 674:10 fussing 467:22 future 401:21 521:13 529:6 655:5 668:22	generate 390:22 403:4 406:22 414:11 415:16 416:17 535:10,11 536:6 660:9 generated 390:4 generating 388:9 507:14 602:15 621:2 generation 659:10 gentleman 533:13 george 462:22 486:20 getting 412:2 453:18 462:2 485:18 497:16 510:13 511:20 520:7 523:15 526:12 550:18 573:10 591:7 596:7 599:20 604:3,17 608:8 612:16 619:4 630:21 633:13 639:1,14 656:8,8 659:8 669:9 gi 367:5 670:8 give 381:21 389:8 400:7 433:9 444:7 473:14,17 475:19 477:1,18,18 484:14 508:3 519:17 528:1 548:13 556:1 565:9 574:2 581:10 586:10 590:9 603:15 612:21 621:22 637:15 640:7,10 652:9 660:3,15 given 379:7 430:16 434:1 472:16 473:15 476:19,20 476:20 477:16,20 498:7 510:22 513:20 528:15 557:19 591:1 612:22 656:10 669:1
g			
g 362:1 gain 362:18 393:4 598:22 game 369:3 gaps 408:9 gas 437:17 gather 460:13 552:8 607:3 655:5 660:19 664:14 gathered 663:7 gathering 590:15 gender 395:16 genentech 652:3 general 405:11 445:14 461:5 534:11 547:20 607:15 608:10 609:13,14,17 632:15 generally 434:15 439:21 593:5			

gives 371:11 582:10	610:10,14 623:6,11	558:10 559:7 560:9	537:14 542:22
glad 362:6	going 366:6 388:11	560:12,13,22 561:3	543:3 546:13
glaxosmithkline	388:14 393:16	562:17 565:9	547:18 550:3
359:13 411:7,7	398:1 400:4 401:22	566:21,22 569:10	555:17 562:8 563:3
global 357:13	404:15 405:9,17	569:12 570:20	576:5 577:4 586:1
358:10 377:1	407:16 408:6,8	571:11,13 576:21	589:11 591:19
globally 580:6	409:13,16 411:2,16	577:19,20 580:17	601:18 603:2
glucose 540:16	412:15 413:17,18	581:5,17,22 582:5	605:21 614:12
go 362:6 365:10	414:19,20,20,22,22	585:9,21 586:7,9,10	617:15 622:12,16
371:9,17 389:19,22	416:11 418:8 423:9	587:3 588:6,19	623:12 627:10
401:1 402:1 409:21	423:13 429:21	589:12 593:6,15,19	635:10 641:16,19
410:12 414:18	431:6 432:14,15,16	596:22 597:7 598:4	645:13 657:20
422:7 423:4 424:14	436:16 437:22	600:22 601:9,11,14	665:13 669:17
425:11,12,14 426:9	443:15 447:6 453:6	601:15,16 603:16	goodness 571:12
426:13 428:21	454:21 463:5,12,17	607:4,19 612:4	goofy 642:22
430:20,21 431:10	463:18,19 464:8,19	613:11,12 621:6	gosh 489:9
433:6,8 446:22	465:17 466:1,13,17	624:1,13 625:21	gotten 385:18 398:5
447:1,19 448:6,16	467:2,9,13 470:19	628:12 629:4	585:20
454:1,19 456:18	471:5,12 473:4,8,12	632:10,13,16 633:3	government 465:12
463:18 464:8	474:11,11 475:3,20	636:12,15,17,17	650:14
466:21 477:6 480:7	476:10 478:18	637:3 638:5,10,15	gracious 571:12
480:20 481:2,6	479:15 480:15,17	638:20 639:10,19	gram 365:19 375:21
482:16 488:8	480:19 481:1 482:9	640:4,7,15 641:4	375:22 377:11,12
489:22 493:1	482:12 483:3,4	642:14,17 644:14	377:16 382:20
503:11 506:12,16	484:3 485:4,16	644:20 645:16	400:18 401:9 402:5
514:6 517:18,19	486:1,2 487:4,7	654:6 658:19 659:8	402:7 423:16 472:3
525:2 529:6,19,22	490:10 491:9 493:8	662:15 663:5,20	476:4,8 478:9
533:9 536:1 538:16	493:18 496:15,16	665:20,21 666:9,22	506:17 639:21,22
538:16 540:15	498:2,18 499:8,8	667:2,2 668:8,10	670:21
543:4,13 544:12	501:15 502:10	669:17 672:15	grams 476:2
550:22 557:7,13	503:1,10,21 504:21	good 362:2 372:3	graph 481:10
558:20 559:13	504:21 505:2 506:6	375:15 381:12	grateful 666:11
570:19 573:2,15	507:4,5,13 508:19	389:20 390:1 397:1	grave 538:6
579:2,8,16 583:3	511:9,11 512:15,18	398:5 403:13	gray 655:17
597:1,12,22 598:4	513:1 516:10,10,11	404:22 407:14	great 356:15 364:15
601:14,19 602:1	516:12 517:14	408:14,15 410:8,12	379:18 384:18
611:15 613:11	518:20 519:9	410:13,18 412:19	391:4 403:9 404:1
618:11 626:1 629:7	520:16 521:22	418:20 431:16	425:2 453:22 454:5
646:17 659:22	522:7,15 529:6	448:13,22 449:12	460:6 471:1 475:20
660:5 662:5,10	532:15,16 533:9,10	449:17 450:3 455:3	487:9 499:2 518:7
667:17	534:3 535:15,19	469:20 470:17	528:11 543:2
goal 365:17 445:21	537:15 538:17	472:18 489:12,13	564:12 590:13
464:14 670:16	539:8,13,18 540:1	490:12,14,16,20	594:21 627:15
god 599:5 610:12	540:14,21 541:1	492:7 498:15,19	637:3 667:20
goes 407:12 434:6	543:21 545:18	501:4 503:9 505:19	greater 369:6
492:22 493:17	551:10 553:14,17	512:22 514:9	370:15 376:20
539:22 541:2	554:3,7,16,20 555:2	515:10 520:3	378:11,16 379:11
558:15 588:9	556:13,20 557:6,12	521:15 527:7 529:7	379:12 387:1

422:20 429:9 431:3 460:5 551:10,21 633:6,6 642:21 greatly 380:5 green 438:1 606:2 grew 382:20 383:14 478:16 497:14 gross 438:17 group 358:11 411:14 422:2 430:14,20 451:7 483:13 489:15 499:4,12 500:5,6 503:14 580:12 582:3,10,14 583:1 585:4 586:22 613:20 614:21 616:8,11 617:9 632:8 634:20 642:4 646:15 654:12 672:7 groups 396:1 544:9 612:21 632:4 637:8 642:2,3 647:6 grow 471:8,10 growing 491:20 grown 613:12 grows 383:19 387:1 491:16 gsk 647:18 guarantee 577:8 611:6 guess 406:18 418:1 513:21 521:13 540:6,21 541:1 550:16 561:14 585:12 612:6 635:21 659:7 660:21 663:3 guessing 496:22 guidance 373:21 403:3 426:7 434:6 448:18 515:1 517:20 527:20 628:6 guide 517:19 guidelines 383:13 386:6 408:18 424:9	471:16,19 473:12 492:22 529:2 gut 367:9 516:11 517:15 guy 470:6 guys 463:13 517:22 609:14 623:19 664:17 gymnastics 515:18 gyrates 572:6 h h 401:11 habp 365:21 409:20 410:4 423:17,22 424:3,17 425:2,8 427:14,16 430:1 431:20 432:20 499:4 500:4,14 502:12,13 526:1,7 531:5 544:1 554:5 557:15,19 559:14 560:1 561:1 562:1 572:3 576:8 641:6 667:8 670:22 haircut 486:15 half 378:20 426:12 483:13 485:20 487:15 488:19,20 492:6 503:7 514:13 559:4 610:9 632:18 hampshire 356:15 hand 433:21 482:3 485:16 497:8 509:21 525:1 533:14,15 548:19 672:4 handed 502:1 handle 663:19 handled 449:10 501:20 handout 453:7,7 463:2 466:15 470:4 479:16 482:1 496:18 507:16 handouts 481:11 hands 407:8 514:3,6 599:15 611:15	hang 558:11 hap 448:20 450:18 472:8 happen 370:8 387:11 397:1 496:19 563:16 615:10 637:7 642:4 642:6 651:21 happened 497:10 559:11 569:20 616:13 happening 387:11 568:7 599:15 600:2 622:2 happens 425:4 486:2 491:17 518:15,19 614:18 617:14 639:2 653:5 660:22 663:13 happy 489:16 496:17 512:18 536:2 611:13 hard 410:11 424:15 466:3 494:16,22 539:3 540:7 548:6 552:5 569:18,19 600:6 601:17 611:18 612:8 617:12,17 623:16 638:12,16 648:18 661:21 663:20 harder 494:19 496:8,10 549:10 612:5 hardware 412:21,22 413:1 harken 380:21 harkening 390:15 395:3 hat 659:20 hate 418:1 hat's 518:3 haven't 512:6 havoc 374:17 hazard 608:21 hbap 519:2 he'll 375:3,7	head 357:20 358:10 358:20 444:6 456:15 549:21 551:22 health 357:13,17 359:10 460:19 healthcare 420:15 healthy 378:4,14,20 386:14 438:12 454:22 647:1 hear 365:3 379:21 416:11 558:12 592:10 600:2 heard 392:7 393:10 409:18 419:18 431:19 435:3 445:14 469:4 516:1 517:19 541:9 542:4 578:9 619:5 642:15 647:8 648:8 heartbreaking 655:2 heavens 599:9 heavily 583:21 heck 623:9 held 453:10 helen 357:8 361:5 364:2 379:22,22 380:1,11 399:10 410:11 433:4 457:21 461:1 474:8 498:22 500:14 502:5,9 563:17 592:4 598:3 600:10 611:1 644:21 646:8 647:17 654:22 659:14 helen's 502:21 503:5 help 368:1 381:5 390:7 393:14 395:17 396:3,6 402:18 409:13 412:15 419:19 423:8 427:15 437:16 451:8 457:18 459:10 460:13 470:19
--	---	--	---

499:21 508:21 528:19 552:3,11 553:21 559:16 584:8 606:19 607:17 612:19 613:9 622:13,14 648:22 650:15 661:10 665:12 668:3 672:4 helped 669:8 670:3 helpful 374:1 390:6 390:8 514:18 549:15 568:19 587:18 592:13 600:10 608:22 616:3 619:17 629:18 helpfully 470:3 helping 396:21 553:9 helps 423:8 471:6 606:17 615:8 648:15 672:14 hematologic 376:4 376:14 421:2 616:8 hemorrhagic 439:7 440:19 hepatic 376:3,5 378:5 421:3 445:2 hepatitis 651:18 hepatocellular 376:8,12 hereto 674:12 here's 476:13 484:22 496:22 497:8 510:3 hesitate 587:16 heterogeneity 485:10 562:2 heterogeneous 612:19 hey 590:16 he's 522:6 hi 363:22 625:20 hide 491:21 hierarchy 450:12 451:18	high 375:4 376:7,8 377:4 386:9,17 388:8 389:16 398:18 416:4 420:22 422:11 432:1 446:17 448:8 472:9,13,15,19 498:7 500:22 506:3 511:4 534:7 540:6 550:2 554:13 565:16 571:3 573:16,16 577:16 579:22 597:20 601:15 613:15 633:8 higher 409:4,6 426:10 430:12,12 432:6 468:19 470:19 482:6 492:17 500:22 536:11 560:4 625:9 638:6 highest 392:11 highlight 397:20 459:16 557:5 highlighted 398:7 414:14 416:14 423:11 451:21 highlights 421:19 highly 440:20 496:9 536:20 537:6 hillin 486:9 513:18 555:19 556:1 563:7 563:11,22 564:11 649:10 652:2,13 654:10 hinges 422:8 hint 492:4 hinting 596:3 hired 576:5 661:4 historic 617:10 historical 452:3 455:18 578:12 581:1 583:9,11 586:17 614:14 615:3,17 617:11,15 618:8 619:2 620:8 620:11 646:19	667:19 historically 389:12 580:17 history 382:12 399:14 647:5,22 648:4 hit 576:4 hits 486:4 hitting 475:16 626:8 626:10 630:17 hiv 358:21 651:18 hold 543:1 holding 509:21 hole 548:14 566:6 holes 491:1 506:7 hollow 377:21 home 382:8 386:13 672:22 homework 405:14 honestly 612:1,2 honor 380:13 hood 480:5 hoofman 505:6,7 509:3 hope 367:11,15 368:3 374:16 384:13 388:2 391:21 395:9 397:1 398:10 402:9 418:6 453:9 505:21 506:8 619:17 641:13 648:2 665:10,13 hopefully 364:18 395:14 398:19 399:3 401:9 532:20 535:15 hoping 605:18 hopkins 359:9 hospice 384:11 659:16 hospital 368:11 382:9 383:6 387:5 409:3 419:11 593:14 601:2 618:3 661:1 hospitalized 429:4 hospitals 385:16 397:7 412:10	597:17 601:2,3 607:20 host 402:18 hour 378:10 477:18 477:20 590:3 hours 373:3 378:11 378:21 439:5,5 446:4 478:20 540:22 541:2 586:11 661:6 howdy 586:2 hsn 461:5 huge 391:7 403:6 460:2 519:15 566:13 570:2 577:12 592:5 601:9 huh 550:6 human 369:3 372:14 373:9,13,20 374:4 394:6 419:22 433:14,19 438:9 439:12,15 458:10 458:16 462:3 574:5 574:7 603:10 604:6 611:21 627:16,18 628:5,8 649:17 humanized 441:14 humans 371:6,22 372:16,21 379:2 434:12,14,19,20 438:11 439:14,18 439:20 440:5,9,11 440:17,20,22 441:2 457:13 458:14 605:19 humbled 671:19 hundred 624:5 hurdles 452:6 hurt 666:17 hyper 643:2 hypothesis 577:20 hypothetical 375:16 454:6 485:17 570:2 582:22 hypothetically 517:3 hystopath 439:6
--	---	--	--

i	471:19 492:22 529:2 595:6	important 366:11 367:6 374:19 380:14 389:9,19 392:13 393:19 394:16 397:4 398:8 398:18 399:22 413:20 415:5,17,21 418:3 446:21 450:9 451:2,6 456:13 471:15 474:5 475:3 495:10 508:17,18 521:4 539:10 548:17 568:12 575:3 594:18,20 595:19 602:21,22 622:1 656:21 658:12,14 666:15 668:20 670:5,10 671:9	506:12 incident 437:17 include 389:3 390:7 392:10 396:1,16 432:7 435:11 450:13,18 458:19 458:21 460:18,20 650:10 included 442:8 452:21 458:17 461:4 533:20 including 375:22 384:2 395:12 402:15 415:6 444:19 451:21 475:13 476:9 595:8 598:18 658:18 666:13 inclusion 398:17 478:12 581:6,18 583:1 621:13 incorporating 648:6 incorrectly 511:16 578:14 increase 376:6 489:1 increased 383:16 438:22 increases 490:2 increasing 414:6 590:3 incredibly 481:1 ind 655:22 index 377:18,21 441:3 566:15 indicate 423:21 indicated 396:17 475:6 530:21 indication 387:18 389:8 390:17 406:7 423:22 426:19 436:14 442:6 452:12 552:17 558:6 573:9 575:2 577:14 664:16,20 665:16,20 indications 427:9 428:1 436:7 442:8
iai 409:19 536:3 537:8,12 547:7 ian 358:13 520:14 522:3 530:1 547:5 572:20 584:6 ian's 524:2 iche 617:7 icu 444:22 454:15 538:7 589:8 590:6 590:21 593:11 599:6 600:13 icus 472:3 494:22 idea 453:12 455:4 483:12 493:11 499:6 507:19 511:10 525:3,6 544:21 571:13 576:7 583:8 587:1 594:21 612:9 613:2 613:19 619:6 620:11 621:9 628:13 636:21 655:16,17 662:11 662:18 666:8 ideal 621:10 ideally 395:20 587:14 604:4 636:18 ideas 362:13 367:2 371:12 402:14 453:9 549:9 587:4 666:10 669:21 identical 543:18 identifiable 496:8 identified 376:4 382:21 383:20 421:2 597:20 identify 368:17 420:8 424:11 432:13 494:3 569:4 589:6 identifying 366:12 400:14 432:21 idp 489:9 idsa 380:17 384:18 396:20 399:7	ignorance 464:18 ignoring 537:19 iii 660:16 illness 392:14 395:16 447:16,21 653:17 illustrate 500:15 562:6 illustrates 406:17 407:3 illustration 405:4 406:12 513:20 imaginary 464:16 470:22 485:1 imagine 409:22 413:5 494:20 552:9 558:3 600:6 613:11 649:2 667:8 imbalance 568:15 imbalances 563:13 564:2 imi 647:6,17,20 immunochromato... 470:13 immunotherapies 527:21 immunotherapy 527:19 impact 394:10 420:4 421:14 428:20 503:16 508:20 592:8 593:20 617:5,18 impairment 378:5 378:18 421:18 445:2 impede 413:7 implementation 476:15 implication 540:1 implicit 465:22 493:3 509:14 implicitly 490:17 importance 421:20 591:2 630:21 631:2 631:8	importantly 381:16 394:9 560:17 660:9 impose 435:9 imposed 657:22 impressed 589:18 impressive 431:15 improve 417:14 658:5 improved 412:9 461:4 improvement 431:14 501:3 improves 456:21 inactive 475:5 inadequate 583:11 inaudible 444:19 464:10 488:12 490:7,15 491:2,5,11 492:9 494:10 511:17 513:14 526:11 532:8 549:18 550:5,7 553:1 564:5 586:4 638:6 652:8,11,19 658:1 incentives 668:6 incidence 426:20 429:12,18 460:9 489:1 505:16	

446:19 451:21 474:12 554:4,17 664:22 indicative 603:10 individual 387:9 396:1 439:22 546:1 563:18 587:20 599:19 individuals 499:7 561:4 industry 365:4 379:16 380:3 391:8 399:17 400:3 405:7 407:7 526:7 inefficient 541:13 infeasible 416:16 infected 412:12 535:14 592:16 infection 359:22 366:9 372:3 373:4 377:13,22 382:20 383:10 384:13,17 385:1 386:10,12,22 386:22 387:15,19 390:18,22 391:1 392:1,13,16,21 393:2 394:12 398:9 402:1 408:4 409:2 416:22 421:7 422:12 423:10 426:20 428:10 443:20 448:20 450:19 451:22 452:14 481:5,5 500:5,7 516:4,13,18 517:5,6,8 518:11 536:12 539:1 579:14 593:20 616:6 636:16 infections 365:18,21 372:18 377:15 387:10,14 388:3 389:14,15 393:13 396:2 398:4,6,18,22 401:3,13 409:1 419:7,10,13 420:2 427:6,7,19 432:6 435:19 462:11	481:13 516:17 517:1 536:10 547:11 551:7 580:8 587:19 589:20 595:17 597:18 599:1 637:16 645:4 670:20,21 infectious 357:8 358:10 364:2,5,14 380:1 387:12 399:14,15 437:12 437:15 440:4 458:12 615:13 infective 359:2,16 364:12 375:7 418:13 infectives 357:20 444:7 650:13 652:14 inferential 388:15 390:20 409:9 413:22 450:22 568:18 575:17 583:19 597:4 inferior 501:5,6 518:16 inferiority 391:20 398:13 403:14,16 408:3 414:1 415:3,9 422:9,21 423:7 426:1,5,13,17 427:12 449:2 463:6 474:18 500:19 512:15 514:11 521:2 526:19,22 540:9,11 546:2 557:22 572:11 575:16 577:14,17 584:4 623:14,15,17 infiltrates 439:6 440:17 infiltration 376:7 inflated 378:15 454:22 487:6 inform 396:3 informal 464:1 information 370:22 374:7,11 375:10	380:9 381:21 395:12,16 398:21 415:6 418:14,15 434:17 435:11 441:17,22 455:4 456:21 474:1 498:14 512:4 519:19 534:3 537:2 537:4 544:9 552:2,8 553:17 555:1,11 592:2 596:21 634:16 636:3 658:17 informational 574:11 informative 436:1 616:15 informed 632:6 infrequent 369:1 infrequently 365:20 419:5 443:7,8 522:1 infusion 378:10 inhalational 437:14 inhale 573:2 inhaled 383:3 398:3 inherent 563:13 inherently 370:15 473:12 inhibitor 404:8 initial 530:16 591:2 664:16,19 initially 447:18 449:16 451:12 534:7 536:12 581:11 656:19 initiate 413:12 536:2 initiated 648:3 initiating 420:4 injectable 375:19 609:3 610:12 innovation 358:11 inoculum 372:18 440:4 604:11 input 365:12 422:4 inside 489:18 508:7 508:8 513:4 547:3,4 570:2	insight 463:14 524:3 565:10 insights 572:8 589:2 589:16 606:18 622:1 instance 589:12 instances 420:7 instant 464:21 465:1 institute 357:3 institution 589:4 590:6 591:5 592:15 593:1 622:21 660:22 institutional 424:12 institutions 618:20 621:14,22 instructive 384:16 integrate 556:11 integrated 496:19 intensity 394:5 intensive 393:5 intents 475:5 496:1 inter 390:18 394:11 572:21 interact 402:4 interaction 378:7 395:17 444:20 522:20 603:14 604:8 interactions 378:22 intercept 635:16 636:6,7 interest 363:1 365:14 369:1 391:15 394:3 470:15 471:4 555:17 573:19 625:16 647:15 interested 362:12 363:3 366:22 374:14 441:20 540:10 561:15 592:3 603:8,8 674:12 675:9 interesting 393:2 401:22 406:1 479:14 514:15
---	--	---	---

525:18 536:18 538:11 589:1 608:19 internal 364:13 519:15 international 357:15 interpret 388:10 interpretation 452:6 538:3 interpreting 620:13 interval 377:20 469:8 482:20 507:21 508:6 510:2 510:3 558:16 565:13 intervals 467:6,17 507:22 508:16 590:3 intervene 372:22 373:2 intervention 370:4 438:3,8 440:22 441:9 interventions 373:19 intra 365:22 450:18 466:19 474:16 475:7 476:17 478:13 479:7,18,22 480:22,22 482:10 484:4 485:8,13,20 487:17,21 488:19 495:21 496:9 515:16 516:2,3 524:1,2 528:14 531:10 535:20 547:20 554:5 559:15 570:6 572:19 intracellular 402:7 intravenous 387:6 442:16 intravenously 441:13 intrinsically 372:17 649:17	introduce 601:20 introduced 602:2 introducing 447:5 introduction 365:2 introductions 363:19 introductory 418:21 intuitively 542:17 545:10 546:11 invalidates 436:22 456:5 invariable 615:15 invasive 616:1,4 invent 454:6 470:18 483:11 571:12 invented 470:6 478:4 485:1 490:22 495:9 509:6 inverted 514:12 invest 411:18 459:20 590:16 investigation 473:4 investigational 460:22 534:5 investigator 410:10 investigators 390:6 409:14 425:3 449:22 579:13,15 662:7 investing 511:10 investor 411:1 555:21,21 556:3,12 567:10 569:6,7 571:10 investor's 541:8 investors 459:19 541:11 invitation 399:8 inviting 380:13 399:21 involved 380:17 481:4 515:18 659:13 involves 457:17 irb 536:4 irrelevant 449:14	isavuconazole 615:22 620:5 644:7 644:16 ish 569:2 587:6 isn't 482:4 489:6 518:21 519:1 533:17 isolate 450:14 477:5 532:22 596:10 isolated 439:15 527:22 isolates 376:22 377:4 417:12 429:6 472:4 535:14 isolating 531:20 issue 362:20 365:7 424:4,20 427:1 428:20 436:11 437:5 456:17 457:7 457:9 477:1 495:3 504:9 506:1 514:11 519:5,6,21 531:13 539:8 547:20 558:1 560:8 567:3 571:18 582:5 586:20 641:22 652:22 653:17,20 663:6 issues 374:1 407:20 423:14 432:19 437:7 456:9 467:7 487:6 519:8,12 562:3 584:4 604:14 608:15 621:4 628:10 665:19 it'll 375:10 415:16 415:16 601:10 italy 481:14 itt 471:3 537:19 538:2,12 539:6,7,13 595:18 itty 517:8 it'll 525:14 it's 476:14,18,21 477:5 479:7,8,11,11 479:19,19 481:2,2,3 481:11 482:2,5,8,15 484:6 485:22 486:20,20 487:15	487:20,20 488:1 489:7 490:2,16,20 491:12,20,22 492:11 493:6,6 495:10,19 496:8 497:6,18,20 498:7 498:11,11 502:17 504:5 506:6,7,14 507:15,18 508:6,8 508:19 510:10 511:13,13 512:5,10 512:18 513:6,7,8,11 513:19 515:10 518:7 519:20 520:6 520:9,20 521:22 523:7 524:4 525:7,9 525:11,12,17 528:8 529:9,15,15,16 530:21 531:16 532:14,16 533:1 534:2 535:6,8 537:7 537:10,18 538:20 539:18 540:3,4,5,15 iv 378:10 383:2,2,5 386:12 398:3 i'd 484:19 490:17 527:18 529:22 535:4 i'll 480:20,21,21 482:10 514:13 i'm 422:3 480:15,19 481:1 482:9,12 483:4 484:20 485:18,18 486:9 488:18,22 489:16 492:11 493:16 494:11 496:22 503:10 504:9 505:7 507:13 513:22 516:10,10,11,12 517:7,9,14 519:13 520:16 524:15 530:8 531:8,14 532:18 535:7 i've 478:14 484:12 484:14 485:17 486:13,18 489:8,15 506:17,18 507:21
---	---	---	--

517:3,4	judgments 388:13	513:10 516:5 529:3	420:11 423:4
j	july 356:9	536:4 540:19 544:5	429:22 430:6,8,22
jack 619:18	justifications 452:7	545:13 556:13,18	431:8 432:8 433:17
january 383:8	justified 381:3	563:13 565:17	435:22 437:16,19
jeff 502:8 520:4,14	k	566:5 571:1 572:10	437:19,20 439:12
jenkins 358:16	kaplan 482:4	573:10 579:3 580:6	442:21,22 443:1
jesus 647:18	kartsonis 358:19	583:13 590:15	446:15 447:12
jezek 399:7	karynn 675:3,14	592:3 596:20 599:6	454:4,5,8,9,11
jittered 495:16	keep 398:8 477:8	599:17,22 602:12	455:2,5,12 456:8
jmi 429:1	503:6 520:5,6	606:2 607:13,17	458:20,22 459:3,5,7
job 405:15 487:9	557:12 604:19	608:12,13 610:2,3	459:8,11,16 460:9
614:9	keeping 455:20	613:14 623:8,12	460:12,17,20 461:4
joe 359:4	542:11 644:21	635:16 636:11	461:8,11,12,17,17
john 358:16 359:18	keeps 374:18	645:10,19 659:8	461:18,19,20,21
359:21 360:4 361:6	kenneth 486:9	666:5	462:1,6,7,10,11,11
361:9 363:21 364:4	513:17 555:18	kinds 393:17 421:22	462:13,16,16 463:7
364:13 365:10	563:6 565:7 649:6,9	479:13	464:3 465:10,14,18
399:11,12,16,19	651:12 665:7	kinetics 434:18	466:7,8 467:21
405:6 406:15	kept 466:12 497:13	kit 478:15 661:3	468:8,11,22 469:11
418:11 420:19	545:14	klebsiella 382:22	469:12,21 470:9,22
423:20 425:15	kert 360:7 624:3	383:14,19 387:2	472:7,20 473:21
433:4 435:4 455:6	key 390:22 441:5	479:3 481:15	474:1,2,4,21 475:22
466:9 488:10	kg 632:16,17,18,21	598:17	476:5,12 477:3,11
497:21 500:13	633:18	klebsiellas 532:12	477:19 478:1,3,11
502:9,11,21 503:12	kidding 526:4	km 482:5	478:17 479:12,18
505:11 508:10	kidney 384:22	knew 599:7 660:6	480:15 482:9,15
512:11 513:18	385:18 386:12,22	knock 503:2 549:8	483:15,18 485:3
514:19 535:2 543:4	kids 384:2	know 362:20 363:19	486:20,20,22 487:2
545:21 550:15	killing 377:19 629:7	364:16,21 365:13	487:14,15,16,18
566:14,17 567:12	629:11 652:5	365:14 366:14,18	488:1,4 489:7,14,20
569:5 571:15	kim 359:1 361:4	367:2,5,7,13,14,20	490:2,12,18 491:7
575:22 588:14	365:2 375:2,3,14	367:21 368:6,8,9,10	491:13,20,22 492:1
592:14 594:2	405:14	368:16,18 369:2,7,7	492:6,6 493:1,7,8
596:16 598:6	kind 385:17,19,22	369:14,14,15,16,17	493:14,16 494:5,13
601:14 605:1	387:21 390:21	369:19,19,20 370:1	494:17 495:18,18
608:17 612:7	391:3 393:1 394:13	370:3,6,14,18,19,21	495:22 496:6,8
624:13 627:22	397:16 405:5 407:3	370:22 371:5,20	497:3,8,9,15,19
632:9 636:15	437:5 445:12,20	372:2,15,19 373:1,2	498:13,18 499:20
639:10 645:16	446:22 447:3 455:2	373:3,12,15 374:7	500:10 501:16,20
659:6 661:20	455:21 456:5	374:12,13,14 375:5	503:6,7,13,18,22
668:16 672:19	461:10 463:3,8	379:22 381:6	505:13,14,20 506:2
johns 359:9	464:20 465:10	385:14 388:5 389:6	506:6,8,11,18,19
joined 668:17	467:22 468:11	390:4 391:11	507:6,18 509:7,12
joining 399:18	470:18 474:17	397:14 398:16	510:9 512:5,9,12
joking 468:8	477:11 482:15	400:2 404:19 407:4	514:17,18,21 515:1
jotted 643:20	484:8 494:16,19	409:11 410:13	515:3,4,5,12,13,13
	509:18 511:2	412:5,18 414:21	517:16,20,21 518:1
		415:2,13,20 416:5	518:3 519:13 520:5

520:11,12,13 522:1 522:17,19 523:13 523:14,19,20,22 524:11,14 525:20 525:20 526:14,16 527:13,14 529:2,4,5 529:12,14 530:10 531:8,10,19,21,21 532:14,16,18 533:1 533:4 534:5,6,15,22 535:10 536:10,11 537:3,14 538:1,11 538:18,21 539:1,8 539:11,13,15,15,17 539:20,22 541:9,9 541:17 542:10 543:12,20 544:7,17 545:6 546:10,11,15 547:3,17 548:2,16 549:3,13,22 550:4 550:13 551:3,5,6,9 551:13,17 552:2,5,7 552:18 553:3,4,6,6 553:8,12,15,16,19 553:21 554:4,14,19 554:20,22 555:2,4,5 555:8,10,10 557:3 557:18 558:5,8 559:22 561:18 562:4,5 564:8,22,22 565:1,3,7,7,13,21 566:1,4 567:9,11,12 567:13,14,17,18,21 568:18 569:12,14 570:8,10,11 571:3,5 571:10,13 572:10 572:21,21 573:5 574:3,5 576:5,11 577:6,7 580:20 582:5 584:9 587:14 587:19,19 588:13 588:16,20 589:2,4,7 589:8,9,11,12 590:5 592:16,17,18 593:2 593:3,5,10,14,19 594:2,5,9,10 595:4 595:14,14,16,21 596:1 597:15 598:2	598:10,11 599:8,13 599:17,19,22 602:18 604:13,22 605:2,21,22 606:11 606:12,14,14,14,19 606:20,21,22 607:2 607:5,8,11,13,18 608:14,19 609:21 610:1,6,7,8,11 611:3,9,11,12,18 612:6 613:13,18,21 614:15,16,18,20 615:1,3,4,5,8,10,14 615:15,16,16,19 616:3,4,11,16,16,17 616:20 617:1,1,3,4 617:5,8,15 618:5,8 618:11,13,16,17,19 619:2,13,16,22 620:6,13,22 621:7,8 621:12,12,16,20 622:1,3,7,8,9,13,17 623:5 624:3 625:1,8 625:9 626:5,12,20 627:1,6,10,11,22 628:1,4,7 629:3,6,6 629:15,19 630:8,11 630:18,20,20,22 631:4,8 632:18 633:20 634:3,3,16 636:14,15,16,21 637:3,6,9 638:12,18 639:2,14,19,22 641:2 642:1,5,7 643:2 646:16,20 647:3,4,14 648:3,10 648:12,12,19 650:5 650:10 651:3,3,9,14 651:17,17,19,20 653:6,10,15,18,21 653:22 654:2,2,4,4 654:8 655:11,17,17 655:19,22 656:1,2,6 657:1,20 659:13 661:13,14,21 663:11,13,14,17,21 663:22 664:1,3,3,4 664:7,8,15,16,17,19	665:2,5,7,8,10,11 665:14,17,18 666:18 667:20,21 668:18,18 669:1,10 669:13,21,22 670:5 670:6,8,10,12,14,14 670:15,18,19 671:1 671:2,4,10,11,16 672:2,2,6,7,9,12 672:12,14 knowing 541:22 626:12 641:4 knowledge 465:1 510:6 674:7 known 455:2 472:11 599:1 knows 524:9 565:13 kpc 481:14 kpcs 415:22 481:8 kumar 590:1 l lab 438:6 479:5 label 395:11 415:6 429:9 458:3,6,9 474:19,19 484:11 484:13,15 496:2 497:6,7 498:4 499:4 502:22 524:10,11 530:20 550:18 554:3,7,11 557:19 580:13,14,15,16 612:10 613:17 650:4,21 660:18,22 labeled 470:4 524:4 labeling 396:17 435:11 458:18 530:9 531:3 539:22 588:10 labels 458:12 667:18 laboratory 438:16 439:1 labs 429:1 lack 481:8 538:8 560:20 620:10 647:11	lady 382:5 384:5,11 386:2 533:12 598:16 laid 638:2 large 391:6 426:3 448:6 511:6 574:1 595:18 616:18 627:21 largely 599:14 larger 409:7 507:17 623:5 largest 480:1,3 larsen 359:4 laryngeal 382:6 lasagna 506:13 lasagna's 506:14 lastly 420:14 435:11 late 383:8 lateral 470:13 478:15 laughter 464:6 520:22 614:7,10 law 506:14 lay 420:3 layers 411:9 ld50 440:3 442:14 lead 409:6 412:8 471:16 656:15 leader 358:10 leads 402:19 410:10 665:20 lean 443:17 leaps 469:12 learn 373:14 381:8 389:17 405:19 490:14 499:13,15 531:22 589:20 595:19 638:13 647:3 learned 512:8 666:4 666:12,21 667:15 learning 636:3 647:4 leave 381:11 392:9 490:13 658:20 left 384:4,12 391:13 393:21 394:2,19 401:18 408:13
---	---	--	--

495:22 501:8,9,15 502:1 560:3 562:21 570:1 632:11 647:18 665:7 legislation 396:14 396:22 657:16 leon 505:7 lesser 536:12 lethal 594:5 lethargy 438:22 440:14 let's 477:12,12 487:7 492:18 497:4 498:19 501:7 510:4 510:21 517:5 524:21 540:15 leukocytosis 439:1 440:15 level 375:4 421:9 449:3 469:6 497:17 511:13 618:1 626:6 626:14 627:2 levels 499:19 512:13 528:18 540:16 553:19 581:11 651:2 levofloxacin 383:12 441:17 442:4,7,16 442:18 605:10,10 liberty 447:4 license 402:12 lie 525:3 life 378:20 387:16 433:18 579:16 life's 623:12 light 452:5 455:12 455:13 518:9 lights 369:21,22 614:17,17 617:13 617:14 liked 572:19 likelihood 421:1 429:14 510:15,18 511:4,14 513:10 520:1,2 535:13 619:1 637:2 638:19 likelihoods 512:13	likewise 523:1 limitation 445:7 450:10 452:18 limitations 443:14 639:20 640:4 664:5 limited 375:20 382:1 384:7 388:14 396:9,10,13,18 398:2,6 399:2 446:19 452:15 459:18 474:20 484:12 534:2 535:8 538:19 547:21 552:11,16 limits 567:19 line 452:13 470:14 482:6,7 554:12 561:20 lines 448:18 470:14 551:5 662:14 linezolid 493:14 link 628:4 list 422:6 437:10,10 541:5 542:7 603:20 643:18 listed 454:17 lists 504:16 liter 376:20,21 377:1,3,6 378:13 literature 402:14 406:5 475:9 483:10 534:18 549:13 little 362:9 380:21 381:17 388:1 396:7 399:22 400:5 406:6 409:18 411:8 423:12 456:7 457:6 463:8 466:20 468:19 470:12 471:10 473:2 475:2 475:19 478:15 479:20 480:5,13 482:2,14 483:12,16 485:6,10 486:6 492:22 495:16,22 499:6,10 500:1 504:18 505:17 514:20 515:11	517:5 518:9 524:20 527:13 540:20 550:19 553:10 555:5 557:4 565:4 565:12 573:21 574:4 584:10 585:9 587:5,15 590:19 595:22 600:5 610:20 613:6,8 629:2 630:14 631:6 631:19,21 632:22 645:14 647:6 653:19 654:7,8 667:22 live 432:3 507:8 lived 619:22 650:2 660:11 liver 376:6,10 439:2 living 382:11 load 651:18,18 local 420:14 424:12 493:9 lock 467:19 569:22 log 379:10,11,12 421:13 483:13 logic 406:19 468:5 482:21 529:5 542:14 logs 483:14 long 378:5 397:7,11 399:14 409:11 440:3 486:5 527:21 619:22 646:9 655:15 longer 440:11 459:8 460:11 467:21 540:4 541:3 590:2 615:11 625:2 643:16 645:4 look 368:2 380:20 384:20 388:22 392:1 400:12 405:21 406:4,11 422:4,18 424:18 425:7,20,21 427:11 429:18 430:7,15 436:19 442:1 449:12 458:4 463:2	467:9 470:3 475:14 476:4 478:9 479:15 479:20 480:5,8,10 480:15 482:1,9,16 497:9 499:11 500:8 501:5 504:15,22 506:19 514:1 515:3 520:11 522:9 524:21 527:7 529:1 537:10 539:7 541:4 542:7 543:22 547:16 550:13 558:12 560:1 561:1 562:1 565:3 567:22 568:5,12,22 570:1 570:16 571:17 572:11 580:9,11 581:22 582:11,11 583:17 591:21 594:4,5,12,18 611:9 616:7 624:5 628:5 630:16 642:5 644:15 645:3,9 646:1 648:12 656:7 658:3,5,21 663:21 665:1 667:17 672:7 672:22 looked 386:14 397:20 425:7 429:2 439:11 483:11 486:13 527:14 535:12 547:13,14 557:3 583:14 611:21 616:11 618:1 644:16 654:3 659:11,14 looking 366:8 368:15,19 370:13 371:10,19 386:21 394:4 400:9,10 404:14 453:13 456:7 457:3,12 458:11 461:13 463:13 494:19 499:7 509:18 515:11,17 517:2 527:20 538:18 541:16 561:18
---	---	---	---

562:11 568:13	617:16 623:9	480:3,6,14 481:1	640:17,19,22
581:10 582:9 587:4	624:11 642:16	508:7 515:2,9,10	642:15,20 643:5,11
590:3 614:21	644:19 645:12	m.d. 356:8 357:6,8	643:13 659:7
621:17 632:3 644:2	646:16,22 647:2,4	357:12 358:1,13,16	660:20
644:13 645:12,16	654:11 658:3 667:3	358:19 359:1,12,15	malignancies 616:8
645:19,20 646:3	lots 496:7 497:7	359:18,21 360:4	maltophilia 385:2
647:21 652:15	513:21 521:21	m.p.h. 356:8 358:1	mammal 574:1
653:1,7 654:3 662:6	649:14 652:3	359:15	man's 659:2
looks 362:4 384:1	loud 468:16	m.s. 359:1	manage 388:12
405:16 457:21	loudit 502:8,8,15,19	m.sc. 358:4	414:21 567:14
476:7 498:5 508:22	503:3 520:15,20	ma'am 566:7	589:21 595:10
527:14 537:10	521:1	643:14,21	managed 496:13
562:20,22 568:1	loudit's 520:4	mabs 403:20	management
574:4 577:6,8	louis 359:8 506:13	machines 413:4	357:17 411:9
591:22 599:2 612:1	510:1,1,16 565:11	macrophage 376:6	550:22 648:4
630:14 631:6	love 459:21 647:3	magic 564:7	managing 402:1
665:13	loved 406:13	magnitude 495:11	606:15
loose 542:11 588:12	lovely 659:3	635:18	manner 402:18
loosely 554:7	low 377:4,8 386:17	main 527:4	manual 521:19
lose 610:13	425:19 426:21	maintain 394:18	manufacturing
loss 438:21	437:7 460:10	420:10 507:6	610:12
lost 507:5	537:13 559:12	maintenance 489:7	marco 357:20 361:8
lot 364:20 369:18	633:18 634:3 637:6	521:18	364:9 444:5,10
370:9 372:11	638:5 642:8	major 405:16	455:8 568:1 620:2
373:22 381:15	lower 386:3 406:11	434:16 451:21	651:7 652:9 656:11
387:17 389:7,10	442:18 482:3,7,7	497:18 534:5	662:14 663:13
392:7 396:14 398:5	498:16 499:3 503:1	665:18	marco's 470:21
401:22 411:20	508:5 536:13	majority 487:20,22	614:1
415:11 416:11	560:11 569:22	536:2	margin 407:7 421:5
419:19 420:9 422:1	570:1 571:1 630:14	making 513:10	422:21 426:1,5,14
427:8 432:12 436:7	631:6 641:14	529:19 530:1 546:9	449:2 469:20
437:7 440:8 441:19	lowest 473:9 633:9	559:5 566:14	479:15 480:2
442:21 443:19	633:12	609:16 610:7	482:11,21 512:17
444:12 445:12	lpad 396:7 399:1	626:15	512:20 513:4,9
451:14 466:13	lto 474:19 477:6	male 438:12 488:10	514:11 526:22
468:2 473:5,6	496:2	488:14,22 492:12	557:15,16,21 573:8
474:10 481:22	lu 364:7 604:20,20	518:6,19 537:17	573:14 575:10,11
485:11 496:6 501:3	luciana 357:6	539:16 543:1 557:8	575:16
503:21 504:10,11	lucky 410:8 500:4	557:11,14 558:8	marginalization
509:5 521:18	lunch 534:16 540:16	574:15 575:12	656:15,22 657:18
525:17 534:17	lung 393:3 427:4	609:6,9,12 624:13	margins 376:10
541:13 542:6 544:8	483:15,19,21	625:3,6,11,17,19,20	391:20 398:13
544:13 551:15	lynn 359:12 411:11	626:4,20 627:1,16	414:1 425:12
578:1,4 580:18	514:9 622:15	628:20 629:5,11,20	467:12 485:7
584:3 591:13 592:2	m	630:1,7,13 635:20	506:21 512:15
595:6 598:6 604:2,8	m 403:5 426:6,7,14	636:5 637:19 638:1	514:21 526:20
604:8,14,16 607:19	479:16,21,22 480:1	638:4,8 639:5,8,13	542:11 547:3 570:3
611:4 612:12		639:16,17 640:3,13	570:22 573:10

632:1 marker 651:11 655:21 market 662:20 marketing 435:3,5 658:21 664:12,12 marketplace 659:5 marks 359:12 411:11 514:10 622:16 marrow 418:4 501:13 maryland 674:18 masquerading 539:2 massive 464:18 match 570:15 matches 585:16 materials 396:19 math 406:16 454:11 471:13 485:6,15 486:6 517:18 575:18 584:13 mathematical 507:19 mathematically 513:7,11 matter 374:7 416:6 557:20 620:14 matters 568:22 mature 654:17 maximize 565:21 maximum 565:22 may've 474:1 ma'am 493:20 mcr 397:17,17 md 356:16 mdr 388:12 398:6 431:5,12,22 446:16 450:14,16 465:4 509:16 583:1 598:16 mdrs 514:12 mean 364:17 366:20 367:17 369:22 374:6,10,13,16 402:3 423:14 433:10 438:10	442:14 458:19 460:4,15 461:17,22 462:3 465:18,20 498:5 500:17 503:12,13,18 504:4 511:8 513:12 515:3 515:10,16 517:3 523:12,17 524:5,13 525:16 531:7,12 534:22 536:17 538:17 539:1 548:21 549:10 550:12,20 551:4 552:5,14,14 553:8 554:16,18 562:5 564:6,8 571:2 577:11 579:2 584:11 587:10 588:18 589:1,3 591:14 592:22 595:2,13 604:14 609:12,18 611:2 612:2 613:7,20 614:13 615:15 616:5 617:12 618:16 619:12 621:8 622:3,6 623:19 624:9 629:15 630:19 634:13 635:12,12 636:22 637:9,10,13 637:20 639:20 641:22 643:1 647:2 647:2 648:10 651:12 653:10 655:11,19 656:6 661:9 662:22 664:16 665:3,3,4 669:11,18 671:17 meaning 528:5 meaningful 374:16 389:8 595:3 632:14 means 413:11 419:16 447:19 465:19 489:2,8 609:2 meant 422:6 457:1 494:4	measure 409:7 607:17 measurements 475:13 mechanism 376:1 396:7 399:1 420:21 434:9 654:12 658:15 661:14 mechanisms 461:6 461:8 658:6 mediated 397:18 medical 357:12 358:13 359:1,18 360:4 364:6 375:6 380:2 386:1 399:13 401:15 418:3 443:3 505:8,8 519:14 medically 514:15 medicine 357:10,10 357:15,21 364:10 364:13 387:16 medicine's 596:15 medicines 358:11 444:6 581:3 medimmune 404:13 meditate 508:4 mediterranean 430:14 505:16 506:7 meet 401:13 405:2 414:15 583:1 632:1 647:9 meeting 356:2 366:20 669:4,5,6 672:21 meetings 366:18 672:8 meets 473:8,9 556:18 557:20 meier 482:4 member 464:10 490:7,15 491:2,5,11 492:9 494:10 511:17 513:14 526:11 532:8 549:18 550:5,7 553:1 564:5 586:4 652:8,11,19	membrane 402:5 meningitis 619:20 mentioned 362:16 366:17 371:17 398:16 411:1,20 418:5 419:21 420:19 423:20 427:22 433:4,21 434:5 436:4 454:15 592:20 604:10 647:17 mentioning 364:16 452:19 merck 358:21 538:4 538:5 merely 568:7 meropenem 429:8 429:11,19 430:4 476:16,20 477:5,15 477:16,19 478:6 493:6 494:4,6,15 495:6 507:5 527:7 528:16 559:10 562:16 564:20 572:4 579:12 626:7 message 499:22 561:20 messy 370:22,22 515:14 613:22 met 415:17 434:5,21 441:11 581:17 668:21 metabolism 444:20 metabolite 470:8,10 470:12,15 metabolize 373:18 metabolizers 643:2 metallo 382:22 method 636:7 metronidazole 531:11 mg 632:16,18,21 633:18 mgs 632:17 mic 376:22 377:2,3 377:5,5,9,20 378:12 378:12 385:13 429:9 464:10
--	---	---	--

488:12 490:7,15 491:2,5,11 492:9 494:10 502:7 511:17 513:14 526:11 532:8 533:13 547:5 549:18 550:5,7 553:1 557:7 561:11 564:5 576:20 586:4 638:6 652:8,11,19 mice 376:4 379:2 michael 356:21 358:9 674:2,16 micro 471:3 microbes 669:1 microbials 547:20 microbiologic 379:9 654:5 microbiological 652:16 microbiologists 548:12 microbiology 376:17 microitt 478:22 495:13 microphone 515:7 525:10 537:16 565:9 566:10 584:7 microphones 363:13 microscopic 438:18 microseconds 454:7 mics 376:19 mid 376:7 mike 450:7 517:2 529:17 596:14 631:10,11 632:19 632:22 633:16,21 634:2,8,10,15,22 milligram 376:20 377:1,6 378:10,12 milligrams 376:21 377:3 million 465:11 569:17 609:5 610:9 mind 459:16 503:7 530:14 542:11	546:15 563:10 580:21 592:15 604:19 623:5 minimal 650:8 minimize 608:15 minimum 395:8 487:3 610:2 minocycline 383:5 minus 369:17 494:6 508:6 558:15,18 570:1,2,15,16 575:21 minute 363:11 466:17 487:7 509:22 548:17 570:20 587:4 652:10 minutes 477:17 533:9 590:4 658:20 miracle 482:18 602:17 miracles 466:12 476:12 mirrors 663:12 miscodes 565:17 miserably 530:15 530:16 659:4 missed 526:15 mistake 513:11 mitt 538:18 596:5 mixed 612:16 model 371:22 372:3 372:7,19,20 373:4,8 373:14,15 377:17 377:21 378:8,9 416:22 433:7 438:1 439:13 443:20 456:8 462:1 510:21 544:5 573:21 574:14,21 591:22 594:6 602:3,7,12,15 603:2,6,16 604:2,4 604:5,9 605:4,15 611:17 628:3 635:14 643:19 649:15 model's 544:6	modeling 475:21 640:8 models 371:15,19 372:10 377:13,17 378:1 403:10 418:17 421:7,8 433:11 435:17 436:5,9 441:20 443:20 461:20 518:1 535:12 603:1 611:4 649:17 moderating 363:16 modern 481:7 482:16 modify 402:13,17 module 607:20 modules 521:2 molecule 407:22 molecules 649:16 moment 401:16 463:22 474:14 491:7,7 497:12 506:11 517:6 639:11 money 391:9 394:6 459:20 460:1 465:9 465:13,14,15 504:10 520:21 521:20 557:2 570:11 601:13 645:12 monitor 410:1 461:14 469:11 monitorable 421:4 monitored 438:15 438:16 461:10 469:1 monitoring 396:19 461:4 607:14 650:22 monkey 438:1 439:18 606:2 monoclonal 402:11 404:12 470:2,7,11 609:16 monomicrobial 426:20 509:15	monotherapy 379:7 424:10,18 451:11 452:4 472:5,11 474:6 484:6 492:21 493:1,10,12 524:3 530:15 534:14 582:5 monotherapy's 449:15 month 410:6 574:18 months 366:19 486:8 597:18 months' 486:12 moon 468:9,13 587:7 morality 500:22 morbidity 573:18 morbidity 434:16 morning 362:2 375:15 418:20 419:21 492:4 505:19 598:15 mortalities 527:2 560:2 mortality 373:3 389:16 392:12 425:8,10 427:15 430:20 431:1,14 438:4 441:8 442:18 449:11 472:16 479:9 500:8,17,20 501:1,9,12,17 502:11,14 503:16 503:19 504:5 534:6 536:11,13 537:12 537:13 543:17 560:4 566:18 590:3 654:3 mother 487:17 move 365:19 370:7 462:21 515:9 565:4 566:15 569:14 572:5 575:13 642:14 670:3 moved 560:9 599:14 movement 564:21 572:2
---	--	---	--

moving 413:15 428:2 432:4 moxy 549:20,21 550:4 mp 492:13 mucor 645:4 mucormycosis 554:11 616:1,7 620:7 multi 554:21 597:3 multidrug 382:21 383:21,22 385:2 429:14 644:2 655:8 multiple 392:1 398:22 401:20 407:17 628:9 641:3 murine 377:22 murky 388:10 mutual 665:21 mvfr 404:7 mycology 358:6	nature 640:6 nausea 386:8 naïve 438:12,12 nda 417:6 557:18 ndms 415:22 near 521:13 nearly 486:8 569:17 necessarily 492:14 524:18 533:17 543:16 578:8 612:21 625:2 632:3 647:10 653:10 necessary 446:10 499:8 necessitating 419:14 neck 520:16 necrosis 376:8,13 need 356:5 368:10 370:19 371:5 372:14 373:6,19 374:18 386:1 393:17 397:20 399:5 401:15 403:8 403:10 405:8,13 408:18 409:6,9 413:4 414:8 416:9 416:12,17 419:14 420:2,3,21 422:22 423:15 424:1 427:10 428:6 430:4 432:13 435:9 436:8 436:22 443:3 445:3 450:4 451:18 454:6 465:17 469:1,2 478:15 480:16 484:10 486:17 487:21 494:5 511:9 511:19 516:12 525:21 538:13 541:19 547:17 552:17 565:16 568:5 581:9 593:15 600:19 604:5 606:16 608:2 620:14 640:1 647:10 658:7 660:16 661:15	663:22 664:11 668:2,21 671:4 672:11 needed 381:13 395:2 399:2 431:10 489:22 511:3 515:20 516:7 518:15 521:20 577:1 611:8 needs 367:22 383:18 443:19 506:19 507:3 510:9 511:10 524:15 658:8 668:3 668:20 negative 365:19 382:20 402:5,8 447:14 472:4 476:8 508:8,9 575:10 657:5 670:21 negatives 375:22 377:11 400:18 423:16 neither 674:8 675:7 nerve 437:17 nested 449:12 451:3 network 384:18 390:3 465:19 621:1 621:10,20 622:8,14 650:15 659:13 660:6 661:9,22 662:4 667:6,9 networks 398:19 neural 384:8 neutrality 559:17 neutropenia 376:15 neutrophilic 440:15 never 370:3 388:5 512:6 526:2,8 527:9 535:21 549:4,5 564:14 597:9 611:22 617:14 nevertheless 448:13 new 356:15 358:16 376:1 380:2 381:4 382:11 384:2 405:9 433:14,16 461:8,15 497:18 512:5 519:7 525:15 528:8 545:2	556:18 579:13 587:13 596:17 598:18 599:16 626:9,9 628:17 630:14 644:11,11 654:12,20 655:6 657:13,16 658:6 665:15 news 397:16 nhsn 607:20 ni 422:16,17,18 425:12,22 niaid 358:7 359:18 nice 402:8 405:14 497:5 508:1 529:15 543:14 545:12 553:9 554:6,9 556:1 587:15 nick 358:19 night 364:19 nih 358:7 359:19 619:22 647:14 nine 376:21 597:18 ninety 376:21 nobody's 411:1 580:20 noise 612:16 nomenclature 480:2 non 376:3,17,21 379:6 391:20 392:6 392:8 398:13 403:14,16 408:2 414:1 415:3,9 421:12 422:9,21 423:7 426:1,5,13,17 427:12 429:5,8,11 430:3,10 437:15 449:2 458:12 463:6 468:20 474:17 476:8 483:8 498:8 500:19 512:15 514:11 518:16 521:2 526:1,19,21 534:1 540:9,11 546:2 572:11 575:15 576:14 577:13,16 584:4 623:14,14,17
n			
n 357:1 361:1,1 362:1 497:11,13 504:17 506:20 507:2,11 659:1 nailed 576:6 nalidixic 400:19 nambiar 359:15 361:7 364:11,11 380:12 418:12,20 457:2 458:5 603:20 603:21 605:9,14,17 605:19,21 606:4 614:8 name 375:17 505:7 659:2 named 470:6 narrow 408:2 414:8 417:16,22 670:14 narrower 367:20 374:17 narrowly 367:12 nasty 599:7 national 656:2 natural 570:5 647:5 647:22 648:3,4			

normal 367:5,5 374:18 646:5 670:8 normally 612:17 north 357:17 573:15 nosocomial 406:3,9 409:2 442:9 454:20 466:19 471:16 473:13 474:15 476:9,22 478:13 479:5,8,10,17,21 480:21 484:3 485:8 485:12,19 487:11 487:22 488:20 494:7 495:12 496:9 524:4 525:12 528:12 539:2 550:8 570:7 572:13 574:3 575:1 578:13,14 658:1 notable 452:20 504:19 notary 674:1,17,20 note 423:21 noted 447:7 noteworthy 506:15 notice 562:18 570:17 notion 395:19 469:4 477:10 489:17 499:5 541:10 574:9 notionally 542:14 547:4 novel 376:1 400:17 401:21 402:15 404:5 420:21 534:11 535:21 646:1 nuclear 437:16 nudged 559:12 number 380:19 388:19 391:7 400:14 401:7 404:6 404:9 405:6 421:12 423:6 426:3 432:2 448:7 450:10 459:6 466:11,21 470:5 476:12 485:4 487:20 498:11	504:17 510:9 565:16 572:5 581:13 609:4,14,17 612:18 620:4 622:19 623:4 633:6 635:2,22 636:1 668:2,5 numbers 369:2 370:14,17 388:11 391:14 394:2 413:21 423:4 425:6 425:15 427:16 428:21 429:20 430:1,7,17,21 431:6 468:4 469:5,17,21 479:20 486:21 487:5 488:6 489:18 495:22 496:12 498:8 502:22 504:6 508:2 515:11,14,17 522:9 548:4,4 558:1 558:12 563:9,19 565:4,11 580:20 583:8,16 606:5 623:1 625:9 numerical 557:22 numerically 559:6 560:11 nutshell 583:14	observe 507:2 508:15 564:13 583:3 611:2 observed 376:11 377:21 379:9,14 obtain 435:16 obvious 400:16 412:18 obviously 398:8 431:3 542:8 632:5 633:7,11 637:12 645:3 653:16 665:4 occasional 610:11 occasionally 373:12 occur 419:8 565:5 occurred 376:13,15 occurs 419:5 436:17 443:7,8 672:3 odd 431:18 654:8 offer 598:11,19 666:3 669:21 offhand 527:1 office 358:1,16 360:1 officer 358:13 359:1 359:21 360:4 364:6 375:6 399:13 505:8 519:14 674:2 oftentimes 367:17 523:17 653:2 664:19 oh 489:9 510:10 529:3 532:9 542:22 543:6 551:1 557:10 576:3 579:7 610:12 624:19 632:10 okay 424:2 454:11 456:1 458:5 462:21 464:3,15,18 470:17 472:6,6,12 477:7 480:19 482:5 485:21 486:9,17 489:9,17 490:6 491:22 493:6,18 495:8,10 499:21 502:19 504:7 508:7 508:8 513:13,17 514:8 520:19	524:21 540:15,19 543:11 545:20 549:6 559:1 560:5 567:13 569:20 570:12 572:9 575:18 577:3 579:9 583:12 585:1 586:2 598:5,12 600:18 602:8 613:9 625:3,3 629:10,13,22 639:7 640:18 643:12,22 646:10 649:8 652:21 ol 477:6 old 382:5 384:17,21 385:15,18 386:2 545:1 630:15 ologist 475:8 487:8 576:5 once 424:22 456:22 489:8,17 493:1 610:13 619:19 665:5 oncology 615:2 649:22 654:19 one's 400:16 ones 479:6,6 489:3 514:22 557:21 664:17 669:13 ongoing 404:17 621:2 660:7 onset 391:12 439:4 440:9 526:2 589:22 onsie 555:13 oops 602:19 op 516:14 open 363:6 449:1,6 455:20 460:17 474:19,19 481:13 484:13,15 489:10 496:2 497:6,7 498:4 498:19,20 499:4 502:22 516:10 554:6,11 568:20 580:13,14,15 612:9 613:17 660:18,21 667:18
--	--	--	---

operating 545:18 operational 413:13 448:10 opine 614:3 opinion 400:2 608:21 657:21 opinions 669:20 opportunities 596:11 665:1 opportunity 362:17 374:6,11 429:16 448:13 523:13 536:14 660:5 opposed 476:2 623:14 optimistic 505:15 505:18 option 396:12 422:8 422:12,15 423:20 424:21 427:12 428:2 432:4 433:3 436:2 437:8 443:18 446:19 448:19 449:12 450:13,14 450:17 451:3,20 455:15,16 474:20 598:21 620:15 663:4 665:4 options 370:12 382:1 384:4,7 394:19 422:3,3 443:11,11,13 448:15 452:15 455:20 484:12 548:11 552:11 589:11 600:12,16 600:17 654:21 655:3,19 oral 386:5 397:21 order 372:14 373:7 395:9 425:17 445:16,19 447:20 451:8 462:15 471:11 476:19 571:7 573:9 580:5 585:4,5 601:12 620:16 641:11 668:9	ordinary 481:20 667:6 organ 395:15 418:4 organism 383:21 385:7 421:15 423:10 430:3 432:21 439:17 470:10 471:8,10 491:20 554:10 599:7 604:11 organisms 367:8 427:8 429:3 584:19 592:18 600:14 644:3,5 ouch 611:2 ought 469:14 473:19 520:4,6 527:14 542:1 612:2 618:18 644:21 outbreak 417:8 436:17 465:5 481:8 481:14 589:7 623:22 outbreaks 495:1 600:13 outcome 370:1 392:16 394:10 412:9 420:4 438:4 449:9 450:20 451:22 499:18 500:6 561:8 614:16 616:17,18 628:2 629:17 631:5 642:6 642:9,22 643:4 645:3 651:15,21 653:8,14 654:1,7,19 659:19 674:13 675:9 outcomes 357:14 369:13 456:16 614:22 617:5 621:17 622:2 653:3 654:17 663:15 outer 402:5 outlandish 498:11 outlined 434:7 outside 453:6 537:5	outweighs 656:17 overall 420:19 429:19 467:8 539:9 595:16 607:12 652:4 654:18 663:10 overenthusiastic 620:8 overlapping 419:16 overlook 463:15 overly 446:20 overview 375:19 owners 502:1 ownership 502:3 oxygen 382:9 383:16,18 <p style="text-align: center;">p</p> p 357:1,1 362:1 431:12 442:20 574:22 575:19 578:8 p.m. 673:3 pa 431:22 package 444:18 452:10 page 361:2 470:3,3 470:4 475:15 481:11 482:3 paid 411:4 pain 382:12 383:18 386:2,3,8,9 614:12 650:2 painful 406:16 557:6 564:22 paint 556:13 pair 512:1 panacea 412:21 panel 363:19 399:8 454:3 505:11 549:16 panelists 364:16 453:6 669:3 671:18 paper 430:8 447:18 449:17 450:3 470:5 475:15 481:9 581:21 659:3	papers 483:16 paradigm 367:21 443:5 parameter 378:14 parameters 379:8 401:1 407:6 409:17 486:5 510:5,8,20 parenteral 397:21 part 375:8 401:19 407:17 425:3 452:16 461:3 467:18 493:12 494:3 496:4 524:7 526:15 529:18 547:22 553:16 556:15 572:19 590:21 608:18 610:15 623:2 636:18,19,20 637:1 637:17 638:18,22 639:18 641:7 647:11 651:6 661:21 664:18 partially 484:5 participants 519:19 participate 581:5 participating 661:2 666:8 672:16 participation 397:6 463:15 668:14 particular 368:15 370:9 420:13 436:6 452:16 466:22 489:18 542:19 555:4 557:5 579:4 619:14 642:8 653:7 669:7 672:4 particularly 365:6 368:7 369:12 370:10 371:13 404:3 419:10 491:19 567:19 597:20 599:6 600:13 631:1 644:20 655:8 parties 674:9,11 675:8
---	--	---	--

parts 391:19 415:22 449:20	535:13 557:22 563:19 566:21	531:15 532:15,20 533:4 534:8 536:9	penetration 475:10
passage 377:8	568:13 572:3,5	538:21 539:11	people 366:20
passages 377:9	575:14 584:3 590:7	552:10 555:9,9	384:19 389:22
passageway 402:5	592:9,9 597:19	560:9,21 561:1,2	391:12 397:14
pastels 470:6	598:9,13 618:12	566:15 567:1	404:19 412:7,22
path 388:17 389:19 396:8 417:17 463:6 518:4	622:2 642:8 658:8 659:15,22 660:4,8 668:20	571:20 573:12,15 579:17,18 585:2,8 587:18 589:6	413:6,9 414:21
pathogen 387:10 391:14 394:3 402:10,13 406:3 415:4,10,14 416:3 446:15 447:14,21 466:21 467:20 468:5 539:4,12 540:10 575:8 603:8 652:5 658:13	patient's 593:17 652:18	590:22 592:16 593:5,11 595:9 596:6 597:18 616:8 616:12 617:6,9 618:12,22 619:3 624:6,15 630:3 632:7 633:8,13 635:11 637:15 638:5,15 641:5 642:1,6,21 643:1 646:6 653:16 654:21,22 655:2 659:15	454:19 471:7 473:2 473:21 481:16 483:8 487:12 488:4 489:3 496:6 500:2,5 500:9,16 501:17 512:16 514:3,14 541:13 566:2 576:8 577:22 578:13 581:4,11,17 582:16 583:3,22 585:13 598:22 601:17 618:7 619:19 637:1 660:6,18 668:6 669:5 671:7
pathogenic 439:17	patients 356:5 365:18 366:12,16 368:11,21 369:4 370:8,14,19 373:5 374:21 378:13 379:6,7,12 381:5,22 381:22 387:17 388:12 389:14 390:7,21 391:7,9,14 392:10,21 394:3,10 394:11 395:14,18 396:1,1 397:11 399:5 401:3 402:18 404:1 407:9 408:6 408:19,22 410:9,16 412:9,12 413:8 419:9 420:3,8,11,14 421:12,17,18,20,22 423:1,6 424:16,18 424:20 425:4 426:4 426:4,8 427:13 428:6,9 429:4,5 430:5 432:7 435:11 435:18 447:20 452:15 454:16 456:15,18 457:17 459:6 462:10 465:9 465:14,17 471:3 472:1,15 473:14 474:20 475:11 481:12 484:12 489:7,19 493:18 496:14 499:20 501:13 503:22 504:11 518:10,17 519:10,16,22 523:15,19 527:8	pattern 574:7 paul 357:3 474:1 524:22 525:2 529:12 553:8 569:2 577:5 592:20 594:3 628:11 634:11,11 634:12 635:1,12,21 637:5 paul's 637:20 639:14 648:11 paul's 522:5 pauses 478:9 pay 410:15,21 495:10 589:20 611:6,10 646:14 668:6 paying 668:7 pays 647:14 pcrv 597:15 pd 376:17 377:18 381:12 389:20 395:1 445:5 452:9 477:17 525:8,13,17 583:21 632:6 pediatrics 507:12	peptide 405:3 percent 369:17 370:1 376:22 377:4 377:19 378:12,13 378:15,16 379:2,2 405:22 406:11 407:5,6,7,11 408:8 425:10,11,13,14,17 425:19 426:1,1,7,11 426:14 429:6,7,13 430:19,20 431:2,13 431:14,17 432:1 447:8,11,17,17,19 469:8,10,16,18,18 469:20 471:11 472:3,17,18 473:16 479:17,19,20,22,22 480:10,13,18,19,20 482:12,13,20 485:1 485:2,7,8,18,20 487:19 488:11,17 488:19 492:19 495:7,11,15,19 497:4 498:10,10 507:3,20,22 508:6,7 508:9,16 512:17,19 515:4,5 518:17 519:10 526:22,22

544:14 557:15,16 557:21 558:15 559:1,2,3,13 560:3 560:3,4 564:21 570:6,7 571:20,20 572:3,4 573:4,8 575:15 578:15 580:6 590:4 601:2 607:10 608:2 623:21 630:2 633:13 634:6 percentage 627:14 perfect 381:1,9,9 394:21 438:10 443:14 464:20 510:3 543:10 perfectly 564:2 perform 533:3 553:7 performing 661:17 performs 544:17 perimeter 454:21 period 383:5 422:5 441:2,10 442:22 521:7 618:22 633:6 647:16 perioperative 517:14 peritonitis 377:16 permitted 464:15 perpetuity 647:16 person 506:4 592:5 623:8 personal 535:18 536:4 personally 554:16 perspective 365:5 380:5,6 399:16 400:7 444:7 448:10 503:4 541:8,8,9 555:21 556:3 567:10 587:17 598:7 perspectives 379:15 379:21 509:11 pestis 438:14 439:14 439:14 604:13	peter 359:1 361:4 365:2 375:2,2,6,12 379:18 pfizer 380:4 pfs 650:3 652:4 ph 429:15 446:1,13 447:3 450:3,12 451:6 454:13 466:13 470:6,7 475:15,18,18 476:4 486:9 487:10 502:9 505:7 514:11 520:4 527:16,17,17 542:22 548:5,20 554:8,8 556:2 563:16,16 566:2 568:13 573:16 574:5,11 576:22 577:10 586:8,14 589:19 590:1 597:15 601:19,21 603:22 612:6,18 615:8 617:8 619:18 620:13 627:6 632:16 635:3 646:14 656:15 657:16,20 658:7,10 659:2 669:7 ph.d. 357:12,20 358:6 359:4,8 360:1 360:7 pharm.d. 357:3 358:9 pharma 556:3 pharmaceutical 660:1 pharmaco 657:16 pharmacodynamics 357:4 434:18 pharmacokinetics 642:22 pharmacology 395:12 444:18 667:1 pharmacometric 569:2 635:5 636:7 648:13	pharmacy 611:7 phase 378:3,3,3,9 379:4 388:4 454:15 468:17,19 480:16 483:4,6,7 575:1 599:13 641:1 658:4 660:16 phenol 423:2 phone 661:1 php 429:3 phrase 567:12 588:6 physical 610:6 physician 364:5 380:2,7,7 399:15 physicians 580:7 pick 478:11 485:4 486:10 487:19 496:10 579:21 618:11 632:5 636:17 637:4 640:20 picked 441:16 525:7 525:8,13 531:16 picking 513:4 529:19 575:2,3 576:7 629:8,13 634:12 pieces 471:20 482:22 484:7 647:7 pig 602:15 piglet 574:1,13,21 piglets 611:20 piocyan 470:7,8 pip 526:21 piperacillin 530:14 pitch 495:14 496:3 554:3,16 pitched 498:16 503:8 537:14 558:19 pitfalls 392:8 pivotal 605:7 pk 376:17 377:18 378:8,9 379:8 381:12 389:20 390:22 393:1 395:1 395:12 405:12 415:16 444:22	445:1,5 452:9,22 454:16 456:17 475:8 477:17 483:3 487:8,9 507:14 525:8,13,17 535:10 576:5 583:21 595:9 595:20,20 626:17 627:7 630:21 631:9 632:6 667:1 place 410:14 471:21 472:6 496:22 544:2 549:3 550:11 551:18 559:18 587:13 593:16 599:4,9 606:21 621:15 637:13 650:20 placebo 442:4,16,19 466:5 476:21 477:21 516:3,15 528:15,16 574:22 585:12 605:3,5,8,11 635:17 646:4 648:12 places 562:16,18 564:19 587:20 647:6 649:22 plague 372:8 417:5 417:8 418:18 433:8 437:13,18 438:2 439:13,16,22 441:4 442:3 plan 406:4 420:11 449:10 466:14 581:7 634:18 637:14,15 641:7 planning 378:6 505:14 521:12 623:18 plans 638:2 plant 609:3 plasma 378:22 475:14 plasmin 397:18 platform 438:2 platforms 359:13 plausible 480:16
--	---	--	--

<p>play 566:17,19 572:6 581:16 582:20 603:7 626:16 641:10 played 481:6 485:5 489:20 playing 547:12 560:19 662:5 plc 359:13,22 please 363:15 491:4 540:17 557:9 601:19 672:3 plenty 525:2 plots 577:6 plug 603:6 plus 369:17 404:5 435:22 466:3,4 476:16 494:6 519:13 522:14 530:3 534:4 575:21 580:10,10 585:10 586:10 pneumonia 377:16 377:22 390:18 401:12 406:9 419:11,12 429:3 439:8 440:19 442:9 442:10 454:20 466:19 471:16 473:14 474:16 476:9,22 478:13 479:8,10,17,21 480:22 484:3 485:8 485:13,19 487:11 487:22 488:21 494:8 495:13 500:21 501:11 524:4 525:12 528:13 530:16 531:1,4 539:3 550:9 570:7 572:13 574:3 575:2 578:13,14 629:7 658:2 pneumoniae 387:2 pneumonias 389:15 496:9 pneumonic 438:2 439:12,15,22</p>	<p>podium 375:12 point 363:8 368:12 373:4 408:22 411:9 413:10,15 417:3 418:2 447:6 449:18 459:1 460:1 468:1 470:5 471:6 480:9 480:11 483:18 484:6 490:12,14,16 490:20 499:2 500:3 503:3 504:13 506:15 508:14 509:6 512:10,11,14 513:6 514:2 520:3 529:6,9 530:1 533:17 534:18 537:18 539:6 546:8 558:18,21 559:4 565:15 566:14 583:18 591:8 600:9 600:20 602:14,21 604:1 631:4 635:22 655:5 661:8 665:2 666:19 671:2 pointed 412:15 471:17 474:8 520:5 557:5 572:20 611:18 630:9 pointing 504:17 545:11 613:19 points 400:15 503:5 522:12 565:12 662:3 poisoning 437:17,17 poke 509:19,19 policy 357:17 437:5 polymicrobial 419:14 423:17 479:2 509:15 547:11 polymyxin 648:6 polyphor 405:3 ponder 488:8 poodle 502:1,3 pool 408:4 545:22 546:3 566:4 611:4 668:6</p>	<p>pooled 543:22 557:20 pooling 422:17 427:13 428:20 543:21 544:8,13 547:1 poor 456:16 561:5 642:9 pop 487:9 555:18 population 378:8,9 391:1,3 396:9,11,18 399:2 407:10 414:3 422:11 423:3 429:20 430:11 432:5,15,19 433:1,2 436:15 452:19 461:9 471:4,4 478:22 483:3 492:13 498:7,12 500:4 503:21 506:8 523:15,18 535:22 537:20 539:9 579:20 593:4 595:9 595:19 596:5 597:7 597:15,19,21 610:18 627:13,14 634:17 populations 432:9 432:11 584:3 657:14 pose 657:17 position 552:4 positive 401:10 469:15 471:5,7 478:18 479:1 522:20 542:16 573:4 620:6 657:21 positives 375:21 377:12 positivity 505:17 506:5 537:22 possibility 393:4 528:12,22 602:16 possible 378:17 381:7,10 395:14 396:13 397:3,10,11 397:12 399:1,4 408:3 409:9 441:4</p>	<p>444:19 445:7 449:16,20 451:11 465:4,7 467:11 474:17 480:1 505:22 553:19 560:14 587:14 603:13 619:1,7 621:19 628:9 667:14 669:6 possibly 364:21 533:20 post 384:19 435:3,5 437:2 459:13 516:14 517:10 596:19 657:1,18,22 658:4 662:20 664:12,12 posterior 510:7,14 510:22 511:5 postulate 606:9 pot 634:5 potential 374:21 390:13 397:17 418:14,22 423:20 438:7 443:3,10 461:15 501:6 522:10 545:7 569:14 658:7 potentially 392:10 422:19 436:15 537:21 539:20 598:19 603:4,12 659:12 potentiators 402:4 power 394:7 407:6 425:11 430:19 450:22 469:18 490:3 509:5 571:20 powered 485:1 578:8 powering 509:4 powers 359:18 ppv 447:15,18 practical 522:9 practically 369:9 practice 367:14 381:5 384:14 396:3 472:20</p>
--	--	--	--

practicing 380:7	470:15 663:8 670:1	prevented 530:19	503:19 504:6
pragmatic 446:7	presentation 371:12	preventing 432:17	524:18 545:16
595:7	420:6,17 435:4	434:16 481:4	557:5 560:15 562:5
pre 370:20 396:18	436:4 561:21	516:16	562:8 571:5 583:15
397:15 437:4	598:13,14	prevention 398:9	589:4 590:6 591:18
442:17 483:1	presentations	previous 431:6	599:6 601:11
532:21 533:21	422:13 433:5	446:4 506:4 510:2	611:13 657:6
535:11 662:20	presented 390:16	566:9,12 568:4	660:14,21 665:22
preapproval 459:14	394:17 404:9	602:1 613:22	669:10 670:18
precedent 437:6	406:15 413:19	previously 423:11	problematic 448:12
525:18	441:22 505:19	556:2 582:13	600:14
precious 608:5	635:1 645:1 647:19	661:13	problems 367:12
precise 369:6	648:11	price 540:6 556:21	419:20 500:16
precision 564:7	presenting 365:6	601:14	601:4 613:1,3
624:7	preserve 397:10	primary 425:9	659:21 665:17
preclinical 381:12	551:18	438:1 449:8 450:21	669:11 671:21
389:20 395:1	president 357:3,12	452:1 478:21	procedure 516:9
405:12 444:17	358:9,19 359:12	532:19 540:13	proceeding 394:18
468:22 553:17	pressure 386:18	546:3	674:3
591:14 650:10	464:11	principally 466:18	proceedings 673:3
predefined 450:12	presume 465:3	prior 478:20 600:5	674:4,6
predict 371:22	483:4 647:20 667:2	643:20 672:18	process 596:20
372:14 525:8	pretend 487:7 517:5	priori 420:9 543:21	650:19 651:4
predictable 384:8	610:21	priors 510:4	produce 574:7
389:16 392:12	pretending 470:17	probability 510:7	producing 383:14
414:17	pretty 383:3 392:8	510:14,22 511:5	387:2 481:14
predicted 378:22	400:4,13 407:8	556:6 626:8,10	product 432:16
379:8 486:22 487:5	431:15 444:13	probably 365:19	435:1,10,13,16
560:18,19	448:16 449:6 450:1	369:5 370:19,20	437:1 457:14
predicting 462:3	451:16 455:18	381:19 393:5 394:7	458:17 460:22
predictive 434:12	467:4 469:11,15,20	402:8 403:17	462:12,14,17
predicts 534:6	487:12,14 488:5	404:20 406:9,10	523:10 528:7,8
predispose 593:13	498:6 500:7,22	455:3 456:9 463:19	556:16 568:11
premarket 607:7	515:14 587:7	475:21 478:5,10	606:15,18 607:4
premature 550:19	589:18 594:4,5	492:18 495:6	609:7 664:5 671:6,7
preparation 364:18	601:15,16 613:15	500:22 506:4 507:3	671:10,13 672:1
595:15	626:18 635:10	515:10 518:14,22	production 382:15
prepared 363:8	656:19 663:12	551:4 558:3 559:16	610:2
390:10,12 417:1,8	prevalence 425:13	582:8 596:6 597:7	products 358:2
675:4	425:16 426:2,10	600:1 603:22 636:1	359:2,16 364:12
preparing 364:18	429:2 430:11,12	648:14 671:18	375:7 418:13
406:14	432:6 437:7 446:17	problem 371:14	433:16 437:9,13,14
prescribing 472:1	447:16	380:15,18 399:22	437:16 443:22
presence 424:13	prevalent 448:21	415:21 418:8	458:6 527:17
present 374:9	506:9	443:15 460:7	645:22 648:8
387:18 401:7	prevent 367:7	471:14 473:18	670:11 671:15
402:22 413:8	433:17 516:13	479:13 482:17	professor 357:9,15
420:14 465:2	528:1 638:10	484:9 495:2 501:16	357:16 359:8

profile 421:1 600:15	propose 577:19	416:22 417:12	674:17
profiles 596:9	proposed 379:8	419:6,12,17 422:12	publications 425:18
profiling 445:5	397:6 417:20 421:4	423:1,2,6,18 424:5	publicly 512:6
profound 594:6	447:18 456:3	424:7 425:13 426:2	published 405:7
program 357:9	479:16	426:5,10,19 427:7	424:9 471:19
379:16 381:4 388:4	proposing 450:2	428:7 429:7,12,15	475:11 526:8
393:18 394:8,22	539:19 626:17	429:21,22 430:3,11	549:15
406:21,22 456:12	pros 374:2 509:10	431:13 432:6,10	pull 595:11 618:7
459:9 465:16 468:3	541:7	435:19 446:16	pulmonary 432:15
474:7 483:4 488:7	prospective 474:13	447:3,15 448:21	432:18
496:5 537:9 541:12	494:20 582:16	451:15 452:14	punch 561:20
542:14 551:18	586:20	456:8 465:1,4	purely 455:1
552:16,18 572:19	prospectively	467:16,21 470:9,20	purpose 545:15
573:7 576:6,9	620:20	472:8 474:21 475:6	purposes 366:3
577:17 584:1	prospectives 621:3	476:8 478:16 479:2	451:9 475:5 496:1
590:12,16 594:10	protein 454:10	479:3,4 483:9,20,21	521:16 528:21
594:11 595:6	630:10	489:3,4 490:11	649:14
598:22 606:16,20	protocol 417:6	491:15,18,19	pursue 384:11
620:21 641:17	476:15 595:4,8	492:14,18 493:2,12	404:15
659:9 660:16	608:8 618:21 621:3	495:4,7 497:1,14	pursued 392:12
664:10 667:12	621:21	500:6,21 505:16	pursues 393:16
programs 397:5,8	protocols 619:21	507:12 509:17	push 453:20 559:7
402:15 413:16	proud 400:13	518:10,21 520:6	638:13,17 645:11
486:14 564:9	proven 390:22	521:8 523:2,20	661:11
599:22 601:16	392:21 396:15	530:15,22 531:15	pushback 579:15
631:15 636:1 645:9	407:11 483:2	531:17 532:20	pushing 567:19
646:2 660:12	provide 363:5 365:5	533:2,3,5,21 538:1	put 407:2 416:5
progression 438:6	378:11 408:9	538:8,20,22 540:12	425:19 447:8 463:9
615:14,19 616:10	409:16 417:1,6	547:7,12,14,15,21	465:13 478:9,9
progressively	418:14 427:3	548:5,13 549:1,21	479:9 482:1 485:12
407:13 409:3	430:22 435:5 436:2	551:3,8 570:6,9	487:18 494:9 503:4
projects 359:12	438:2 514:16 584:2	576:20 578:1	504:14 510:6 514:3
645:19	provided 452:8	579:14,18,20 580:8	517:7,9 520:16
prominent 396:17	469:12 657:3,4	581:13 583:1 585:7	523:8 525:17 540:2
promising 405:17	provides 428:13	585:10 588:21	554:2 562:17
417:16 420:20	providing 380:6,9	589:5 590:8,9,22	572:12 574:2 578:3
662:1	399:16	592:17 593:13	580:2 603:9 606:20
promoted 527:10	provisions 371:7	595:17 597:16,18	618:18 620:8
promotional 396:19	provoking 513:20	601:6 603:1 604:13	650:20 657:6 659:1
proof 379:4 421:11	ps 518:16,21	611:20 624:20	661:3 667:11
properly 565:12	pseudomonas	625:2,7,14 626:7	puts 559:17 577:5
properties 597:11	368:19 375:20	635:3 662:5,6	putting 514:9
prophylaxis 404:15	376:2,18 377:10,14	pseudomonases	659:20 672:9
516:7,12	379:10 388:3,6	584:14	pyramid 514:12
proportionate	391:12 404:13	public 356:4 359:10	q
550:2	405:22 406:2,6,8	362:3 363:6 366:18	q24 478:1
proposal 449:6,17	407:11 408:12,14	441:18 633:19	
	409:1 415:21	670:13 672:8 674:1	

q8 477:16,19	541:5 548:9 549:17	randomize 484:16	492:17 498:6,9,16
qt 378:6	559:8 565:6 567:4,6	485:4 491:8 533:19	506:12 536:11
qualitative 496:15	621:11 639:12	534:4,8 612:18	543:17 580:1,5
qualitatively 496:16	649:15	randomized 389:1,6	ratio 489:13 624:10
quality 388:8	quick 502:10 514:10	390:16 392:3,6,8	rational 421:16
398:19 461:12	541:4 641:20	398:12 442:15	483:1
561:5 565:17	668:11	448:19 474:14	ratios 379:1 489:16
566:13 571:3	quickly 366:1,1	476:13 494:20	495:11
quantified 440:2	643:3	501:14 502:2,3,4	raw 488:16
quantify 545:4,18	quiet 362:4	525:11 554:9	rct 484:1 496:16
quarter 493:17	quinolone 549:19	range 367:19 370:5	498:17 554:6
question 367:15,15	quit 467:22	426:11,15 431:5,18	reach 573:16 589:13
368:22 370:22	quite 373:15 374:1	432:1 438:20	658:7
372:21 385:11	383:4 386:21 411:2	465:11 489:15	reached 442:16
388:9 403:11	439:5 447:9 458:5	510:8 511:1 641:11	react 434:12
407:16 409:10	467:6 481:18	641:12	read 403:3 506:17
455:7 457:21 488:9	515:19 547:11	ranged 440:3,10	517:19,20 575:4
491:10 492:7	560:14 569:12	ranges 406:10 638:6	reading 375:2
497:19 498:20	593:8 614:20	ranging 431:2	real 366:14 380:13
502:6,11 506:16	632:16 657:1	639:18 640:14	423:14 461:11
509:19 510:12,19	quo 394:19	ranks 612:6	462:17 464:15
511:7,14 513:8	quote 462:22 506:14	rapid 366:10 367:22	482:10 528:17
514:10 515:2,10	r	382:18 405:18	536:21 537:7 541:4
516:6 518:5 527:19	r 357:1 362:1	409:12 411:19,21	560:15 567:3
533:13 534:11,15	r&d 358:10	412:6 419:19 423:8	579:16 583:2
537:14 542:20	rabbit 574:2	445:16,19 446:7,11	595:10 606:1 607:6
550:16 553:2 557:1	rabbis 574:6	447:6,13 448:1,10	623:3,3,7,18 670:13
557:2 558:11 561:6	611:20	521:4 589:22	realistically 548:11
563:22 565:8,11	radiation 382:7	rapidly 488:5	realities 505:1
567:11 572:15	radiologic 437:16	rare 419:7,22 420:9	reality 408:17 460:2
573:19 588:5,9,12	439:6 440:16	465:5 467:21	realization 406:20
588:15 600:4 601:1	raise 460:1 533:14	644:17 657:14	realize 406:5 454:9
605:1,1 622:6,12	raised 451:18 519:9	667:11	460:8 500:21
637:18 638:22	533:14 537:18	rarely 423:17 672:3	527:12
639:4 642:7,10	548:19	rate 407:5 425:10	realized 541:19
646:11 647:13	raises 415:11	430:20 431:1,14,20	really 362:17
652:1 655:13 659:8	436:18	470:20 485:2,19	364:21 366:2,7,21
663:3	raising 569:16	488:16,17 492:13	368:10,12 369:9,21
questions 363:14	random 564:3	516:16 517:1	371:21 372:10,13
365:9 372:2,11,12	randomization	536:13 549:21	373:11 380:6,14
373:11 381:6	393:9 425:11	559:12 570:5,9	382:1 383:17
415:12 417:11	430:18 451:5	573:4 582:1,22	384:18 386:20
436:18 454:2 455:6	469:19 503:15	584:18 585:6,13,15	390:1,4,7 392:13
456:11,13 462:19	541:10 563:12	593:2 595:16	395:15,15 396:2
488:7 491:10	582:18 583:5	rate's 407:11	397:4,4 398:13,18
492:11 495:8 498:3	586:19 619:8	rates 369:16,16	400:18 401:14
498:20 508:11	622:19 624:10	409:6 469:16	402:22 403:1,11
509:6,10 524:22		486:15,22 487:1	405:2,16 409:7,10

411:1,10 412:16 415:20 416:2 419:7 419:17 421:9 423:8 423:9 424:15 426:6 427:10 429:13,20 430:2,2 431:16 432:1,2,5,13,19 433:16 436:1,4,12 436:16,22 437:2,20 439:8 445:18 454:8 457:4,9 458:20 459:14 461:6 469:19 473:12,19 473:22 478:1 486:21 489:10 496:17,20 497:16 499:6,17,18 500:1 500:15 501:15 503:15 504:16,22 515:3 521:3 522:20 525:2,15,16 527:8 529:3,6,20 530:2,11 531:18,22 532:6 535:9 537:14 540:7 541:20,22 546:14 546:16,22 548:6,17 552:14 554:13 555:13 557:6 560:7 560:16 561:5 562:4 565:20 567:19,22 568:13 570:15 571:10,13 572:16 573:16 574:7 576:5 587:13 589:19 590:17 593:21 594:12 595:18 596:20 598:20 608:5,11,13 611:21 612:11,19 613:10 613:22 614:19 615:16 617:12,19 620:7 625:21 626:14,18 631:2 632:17 643:11 656:4 660:17 666:10,15 667:16 668:18 670:12	reason 374:12 414:9 457:7 463:12 473:16 477:18 478:19 483:21 497:4 501:2 527:4,9 527:22 529:15 538:18 539:13 547:22 565:1 573:22 574:8 593:17 601:18 606:11 611:14 642:7 647:11 663:17 reasonable 381:16 381:20 394:21 395:5,6 421:2 462:8 497:16 556:21,21 624:6,7 667:12 reasonably 434:8 641:12,16 reasons 385:6 435:13 500:10 526:3 539:16 567:16 reassuring 543:15 receptor 657:20 received 441:14 468:18 657:21 receiving 539:11 660:13 recipient 384:22 recognition 663:19 664:10 665:22 recognize 406:2 408:5 418:22 419:3 445:10 448:3 546:21 616:5 670:17 recognized 363:15 403:16 recognizes 606:12 recognizing 596:6 628:9 651:12 664:5 recollection 538:6 recommend 496:20 recommendation 446:9	recommended 479:6 recommends 628:6 recomputed 507:21 record 453:17 540:18 674:6 recorded 674:4 records 460:19 618:12 recovery 485:19 recruit 401:2 410:6 410:16 413:8 recrutable 519:18 recruiting 416:3 450:16 reduce 373:3 445:22 reduced 674:5 reducing 483:12 619:1 reduction 377:15 379:10,11 421:13 651:17 652:6 reductions 379:12 refer 555:12 referenced 452:16 referring 635:14 reflect 400:5 496:3 565:14 reflected 640:9 reflection 444:14 445:14 506:21 reflective 604:6 refractory 385:1 regard 614:22 regarding 376:14 505:16 regards 537:1 607:8 622:2 665:1 regimen 522:13,13 523:3,6 530:2,3,4,7 531:19 533:19 539:20 590:21 626:10 630:14,15 regimens 441:14,15 regional 657:16 registration 674:20 registrational 425:16	registries 460:18 596:19 645:10 647:2 658:12,14 registry 420:10 608:13 644:17,22 646:7,9 647:9 658:16 regulations 433:13 434:7 458:20 regulator's 541:8 regulators 541:11 550:16 556:8 regulatory 400:9 405:5 506:22 511:15 518:8 556:9 603:14 656:14 rehab 382:11 383:15 reject 466:13 577:16 rejecting 535:3 relate 565:15 619:10 related 434:14 458:12 512:12 554:10,10 619:2 635:3,8 674:8 675:7 relations 357:15 relationship 639:17 relative 674:10 relatively 394:2 413:7 563:7 650:9 relatives 599:17 relaxed 449:3 relentless 615:20 616:9 relevance 452:19 relevant 444:21 451:4 535:11 553:18 610:7 reliable 408:14 480:3 617:16 622:11 reliably 562:6 reliance 460:19 relied 605:8 reluctance 425:2
---	---	---	--

rely 415:2 418:6 434:21 544:11 583:21 relying 405:12 remain 415:15 remainder 463:21 remaining 463:22 501:19 remains 476:12 511:14 remarks 363:8 remember 363:9 389:10 412:11 414:18 494:22 515:15 527:1,3 559:15 removed 385:4 651:16 653:4 renal 378:5,18 384:8 421:17,19 445:1,2 455:1 478:3 573:17 renally 378:16 478:4 repeat 492:11 505:5 repeated 530:17 replace 629:15,17 629:21 replenish 489:9 replicating 539:18 reported 356:21 reporting 356:22 represent 400:2 representative 554:22 represented 452:21 representing 365:4 requested 555:20 require 404:11 412:21 465:5 521:18 540:1 662:19 required 414:11 436:20 466:11 511:1 521:18 requirement 417:4 435:5 442:12 469:3 602:17	requirements 401:14 414:16 415:17 435:2 475:17 664:13 requires 410:13 449:11 requiring 383:16 657:1 rescue 404:1 411:19 593:18 research 358:20 359:5 reservation 547:6 551:17 reservations 552:18 reserve 363:6 551:12 resistance 367:9 377:7 383:22 397:18 421:1 429:12,19 472:2 494:4 507:5 528:2 530:19 535:12 538:8 580:1,5 582:1 584:18 589:5,9 593:2 596:9 600:15 601:4,11 648:1 651:2 655:9 resistant 372:17 382:22 383:20,21 385:3,8 387:3,10 388:3,6 415:4 428:7 429:15,15 430:4 472:4 477:6 496:10 522:22 528:6 550:2 581:12 582:10 584:12,14,19,20 585:6 592:18 596:9 597:3 598:17 644:2 resolution 497:17 resource 393:5 394:5 resources 391:7 394:6 460:5 respect 446:11 respectively 379:3 respiratory 382:12 382:16 383:9	401:10 438:21,22 respond 558:4 588:7 response 402:18 434:12 445:8 469:18 479:7,10 481:8 482:5 485:2 495:15 498:6,9,16 517:10 559:12 569:3 581:11 582:1 582:22 585:6,13 626:22 631:14,22 632:2,11 633:4,5,10 634:17,18,21 635:15 639:2,15 640:7 641:8 643:19 648:11 652:16,18 652:20 responses 627:5 634:21 responsible 406:6 501:19 restrict 435:9 606:21 restricted 593:4 restriction 606:17 restrictions 371:7 435:10 462:6,14 608:9 650:20 671:11 result 400:8 495:18 504:12 508:22 538:2 542:17 657:5 670:9 results 414:6 416:6 467:3 472:11 493:5 559:10 562:15 574:12 575:9 600:11 retrospective 581:3 return 556:10,16,21 reveal 453:8 614:8 reverse 511:6 reversible 376:8 review 396:18 400:7 401:8 413:17 416:12 425:12 662:21,22 663:1	reviewed 475:8 reviewer 360:1 reviewing 405:15 rex 359:21 361:9 363:16 364:13,13 365:10 380:13 405:6 406:15 453:5 453:18 454:17 457:21 461:1 462:19 464:7,11 488:13,16 489:2 490:8,16 491:3,6,12 492:10,20 494:1,11 497:22 498:2,15 502:1,13,17 503:2,6 504:8,13 505:3 506:13 508:11 509:2,4,9 510:13 511:18 513:2,15 514:8,17 515:7,22 518:18 520:3,19 521:15 522:5 524:1 524:7,21 525:10,19 526:4,10,12,18 527:1,11 528:4,10 529:11 531:6 532:1 532:4,9,11 533:8 534:10,14 535:7 537:8 538:11 540:6 540:15,19 542:22 543:3,6,9,11 545:10 545:16,20 546:5,10 546:21 547:9,19 548:16 549:2,19 550:2,6,8,11 552:9 552:15,22 554:2 555:22 556:14 557:10,12 558:7,10 559:22 561:10,13 562:10,13 563:10 563:21 564:18 565:20 566:10 567:4 569:1,16 572:2 574:17 575:13 576:3 577:2 577:4,18 578:5,9,17 578:21 579:7 580:13,15 581:16
--	---	--	---

581:20 582:3,20 583:7,12 584:6,17 585:1,3,11,17,20 586:2 587:1 588:1,4 598:3,12,15 600:19 601:19 602:4,6,9,12 602:19 603:18 604:20 605:12,15 605:18,20,22 606:6 609:1,8,11,13 613:6 614:11 617:20 619:18 622:15 624:19 625:5,8,13 625:18,22 626:16 626:22 627:4,21 631:10 632:10,20 633:15,17,22 634:7 634:9,11 636:11 641:10 642:11,14 643:8,14,17 644:9 646:9 649:6 651:7 658:19 660:11 661:3,19 662:2 666:2 rex's 390:15 420:17 ribosomal 376:2 rid 492:5 544:13 right 362:2 364:15 401:9 402:12 408:7 418:11 436:21 443:16 456:4 458:10 464:8,12 465:7 468:9 474:11 476:7 477:4,9 479:19 482:3 484:3 484:6,21 488:13,16 489:5 492:12,15,19 494:2 502:2,20 503:5 508:2 509:2,4 509:9 513:16 517:6 524:12 525:5,9 526:18 529:10,18 532:1 533:12 536:6 543:2 545:12 546:21 550:14 558:17 559:6 560:4 560:10 562:20 564:22 566:20	567:4 570:3 572:17 574:20 575:13 576:11 577:7,8 578:11,20 579:5 582:4,4 583:6 586:16 587:1 601:19 604:7 605:15 606:6 610:9 613:7,13 618:3 621:7 622:17 623:11 626:4,6 627:4 630:10,12,21 634:7 637:18,20 638:3,7,12 640:2,12 643:15,17 644:9 653:9 655:10,19 666:2 672:20 rigorous 381:3 390:5,5 504:22 595:8 rigorously 392:17 rise 421:9 risk 394:14,17 396:11 412:16 414:6,19 416:4 417:14 422:11 424:13,14 456:22 472:1,9,13,16,19 493:22 504:18 511:15 512:21 513:10,11 518:18 519:17 520:2 533:17 541:15 544:13 545:7 558:2 558:9 561:9 564:9 565:8 567:13,14 568:9 573:17 577:16 586:3 588:10 589:6 593:12 597:20 606:15 607:2 625:20 627:5 632:7 642:21 649:3 656:17 658:11 risks 461:15 504:16 506:16 520:10 545:3 569:9	risky 546:8 road 651:22 robust 445:5 594:4 594:5 620:11 roche 404:8 rod 365:20 rodriguez 647:19 rods 670:21 role 424:17 445:16 462:12 531:20 545:21 547:12 560:19 659:9 664:21 room 356:15 380:19 383:11 386:20 514:3,6 548:13 561:5,6 631:13 root 439:18 roughly 409:19 round 480:18 rounding 480:7,13 route 392:12 416:20 656:14 routine 421:8 rpr 356:21 rs 384:1 rubin 360:1 rugged 470:16 rule 371:4,6,10,16 372:6 373:21 374:8 389:4 415:14 416:11 417:5,10,21 418:15 422:14 433:5,6,11 434:5 435:15 437:1,12 443:18 456:4 457:8 457:11,15,20 458:7 461:18 462:5 469:4 480:12 573:19 587:6 598:1 604:16 605:7 627:9,21 628:2,6 667:16 rule's 416:13 rules 478:12 ruling 455:21 run 373:17 448:4 473:1 486:5,14 488:11 504:6 514:4	520:16,17 537:8 557:1 570:13 583:15 584:4 609:3 610:11 622:21 628:10 660:16 running 489:14 520:7 568:18 662:4 667:8,9 runs 610:1 620:22 s s 357:1 361:1 362:1 659:1,1 safe 374:15 396:15 435:10 462:6 672:22 safeguards 396:14 399:2 safely 462:17 safety 371:5 376:3 376:10 381:17 389:9,10,21 391:2 393:4,17 395:5,11 407:14 421:1,5 435:6 446:2 458:10 468:16 469:2,5 476:3 489:22 490:5 490:18,19 497:11 497:17 519:8,12 523:6 539:8 552:8 560:16 591:13,14 591:17 607:1,9 628:10 634:16 645:7 649:13,19 650:11 651:5 657:19 665:12,17 sake 446:3 620:12 salvage 537:13 sample 409:7 414:4 425:7,20 426:2,11 426:15 430:15 431:4,15 511:3 544:14 562:3,7 samples 413:20 414:3 samuel 357:12 san 357:16
--	--	--	---

sandbox 621:10 sat 362:5 485:5 satisfactory 667:21 save 412:14,15 436:16 505:3 saw 428:16 440:8 499:10 533:14 548:4 594:3 614:17 616:12 saying 413:19 415:20 473:22 474:2 488:3,18 498:17 511:19 512:19,21 513:12 524:15 528:13 535:3,7,19 576:19 582:21 594:15 603:19 611:11 624:14 629:20 642:20 653:12 says 411:10 473:19 493:8 505:22 577:6 617:8 635:9 650:22 scale 536:15 scapegoat 505:9 scary 397:16,19 464:8 scenario 385:17 392:6 431:7 436:17 458:3 463:12,20 465:8 467:8,9,9,10 467:14,14,16,17 468:5 470:1 486:1,4 505:4 550:17 556:13 559:9 560:12 563:4,5,12 569:6,6,20 570:1,4 573:2,11,13 576:4 587:2,12 598:7 611:16,17 616:22 625:12 626:1 631:12 638:19 643:18 653:12 654:8,22 656:1 665:14 scenario's 623:22 scenarios 452:11 463:5,9 466:16	551:20 557:3 567:12 616:14,16 schema 390:15 school 357:10 359:10 schoolteacher 386:2 science 401:22 405:9 417:17 671:17,19 sciences 359:13 scientific 362:21 381:6 scientist 357:6 359:18 360:8 364:8 scores 392:14 screen 448:7 screening 410:5 486:8,12 521:9 scrounged 527:13 scrutinizing 603:16 se 524:18 647:9 search 667:10 second 406:19 409:2 422:9 424:4 428:2 453:21 462:2 472:10 480:18 485:11 487:4 491:13 492:4 519:6 521:1,14 529:9 562:14 570:17 588:5 636:20,22 661:8 666:21 secondary 395:20 449:13 451:4 538:13 secondly 659:12 secretions 438:22 section 358:20 409:8 452:17,18 458:9 504:16 see 362:6,12 365:17 372:9 375:9 388:5 395:18 397:1 398:10 403:3,5 404:18 406:8 407:12 413:17 417:15,18 418:1 426:2 429:13	442:17 445:4 447:10,16 463:7 466:16 469:19 470:5 472:15 474:9 474:14 479:16 485:11,13,15 496:19 497:9 500:16 501:10 510:20 513:15 515:13 533:18 534:8 541:5 547:2,5 548:7 550:17 551:19 552:6 557:8 559:16 564:3,9 566:17 567:5,8 569:2 572:10 587:18 591:3,22 592:3 597:5,9,22 599:5,12 605:4 611:15 613:15 616:10 622:4 632:12 635:5 636:9 651:12,16 652:1 655:14 656:21 662:12 671:7 seeing 363:3 380:10 451:9 469:7 486:15 499:7 515:12 597:8 673:1 seek 369:15 566:2 581:17 seeking 584:12 seen 379:11,13 383:11 425:1 447:6 469:9,10 499:9 555:8 556:1 576:16 617:3,20 618:4,5,6 624:17 639:21 sees 570:8 655:2 select 417:22 434:19 selected 390:11 620:1 selecting 487:9 selection 447:1 570:4 selective 417:13 self 463:1	sell 667:18 selling 459:22 senate 396:9 send 519:2 senior 358:9 359:12 359:18,21 360:7 sense 412:19 453:8 457:3 460:13 474:10 484:17 493:15 496:11 554:5 608:10 632:15 668:9 sensitive 408:8 411:16 sensitivity 447:17 451:8 470:22 579:13 sent 386:13 659:15 separate 474:15 476:14 543:14 544:11 632:17 separately 645:8 sepsis 377:17 septic 472:9,13 590:7 592:10 593:11 595:9 serial 377:8 series 362:4 365:3 379:21 463:4 483:15 613:17 serious 365:20 366:9 368:6 369:13 387:10 433:17 516:6 636:16 637:12,16 657:1 670:21 seriously 392:11 454:15 658:5 serum 560:21 service 413:2 servicing 413:4 ses 589:19 session 375:9 sessions 363:17 set 368:20 401:19 431:8 437:6 445:8 465:16 471:19 478:2 508:3 513:5
---	---	---	--

533:11 544:6 556:8 620:19 645:11 sets 430:22 431:9 633:19 setting 371:5 392:19 420:13 440:1 446:13 474:9 514:22 525:18 536:20 537:6 547:10 554:10 565:19 600:13 620:11,16 624:4 631:18 656:2 658:16 settings 484:14 598:9 606:22 608:7 settle 468:13 setup 454:4 455:6 462:20 485:17 seven 533:9 severe 389:14 396:2 398:17 498:12 536:10,12,16 severity 392:14 566:1,15 sew 516:12 shaming 633:20 share 385:21 614:11 shared 393:22 533:18 sharing 514:7 sharp 487:16 she'll 372:7 380:5 shed 518:9 609:21 sheer 428:21 shift 508:16 565:5 shlaes 613:18 643:19 655:14 shock 472:9,13 590:7 592:10 593:12 595:10 shoot 506:6 555:3 shooting 637:1 short 442:22 466:11 521:7 shortcomings 428:11	shortcuts 499:16 shot 474:22 shouldn't 494:2 506:10 should've 482:1 show 368:11 394:17 461:22 466:4 467:3 471:18 484:2 507:15 517:15,22 538:14 540:11,20 554:13 577:22 578:11 611:16 627:10,12 630:2 641:8 642:3 showed 378:9 380:17 391:8 425:15 440:16 448:16 517:13 553:5 563:3 594:2 606:1 635:22 637:20 showing 372:1 450:7 453:10 502:12,16,20 568:16 571:22 637:2 638:19 shown 374:15 377:8 380:16 430:17 448:18 512:2 575:4 637:11 shows 483:6,19 577:13 637:6 shrink 566:4 shrinkage 652:6 shrinks 558:16 shut 453:20 sick 384:4 395:15 414:3 420:3 424:2 500:2 527:8 533:19 590:22 sicker 386:17 409:4 409:5 566:16 side 363:20 369:3 446:1 511:2 520:13 562:17,17,19,19 597:1 sidebar 475:2	sided 414:1 425:10 430:18 sides 634:14 sideways 572:11 625:21 626:1 sign 473:2 474:18 633:17 639:20 signal 376:5 497:18 signals 468:22 597:5 signature 674:15 significance 414:2 significant 378:21 442:20 593:2,6,8 595:10 632:4 665:18,18 669:13 significantly 442:18 503:1 521:9 signing 575:18,19 signs 440:13 silver 356:16 similar 372:16 432:19 440:13,17 443:22 478:5 499:9 521:12 581:3 618:14,21 620:21 621:21 628:17 636:14 663:14,15 663:15 similarities 440:8 467:4 similarity 544:10 similarly 443:22 simple 413:7 469:17 470:16 simplification 485:3 simply 369:4,8 466:14 simulated 364:22 simulations 378:8 simultaneous 631:17 634:19 simultaneously 475:14 634:14 single 356:6 362:15 365:7 366:5,6,8,22 367:4 375:17 380:9 389:8 402:10 406:7 416:3 419:2,4	422:16,18 442:4 443:7 444:9 450:2 529:13 533:20 535:9 557:21 563:19 576:8 620:13 670:15 sins 507:7 sir 492:8 526:14 sit 463:10 562:1 site 391:1 408:4 410:11 422:17,18 427:6,21 443:8 447:1 453:2 455:9 457:18 476:6 489:14 521:19,19 544:21 546:2 553:14,17,18 554:21 555:4,9,9,10 sites 387:14 390:1,5 392:2 393:2 395:14 398:22 401:4 410:12,12,16,18 413:1 422:17 426:9 426:16 427:4 430:9 430:9,13 443:9 444:21 447:1 457:16 473:7 486:8 489:8,8,10 509:12 542:3,9 543:5,16,19 544:17,18,20 548:1 552:21 553:3,4,7 555:1,13,16 662:7 situated 443:22 situation 369:9,21 380:8 407:3 433:20 435:8 450:7 457:19 460:3 467:2,15 500:15 511:4 515:9 519:2 592:19,19,20 593:1 597:3 607:5 612:8 615:18 656:9 657:3,7,9,13 672:10 672:13 situations 424:11 600:11 614:15 615:3 617:3 619:13 619:16 651:15 663:19 665:9 672:5
--	---	---	--

six 373:7 666:2 668:5,11 size 409:7 425:7 426:11 430:15 431:4 448:6 468:3,4 469:20 511:3 544:14 573:7 651:17 sized 548:13 641:17 sizes 425:21 426:3 426:15 431:15 573:14 skewed 406:10 skills 674:7 skin 365:18 394:8 401:13 475:7 670:20 skip 414:9 slide 368:4 380:18 406:13 481:10 482:2 484:17 487:18 504:14 506:17 542:13 543:4 562:17 602:1 604:1 611:16 slides 365:3 402:2 428:22 614:17 670:19 slightly 362:8 430:12 433:20 440:10 470:19 621:12 625:9 slip 418:1 slow 491:20 small 370:17 388:11 391:14 394:2 395:4 398:12,14 411:5 413:20 414:3 421:11 430:2 451:7 456:15 468:1 482:11 498:8,11 503:14 506:20 507:11 534:2 558:1 562:7 563:8,16,19 565:19 568:5,18 577:21 587:7 599:1 601:3 612:18 622:18 623:1	648:19 649:16 662:19 smaller 370:14 389:2 394:4 405:11 431:4 504:6 584:2 615:5,7 smart 596:19 smarter 502:9 smiling 614:1 smokers 502:2 smpc 446:10 452:16 sobering 505:18 536:22 solely 614:3 solid 418:4 solution 460:7 520:12 solutions 453:10 464:17 466:13 solvable 531:12 solve 368:2 371:13 418:8 419:20 443:15 518:3 613:3 669:12 somebody 399:17 411:10,11 460:4 502:6 505:22 509:21 518:3 520:20 548:19 609:20 611:10 633:7 656:5,5 668:3 669:15 someplace 601:14 somewhat 397:19 596:2 653:12 671:18 sonita 669:7 soon 401:8 404:18 453:16 477:3 586:8 673:1 sophisticated 626:19 647:22 sorry 491:3 492:10 506:1 524:22 527:15 533:16 543:6 557:10 566:10,11 570:19 575:16 584:17	598:3,4 624:19,19 632:20 636:11 649:7 652:12 sort 364:22 365:10 365:11 368:14,20 369:2 370:6 371:18 372:19 374:5,10 375:4 380:20 381:1 382:14 386:21 387:9,9,18 390:15 395:19 397:2,13,16 398:7 420:10 430:7 437:19 442:22 453:11 454:4 457:5 458:14 461:21 462:1,2,20 464:16 465:10,12 467:19 468:5 473:18 474:17,22 476:5,10 477:12 478:5 481:19 492:2,7 503:9 512:3,9 514:22 515:17 521:19 522:15 524:15,15 530:4 536:14,14 537:11 537:12 541:1 546:17 547:1 551:17,18 553:9,21 554:1,7,12 555:12 565:4,6,22 567:4 572:10,13 573:1 577:14,17 579:4 584:1,9 587:16 592:14,18 595:22 596:16 598:3 606:16,17,20 607:11 609:16 610:1 613:19 615:17 617:1 618:10,10,11 621:10,16 623:6 631:17,19 633:11 636:9 639:1,3 644:15 655:1,17,18 655:20 656:8,9 664:9 670:2,12 672:5,14	sorted 486:16 sorts 553:20 565:6 622:7 671:12 sought 442:6 sound 449:17 612:10 sounds 450:3 503:13 584:8 592:15 596:3 600:11 627:15 655:10,13 source 382:19 546:3 589:21 sources 387:19 427:19 space 499:9 620:4 646:21,22 speak 431:9 609:21 speaker 361:2 375:2 399:11 488:10,14 488:22 492:12 493:21 518:6,19 533:16 534:13 537:17 539:16 543:1 550:15,21 552:20 557:8,11,14 558:8 566:8,11 574:15 575:12 609:6,9,12 624:13 625:3,6,11,17,19,20 626:4,20 627:1,16 628:20 629:5,11,20 630:1,7,13 635:20 636:5 637:19 638:1 638:4,8 639:5,8,13 639:16,17 640:3,13 640:17,19,22 642:15,20 643:5,11 643:13,22 644:10 659:7 660:20 speaking 409:19 422:8 special 385:12 420:15 461:9 species 356:7 362:15 365:8 366:5 366:6,8,22 367:4 368:16 369:1
--	--	---	---

372:15,15 375:17 377:10 380:9 419:2 419:4 434:11,11 442:11,13 443:7 444:9 603:7 670:15 672:3 specific 371:18 397:21 408:8 423:2 443:19 449:6 450:20 451:22 453:2 461:9 508:15 655:7 657:2 specifically 450:14 530:12 542:4 555:20 580:11 specificity 447:7,11 specifics 371:10 specified 442:17 specify 478:10 662:21 specifying 530:9 597:19 spectrum 367:20 374:17 377:5 400:22 401:11 408:2,9 414:9 417:16,22 419:16 530:4,6 535:6 538:19 670:14 speculate 606:10 spend 381:15 393:5 504:10 511:19 542:1 557:2 611:3 645:12 spent 569:16 604:17 spero 360:4 364:5 399:13 402:3 404:8 spill 516:11 spilling 567:2 spin 453:12 spoke 654:14 sponsor 378:2,6 468:15 473:1 474:10 524:9 557:17 558:3 570:8 600:1 620:21 647:15 657:18	sponsoring 647:20 sponsors 378:4 384:19 473:6 603:3 603:12 658:18 spontaneous 377:7 spot 364:21 494:5 577:7,8 spread 633:11 spreads 633:5 spring 356:16 sputum 379:11 382:15,20 383:13 464:22 squeak 632:8 stab 589:17 stable 475:4 621:21 staff 410:11,13,13 410:15,18 609:22 stage 649:18 650:19 651:4 stagger 537:15 stand 549:7 standalone 413:16 413:18 standard 387:14 388:22 390:17,21 391:3 403:13 404:4 404:5 408:1 409:17 423:7 425:22 466:3 466:4,7,8 478:12 479:6 512:7 626:5 652:14 655:20 standardize 477:13 standing 603:19 standpoint 380:6 399:17 437:5 439:1 440:7 stands 476:7 staph 365:16,18 670:20 staring 653:8 stars 468:9,14 587:7 start 363:19,20 368:9,10 372:12 380:20 382:3 412:5 420:3 491:8 506:11 541:4 551:19 566:16 569:8 572:6	583:16 592:5 593:21 638:13 648:20 662:5 started 386:4 397:14 424:21 445:1 453:18 468:8 481:18 501:10 576:9 583:9 starting 449:18 starts 566:19 state 458:21 630:9 674:18 stated 419:6 444:16 452:19 540:22 statement 456:3 statements 363:8 states 397:8 411:22 530:21 601:9,15 607:14 610:17,20 statistic 505:18 568:10 statistical 360:1,7 363:22 369:10 389:1 393:8 394:7 449:10 490:3 506:22 518:8 542:9 563:20 568:8 577:19 619:6 statistically 381:3 632:3 statistician 562:2,13 statistics 512:8 557:9 575:17 624:16 stats 478:21 status 394:19 630:10 statute 651:6 statutory 401:13 415:17 stay 490:10 stayed 656:16 stays 569:13 steadily 487:14 stenotrophomonas 385:2 625:1,15 step 368:15 467:19 468:6 514:1 535:5	635:21 650:8 666:5 steps 542:16 sterile 483:18 554:14 610:11 steroids 385:6 stewardship 397:4,5 397:8 398:9 399:3 412:8 461:6 598:21 599:22 601:16 607:13 stick 487:16 660:18 stop 375:1 453:3 464:5 477:3,5 518:20,22 534:21 541:3 593:15 641:21 stories 483:12 story 400:19 517:19 569:17 659:5 straight 525:10 straightforward 437:21 448:12 563:8 strain 438:13 439:15 442:14 601:7 604:13 strains 522:22 strange 527:9 strategies 607:12 strategy 359:21 402:8 404:11 466:2 stream 385:1 587:19 streams 563:16 strength 512:4 strengths 391:4 392:21 stress 444:17 452:17 515:2 631:6 stressed 630:16 631:5 stressing 630:15 stretch 529:21 strict 392:13 393:12 396:19 striking 631:2 strong 398:16 416:1 483:1 561:3 565:16
---	---	---	---

613:21 648:15 stronger 648:15 struggle 373:12 struggling 445:17 504:10 552:6 588:14,16 stuck 407:7 562:4 582:9 613:9 studied 401:12 438:13 456:19 476:2 535:21 590:8 studies 377:8 378:2 378:3,6,7 381:4,11 381:12 388:11 389:18 390:1,20 392:6,9,20 395:2,17 398:14 404:17 405:11 410:15 411:3 413:20 415:19 420:22 421:10 433:15,19 434:22 435:3,4,5,13 435:14 438:19 450:18 452:22 458:22 486:16 516:15 562:1 596:1 605:7 615:10 646:4 660:7 661:15 662:20 667:6 study 364:19 368:7 368:13,21 370:20 378:3,4,5 379:4,5 389:14 390:17 392:3 395:10 396:4 402:16 403:14,16 404:3,4,14 405:6 407:8,15 408:3 409:19 410:19,19 410:21 411:17 414:11 415:3,4,8,9 415:10,15 416:3,6 416:16,18 417:4,7 417:13 419:3 420:1 421:11 426:18 427:9 429:1,22 430:13 433:22 434:1,3,13 435:7,21 437:2 441:7 442:6,7	442:7,11 448:19 450:15,21 451:21 455:8,9 456:3,11 457:1,4 458:8,9 459:10 460:16,22 465:3 466:17 467:2 468:20 471:15 473:1,5 474:18,19 477:7 483:6,7,19 484:13,15,22 486:4 486:6 487:2,8,18 488:12 490:11,13 494:2,9,14,18 496:2 496:4 497:7 506:12 509:1 511:10 518:11,20,20,22 519:18 520:5,16,17 521:11,12 526:21 528:5 532:22 534:2 535:20 536:1,3 539:17 540:3,9 549:14 562:14 569:8 572:11 576:14,17 582:16 584:21,22 585:9 586:21 591:22 594:7,22 596:11 608:14 616:4 630:2 647:21 649:21 650:16 657:19,22 658:2 660:18,22 661:2,3,12 664:20 665:11,19 667:7 studying 370:18 429:21 443:6 466:18 504:11 619:15 stuff 380:22 414:10 463:22 473:7 493:15 529:20 542:15 544:3 554:14 600:8 610:10 623:8 648:14 666:3,19 sub 474:15 476:14 482:21 485:5 632:7 633:13 637:16 638:16	subgroup 568:6,14 subgroups 449:13 451:3 subject 472:11 subjects 378:20 466:20 468:2 469:9 472:17 482:8 486:8 487:15 529:14 537:20 575:7 submit 388:1 389:13 395:13 417:6 590:15 595:12 submitted 401:8 413:17 526:2,9 527:4 656:19 submitting 557:18 subsequent 533:4 665:19 subset 479:1 582:1 620:1 subsets 542:17 545:1 substantial 406:22 414:11,16 415:1,10 415:18 416:17 417:1 459:20 649:13,19 651:5,10 663:21 substitution 539:19 success 369:16 400:5,14 482:19 505:14 556:6,10 560:11 successes 499:3 570:18,18 successful 400:6 414:22 succumb 503:22 653:16 succumbed 438:17 440:4 sucking 667:20 suddenly 415:9 suffered 481:7 sufficient 413:21 511:11 555:11	sufficiently 452:21 511:5 613:4 622:10 622:11 suggest 387:9 420:22 424:10 425:18 471:22 472:14 539:14 558:7 584:13 632:11 644:14 667:13 suggested 449:21 507:16 547:22 574:19 suggesting 662:15 suggestion 525:20 suggestions 669:21 suggests 469:1 474:3 560:15 637:9 suitable 455:22 sulfa 387:4 sumathi 359:15 361:7 364:11 371:9 371:17 372:4 399:21 418:12,19 444:4 451:13 454:14 456:2 458:2 460:16 471:17 514:20 573:20 574:13 584:13 605:1 614:2 summary 443:1 496:20 662:3 666:3 summoned 584:7 sun 468:9,13 587:7 super 486:18 584:12 superior 563:4 564:13 585:21 superiority 392:5 404:4,14 422:10 428:3,4,6,13,15,18 429:17 430:16 449:13 451:1,3 465:3 466:4 578:6 578:11 579:10 597:1,5,10 637:10 642:3 646:4 supplement 564:10 658:9
---	--	---	--

supplemented 435:18 supply 660:15,15 support 394:8 418:3 435:1 465:12 569:10 583:9 587:6 595:6 646:6 supported 453:1 supporting 416:7 supportive 403:4 415:7,15 416:1 498:6 546:1 591:17 suppose 437:21 523:18 563:1 566:3 625:10 646:11 supposed 477:16 550:21 657:13 supposedly 528:6 sure 381:15 397:9 399:12 402:2 413:13 422:3 458:5 508:12 509:9,19 513:22 524:22 528:2 540:13 542:5 542:21 547:11 555:19 567:6 576:9 576:17 578:9 609:1 612:13,22 613:4 620:19 622:4 623:9 623:20 648:5 665:3 671:17 surgery 382:7 394:12 481:13 484:5 516:8 572:22 surgical 427:6 surrogate 615:8 651:11 652:6 653:2 654:14 655:21 surrogates 651:20 653:3 surveillance 398:10 survey 377:1 506:6 surveys 505:15 survival 377:17 434:15 482:5 502:15,18,19 560:2 560:11 574:22 578:15 652:4	654:18 surviving 589:19 susceptibilities 424:22 susceptibility 464:21 477:4 491:15,17 493:5 529:16 599:20 623:21 susceptible 429:8,11 430:3 440:20 493:2 493:6,7 535:14 601:7 614:20 suspect 401:21 514:5 suspected 590:22 suspicion 441:4 switch 586:9 switched 383:5 symptomatic 438:5 symptoms 382:18 383:18 440:13 synergize 522:21 system 603:7 608:1 systematic 608:4 systems 402:15 607:17	533:10 535:4 541:3 548:7 551:9 558:2 561:1 563:12 570:12 571:5 573:12 574:1 589:17 590:5 608:14 610:1 612:5 621:16 takeaways 541:21 taken 405:4 516:2 674:3,9 takes 410:5 433:3 488:20,21 631:7 talk 371:9 380:14 381:11 395:3 399:21 406:5 418:22 421:10 449:6 453:15 457:4 463:5 467:13 471:21 480:18 482:13 504:15 509:11 512:12 513:8 525:10 542:5 546:22 561:11,13 563:2 579:16 600:19 613:6 631:21 652:10 662:17 666:5 670:3 672:4 talked 366:10,20 368:5,8 380:22 381:17 388:16 391:5 413:3 414:4,7 423:19 443:13 474:2 480:17 484:13 485:17 506:18 514:20 539:17 542:6 556:4 560:8 582:6,7 595:15 598:9 615:1 621:9 622:16 623:19 634:4 655:15 664:8 talking 362:14 366:4 371:3 372:7 374:2,4 375:3 381:16 393:6 401:6 414:10 433:10	445:11 499:5 506:20 511:21 536:19,19 538:1 544:4 566:18 598:12 604:4 614:5 618:19 624:9 625:6 625:12 629:16 640:15 656:1 662:17 663:13,17 665:7 talks 374:8 417:7 556:2 tapers 488:5 tapped 660:8 tapping 599:10 target 356:6 362:15 367:11 376:2,11 378:17 402:7 412:12 413:21 415:4,10,14 438:15 447:21 483:2 487:10 539:12 575:8 576:1,22 627:11,12 628:14 628:17 629:8,14 633:19 634:4,6 targeted 376:13,16 391:11 423:18 targeting 365:16 367:19 375:16 432:5 444:9 655:8 670:15 672:2 targets 365:7 tazo 526:21 599:18 tazobactam 384:3 530:14 531:9 teach 671:20 teasing 613:8 technical 556:6,9 techniques 619:9 teeny 558:16 tell 389:7 405:13 410:7 412:1 414:20 417:2 454:8 482:17 504:1 521:6 534:22 550:22 558:17 568:10 574:17 576:1 578:12
	t		
	t 361:1,1 table 363:2 425:12 447:5 466:15 477:2 tables 439:10 tachycardia 440:14 tachypnea 440:14 tail 529:13 565:2 take 369:22 401:16 401:19 405:8 409:12 413:22 417:4,10 430:7 442:3,3 448:4 453:6 459:15 460:6 463:8 464:1 469:5 473:15 474:22 476:11 477:1 480:12 486:5 491:18 493:8 513:22 514:2 522:8 524:2 532:16		

579:14 591:10,12 595:1 600:11 639:1 telling 520:1 571:21 648:21 tells 373:13 562:7 600:15 615:11 temperature 441:1 441:11 tend 372:16 419:13 427:6 432:10 617:8 624:5 632:12 tends 420:6 421:21 439:20 537:13 tension 388:7 term 397:7 429:3 460:11 614:16 615:11 622:17 646:9 terminal 378:19 terms 379:10 391:8 391:17 394:5 448:1 450:4 454:16 455:19 463:17 468:4 490:18 500:7 510:14 511:16 529:20 591:16 636:9 645:21 650:20 663:21 terribly 481:20 test 368:17,19 372:22 385:14 403:12,19 431:2,15 439:1,2 441:12 445:16,19 446:7,12 447:7,8 448:1,11,22 449:9 450:20 452:1 468:6 470:21 471:3 471:8 472:11 492:15,17 493:2,9 498:13 521:5 523:14 524:15 530:11 531:20 533:21 536:14 539:3 541:20 547:7 547:18 583:19 596:8 652:15 tested 385:8	testing 385:12,13 388:15 389:1 390:21 392:5 393:9 409:9 413:22 414:2 438:3 449:12 450:22 530:2 538:20 541:17 568:19 589:9 597:4 599:20 tests 438:16 447:13 521:6 652:17 text 471:20 textbook 387:18 thank 375:14 379:17 380:11 399:6,20,21 418:9 418:11,19 444:2,11 453:3 490:20,20 505:6 514:8 522:7 599:9 600:18 603:18,21 606:8 625:18 669:7 671:22 672:16,21 673:2 thanks 364:15 379:18 399:8,10 444:4 453:5,21 456:1 513:18 621:7 654:10 666:7 668:13,16,17 669:2 669:3 that'd 465:7 470:22 that'll 504:14 that's 480:14 482:2 482:17 483:14 485:3 486:13 487:4 489:17 490:12,14 492:6 493:3 494:4,8 495:4 498:19,19 499:2 500:6 501:1 502:15 503:9,18 508:17,21 511:9 513:3 514:17,18 516:5,21 517:12 518:18 523:7 531:12,12,21 532:13 535:5,7 537:18 538:9	539:10,21 themes 541:7 theoretically 628:22 theory 468:21 480:1 therapeutic 376:12 376:14,16 403:12 405:17 438:3,7 462:12 619:4 632:7 633:14 637:16 638:16 641:2,3 664:21 670:10 therapeutics 360:5 364:6 399:13 402:3 403:2,19 417:22 669:2 therapies 402:13 403:21 404:16 417:19 418:7 509:17 528:1 593:3 648:7 654:20 therapy 367:18 368:10 370:19 383:4,4 387:6 391:11 392:3 402:21,22 404:2 419:15,15 420:3,4,6 424:5,7,21 425:4 428:5,8,16 432:21 445:12 446:5 450:1 450:5,8,11 451:16 451:17,19 466:2 471:22 472:18 473:17 477:9 478:20 481:17 494:7 501:6 507:9 509:13 516:3,19 527:19 530:20 532:22 534:7 540:2 542:7 589:22 591:2 there's 477:18 479:12 480:13 481:9 495:18 496:2 496:7 499:16 500:18 501:3 502:6 503:21 504:15 507:4,4 509:14 511:4 513:21 514:14 527:11	529:13 534:17 536:13 539:2,7,9 thesis 407:18 414:13 416:10 they'll 514:5 they're 487:14 489:4 493:7 495:13 496:16 503:8 519:11 599:17 they've 529:2 thigh 377:16,22 thing 373:17 388:17 395:8 413:9 460:6 464:3,16 467:18 478:14 492:7 508:1 508:10,13 512:9 521:16 523:12 524:5 540:8 543:14 560:1 561:18,22 571:15 584:22 603:4 613:10,11 614:12 632:20 644:15 647:3 666:12,15,21 667:5 667:15 things 371:3 392:14 392:17,18 394:13 401:5 408:13,16 418:5 454:5,9 459:3 459:13 461:2,16 470:13 473:6 474:7 476:10 495:11 499:15 500:10 501:18 503:15,21 504:3 515:12 521:21 528:18 532:12,14 536:15 542:12 549:11 553:21 554:1 556:11 560:22 563:16 564:15 575:4,20 576:11 595:14 600:7 608:7 622:10 625:15 630:10,17 640:5 643:18 644:1,3 645:2,15,21 648:9 649:3,10 654:16
--	---	--	--

661:12 662:8 665:4 666:2 667:7 668:7 670:3 671:12 think 362:5 363:9 363:20 365:16 367:14,21 368:1 369:15 370:5 374:12,19 379:22 381:8,18 385:20 387:8 388:20 389:9 389:19,21 390:9,13 391:4 392:7,20 393:21 394:13,16 394:21,22 395:6,8 396:22 397:14,19 398:1,10,18,21 400:12 403:15 404:14 405:2,18 406:1,13 409:9,18 411:10,15 412:2,3,6 412:17 414:7 415:2 415:5,11 416:2 417:15,20 418:6,20 420:16,18 423:5,13 426:21 427:8 428:19 431:6 433:9 433:21 436:11 437:4 441:5 443:3 443:15 444:12 445:18 449:16 451:13 453:3 455:20 456:10 457:2,7 458:14 459:4 461:7 462:13 463:1,19 466:6 479:18 480:17 481:10 482:11 484:17 487:3,3,4 488:1 495:1,3,5 497:10 499:1,2,16 500:3,14 501:16 502:22 503:4 504:20,21,22 505:4 506:18 507:3 511:18 513:20 514:17,18 515:1 518:6 522:10 523:2 523:2,12,13,18,20	525:8,19 526:13 528:10,18 530:1,13 531:7,21,22 534:10 534:14 535:21 536:18 538:9,12 540:7,8,12 541:21 542:13 546:10 547:16,19 548:3 549:6 551:1,19 553:15 555:4,17,17 556:4,5,12,17 559:8 560:14,16 561:8 562:5,11 563:15,22 564:11 567:9 568:3 569:8 571:15 573:18 576:15,21 577:9,11,13 578:2,2 579:1,2 587:10,13 588:8 590:4 591:7 592:10 593:9,21 594:18 595:5,14 596:13,17 597:1,10 597:12 598:8 599:14,21 600:4,8 601:2,9,13 602:4,16 602:21 603:5,11 604:7,10,16,19 605:9 606:4,12,14 607:11 608:17 613:1 615:9,18,21 616:15 618:2,13,16 618:17 619:6,12 620:3,10,14 621:10 622:12,17 627:14 627:20,22 628:11 629:17 630:16,19 630:21 631:4,6,7,14 631:18 633:2,10 634:2,3,10 635:2,13 636:6,13,18 637:14 637:18,19,20 639:5 639:8,11,14 640:6 640:15 643:18 645:16,19 646:3,15 647:2,5 648:9,17 649:10 650:12 652:5 653:5 654:15 655:1 656:7 657:9	657:19 658:13,14 659:14,15,20 660:17 661:9,10 662:13,17,17 663:2 663:9 664:2,7 665:7 667:13 668:20 669:16 670:3 671:9 671:10 672:13 thinking 393:18 445:18 457:8 461:16 468:16 492:2 531:9 546:11 566:9 567:11 579:3 579:9 591:17 592:19 595:22 596:17 597:2,14 603:12 607:3 608:12,18 617:4 623:16 634:20 637:15 648:10 thinks 556:12 646:8 third 422:10 432:4 485:12 492:5 521:3 593:7 667:5 thirdly 597:14 thirds 485:13,21 486:16 488:18 thirty 575:12,13 thomas 359:8 thorough 378:6 444:18 thought 363:18 373:16 380:21 382:2 384:15 427:5 427:13 453:13 498:17 513:19 517:20 520:8 533:13,14 536:7 550:3 561:7 596:22 597:9 609:2 616:9 616:12 631:1 669:16 thoughtful 513:19 534:17 thoughts 443:1 509:16 589:16 threat 435:8 436:10 436:13,17 457:4,5	604:11 threatening 433:18 three 411:17 430:22 435:2 437:12,13 439:10 440:10 463:5 466:18 469:4 469:6 471:20 474:12 489:11 491:22 520:17 537:21 544:17 545:3,11 554:3,17 555:9 610:18,20 threshold 441:11 566:3 629:8 661:11 throw 574:11 thrown 545:13 tie 464:2,4,4 tied 626:13,19 627:4 627:5 tier 390:14 391:22 393:7,20,21 394:15 394:15 398:14 401:20 403:17 406:21,21 413:16 413:18,18 415:2,8 415:13 416:3,6 417:21 575:21 tiered 405:5 tiers 551:16 tigecycline 481:19 482:6 520:12 635:4 tigesycline 383:2 398:6 408:14 tighter 512:20 tightly 570:15 till 463:18 tilt 562:20,21 tilting 565:18 time 362:5 363:6,7,8 365:9,11 368:12 370:9 373:5 377:19 378:12 381:16 383:1 391:9 393:6 394:6 404:20 410:3 412:15,16 420:5,9 424:16 440:9,11 441:2,10 442:5,22 448:2,4 453:11
--	---	---	---

457:13 470:21 473:13 475:16 491:3 492:10 495:7 511:19 514:9 521:7 525:3 527:5,18 533:8 538:5 540:22 542:1 556:5 562:14 562:15 571:18 579:5,7 595:10 604:17 605:6 611:4 612:17 614:19 615:21 618:3,21 621:15,22 622:11 622:21 623:13,16 626:1 647:16 653:4 655:4 657:9 663:11 665:2 666:18 669:4 670:1 timed 465:5 timelines 413:11 timely 607:17 times 376:11,13,16 401:20 407:17 486:11 610:17,18 610:20 614:14 619:5 667:3 timing 441:9 463:17 tiniest 558:19 tiny 495:17 504:17 517:8 558:16 tips 549:2 tired 383:17 671:18 671:19 tissue 553:19 title 406:16 today 362:8 363:18 365:1 366:3 370:13 371:4 374:2,13 381:16,18 388:20 399:18 401:6 407:17 409:10 421:10 434:2 463:1 590:17 608:18 614:17 663:18 666:4 668:12 669:18 today's 363:17 473:18	today's 514:2 todd 548:20,21 told 452:13 515:21 612:4 tolerable 598:20 tolerance 485:10 tom 509:22 510:1 542:20 566:9,12 574:5 tom's 565:8 tomayko 360:4 361:6 364:4,4 399:11,20 420:19 425:15 455:7 459:15 466:9 500:13 535:2,8 561:10,12,14 562:11 566:17 575:22 576:19 577:3 589:17 591:4 591:7,10,12 593:10 594:16,20 595:2 608:6 627:9,18 634:22 647:17 tomayko's 435:4 567:12 tomayko's 503:12 tongue 602:20 tool 384:18 476:11 542:2 657:7 tools 656:13 658:3 664:4 top 382:15 551:22 562:20 563:5 570:16 623:20 657:15 topic 362:8,13 555:20 643:15 total 426:3 492:13 624:18 totally 386:5 touch 537:18 touched 418:21 423:12 428:19 touching 402:19 tough 375:8 617:19 653:15 667:18	tougher 629:2 toxic 383:4 toxicities 384:9 421:5 toxicity 376:4,5,14 421:3 560:17 tracheal 597:21 tracheobronchitis 382:10 track 492:17 645:3 tract 383:10 386:22 387:14 670:8 tractable 403:17 traded 562:16,18 tradeoffs 666:20 traditional 401:16 train 412:22 413:12 trained 593:22 transcriber 675:1 transcript 675:4 transect 516:11 517:14 transferred 382:10 translate 373:8 translates 373:5 422:20 translational 403:10 417:18 transplant 384:22 385:5,7,19 418:4,4 trauma 456:16 travels 672:22 travis 601:21 treat 391:10 397:21 423:16 424:2 432:14 433:17 519:10 536:9 551:7 579:17 580:7,9,22 590:9 611:4 623:21 635:11 644:2 treated 383:2 387:3 387:5 394:3 396:2 472:3 480:9 537:21 578:14 581:11 585:2,3,5 586:6 treating 365:17 366:15 374:21 377:14 385:17	432:20 481:5 517:1 517:8,9 530:6 586:21 592:9 624:15 treatment 382:1 392:22 403:2,5 409:7 419:18 424:6 424:9 425:5 427:22 428:14 431:3,17 432:15,18 433:8 452:14,15 474:20 480:4 484:12 515:21 519:1 530:22 531:4 543:18 551:6 552:11 597:6,12,22 605:4 612:20 616:19 635:19 636:10 640:9 648:16 treatments 519:3 tree 455:14 tremendous 400:14 588:19 589:4 606:13 tremendously 471:9 616:17 622:14 669:8 trial 366:13 369:11 389:1 391:15 398:19 401:1 406:4 413:11 414:15 419:9 420:12 421:19 422:9,10,11 422:16,17,18,22 423:7 425:8,22 426:17,21 427:11 427:12,16 428:3,5 428:10,13,18 430:16 431:20 436:2,19,19,21 442:5 451:10 457:10 459:5,9 465:19 474:13,15 476:14 502:22 505:1 508:19 514:4 519:10 525:12 526:1,5,6,7 531:15
--	---	--	--

535:16 536:20 537:4,6 553:11,22 554:9 556:7,7 570:10 571:12 574:9,10 579:22 580:3,4 581:5,7,18 582:14,19 583:2,4 616:20 617:6,10 618:2,14 619:10 620:21 621:10,13 621:14,18,18,18,20 622:14 623:3 638:9 639:2,18 640:14 641:6 650:15 661:9 661:22 667:5,8 trials 369:3 371:2 388:18,20 389:7,11 390:1,3,11 398:12 425:1,16 431:21 436:11 445:10,15 445:20 446:9,22 447:2 448:5,11 474:11,12 475:1 494:21 505:13 507:7 530:16,17 533:4 597:16 604:19 612:10 620:13 623:13 640:6 645:8 659:13 trickier 375:10,11 tricky 492:11 tried 403:4 425:19 430:22 439:11 611:19 tries 565:14 trigger 440:22 442:17 604:10 triggers 438:7 trimethoprim 387:4 triple 468:3 trouble 374:19 469:17 612:11 true 489:13 494:9 510:8,13,20 511:3,9 513:6 596:4 653:18 653:19 674:6 truly 426:9 431:12 564:13	trump 654:6 truth 510:22 568:11 try 362:21 372:10 402:18 406:4 430:16 444:13 445:22 446:12,17 447:1,10 448:13 451:2 456:19 459:16 499:12 513:16 522:11,15 532:22 533:2 536:11 568:6,14 579:17 583:8 596:11 608:15,21 619:9 621:11 628:7 638:16 639:20 658:19 670:10 672:6 trying 365:15 368:2 371:21 372:13 391:9 402:16 411:21 420:1 421:20 422:10 429:13 457:14 459:12 460:11 484:20 492:11 493:16 494:22 505:1 515:18 531:18,22 532:6,18 536:9 550:20 551:2 551:2 552:6 562:6 569:10 588:16 589:14 590:19 591:11 592:22 594:9,17 596:13 597:5 603:15 618:14,18,20,20,21 621:6 628:3,15,16 629:16 631:8,13,15 632:1 634:15 639:3 642:3,5 645:7,11,20 646:5 655:12 660:2 663:18 671:3 tuesday 356:9 tufts 357:10 364:3 380:2 tumor 651:17 652:7	tumors 615:5,7 turn 410:6 666:4 turns 485:14 564:16 twenty 429:7 twice 413:4 489:8 two 371:15 374:7 378:21 383:2 384:2 386:7,15 400:15 402:15 410:9 411:4 423:14 425:10 429:7 439:10 442:13 467:2 470:14 471:17 473:14,21 474:4,11 474:12 475:1 476:2 476:15 480:9 483:14 484:1 485:4 485:13,21 486:16 487:15 488:2,4,4,18 492:6 500:18 504:2 509:12 518:13 519:14 521:1 522:20 523:3,9 526:12 527:2 529:1 529:4 540:22 542:3 542:8,17 543:5,5,16 543:19 544:16,22 545:1,2,13 546:11 546:12 548:1,1,7 555:3,8 564:19 565:1,12 570:14 571:22 582:14 584:14 588:4,6 592:14 598:18 599:16 605:2 609:7 632:13 637:4,8 650:8,19 651:4 653:11 654:18 twosies 555:13 tygecycline 547:14 tying 607:11 type 376:20,21 377:2 390:10 391:22 392:5 393:21 394:15 398:14 427:18 448:20 455:9 460:6 498:14 500:19	519:17 544:16 545:8 550:17 557:17 558:2,5 595:7 603:4 607:16 607:17 620:21 types 372:17 374:7 381:11 388:19 423:2 427:18 428:10 461:7 537:1 537:2,4 609:10 649:12 650:21 typewriting 674:5 typical 407:4,5 457:2 typically 408:19 409:4 410:15,19 424:6 458:6 605:13 617:10 670:20 tyranny 563:8,10 u u.s. 400:11,18 415:22 430:9,9,13 430:14 601:2,22 608:3 624:15 647:7 658:15 662:12 663:12 udr 415:8 580:4 ultimate 634:18 ultimately 382:21 383:4 659:11 un 572:18 unavailable 507:4 uncertainties 452:20 455:13 656:18 uncertainty 368:9 369:7 370:16,16 420:5 422:20 461:19 462:4,16 551:11,21 569:11 588:19 594:14 606:13 671:13 unchanged 559:10 unclear 417:17 uncomfortable 512:16 543:20
---	---	--	--

uncontrolled 379:5 389:3 395:22 450:15 451:20 455:8 uncovered 607:6 665:19 undergoing 404:17 underlying 510:5,12 513:7 627:7 653:16 underneath 489:14 underscored 631:2 understand 372:10 381:13 423:5 451:8 451:9 456:17,20 459:11 461:14 473:2 499:13 510:14 511:20 512:1 515:15 525:15 535:13 539:10 540:13 552:3 553:9,19 560:12 567:13 568:6,14 569:18 573:11 590:19 594:19 606:19 615:9 617:4,17 619:9,14 622:5 636:19 649:1,3 653:18 661:16 664:21 understanding 388:14 395:2 429:10 456:20 553:14 561:15 590:20 592:7 648:14 658:11 667:1 understatement 471:15 understood 434:9 628:18 undertaken 372:5 393:10 unethical 433:20,22 unexpectedly 383:8 unfold 365:11 unfortunate 440:1	unfortunately 386:7 386:15 615:15 unhappy 567:17 unidentified 488:10 488:14,22 492:12 493:21 518:6,19 533:16 534:13 537:17 539:16 543:1 550:15,21 552:20 557:8,11,14 558:8 566:8,11 574:15 575:12 609:6,9,12 624:13 625:3,6,11,17,19,20 626:4,20 627:1,16 628:20 629:5,11,20 630:1,7,13 635:20 636:5 637:19 638:1 638:4,8 639:5,8,13 639:16,17 640:3,13 640:17,19,22 642:15,20 643:5,11 643:13,22 644:10 659:7 660:20 uniformly 440:21 uninformative 510:4,17 unique 376:2 420:1 433:2 unit 359:22 united 397:8 411:22 601:8,15 607:14 610:17,20 units 377:15 593:13 universal 607:14 university 357:10 357:16,17 359:9 unmanageable 416:4 unmet 356:5 386:1 401:15 405:8 420:21 443:3 480:16 484:10 663:22 unnecessarily 632:6 unpredictable 414:5	unrealistic 447:12 unreasonable 488:1 untreated 440:21 472:17 480:9 500:21 578:13 unusual 619:21 unveil 375:10 upper 482:6 upside 473:18 514:17 516:22 528:12 623:15 647:4 urgency 368:9 654:20 655:11 urgent 420:2 urinary 383:10,17 386:22 387:14 urination 386:3 urine 383:13,19 386:10 387:1 496:7 554:12,14 usage 591:3 594:12 use 381:21 385:15 387:19 390:10,12 390:14 391:11 395:10 396:20 397:2,9 398:2,3 399:2,3 404:19,21 407:5,6 408:19 411:21 412:7,13,22 413:6 427:14 432:16 433:11 434:3,13 435:10,15 446:6,11,19 448:1 449:19 457:11 461:5 462:6 463:17 480:2,8 498:13 506:5 507:16,17,20 509:14 515:7 528:8 530:21 532:2 537:1 540:21 549:19,20 551:12 552:10 578:10 581:7 583:20 588:7,8,9 590:21 591:1 593:1 593:8,16,19 596:19 596:20 599:5,21 601:10,17 606:17	606:21,22 607:15 607:22 608:4 614:13,15,16 629:19 635:15 636:6,6 639:14 641:11 650:21 656:3 668:8 671:11 useful 392:18 396:5 399:1 446:2 512:14 522:8 619:13 620:16 636:3 658:17 660:17 useless 519:11 user 521:19 uses 425:8 usual 369:10 385:6 415:3 665:14 usually 370:6 385:3 554:18 618:8,9 651:14 652:22 653:8 655:22 665:19 uti 365:22 390:18 409:19 426:18 450:19 451:12,15 475:7 496:6 536:1,3 554:5,6 670:22 utility 419:1 461:15 utilize 659:18 utilized 374:15 418:17 659:19 660:10 664:9 utilizing 374:8
v			
v 659:1,1 vabp 365:21 402:16 403:21 404:16 406:10 408:18,19 409:20 410:4 423:17,22 424:3,17 425:2,8 427:14,16 429:5,5,5 430:1,10 430:10,11 431:20 432:20 475:11 476:9 499:4 500:4 500:14 502:12,13 526:2,7,7 531:5			

557:15,19 559:14 560:1 561:1 562:1 572:3 576:8 641:6 667:8 670:22 vaccines 357:21 444:7 valiant 618:7 valid 449:18 524:16 validate 582:13 668:2 validated 416:22 476:10 602:15 validation 603:14 valuable 389:17 412:7 474:8 542:2 595:20 value 385:13 442:20 556:19 612:2 vancomycin 478:10 vander 659:2 vap 448:20 450:18 472:8 601:6 variability 370:10 414:4 425:20 474:3 544:21 564:3 592:21 593:6 614:21 616:18 617:13,17,18 622:4 622:4 633:4,9 637:5 638:15 641:4 variability's 474:5 variable 369:14 377:9 439:5 447:9 variance 378:15 variants 572:12 variation 562:3 variations 489:21 varies 440:5 441:3 variety 365:20 387:19,20 435:19 460:20 596:7 various 366:18 391:19 401:4 438:3 449:20 457:17 551:16 vary 369:16 428:1 varying 378:17	vbap 519:2 vehicle 397:9 ventilated 526:1 574:13,21 ventilator 419:11 574:2 venture 411:5,14 version 467:10 524:8 627:18 versions 644:11 versus 392:3,4 404:5 408:1 416:8 430:9 475:5 476:16 476:21 494:15 496:1 509:5,15 515:4,5 516:18 520:1 526:21 527:19 528:15 549:21 556:10 605:10 632:16,18 viable 466:2 646:8 vial 523:9 610:6 vials 610:8,14 vice 357:12 358:9 358:19 359:12 victor 659:1 viele 360:7 view 460:7 546:7 violated 602:16 viral 651:18,18 virulence 402:13 403:20 404:10 viruses 382:19 visit 409:22 489:8 vitro 385:12 420:22 vividly 637:21 voila 603:9 volume 388:8 591:3 volunteer 378:4 volunteers 378:14 454:22 vomiting 386:19 voriconazole 554:8 646:18 vossen 659:2 vote 514:2 598:1,2 vp 359:21	vulnerable 535:22 w wait 391:11 579:5 624:19 654:17,18 walk 365:2,11 372:4 375:3,7,12 379:20 425:6 433:7 437:18 463:20,21 walked 442:21 wall 517:4,15 walsh 574:5 want 363:14 374:9 381:2,2 387:13 388:5 400:16 408:10,22 410:12 413:14 423:21 434:3 450:6 465:6,6 470:2 472:5,20 478:8 488:8 494:11 495:14 496:14,19 497:20 504:4 505:4 507:2,6,15 508:11 509:9 513:9 515:22 517:16 518:9 523:11,16,21 525:3 527:7 529:4 537:5 540:12 542:19 543:6 549:17 553:3 554:21 555:2,7 557:4 559:4 564:14 564:15,15 569:21 575:9 580:2,4 581:14 582:11 585:12,15 588:11 592:10 593:18 594:2 595:3 597:2 599:12 603:3,18 608:6 609:1 610:5 611:2,4 632:9 633:2 633:3 637:12 639:12 652:1 669:7 671:22 wanted 363:6 456:6 485:9 490:1,5,13 507:8,9 513:15 514:7 522:1,4 527:6 529:20 531:2	555:19 606:8 662:10 wanting 557:18 633:12 wants 363:7 472:19 541:6 624:3 656:11 warm 610:2,22 662:3 warn 471:12 warning 452:17 519:17 warren 601:21,21 602:5,8,11,14,20 washy 529:3 wasn't 483:17 521:17 527:4 watch 467:18 watching 535:16 water 466:6 waving 525:1 way 374:16 389:2,4 396:4 397:3,10 399:4 403:17 437:22 443:4 446:13 450:3 452:8 461:10,14 462:2 464:1 468:6 471:13 476:1 483:3,10 488:7 490:19 496:11 501:21 505:1 507:18 512:3 513:1 522:10 523:7 524:16 526:19 528:13 529:3,19 537:11 539:8,14,21 547:2 548:3 555:17 557:12 578:4 584:2 584:9 598:8 600:1,6 602:9 605:13 612:9 617:16 618:9 622:9 623:4,11 630:16 635:1 638:10 646:3 647:22 649:20 650:7 652:13 655:2 655:3,4,6 656:6 660:8 663:3,4 667:16 671:14
--	--	--	--

ways 396:6 415:6 500:18 511:13 523:17 543:12 564:6 578:4 582:15 582:15 584:10 645:13 646:20 647:2 648:5 650:14 654:9,15 655:12 662:12 664:2,14	we'd 478:14 511:22 we'll 477:10 482:13 506:16 534:15 539:19 we're 480:16 483:3 485:4 486:2 488:13 492:20 498:2,7 502:20 512:21 521:12 523:3,10 525:14 530:6 531:15,18,22 532:6 532:15 533:8,10 534:21 535:19 536:19,19 538:18 538:19 we've 478:4 479:12 480:17 483:6,7 485:3 486:14 494:13 499:8 506:20 507:12 509:6,11,17 512:21 514:8 524:22 530:4 531:8,16	556:22 633:17,22 willingness 608:20 669:20 670:2 willman 675:3,14 wind 610:3 winds 467:16 wisdom 568:1 wish 672:22 wishy 529:3 withdrawn 650:4 woman 598:20 wonder 514:1 556:2 591:21 611:9 620:18 650:7 wonderful 506:14 wondering 459:3 won't 496:17 497:4 word 416:14 457:3 506:2 561:19 659:1 wording 471:18 552:10 words 511:6 672:19 work 362:21 363:21 364:5,20 372:8,9 381:9 394:22 402:9 404:9 410:11 411:5 413:2,18 416:20 424:1 427:4 431:10 432:12 436:7 437:7 443:19 459:21 461:8 472:5 473:6,7 476:6 478:2 486:12 486:19,19 494:12 501:7,8 505:12 506:20 512:5 515:18 518:7 525:14,16 527:14 538:5 544:15 551:16,20 553:16 569:19 571:4,11,14 571:19 577:12 580:18,19,21 587:11,11,14 597:16 600:7 601:1 604:2,17 608:21 609:20 612:12 621:11 648:18 650:5 651:4 664:2	666:9 667:3 669:14 671:2,4,16,21 672:1 672:5 worked 367:22 411:6 412:7 456:10 461:20 530:18 552:1 587:12 671:5 working 380:18 402:3 404:8 413:10 518:21 519:1 537:10 546:17 561:17 600:7 601:5 607:5,12 647:18 657:14 668:6 669:22 works 365:17 372:20 432:2 459:11 520:8 533:6 552:3 613:16 626:5 workshop 356:4 362:3,16 400:10 669:8,16 world 366:14 381:1 381:9 387:11 391:19 448:7 449:20 461:11 462:18 473:19 536:22 537:7 606:1 607:6 623:18 649:22 650:12 661:5,6 worldwide 473:5 658:15 worried 630:4,14 worrisome 410:3 559:18 worse 383:15 407:13 491:21 512:19 544:1 559:1 559:2,3 562:22 571:18 591:16 643:4 worst 587:18 worth 382:2 412:1 437:8 486:12 488:4 498:8 515:11 558:14
---	---	--	--

wow 667:17 wrap 658:19 write 476:18 574:19 575:11,16 written 481:2 524:8 wrong 486:21,22 514:5 529:3 539:8 539:14 540:14 557:12 593:17 623:4 wrote 479:18 547:2	504:4,7,9,20 508:13 509:8,22 511:8,12 511:18 513:12 515:8 520:3 521:15 524:6,12 526:10 528:10 529:11,22 531:7 534:19 535:8 537:8,17 538:11,16 540:15 543:8 545:16 546:5,6,19 550:11 551:1,1 552:13,13,15 554:2 554:18 557:14 559:22 561:12 564:18 566:8 568:3 569:1,5,16 574:17 578:16 579:1 580:14,16 581:19 585:19 588:13 591:9 592:12 594:8 596:14 600:22 602:6 603:21 605:14 606:4,8 608:17,19 609:15 612:8,17 614:5 619:18 620:3,10 621:8 624:12 627:19 629:5,14 630:6,19 631:11 632:19,22 635:13 636:5,13 637:22 639:5,16 640:17,21 643:1,5,7,7,9 648:22 649:3 651:9 652:20,21 656:5,12 660:20 661:19 662:2 year 382:5,14 384:16,21 385:18 386:1 410:9 411:17 413:4 459:5 489:9 526:18 537:9 569:16,18 601:6 609:4 610:13,17,21 years 380:19 382:6 465:20 473:21 489:11 519:13 574:6 601:4 604:17	646:17 651:21 654:18 655:16 662:16 yellow 533:12 yep 534:13 yersinia 438:14 yesterday 362:10,16 363:13 366:11 368:5,8 380:22 381:18 390:3,16 391:6,8 392:7 393:10 395:4 396:7 402:20 403:15 409:18 420:17 427:2,22 428:17 444:16,22 448:17 450:7 452:13 469:4 499:10 529:12 544:4 589:18 631:1 635:1 656:13 669:15 you'd 479:9 488:1 503:7 534:16 540:12 you'll 479:16 485:11 491:16 497:1 505:4 518:21 523:16,21 540:7 you're 477:6 485:16 492:21 493:1,11 494:8 497:15 500:19 501:8,15 502:12,15 503:13 504:17 505:13,14 506:6 508:18 509:4 509:18 510:13 511:19,21 512:2,20 513:16,20 515:1,9 518:20 519:9 520:7 521:22 522:13,14 525:18 526:4,13 529:18 534:3,10,20 535:3,3,15 536:9 537:19 538:1 540:10 you've 476:18 478:16,17,18 479:10 482:16,17	493:4,4 497:2 501:12 505:20 507:10 516:1 517:19 530:5 535:12,20
x			z
x 375:17,19 376:1 376:18 377:9,13 378:15,20 379:1,7 380:21 387:22 394:4 395:8 398:10 402:11 405:13 407:20 413:15 414:15 416:2 420:18 423:17 428:4 430:9,13 435:16 436:14 443:2,6,21 453:19 454:4 459:6 466:3 474:6,22 476:16,21 477:15,19 478:4 484:19 485:14 490:1,10 493:6 519:7 523:14,17,22 528:15 530:3 531:20 532:22 539:19 551:3,5 559:11,12 562:15 562:16,20,22 563:3 563:4 572:4 574:22 575:7 579:11 590:14,16 612:1 617:22 644:1,3,13 xy 631:12			zero 467:5 491:7 495:19 571:2 zone 483:5,14
y			
y 439:14,14 604:13 yeah 375:2 411:11 453:21 455:7,11 457:2 460:8 464:3 464:11 484:20 494:11 503:6,17			